<html lang="en" class="js"><head><link rel="preload" href="/static/fonts/HardingText-Regular-Web-cecd90984f.woff2" as="font" type="font/woff2" crossorigin=""><script async="" src="https://scripts.webcontentassessor.com/scripts/93dabb8d80079a87fec7bb6f67b807fce90e1688f8957ad7ad152bfd58ea01c2"></script><script type="text/javascript" async="" src="https://pagead2.googlesyndication.com/tag/js/gpt.js"></script><script async="" src="https://www.googletagmanager.com/gtm.js?id=GTM-MRVXSHQ"></script><script type="text/javascript" src="https://www.nature.com/oDWRvZD9Uwe75C0IIM-oTvKdQ5vXdq0Vm48yP_-lsFRtItyuQaudO2ALSdCcZ5Oo8Wme_XbMna0Nh0_15jtN5g=="></script><script src="https://cmp.nature.com/production_live/en/consent-bundle-8-85.js" onload="initGTM(window,document,'script','dataLayer','GTM-MRVXSHQ')"></script>
    <title>Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial | Nature Medicine</title>
    
        
<link rel="alternate" type="application/rss+xml" href="https://www.nature.com/nm.rss">


    
        

        <script id="save-data-connection-testing">
            function hasConnection() {
                return navigator.connection || navigator.mozConnection || navigator.webkitConnection || navigator.msConnection;
            }

            function createLink(src) {
                var preloadLink = document.createElement("link");
                preloadLink.rel = "preload";
                preloadLink.href = src;
                preloadLink.as = "font";
                preloadLink.type = "font/woff2";
                preloadLink.crossOrigin = "";
                document.head.insertBefore(preloadLink, document.head.firstChild);
            }

            var connectionDetail = {
                saveDataEnabled: false,
                slowConnection: false
            };

            var connection = hasConnection();
            if (connection) {
                connectionDetail.saveDataEnabled = connection.saveData;
                if (/\slow-2g|2g/.test(connection.effectiveType)) {
                    connectionDetail.slowConnection = true;
                }
            }

            if (!(connectionDetail.saveDataEnabled || connectionDetail.slowConnection)) {
                createLink("/static/fonts/HardingText-Regular-Web-cecd90984f.woff2");
            } else {
                document.documentElement.classList.add('save-data');
            }
        </script>
    

<link rel="preconnect" href="https://cmp.nature.com" crossorigin="">

<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta name="applicable-device" content="pc,mobile">
<meta name="viewport" content="width=device-width,initial-scale=1.0,maximum-scale=5,user-scalable=yes">
<meta name="360-site-verification" content="5a2dc4ab3fcb9b0393241ffbbb490480">

<script data-test="dataLayer">
    window.dataLayer = [{"content":{"category":{"contentType":"article","legacy":{"webtrendsPrimaryArticleType":"research","webtrendsSubjectTerms":"cancer-genomics;cancer-immunotherapy;mesothelioma;phase-ii-trials;tumour-immunology","webtrendsContentCategory":null,"webtrendsContentCollection":null,"webtrendsContentGroup":"Nature Medicine","webtrendsContentGroupType":null,"webtrendsContentSubGroup":"Article","status":null}},"article":{"doi":"10.1038/s41591-021-01541-0"},"attributes":{"cms":null,"deliveryPlatform":"oscar","copyright":{"open":true,"legacy":{"webtrendsLicenceType":"http://creativecommons.org/licenses/by/4.0/"}}},"contentInfo":{"authors":["Patrick M. Forde","Valsamo Anagnostou","Zhuoxin Sun","Suzanne E. Dahlberg","Hedy L. Kindler","Noushin Niknafs","Thomas Purcell","Rafael Santana-Davila","Arkadiusz Z. Dudek","Hossein Borghaei","Mara Lanis","Zineb Belcaid","Kellie N. Smith","Archana Balan","James R. White","Christopher Cherry","I. K. Ashok Sivakumar","Xiaoshan M. Shao","Hok Yee Chan","Dipika Singh","Sampriti Thapa","Peter B. Illei","Drew M. Pardoll","Rachel Karchin","Victor E. Velculescu","Julie R. Brahmer","Suresh S. Ramalingam"],"publishedAt":1636329600,"publishedAtString":"2021-11-08","title":"Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial","legacy":null,"publishedAtTime":null,"documentType":"aplusplus","subjects":"Cancer genomics,Cancer immunotherapy,Mesothelioma,Phase II trials,Tumour immunology"},"journal":{"pcode":"nm","title":"nature medicine","volume":"27","issue":"11","id":41591,"publishingModel":"Hybrid Access"},"authorization":{"status":true},"features":[{"name":"furtherReadingSection","present":true}],"collection":null},"page":{"category":{"pageType":"article"},"attributes":{"template":"mosaic","featureFlags":[{"name":"nature-onwards-journey","active":false}],"testGroup":null},"search":null},"privacy":{},"version":"1.0.0","product":null,"session":null,"user":null,"backHalfContent":true,"country":"BR","hasBody":true,"uneditedManuscript":false,"twitterId":["o3xnx","o43y9","o3ef7"],"baiduId":"d38bce82bcb44717ccc29a90c4b781ea","japan":false}];
    window.dataLayer.push({
        ga4MeasurementId: 'G-ERRNTNZ807',
        ga360TrackingId: 'UA-71668177-1',
        twitterId: ['3xnx', 'o43y9', 'o3ef7'],
        baiduId: 'd38bce82bcb44717ccc29a90c4b781ea',
        ga4ServerUrl: 'https://collect.nature.com',
        imprint: 'nature'
    });
</script>

<script>
    (function(w, d) {
        w.config = w.config || {};
        w.config.mustardcut = false;

        
        if (w.matchMedia && w.matchMedia('only print, only all and (prefers-color-scheme: no-preference), only all and (prefers-color-scheme: light), only all and (prefers-color-scheme: dark)').matches) {
            w.config.mustardcut = true;
            d.classList.add('js');
            d.classList.remove('grade-c');
            d.classList.remove('no-js');
        }
    })(window, document.documentElement);
</script>
 



     
    
    
        
    
    <style>@media only print, only all and (prefers-color-scheme: no-preference), only all and (prefers-color-scheme: light), only all and (prefers-color-scheme: dark) {  .c-article-editorial-summary__container .c-article-editorial-summary__article-title,.c-card--major .c-card__title,.c-card__title,.u-h2,.u-h3,h2,h3{font-weight:700;-webkit-font-smoothing:antialiased;font-family:Harding,Palatino,serif;letter-spacing:-.0117156rem}.c-article-editorial-summary__container .c-article-editorial-summary__article-title,.c-card__title,.u-h3,h3{font-size:1.25rem;line-height:1.4rem}.c-reading-companion__figure-title,.u-h4,h4{font-weight:700;-webkit-font-smoothing:antialiased;line-height:1.4rem}html{line-height:1.15;text-size-adjust:100%;box-sizing:border-box;font-size:100%;height:100%;overflow-y:scroll}body{background:#eee;color:#222;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:1.125rem;line-height:1.76;margin:0;min-height:100%}details,main{display:block}h1{font-size:2em;margin:.67em 0}a,sup{vertical-align:baseline}a{background-color:transparent;color:#069;overflow-wrap:break-word;text-decoration:underline;text-decoration-skip-ink:auto;word-break:break-word}b{font-weight:bolder}sup{font-size:75%;line-height:0;position:relative;top:-.5em}img{border:0;height:auto;max-width:100%;vertical-align:middle}button,input,select{font-family:inherit;font-size:100%;line-height:1.15;margin:0}button,input{overflow:visible}button,select{text-transform:none}[type=submit],button{-webkit-appearance:button}[type=checkbox]{box-sizing:border-box;padding:0}summary{display:list-item}[hidden]{display:none}button{border-radius:0;cursor:pointer;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif}h1{font-weight:700;-webkit-font-smoothing:antialiased;font-family:Harding,Palatino,serif;font-size:2rem;letter-spacing:-.0390625rem;line-height:2.25rem}.c-card--major .c-card__title,.u-h2,.u-h3,h2{font-family:Harding,Palatino,serif;letter-spacing:-.0117156rem}.c-card--major .c-card__title,.u-h2,h2{font-weight:700;-webkit-font-smoothing:antialiased;font-size:1.5rem;line-height:1.6rem}.u-h3{font-size:1.25rem}.c-card__title,.c-reading-companion__figure-title,.u-h3,.u-h4,h4,h5,h6{font-weight:700;-webkit-font-smoothing:antialiased;line-height:1.4rem}.c-article-editorial-summary__container .c-article-editorial-summary__article-title,.c-card__title,h3{font-family:Harding,Palatino,serif;font-size:1.25rem}.c-article-editorial-summary__container .c-article-editorial-summary__article-title,h3{font-weight:700;-webkit-font-smoothing:antialiased;letter-spacing:-.0117156rem;line-height:1.4rem}.c-reading-companion__figure-title,.u-h4,h4{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:1.125rem;letter-spacing:-.0117156rem}input+label{padding-left:.5em}nav ol,nav ul{list-style:none none}p:empty{display:none}.sans-serif{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif}.article-page{background:#fff}.c-article-header{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;margin-bottom:40px}.c-article-identifiers{color:#6f6f6f;display:flex;flex-wrap:wrap;font-size:1rem;line-height:1.3;list-style:none;margin:0 0 8px;padding:0}.c-article-identifiers__item{border-right:1px solid #6f6f6f;list-style:none;margin-right:8px;padding-right:8px}.c-article-identifiers__item:last-child{border-right:0;margin-right:0;padding-right:0}.c-article-title{font-size:1.5rem;line-height:1.25;margin:0 0 16px}@media only screen and (min-width:768px){.c-article-title{font-size:1.875rem;line-height:1.2}}.c-article-author-list{display:inline;font-size:1rem;list-style:none;margin:0 8px 0 0;padding:0;width:100%}.c-article-author-list__item{display:inline;padding-right:0}.c-article-author-list svg{margin-left:4px}.c-article-author-list__show-more{display:none;margin-right:4px}.c-article-author-list__button,.js .c-article-author-list__item--hide,.js .c-article-author-list__show-more{display:none}.js .c-article-author-list--long .c-article-author-list__show-more,.js .c-article-author-list--long+.c-article-author-list__button{display:inline}@media only screen and (max-width:539px){.js .c-article-author-list__item--hide-small-screen{display:none}.js .c-article-author-list--short .c-article-author-list__show-more,.js .c-article-author-list--short+.c-article-author-list__button{display:inline}}#uptodate-client,.js .c-article-author-list--expanded .c-article-author-list__show-more{display:none!important}.js .c-article-author-list--expanded .c-article-author-list__item--hide-small-screen{display:inline!important}.c-article-author-list__button,.c-button-author-list{background:#ebf1f5;border:4px solid #ebf1f5;border-radius:20px;color:#666;font-size:.875rem;line-height:1.4;padding:2px 11px 2px 8px;text-decoration:none}.c-article-author-list__button svg,.c-button-author-list svg{margin:1px 4px 0 0}.c-article-author-list__button:hover,.c-button-author-list:hover{background:#069;border-color:transparent;color:#fff}.c-article-info-details{font-size:1rem;margin-bottom:8px;margin-top:16px}.c-article-info-details__cite-as{border-left:1px solid #6f6f6f;margin-left:8px;padding-left:8px}.c-article-metrics-bar{display:flex;flex-wrap:wrap;font-size:1rem;line-height:1.3}.c-article-metrics-bar__wrapper{margin:16px 0}.c-article-metrics-bar__item{align-items:baseline;border-right:1px solid #6f6f6f;margin-right:8px}.c-article-metrics-bar__item:last-child{border-right:0}.c-article-metrics-bar__count{font-weight:700;margin:0}.c-article-metrics-bar__label{color:#626262;font-style:normal;font-weight:400;margin:0 10px 0 5px}.c-article-metrics-bar__details{margin:0}.c-article-main-column{font-family:Harding,Palatino,serif;margin-right:8.6%;width:60.2%}@media only screen and (max-width:1023px){.c-article-main-column{margin-right:0;width:100%}}.c-article-extras{float:left;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;width:31.2%}@media only screen and (max-width:1023px){.c-article-extras{display:none}}.c-article-associated-content__container .c-article-associated-content__title,.c-article-section__title{border-bottom:2px solid #d5d5d5;font-size:1.25rem;margin:0;padding-bottom:8px}@media only screen and (min-width:768px){.c-article-associated-content__container .c-article-associated-content__title,.c-article-section__title{font-size:1.5rem;line-height:1.24}}.c-article-associated-content__container .c-article-associated-content__title{margin-bottom:8px}.c-article-body p{margin-bottom:24px;margin-top:0}.c-article-section{clear:both}.c-article-section__content{margin-bottom:40px;padding-top:8px}@media only screen and (max-width:1023px){.c-article-section__content{padding-left:0}}.c-article-authors-search{margin-bottom:24px;margin-top:0}.c-article-authors-search__item,.c-article-authors-search__title{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif}.c-article-authors-search__title{color:#626262;font-size:1.05rem;font-weight:700;margin:0;padding:0}.c-article-authors-search__item{font-size:1rem}.c-article-authors-search__text{margin:0}.c-code-block{border:1px solid #eee;font-family:monospace;margin:0 0 24px;padding:20px}.c-code-block__heading{font-weight:400;margin-bottom:16px}.c-code-block__line{display:block;overflow-wrap:break-word;white-space:pre-wrap}.c-article-share-box__no-sharelink-info{font-size:.813rem;font-weight:700;margin-bottom:24px;padding-top:4px}.c-article-share-box__only-read-input{border:1px solid #d5d5d5;box-sizing:content-box;display:inline-block;font-size:.875rem;font-weight:700;height:24px;margin-bottom:8px;padding:8px 10px}.c-article-share-box__button--link-like{background-color:transparent;border:0;color:#069;cursor:pointer;font-size:.875rem;margin-bottom:8px;margin-left:10px}.c-article-editorial-summary__container{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:1rem}.c-article-editorial-summary__container .c-article-editorial-summary__content p:last-child{margin-bottom:0}.c-article-editorial-summary__container .c-article-editorial-summary__content--less{max-height:9.5rem;overflow:hidden}.c-article-editorial-summary__container .c-article-editorial-summary__button{background-color:#fff;border:0;color:#069;font-size:.875rem;margin-bottom:16px}.c-article-editorial-summary__container .c-article-editorial-summary__button.active,.c-article-editorial-summary__container .c-article-editorial-summary__button.hover,.c-article-editorial-summary__container .c-article-editorial-summary__button:active,.c-article-editorial-summary__container .c-article-editorial-summary__button:hover{text-decoration:underline;text-decoration-skip-ink:auto}.c-article-associated-content__container .c-article-associated-content__collection-label{font-size:.875rem;line-height:1.4}.c-article-associated-content__container .c-article-associated-content__collection-title{line-height:1.3}.c-context-bar{box-shadow:0 0 10px 0 rgba(51,51,51,.2);position:relative;width:100%}.c-context-bar__title{display:none}.c-reading-companion{clear:both;min-height:389px}.c-reading-companion__sticky{max-width:389px}.c-reading-companion__scroll-pane{margin:0;min-height:200px;overflow:hidden auto}.c-reading-companion__tabs{display:flex;flex-flow:row nowrap;font-size:1rem;list-style:none;margin:0 0 8px;padding:0}.c-reading-companion__tabs>li{flex-grow:1}.c-reading-companion__tab{background-color:#eee;border:1px solid #d5d5d5;border-image:initial;border-left-width:0;color:#069;font-size:1rem;padding:8px 8px 8px 15px;text-align:left;width:100%}.c-reading-companion__tabs li:first-child .c-reading-companion__tab{border-left-width:1px}.c-reading-companion__tab--active{background-color:#fff;border-bottom:1px solid #fff;color:#222;font-weight:700}.c-reading-companion__sections-list{list-style:none;padding:0}.c-reading-companion__figures-list,.c-reading-companion__references-list{list-style:none;min-height:389px;padding:0}.c-reading-companion__references-list--numeric{list-style:decimal inside}.c-reading-companion__sections-list{margin:0 0 8px;min-height:50px}.c-reading-companion__section-item{font-size:1rem;padding:0}.c-reading-companion__section-item a{display:block;line-height:1.5;overflow:hidden;padding:8px 0 8px 16px;text-overflow:ellipsis;white-space:nowrap}.c-reading-companion__figure-item{border-top:1px solid #d5d5d5;font-size:1rem;padding:16px 8px 16px 0}.c-reading-companion__figure-item:first-child{border-top:none;padding-top:8px}.c-reading-companion__reference-item{border-top:1px solid #d5d5d5;font-size:1rem;padding:8px 8px 8px 16px}.c-reading-companion__reference-item:first-child{border-top:none}.c-reading-companion__reference-item a{word-break:break-word}.c-reading-companion__reference-citation{display:inline}.c-reading-companion__reference-links{font-size:.813rem;font-weight:700;list-style:none;margin:8px 0 0;padding:0;text-align:right}.c-reading-companion__reference-links>a{display:inline-block;padding-left:8px}.c-reading-companion__reference-links>a:first-child{display:inline-block;padding-left:0}.c-reading-companion__figure-title{display:block;margin:0 0 8px}.c-reading-companion__figure-links{display:flex;justify-content:space-between;margin:8px 0 0}.c-reading-companion__figure-links>a{align-items:center;display:flex}.c-reading-companion__figure-full-link svg{height:.8em;margin-left:2px}.c-reading-companion__panel{border-top:none;display:none;margin-top:0;padding-top:0}.c-cod,.c-reading-companion__panel--active{display:block}.c-cod{font-size:1rem;width:100%}.c-cod__form{background:#ebf0f3}.c-cod__prompt{font-size:1.125rem;line-height:1.3;margin:0 0 24px}.c-cod__label{display:block;margin:0 0 4px}.c-cod__row{display:flex;margin:0 0 16px}.c-cod__row:last-child{margin:0}.c-cod__input{border:1px solid #d5d5d5;border-radius:2px;flex-basis:75%;flex-shrink:0;margin:0;padding:13px}.c-cod__input--submit{background-color:#069;border:1px solid #069;color:#fff;flex-shrink:1;margin-left:8px;transition:background-color .2s ease-out 0s,color .2s ease-out 0s}.c-cod__input--submit-single{flex-basis:100%;flex-shrink:0;margin:0}.c-cod__input--submit:focus,.c-cod__input--submit:hover{background-color:#fff;color:#069}.c-pdf-download__link .u-icon{padding-top:2px}.c-pdf-download{display:flex;margin-bottom:16px;max-height:48px}@media only screen and (min-width:540px){.c-pdf-download{max-height:none}}@media only screen and (min-width:1024px){.c-pdf-download{max-height:48px}}.c-pdf-download__link{display:flex;flex:1 1 0%}.c-pdf-download__link:hover{text-decoration:none}.c-pdf-download__text{padding-right:4px}@media only screen and (max-width:539px){.c-pdf-download__text{text-transform:capitalize}}@media only screen and (min-width:540px){.c-pdf-download__text{padding-right:8px}}.c-context-bar--sticky .c-pdf-download{display:block;margin-bottom:0;white-space:nowrap}@media only screen and (max-width:539px){.c-pdf-download .u-sticky-visually-hidden{border:0;clip:rect(0,0,0,0);height:1px;margin:-100%;overflow:hidden;padding:0;position:absolute!important;width:1px}}.c-pdf-container{display:flex;justify-content:flex-end}@media only screen and (max-width:539px){.c-pdf-container .c-pdf-download{display:flex;flex-basis:100%}}.c-pdf-container .c-pdf-download+.c-pdf-download{margin-left:16px}.c-article-extras .c-pdf-container .c-pdf-download{width:100%}.c-article-extras .c-pdf-container .c-pdf-download+.c-pdf-download{margin-left:0}@media only screen and (min-width:540px){.c-context-bar--sticky .c-pdf-download__link{align-items:center;flex:1 1 183px}}@media only screen and (max-width:320px){.c-context-bar--sticky .c-pdf-download__link{padding:16px}}.article-page--commercial .c-article-main-column .c-pdf-button__container .c-pdf-download{display:none}@media only screen and (max-width:1023px){.article-page--commercial .c-article-main-column .c-pdf-button__container .c-pdf-download{display:block}}.c-recommendations-column-switch .c-meta{margin-top:auto}.c-article-recommendations-card__meta-type,.c-meta .c-meta__item:first-child{font-weight:700}.c-article-metrics__heading a,.c-article-metrics__posts .c-card__title a{color:inherit}.c-article-metrics__posts .c-card__title{font-size:1.05rem}.c-article-metrics__posts .c-card__title+span{color:#6f6f6f;font-size:1rem}p{overflow-wrap:break-word;word-break:break-word}.c-ad{text-align:center}@media only screen and (min-width:320px){.c-ad{padding:8px}}.c-ad--728x90{background-color:#ccc;display:none}.c-ad--728x90 .c-ad__inner{min-height:calc(1.5em + 94px)}@media only screen and (min-width:768px){.js .c-ad--728x90{display:none}.js .u-show-following-ad+.c-ad--728x90{display:block}}.c-ad__label{color:#333;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:.875rem;font-weight:400;line-height:1.5;margin-bottom:4px}.app-author-list{color:#6f6f6f;font-family:inherit;font-size:1rem;line-height:inherit;list-style:none;margin:0;padding:0}.app-author-list>li,.c-breadcrumbs>li,.c-footer__links>li,.js .app-author-list,.u-list-comma-separated>li,.u-list-inline>li{display:inline}.app-author-list>li:not(:first-child):not(:last-child):before{content:", "}.app-author-list>li:not(:only-child):last-child:before{content:" & "}.app-author-list--compact{font-size:.875rem;line-height:1.4}.app-author-list--truncated>li:not(:only-child):last-child:before{content:" ... "}.js .app-author-list__hide{display:none;visibility:hidden}.js .app-author-list__hide:first-child+*{margin-block-start:0}.c-meta{color:inherit;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:.875rem;line-height:1.4;list-style:none;margin:0;padding:0}.c-meta--large{font-size:1rem}.c-meta--large .c-meta__item{margin-bottom:8px}.c-meta__item{display:inline-block;margin-bottom:4px}.c-meta__item:not(:last-child){border-right:1px solid #d5d5d5;margin-right:4px;padding-right:4px}@media only screen and (max-width:539px){.c-meta__item--block-sm-max{display:block}.c-meta__item--block-sm-max:not(:last-child){border-right:none;margin-right:0;padding-right:0}}@media only screen and (min-width:1024px){.c-meta__item--block-at-lg{display:block}.c-meta__item--block-at-lg:not(:last-child){border-right:none;margin-right:0;padding-right:0}}.c-meta__type{font-weight:700;text-transform:none}.c-skip-link{background:#069;bottom:auto;color:#fff;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:.875rem;padding:8px;position:absolute;text-align:center;transform:translateY(-100%);z-index:9999}@media (prefers-reduced-motion:reduce){.c-skip-link{transition:top .3s ease-in-out 0s}}@media print{.c-skip-link{display:none}}.c-skip-link:link{color:#fff}.c-status-message{align-items:center;box-sizing:border-box;display:flex;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:1rem;position:relative;width:100%}.c-card__summary>p:last-child,.c-status-message :last-child{margin-bottom:0}.c-status-message--boxed{background-color:#fff;border:1px solid #eee;border-radius:2px;line-height:1.4;padding:16px}.c-status-message__heading{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:1rem;font-weight:700}.c-status-message__icon{fill:currentcolor;display:inline-block;flex:0 0 auto;height:1.5em;margin-right:8px;transform:translate(0);vertical-align:text-top;width:1.5em}.c-status-message__icon--top{align-self:flex-start}.c-status-message--info .c-status-message__icon{color:#003f8d}.c-status-message--boxed.c-status-message--info{border-bottom:4px solid #003f8d}.c-status-message--error .c-status-message__icon{color:#c40606}.c-status-message--boxed.c-status-message--error{border-bottom:4px solid #c40606}.c-status-message--success .c-status-message__icon{color:#00b8b0}.c-status-message--boxed.c-status-message--success{border-bottom:4px solid #00b8b0}.c-status-message--warning .c-status-message__icon{color:#edbc53}.c-status-message--boxed.c-status-message--warning{border-bottom:4px solid #edbc53}.c-breadcrumbs{color:#000;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:1rem;list-style:none;margin:0;padding:0}.c-breadcrumbs__link{color:#666}svg.c-breadcrumbs__chevron{margin:4px 4px 0;fill:#888;height:10px;width:10px}@media only screen and (max-width:539px){.c-breadcrumbs .c-breadcrumbs__item{display:none}.c-breadcrumbs .c-breadcrumbs__item:last-child,.c-breadcrumbs .c-breadcrumbs__item:nth-last-child(2){display:inline}}.c-card{background-color:transparent;border:0;box-shadow:none;display:flex;flex-direction:column;font-size:14px;min-width:0;overflow:hidden;padding:0;position:relative}.c-card--no-shape{background:0 0;border:0;box-shadow:none}.c-card__image{display:flex;justify-content:center;overflow:hidden;padding-bottom:56.25%;position:relative}@supports (aspect-ratio:1/1){.c-card__image{padding-bottom:0}}.c-card__image img{left:0;min-height:100%;min-width:100%;position:absolute}@supports ((-o-object-fit:cover) or (object-fit:cover)){.c-card__image img{height:100%;object-fit:cover;width:100%}}.c-card__body{flex:1 1 auto;padding:16px}.c-card--no-shape .c-card__body{padding:0}.c-card--no-shape .c-card__body:not(:first-child){padding-top:16px}.c-card__title{letter-spacing:-.01875rem;margin-bottom:8px;margin-top:0}[lang=de] .c-card__title{hyphens:auto}.c-card__summary{line-height:1.4}.c-card__summary>p{margin-bottom:5px}.c-card__summary a{text-decoration:underline}.c-card__link:not(.c-card__link--no-block-link):before{bottom:0;content:"";left:0;position:absolute;right:0;top:0}.c-card--flush .c-card__body{padding:0}.c-card--major{font-size:1rem}.c-card--dark{background-color:#29303c;border-width:0;color:#e3e4e5}.c-card--dark .c-card__title{color:#fff}.c-card--dark .c-card__link,.c-card--dark .c-card__summary a{color:inherit}.c-header{background-color:#fff;border-bottom:5px solid #000;font-size:1rem;line-height:1.4;margin-bottom:16px}.c-header__row{padding:0;position:relative}.c-header__row:not(:last-child){border-bottom:1px solid #eee}.c-header__split{align-items:center;display:flex;justify-content:space-between}.c-header__logo-container{flex:1 1 0px;line-height:0;margin:8px 24px 8px 0}.c-header__logo{transform:translateZ(0)}.c-header__logo img{max-height:32px}.c-header__container{margin:0 auto;max-width:1280px}.c-header__menu{align-items:center;display:flex;flex:0 1 auto;flex-wrap:wrap;font-weight:700;gap:8px 8px;line-height:1.4;list-style:none;margin:0 -8px;padding:0}@media print{.c-header__menu{display:none}}@media only screen and (max-width:1023px){.c-header__menu--hide-lg-max{display:none;visibility:hidden}}.c-header__menu--global{font-weight:400;justify-content:flex-end}.c-header__menu--global svg{display:none;visibility:hidden}.c-header__menu--global svg:first-child+*{margin-block-start:0}@media only screen and (min-width:540px){.c-header__menu--global svg{display:block;visibility:visible}}.c-header__menu--journal{font-size:.875rem;margin:8px 0 8px -8px}@media only screen and (min-width:540px){.c-header__menu--journal{flex-wrap:nowrap;font-size:1rem}}.c-header__item{padding-bottom:0;padding-top:0;position:static}.c-header__item--pipe{border-left:2px solid #eee;padding-left:8px}.c-header__item--padding{padding-bottom:8px;padding-top:8px}@media only screen and (min-width:540px){.c-header__item--dropdown-menu{position:relative}}@media only screen and (min-width:1024px){.c-header__item--hide-lg{display:none;visibility:hidden}}@media only screen and (max-width:767px){.c-header__item--hide-md-max{display:none;visibility:hidden}.c-header__item--hide-md-max:first-child+*{margin-block-start:0}}.c-header__link{align-items:center;color:inherit;display:inline-flex;gap:4px 4px;padding:8px;white-space:nowrap}.c-header__link svg{transition-duration:.2s}.c-header__show-text{display:none;visibility:hidden}.has-tethered .c-header__heading--js-hide:first-child+*{margin-block-start:0}@media only screen and (min-width:540px){.c-header__show-text{display:inline;visibility:visible}}.c-header__dropdown{background-color:#000;border-bottom:1px solid #2f2f2f;color:#eee;font-size:.875rem;line-height:1.2;padding:16px 0}@media print{.c-header__dropdown{display:none}}.c-header__heading{display:inline-block;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:1.25rem;font-weight:400;line-height:1.4;margin-bottom:8px}.c-header__heading--keyline{border-top:1px solid;border-color:#2f2f2f;margin-top:16px;padding-top:16px;width:100%}.c-header__list{display:flex;flex-wrap:wrap;gap:0 16px;list-style:none;margin:0 -8px}.c-header__flush{margin:0 -8px}.c-header__visually-hidden{border:0;clip:rect(0,0,0,0);height:1px;margin:-100%;overflow:hidden;padding:0;position:absolute!important;width:1px}.c-header__search-form{margin-bottom:8px}.c-header__search-layout{display:flex;flex-wrap:wrap;gap:16px 16px}.c-header__search-layout>:first-child{flex:999 1 auto}.c-header__search-layout>*{flex:1 1 auto}.c-header__search-layout--max-width{max-width:720px}.c-header__search-button{align-items:center;background-color:transparent;background-image:none;border:1px solid #fff;border-radius:2px;color:#fff;cursor:pointer;display:flex;font-family:sans-serif;font-size:1rem;justify-content:center;line-height:1.15;margin:0;padding:8px 16px;position:relative;text-decoration:none;transition:all .25s ease 0s,color .25s ease 0s,border-color .25s ease 0s;width:100%}.u-button svg,.u-button--primary svg{fill:currentcolor}.c-header__input,.c-header__select{border:1px solid;border-radius:3px;box-sizing:border-box;font-size:1rem;padding:8px 16px;width:100%}.c-header__select{-webkit-appearance:none;background-image:url("data:image/svg+xml,%3Csvg height='16' viewBox='0 0 16 16' width='16' xmlns='http://www.w3.org/2000/svg'%3E%3Cpath d='m5.58578644 3-3.29289322-3.29289322c-.39052429-.39052429-.39052429-1.02368927 0-1.41421356s1.02368927-.39052429 1.41421356 0l4 4c.39052429.39052429.39052429 1.02368927 0 1.41421356l-4 4c-.39052429.39052429-1.02368927.39052429-1.41421356 0s-.39052429-1.02368927 0-1.41421356z' fill='%23333' fill-rule='evenodd' transform='matrix(0 1 -1 0 11 3)'/%3E%3C/svg%3E");background-position:right .7em top 50%;background-repeat:no-repeat;background-size:1em;box-shadow:0 1px 0 1px rgba(0,0,0,.04);display:block;margin:0;max-width:100%;min-width:150px}@media only screen and (min-width:540px){.c-header__menu--journal .c-header__item--dropdown-menu:last-child .c-header__dropdown.has-tethered{left:auto;right:0}}@media only screen and (min-width:768px){.c-header__menu--journal .c-header__item--dropdown-menu:last-child .c-header__dropdown.has-tethered{left:0;right:auto}}.c-header__dropdown.has-tethered{border-bottom:0;border-radius:0 0 2px 2px;left:0;position:absolute;top:100%;transform:translateY(5px);width:100%;z-index:1}@media only screen and (min-width:540px){.c-header__dropdown.has-tethered{transform:translateY(8px);width:auto}}@media only screen and (min-width:768px){.c-header__dropdown.has-tethered{min-width:225px}}.c-header__dropdown--full-width.has-tethered{padding:32px 0 24px;transform:none;width:100%}.has-tethered .c-header__heading--js-hide{display:none;visibility:hidden}.has-tethered .c-header__list--js-stack{flex-direction:column}.has-tethered .c-header__item--keyline,.has-tethered .c-header__list~.c-header__list .c-header__item:first-child{border-top:1px solid #d5d5d5;margin-top:8px;padding-top:8px}.c-header__item--snid-account-widget{display:flex}.c-header__container{padding:0 4px}.c-header__list{padding:0 12px}.c-header__menu .c-header__link{font-size:14px}.c-header__item--snid-account-widget .c-header__link{padding:8px}.c-header__menu--journal{margin-left:0}@media only screen and (min-width:540px){.c-header__container{padding:0 16px}.c-header__menu--journal{margin-left:-8px}.c-header__menu .c-header__link{font-size:16px}.c-header__link--search{gap:13px 13px}}.u-button{align-items:center;background-color:transparent;background-image:none;border:1px solid #069;border-radius:2px;color:#069;cursor:pointer;display:inline-flex;font-family:sans-serif;font-size:1rem;justify-content:center;line-height:1.3;margin:0;padding:8px;position:relative;text-decoration:none;transition:all .25s ease 0s,color .25s ease 0s,border-color .25s ease 0s;width:auto}.u-button--primary{background-color:#069;background-image:none;border:1px solid #069;color:#fff}.u-button--full-width{display:flex;width:100%}.u-display-none{display:none}.js .u-js-hide,.u-hide{display:none;visibility:hidden}.u-hide:first-child+*{margin-block-start:0}.u-visually-hidden{border:0;clip:rect(0,0,0,0);height:1px;margin:-100%;overflow:hidden;padding:0;position:absolute!important;width:1px}@media print{.u-hide-print{display:none}}@media only screen and (min-width:1024px){.u-hide-at-lg{display:none;visibility:hidden}.u-hide-at-lg:first-child+*{margin-block-start:0}}.u-clearfix:after,.u-clearfix:before{content:"";display:table}.u-clearfix:after{clear:both}.u-color-open-access{color:#b74616}.u-float-left{float:left}.u-icon{fill:currentcolor;display:inline-block;height:1em;transform:translate(0);vertical-align:text-top;width:1em}.u-full-height{height:100%}.u-list-reset{list-style:none;margin:0;padding:0}.u-container{margin:0 auto;max-width:1280px;padding:0 16px}.u-justify-content-space-between{justify-content:space-between}.u-mt-32{margin-top:32px}.u-mb-8{margin-bottom:8px}.u-mb-16{margin-bottom:16px}.u-mb-24{margin-bottom:24px}.u-mb-32{margin-bottom:32px}.c-nature-box svg+.c-article__button-text,.u-ml-8{margin-left:8px}.u-pa-16{padding:16px}html *,html :after,html :before{box-sizing:inherit}.c-article-section__title,.c-article-title{font-weight:700}.c-card__title{line-height:1.4em}.c-article__button{background-color:#069;border:1px solid #069;border-radius:2px;color:#fff;display:flex;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:.875rem;line-height:1.4;margin-bottom:16px;padding:13px;transition:background-color .2s ease-out 0s,color .2s ease-out 0s}.c-article__button,.c-article__button:hover{text-decoration:none}.c-article__button--inverted,.c-article__button:hover{background-color:#fff;color:#069}.c-article__button--inverted:hover{background-color:#069;color:#fff}.c-header__link{text-decoration:inherit}.grade-c-hide{display:block}.c-nature-box{background-color:#fff;border:1px solid #d5d5d5;border-radius:2px;box-shadow:0 0 5px 0 rgba(51,51,51,.1);line-height:1.3;margin-bottom:24px;padding:16px 16px 3px}.c-nature-box__text{font-size:1rem;margin-bottom:16px}.c-nature-box--access-to-pdf{display:none}@media only screen and (min-width:1024px){.c-nature-box--mobile{display:none}}.c-nature-box .c-pdf-download{margin-bottom:16px!important}.c-nature-box--version{background-color:#eee}.c-nature-box__wrapper{transform:translateZ(0)}.c-nature-box__wrapper--placeholder{min-height:165px}.c-pdf-download__link{padding:13px 24px} } </style>




    
        <link data-test="critical-css-handler" data-inline-css-source="critical-css" rel="stylesheet" href="/static/css/enhanced-article-nature-branded-1dd982e2cc.css" media="only print, only all and (prefers-color-scheme: no-preference), only all and (prefers-color-scheme: light), only all and (prefers-color-scheme: dark)" onload="this.media='only print, only all and (prefers-color-scheme: no-preference), only all and (prefers-color-scheme: light), only all and (prefers-color-scheme: dark)';this.onload=null">
    
    <noscript>
        <link rel="stylesheet" type="text/css" href="/static/css/enhanced-article-nature-branded-1dd982e2cc.css" media="only print, only all and (prefers-color-scheme: no-preference), only all and (prefers-color-scheme: light), only all and (prefers-color-scheme: dark)">
    </noscript>

<link rel="stylesheet" type="text/css" href="/static/css/article-print-c9121fecab.css" media="print">
    



<link rel="apple-touch-icon" sizes="180x180" href="/static/images/favicons/nature/apple-touch-icon-f39cb19454.png">
<link rel="icon" type="image/png" sizes="48x48" href="/static/images/favicons/nature/favicon-48x48-b52890008c.png">
<link rel="icon" type="image/png" sizes="32x32" href="/static/images/favicons/nature/favicon-32x32-3fe59ece92.png">
<link rel="icon" type="image/png" sizes="16x16" href="/static/images/favicons/nature/favicon-16x16-951651ab72.png">
<link rel="manifest" href="/static/manifest.json" crossorigin="use-credentials">
<link rel="mask-icon" href="/static/images/favicons/nature/safari-pinned-tab-69bff48fe6.svg" color="#000000">
<link rel="shortcut icon" href="/static/images/favicons/nature/favicon.ico">
<meta name="msapplication-TileColor" content="#000000">
<meta name="msapplication-config" content="/static/browserconfig.xml">
<meta name="theme-color" content="#000000">
<meta name="application-name" content="Nature">


<script>
    (function () {
        if ( typeof window.CustomEvent === "function" ) return false;
        function CustomEvent ( event, params ) {
            params = params || { bubbles: false, cancelable: false, detail: null };
            var evt = document.createEvent( 'CustomEvent' );
            evt.initCustomEvent( event, params.bubbles, params.cancelable, params.detail );
            return evt;
        }

        CustomEvent.prototype = window.Event.prototype;

        window.CustomEvent = CustomEvent;
    })();
</script>



<!-- Google Tag Manager -->
<script data-test="gtm-head">
    window.initGTM = function() {
        if (window.config.mustardcut) {
            (function (w, d, s, l, i) {
                w[l] = w[l] || [];
                w[l].push({'gtm.start': new Date().getTime(), event: 'gtm.js'});
                var f = d.getElementsByTagName(s)[0],
                        j = d.createElement(s),
                        dl = l != 'dataLayer' ? '&l=' + l : '';
                j.async = true;
                j.src = 'https://www.googletagmanager.com/gtm.js?id=' + i + dl;
                f.parentNode.insertBefore(j, f);
            })(window, document, 'script', 'dataLayer', 'GTM-MRVXSHQ');
        }
    }
</script>
<!-- End Google Tag Manager -->

    <script>
    (function(w,d,t) {
        function cc() {
            var h = w.location.hostname;
            if (h.indexOf('preview-www.nature.com') > -1) return;

            var e = d.createElement(t),
                    s = d.getElementsByTagName(t)[0];

            if (h.indexOf('nature.com') > -1) {
                if (h.indexOf('test-www.nature.com') > -1) {
                    e.src = 'https://cmp.nature.com/production_live/en/consent-bundle-8-85.js';
                    e.setAttribute('onload', "initGTM(window,document,'script','dataLayer','GTM-MRVXSHQ')");
                } else {
                    e.src = 'https://cmp.nature.com/production_live/en/consent-bundle-8-85.js';
                    e.setAttribute('onload', "initGTM(window,document,'script','dataLayer','GTM-MRVXSHQ')");
                }
            } else {
                e.src = '/static/js/cookie-consent-es5-bundle-cb57c2c98a.js';
                e.setAttribute('data-consent', h);
            }
            s.insertAdjacentElement('afterend', e);
        }

        cc();
    })(window,document,'script');
</script>


<script id="js-position0">
    (function(w, d) {
        w.idpVerifyPrefix = 'https://verify.nature.com';
        w.ra21Host = 'https://wayf.springernature.com';
        var moduleSupport = (function() {
            return 'noModule' in d.createElement('script');
        })();

        if (w.config.mustardcut === true) {
            w.loader = {
                index: 0,
                registered: [],
                scripts: [
                    
                        {src: '/static/js/global-article-es6-bundle-c8a573ca90.js', test: 'global-article-js', module: true},
                        {src: '/static/js/global-article-es5-bundle-d17603b9e9.js', test: 'global-article-js', nomodule: true},
                        {src: '/static/js/shared-es6-bundle-e9d2061c95.js', test: 'shared-js', module: true},
                        {src: '/static/js/shared-es5-bundle-1cbf3a8b56.js', test: 'shared-js', nomodule: true},
                        {src: '/static/js/header-150-es6-bundle-5bb959eaa1.js', test: 'header-150-js', module: true},
                        {src: '/static/js/header-150-es5-bundle-994fde5b1d.js', test: 'header-150-js', nomodule: true}
                    
                ].filter(function (s) {
                    if (s.src === null) return false;
                    if (moduleSupport && s.nomodule) return false;
                    return !(!moduleSupport && s.module);
                }),

                register: function (value) {
                    this.registered.push(value);
                },

                ready: function () {
                    if (this.registered.length === this.scripts.length) {
                        this.registered.forEach(function (fn) {
                            if (typeof fn === 'function') {
                                setTimeout(fn, 0); 
                            }
                        });
                        this.ready = function () {};
                    }
                },

                insert: function (s) {
                    var t = d.getElementById('js-position' + this.index);
                    if (t && t.insertAdjacentElement) {
                        t.insertAdjacentElement('afterend', s);
                    } else {
                        d.head.appendChild(s);
                    }
                    ++this.index;
                },

                createScript: function (script, beforeLoad) {
                    var s = d.createElement('script');
                    s.id = 'js-position' + (this.index + 1);
                    s.setAttribute('data-test', script.test);
                    if (beforeLoad) {
                        s.defer = 'defer';
                        s.onload = function () {
                            if (script.noinit) {
                                loader.register(true);
                            }
                            if (d.readyState === 'interactive' || d.readyState === 'complete') {
                                loader.ready();
                            }
                        };
                    } else {
                        s.async = 'async';
                    }
                    s.src = script.src;
                    return s;
                },

                init: function () {
                    this.scripts.forEach(function (s) {
                        loader.insert(loader.createScript(s, true));
                    });

                    d.addEventListener('DOMContentLoaded', function () {
                        loader.ready();
                        var conditionalScripts;
                        
                            conditionalScripts = [
                                {match: 'div[data-pan-container]', src: '/static/js/pan-zoom-es6-bundle-464a2af269.js', test: 'pan-zoom-js',  module: true },
                                {match: 'div[data-pan-container]', src: '/static/js/pan-zoom-es5-bundle-98fb9b653b.js', test: 'pan-zoom-js',  nomodule: true },
                                {match: 'math,span.mathjax-tex', src: '/static/js/math-es6-bundle-23597ae350.js', test: 'math-js', module: true},
                                {match: 'math,span.mathjax-tex', src: '/static/js/math-es5-bundle-6532c6f78b.js', test: 'math-js', nomodule: true}
                            ];
                        

                        if (conditionalScripts) {
                            conditionalScripts.filter(function (script) {
                                return !!document.querySelector(script.match) && !((moduleSupport && script.nomodule) || (!moduleSupport && script.module));
                            }).forEach(function (script) {
                                loader.insert(loader.createScript(script));
                            });
                        }
                    }, false);
                }
            };
            loader.init();
        }
    })(window, document);
</script><script id="js-position1" data-test="global-article-js" defer="" src="/static/js/global-article-es6-bundle-c8a573ca90.js"></script><script id="js-position2" data-test="shared-js" defer="" src="/static/js/shared-es6-bundle-e9d2061c95.js"></script><script id="js-position3" data-test="header-150-js" defer="" src="/static/js/header-150-es6-bundle-5bb959eaa1.js"></script>










<meta name="robots" content="noarchive">
<meta name="access" content="Yes">


<link rel="search" href="https://www.nature.com/search">
<link rel="search" href="https://www.nature.com/opensearch/opensearch.xml" type="application/opensearchdescription+xml" title="nature.com">
<link rel="search" href="https://www.nature.com/opensearch/request" type="application/sru+xml" title="nature.com">





    
    <script type="application/ld+json">{"mainEntity":{"headline":"Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial","description":"Mesothelioma is a rare and fatal cancer with limited therapeutic options until the recent approval of combination immune checkpoint blockade. Here we report the results of the phase 2 PrE0505 trial (\n                NCT02899195\n                \n              ) of the anti-PD-L1 antibody durvalumab plus platinum-pemetrexed chemotherapy for 55 patients with previously untreated, unresectable pleural mesothelioma. The primary endpoint was overall survival compared to historical control with cisplatin and pemetrexed chemotherapy; secondary and exploratory endpoints included safety, progression-free survival and biomarkers of response. The combination of durvalumab with chemotherapy met the pre-specified primary endpoint, reaching a median survival of 20.4 months versus 12.1 months with historical control. Treatment-emergent adverse events were consistent with known side effects of chemotherapy, and all adverse events due to immunotherapy were grade 2 or lower. Integrated genomic and immune cell repertoire analyses revealed that a higher immunogenic mutation burden coupled with a more diverse T cell repertoire was linked to favorable clinical outcome. Structural genome-wide analyses showed a higher degree of genomic instability in responding tumors of epithelioid histology. Patients with germline alterations in cancer predisposing genes, especially those involved in DNA repair, were more likely to achieve long-term survival. Our findings indicate that concurrent durvalumab with platinum-based chemotherapy has promising clinical activity and that responses are driven by the complex genomic background of malignant pleural mesothelioma. In a phase 2 trial, the combination of chemotherapy with durvalumab, an anti-PD-L1 antibody, exhibited promising clinical activity in patients with previously untreated, unresectable mesothelioma, with additional analyses providing insights into genomic and immunologic features potentially associated with response.","datePublished":"2021-11-08T00:00:00Z","dateModified":"2021-11-08T00:00:00Z","pageStart":"1910","pageEnd":"1920","license":"http://creativecommons.org/licenses/by/4.0/","sameAs":"https://doi.org/10.1038/s41591-021-01541-0","keywords":["Cancer genomics","Cancer immunotherapy","Mesothelioma","Phase II trials","Tumour immunology","Biomedicine","general","Cancer Research","Metabolic Diseases","Infectious Diseases","Molecular Medicine","Neurosciences"],"image":["https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41591-021-01541-0/MediaObjects/41591_2021_1541_Fig1_HTML.png","https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41591-021-01541-0/MediaObjects/41591_2021_1541_Fig2_HTML.png","https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41591-021-01541-0/MediaObjects/41591_2021_1541_Fig3_HTML.png","https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41591-021-01541-0/MediaObjects/41591_2021_1541_Fig4_HTML.png","https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41591-021-01541-0/MediaObjects/41591_2021_1541_Fig5_HTML.png"],"isPartOf":{"name":"Nature Medicine","issn":["1546-170X","1078-8956"],"volumeNumber":"27","@type":["Periodical","PublicationVolume"]},"publisher":{"name":"Nature Publishing Group US","logo":{"url":"https://www.springernature.com/app-sn/public/images/logo-springernature.png","@type":"ImageObject"},"@type":"Organization"},"author":[{"name":"Patrick M. Forde","url":"http://orcid.org/0000-0001-6925-6344","affiliation":[{"name":"Johns Hopkins University School of Medicine","address":{"name":"The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, USA","@type":"PostalAddress"},"@type":"Organization"},{"name":"Johns Hopkins University School of Medicine","address":{"name":"The Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, USA","@type":"PostalAddress"},"@type":"Organization"}],"email":"pforde1@jhmi.edu","@type":"Person"},{"name":"Valsamo Anagnostou","url":"http://orcid.org/0000-0001-9480-3047","affiliation":[{"name":"Johns Hopkins University School of Medicine","address":{"name":"The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, USA","@type":"PostalAddress"},"@type":"Organization"},{"name":"Johns Hopkins University School of Medicine","address":{"name":"The Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, USA","@type":"PostalAddress"},"@type":"Organization"}],"email":"vanagno1@jhmi.edu","@type":"Person"},{"name":"Zhuoxin Sun","affiliation":[{"name":"ECOG-ACRIN Biostatistics Center","address":{"name":"ECOG-ACRIN Biostatistics Center, Boston, USA","@type":"PostalAddress"},"@type":"Organization"},{"name":"Frontier Science Foundation","address":{"name":"Frontier Science Foundation, Boston, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Suzanne E. Dahlberg","affiliation":[{"name":"Boston Children’s Hospital","address":{"name":"Boston Children’s Hospital, Boston, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Hedy L. Kindler","affiliation":[{"name":"University of Chicago Medicine","address":{"name":"University of Chicago Medicine, Chicago, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Noushin Niknafs","affiliation":[{"name":"Johns Hopkins University School of Medicine","address":{"name":"The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Thomas Purcell","affiliation":[{"name":"University of Washington School of Medicine & Fred Hutchinson Cancer Research Center","address":{"name":"University of Washington School of Medicine & Fred Hutchinson Cancer Research Center, Seattle, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Rafael Santana-Davila","affiliation":[{"name":"University of Washington School of Medicine & Fred Hutchinson Cancer Research Center","address":{"name":"University of Washington School of Medicine & Fred Hutchinson Cancer Research Center, Seattle, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Arkadiusz Z. Dudek","affiliation":[{"name":"Metro-Minnesota Community Oncology Research Consortium","address":{"name":"Metro-Minnesota Community Oncology Research Consortium, St. Louis Park, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Hossein Borghaei","affiliation":[{"name":"Fox Chase Cancer Center","address":{"name":"Fox Chase Cancer Center, Philadelphia, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Mara Lanis","affiliation":[{"name":"Johns Hopkins University School of Medicine","address":{"name":"The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Zineb Belcaid","affiliation":[{"name":"Johns Hopkins University School of Medicine","address":{"name":"The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Kellie N. Smith","affiliation":[{"name":"Johns Hopkins University School of Medicine","address":{"name":"The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, USA","@type":"PostalAddress"},"@type":"Organization"},{"name":"Johns Hopkins University School of Medicine","address":{"name":"The Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Archana Balan","affiliation":[{"name":"Johns Hopkins University School of Medicine","address":{"name":"The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"James R. White","affiliation":[{"name":"Johns Hopkins University School of Medicine","address":{"name":"The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Christopher Cherry","affiliation":[{"name":"Johns Hopkins University School of Medicine","address":{"name":"The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"I. K. Ashok Sivakumar","affiliation":[{"name":"Johns Hopkins University","address":{"name":"Institute for Computational Medicine, Johns Hopkins University, Baltimore, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Xiaoshan M. Shao","url":"http://orcid.org/0000-0003-3190-2288","affiliation":[{"name":"Johns Hopkins University","address":{"name":"Institute for Computational Medicine, Johns Hopkins University, Baltimore, USA","@type":"PostalAddress"},"@type":"Organization"},{"name":"Johns Hopkins University","address":{"name":"Department of Biomedical Engineering, Johns Hopkins University, Baltimore, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Hok Yee Chan","affiliation":[{"name":"Johns Hopkins University School of Medicine","address":{"name":"The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, USA","@type":"PostalAddress"},"@type":"Organization"},{"name":"Johns Hopkins University School of Medicine","address":{"name":"The Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Dipika Singh","affiliation":[{"name":"Johns Hopkins University School of Medicine","address":{"name":"The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, USA","@type":"PostalAddress"},"@type":"Organization"},{"name":"Johns Hopkins University School of Medicine","address":{"name":"The Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Sampriti Thapa","affiliation":[{"name":"Johns Hopkins University School of Medicine","address":{"name":"The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, USA","@type":"PostalAddress"},"@type":"Organization"},{"name":"Johns Hopkins University School of Medicine","address":{"name":"The Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Peter B. Illei","affiliation":[{"name":"Johns Hopkins University School of Medicine","address":{"name":"The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, USA","@type":"PostalAddress"},"@type":"Organization"},{"name":"Johns Hopkins University School of Medicine","address":{"name":"Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Drew M. Pardoll","affiliation":[{"name":"Johns Hopkins University School of Medicine","address":{"name":"The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, USA","@type":"PostalAddress"},"@type":"Organization"},{"name":"Johns Hopkins University School of Medicine","address":{"name":"The Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Rachel Karchin","url":"http://orcid.org/0000-0002-5069-1239","affiliation":[{"name":"Johns Hopkins University School of Medicine","address":{"name":"The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, USA","@type":"PostalAddress"},"@type":"Organization"},{"name":"Johns Hopkins University","address":{"name":"Institute for Computational Medicine, Johns Hopkins University, Baltimore, USA","@type":"PostalAddress"},"@type":"Organization"},{"name":"Johns Hopkins University","address":{"name":"Department of Biomedical Engineering, Johns Hopkins University, Baltimore, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Victor E. Velculescu","url":"http://orcid.org/0000-0003-1195-438X","affiliation":[{"name":"Johns Hopkins University School of Medicine","address":{"name":"The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, USA","@type":"PostalAddress"},"@type":"Organization"},{"name":"Johns Hopkins University School of Medicine","address":{"name":"The Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, USA","@type":"PostalAddress"},"@type":"Organization"},{"name":"Johns Hopkins University","address":{"name":"Department of Biomedical Engineering, Johns Hopkins University, Baltimore, USA","@type":"PostalAddress"},"@type":"Organization"},{"name":"Johns Hopkins University School of Medicine","address":{"name":"Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Julie R. Brahmer","affiliation":[{"name":"Johns Hopkins University School of Medicine","address":{"name":"The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, USA","@type":"PostalAddress"},"@type":"Organization"},{"name":"Johns Hopkins University School of Medicine","address":{"name":"The Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Suresh S. Ramalingam","url":"http://orcid.org/0000-0002-0757-3106","affiliation":[{"name":"Emory University School of Medicine, Winship Cancer Institute","address":{"name":"Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute, Atlanta, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"}],"isAccessibleForFree":true,"@type":"ScholarlyArticle"},"@context":"https://schema.org","@type":"WebPage"}</script>




    
    
    


    
    <link rel="canonical" href="https://www.nature.com/articles/s41591-021-01541-0">
    
    
    <meta name="journal_id" content="41591">
    <meta name="dc.title" content="Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial">
    <meta name="dc.source" content="Nature Medicine 2021 27:11">
    <meta name="dc.format" content="text/html">
    <meta name="dc.publisher" content="Nature Publishing Group">
    <meta name="dc.date" content="2021-11-08">
    <meta name="dc.type" content="OriginalPaper">
    <meta name="dc.language" content="En">
    <meta name="dc.copyright" content="2021 The Author(s)">
    <meta name="dc.rights" content="2021 The Author(s)">
    <meta name="dc.rightsAgent" content="journalpermissions@springernature.com">
    <meta name="dc.description" content="Mesothelioma is a rare and fatal cancer with limited therapeutic options until the recent approval of combination immune checkpoint blockade. Here we report the results of the phase 2 PrE0505 trial ( NCT02899195 ) of the anti-PD-L1 antibody durvalumab plus platinum-pemetrexed chemotherapy for 55 patients with previously untreated, unresectable pleural mesothelioma. The primary endpoint was overall survival compared to historical control with cisplatin and pemetrexed chemotherapy; secondary and exploratory endpoints included safety, progression-free survival and biomarkers of response. The combination of durvalumab with chemotherapy met the pre-specified primary endpoint, reaching a median survival of 20.4 months versus 12.1 months with historical control. Treatment-emergent adverse events were consistent with known side effects of chemotherapy, and all adverse events due to immunotherapy were grade 2 or lower. Integrated genomic and immune cell repertoire analyses revealed that a higher immunogenic mutation burden coupled with a more diverse T cell repertoire was linked to favorable clinical outcome. Structural genome-wide analyses showed a higher degree of genomic instability in responding tumors of epithelioid histology. Patients with germline alterations in cancer predisposing genes, especially those involved in DNA repair, were more likely to achieve long-term survival. Our findings indicate that concurrent durvalumab with platinum-based chemotherapy has promising clinical activity and that responses are driven by the complex genomic background of malignant pleural mesothelioma. In a phase 2 trial, the combination of chemotherapy with durvalumab, an anti-PD-L1 antibody, exhibited promising clinical activity in patients with previously untreated, unresectable mesothelioma, with additional analyses providing insights into genomic and immunologic features potentially associated with response.">
    <meta name="prism.issn" content="1546-170X">
    <meta name="prism.publicationName" content="Nature Medicine">
    <meta name="prism.publicationDate" content="2021-11-08">
    <meta name="prism.volume" content="27">
    <meta name="prism.number" content="11">
    <meta name="prism.section" content="OriginalPaper">
    <meta name="prism.startingPage" content="1910">
    <meta name="prism.endingPage" content="1920">
    <meta name="prism.copyright" content="2021 The Author(s)">
    <meta name="prism.rightsAgent" content="journalpermissions@springernature.com">
    <meta name="prism.url" content="https://www.nature.com/articles/s41591-021-01541-0">
    <meta name="prism.doi" content="doi:10.1038/s41591-021-01541-0">
    <meta name="citation_pdf_url" content="https://www.nature.com/articles/s41591-021-01541-0.pdf">
    <meta name="citation_fulltext_html_url" content="https://www.nature.com/articles/s41591-021-01541-0">
    <meta name="citation_journal_title" content="Nature Medicine">
    <meta name="citation_journal_abbrev" content="Nat Med">
    <meta name="citation_publisher" content="Nature Publishing Group">
    <meta name="citation_issn" content="1546-170X">
    <meta name="citation_title" content="Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial">
    <meta name="citation_volume" content="27">
    <meta name="citation_issue" content="11">
    <meta name="citation_publication_date" content="2021/11">
    <meta name="citation_online_date" content="2021/11/08">
    <meta name="citation_firstpage" content="1910">
    <meta name="citation_lastpage" content="1920">
    <meta name="citation_article_type" content="Article">
    <meta name="citation_fulltext_world_readable" content="">
    <meta name="citation_language" content="en">
    <meta name="dc.identifier" content="doi:10.1038/s41591-021-01541-0">
    <meta name="DOI" content="10.1038/s41591-021-01541-0">
    <meta name="size" content="275981">
    <meta name="citation_doi" content="10.1038/s41591-021-01541-0">
    <meta name="citation_springer_api_url" content="http://api.springer.com/xmldata/jats?q=doi:10.1038/s41591-021-01541-0&amp;api_key=">
    <meta name="description" content="Mesothelioma is a rare and fatal cancer with limited therapeutic options until the recent approval of combination immune checkpoint blockade. Here we report the results of the phase 2 PrE0505 trial ( NCT02899195 ) of the anti-PD-L1 antibody durvalumab plus platinum-pemetrexed chemotherapy for 55 patients with previously untreated, unresectable pleural mesothelioma. The primary endpoint was overall survival compared to historical control with cisplatin and pemetrexed chemotherapy; secondary and exploratory endpoints included safety, progression-free survival and biomarkers of response. The combination of durvalumab with chemotherapy met the pre-specified primary endpoint, reaching a median survival of 20.4 months versus 12.1 months with historical control. Treatment-emergent adverse events were consistent with known side effects of chemotherapy, and all adverse events due to immunotherapy were grade 2 or lower. Integrated genomic and immune cell repertoire analyses revealed that a higher immunogenic mutation burden coupled with a more diverse T cell repertoire was linked to favorable clinical outcome. Structural genome-wide analyses showed a higher degree of genomic instability in responding tumors of epithelioid histology. Patients with germline alterations in cancer predisposing genes, especially those involved in DNA repair, were more likely to achieve long-term survival. Our findings indicate that concurrent durvalumab with platinum-based chemotherapy has promising clinical activity and that responses are driven by the complex genomic background of malignant pleural mesothelioma. In a phase 2 trial, the combination of chemotherapy with durvalumab, an anti-PD-L1 antibody, exhibited promising clinical activity in patients with previously untreated, unresectable mesothelioma, with additional analyses providing insights into genomic and immunologic features potentially associated with response.">
    <meta name="dc.creator" content="Forde, Patrick M.">
    <meta name="dc.creator" content="Anagnostou, Valsamo">
    <meta name="dc.creator" content="Sun, Zhuoxin">
    <meta name="dc.creator" content="Dahlberg, Suzanne E.">
    <meta name="dc.creator" content="Kindler, Hedy L.">
    <meta name="dc.creator" content="Niknafs, Noushin">
    <meta name="dc.creator" content="Purcell, Thomas">
    <meta name="dc.creator" content="Santana-Davila, Rafael">
    <meta name="dc.creator" content="Dudek, Arkadiusz Z.">
    <meta name="dc.creator" content="Borghaei, Hossein">
    <meta name="dc.creator" content="Lanis, Mara">
    <meta name="dc.creator" content="Belcaid, Zineb">
    <meta name="dc.creator" content="Smith, Kellie N.">
    <meta name="dc.creator" content="Balan, Archana">
    <meta name="dc.creator" content="White, James R.">
    <meta name="dc.creator" content="Cherry, Christopher">
    <meta name="dc.creator" content="Ashok Sivakumar, I. K.">
    <meta name="dc.creator" content="Shao, Xiaoshan M.">
    <meta name="dc.creator" content="Chan, Hok Yee">
    <meta name="dc.creator" content="Singh, Dipika">
    <meta name="dc.creator" content="Thapa, Sampriti">
    <meta name="dc.creator" content="Illei, Peter B.">
    <meta name="dc.creator" content="Pardoll, Drew M.">
    <meta name="dc.creator" content="Karchin, Rachel">
    <meta name="dc.creator" content="Velculescu, Victor E.">
    <meta name="dc.creator" content="Brahmer, Julie R.">
    <meta name="dc.creator" content="Ramalingam, Suresh S.">
    <meta name="dc.subject" content="Cancer genomics">
    <meta name="dc.subject" content="Cancer immunotherapy">
    <meta name="dc.subject" content="Mesothelioma">
    <meta name="dc.subject" content="Phase II trials">
    <meta name="dc.subject" content="Tumour immunology">
    <meta name="citation_reference" content="citation_journal_title=Occup. Environ. Med.; citation_title=Estimation of the global burden of mesothelioma deaths from incomplete national mortality data; citation_author=CO Odgerel; citation_volume=74; citation_publication_date=2017; citation_pages=851-858; citation_doi=10.1136/oemed-2017-104298; citation_id=CR1">
    <meta name="citation_reference" content="citation_journal_title=Nat. Rev. Cancer; citation_title=Asbestos and its lethal legacy; citation_author=G Tweedale; citation_volume=2; citation_publication_date=2002; citation_pages=311-315; citation_doi=10.1038/nrc774; citation_id=CR2">
    <meta name="citation_reference" content="citation_journal_title=J. Clin. Oncol.; citation_title=Frequency of germline mutations in cancer susceptibility genes in malignant mesothelioma; citation_author=V Panou; citation_volume=36; citation_publication_date=2018; citation_pages=2863-2871; citation_doi=10.1200/JCO.2018.78.5204; citation_id=CR3">
    <meta name="citation_reference" content="citation_journal_title=Nat. Rev. Cancer; citation_title=Tumour predisposition and cancer syndromes as models to study gene–environment interactions; citation_author=M Carbone; citation_volume=20; citation_publication_date=2020; citation_pages=533-549; citation_doi=10.1038/s41568-020-0265-y; citation_id=CR4">
    <meta name="citation_reference" content="citation_journal_title=J. Clin. Oncol.; citation_title=Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma; citation_author=NJ Vogelzang; citation_volume=21; citation_publication_date=2003; citation_pages=2636-2644; citation_doi=10.1200/JCO.2003.11.136; citation_id=CR5">
    <meta name="citation_reference" content="citation_journal_title=Lung Cancer; citation_title=Randomized phase II trial of pemetrexed/cisplatin with or without CBP501 in patients with advanced malignant pleural mesothelioma; citation_author=LM Krug; citation_volume=85; citation_publication_date=2014; citation_pages=429-434; citation_doi=10.1016/j.lungcan.2014.06.008; citation_id=CR6">
    <meta name="citation_reference" content="citation_journal_title=Lancet Respir. Med.; citation_title=Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial; citation_author=GV Scagliotti; citation_volume=7; citation_publication_date=2019; citation_pages=569-580; citation_doi=10.1016/S2213-2600(19)30139-0; citation_id=CR7">
    <meta name="citation_reference" content="citation_journal_title=J. Clin. Oncol.; citation_title=Phase II trial of cediranib in combination with cisplatin and pemetrexed in chemotherapy-naive patients with unresectable malignant pleural mesothelioma (SWOG S0905); citation_author=AS Tsao; citation_volume=37; citation_publication_date=2019; citation_pages=2537-2547; citation_doi=10.1200/JCO.19.00269; citation_id=CR8">
    <meta name="citation_reference" content="citation_journal_title=Lancet; citation_title=Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial; citation_author=G Zalcman; citation_volume=387; citation_publication_date=2016; citation_pages=1405-1414; citation_doi=10.1016/S0140-6736(15)01238-6; citation_id=CR9">
    <meta name="citation_reference" content="citation_journal_title=Lancet Oncol.; citation_title=Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial; citation_author=EW Alley; citation_volume=18; citation_publication_date=2017; citation_pages=623-630; citation_doi=10.1016/S1470-2045(17)30169-9; citation_id=CR10">
    <meta name="citation_reference" content="citation_journal_title=J. Thorac. Oncol.; citation_title=Programmed death 1 blockade with nivolumab in patients with recurrent malignant pleural mesothelioma; citation_author=J Quispel-Janssen; citation_volume=13; citation_publication_date=2018; citation_pages=1569-1576; citation_doi=10.1016/j.jtho.2018.05.038; citation_id=CR11">
    <meta name="citation_reference" content="citation_journal_title=Clin. Cancer Res.; citation_title=Clinical efficacy and safety of nivolumab: results of a multicenter, open-label, single-arm, Japanese phase II study in malignant pleural mesothelioma (MERIT); citation_author=M Okada; citation_volume=25; citation_publication_date=2019; citation_pages=5485-5492; citation_doi=10.1158/1078-0432.CCR-19-0103; citation_id=CR12">
    <meta name="citation_reference" content="citation_journal_title=Trials; citation_title=CONFIRM: a double-blind, placebo-controlled phase III clinical trial investigating the effect of nivolumab in patients with relapsed mesothelioma: study protocol for a randomised controlled trial; citation_author=DA Fennell; citation_volume=19; citation_publication_date=2018; citation_doi=10.1186/s13063-018-2602-y; citation_id=CR13">
    <meta name="citation_reference" content="citation_journal_title=N. Engl. J. Med.; citation_title=Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer; citation_author=L Gandhi; citation_volume=378; citation_publication_date=2018; citation_pages=2078-2092; citation_doi=10.1056/NEJMoa1801005; citation_id=CR14">
    <meta name="citation_reference" content="citation_journal_title=Lancet Oncol.; citation_title=Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in; citation_author=AK Nowak; citation_volume=21; citation_publication_date=2020; citation_pages=1213-1223; citation_doi=10.1016/S1470-2045(20)30462-9; citation_id=CR15">
    <meta name="citation_reference" content="citation_journal_title=Lancet; citation_title=First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial; citation_author=P Baas; citation_volume=397; citation_publication_date=2021; citation_pages=375-386; citation_doi=10.1016/S0140-6736(20)32714-8; citation_id=CR16">
    <meta name="citation_reference" content="citation_journal_title=Cancer Discov.; citation_title=Integrative molecular characterization of malignant pleural mesothelioma; citation_author=J Hmeljak; citation_volume=8; citation_publication_date=2018; citation_pages=1548-1565; citation_doi=10.1158/2159-8290.CD-18-0804; citation_id=CR17">
    <meta name="citation_reference" content="citation_journal_title=Nat. Genet.; citation_title=Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations; citation_author=R Bueno; citation_volume=48; citation_publication_date=2016; citation_pages=407-416; citation_doi=10.1038/ng.3520; citation_id=CR18">
    <meta name="citation_reference" content="citation_journal_title=J. Thorac. Oncol.; citation_title=Neoantigenic potential of complex chromosomal rearrangements in mesothelioma; citation_author=AS Mansfield; citation_volume=14; citation_publication_date=2019; citation_pages=276-287; citation_doi=10.1016/j.jtho.2018.10.001; citation_id=CR19">
    <meta name="citation_reference" content="Panou, V. &amp; Roe, O. D. Inherited genetic mutations and polymorphisms in malignant mesothelioma: a comprehensive review. Int. J. Mol. Sci. 21, 4327 (2020).">
    <meta name="citation_reference" content="citation_journal_title=Nat. Genet.; citation_title=Germline BAP1 mutations predispose to malignant mesothelioma; citation_author=JR Testa; citation_volume=43; citation_publication_date=2011; citation_pages=1022-1025; citation_doi=10.1038/ng.912; citation_id=CR21">
    <meta name="citation_reference" content="Bononi, A. et al. Heterozygous germline BLM mutations increase susceptibility to asbestos and mesothelioma. Proc. Natl Acad. Sci. USA 117, 33466–33473 (2020).">
    <meta name="citation_reference" content="citation_journal_title=Am. J. Clin. Oncol.; citation_title=Toxicity and response criteria of the Eastern Cooperative Oncology Group; citation_author=MM Oken; citation_volume=5; citation_publication_date=1982; citation_pages=649-655; citation_doi=10.1097/00000421-198212000-00014; citation_id=CR23">
    <meta name="citation_reference" content="citation_journal_title=J. Thorac. Oncol.; citation_title=A practical guide of the Southwest Oncology Group to measure malignant pleural mesothelioma tumors by RECIST and modified RECIST criteria; citation_author=AS Tsao; citation_volume=6; citation_publication_date=2011; citation_pages=598-601; citation_doi=10.1097/JTO.0b013e318208c83d; citation_id=CR24">
    <meta name="citation_reference" content="citation_journal_title=Nat. Med.; citation_title=Evolutionary divergence of HLA class I genotype impacts efficacy of cancer immunotherapy; citation_author=D Chowell; citation_volume=25; citation_publication_date=2019; citation_pages=1715-1720; citation_doi=10.1038/s41591-019-0639-4; citation_id=CR25">
    <meta name="citation_reference" content="citation_journal_title=Oncogene; citation_title=Minimal asbestos exposure in germline BAP1 heterozygous mice is associated with deregulated inflammatory response and increased risk of mesothelioma; citation_author=A Napolitano; citation_volume=35; citation_publication_date=2016; citation_pages=1996-2002; citation_doi=10.1038/onc.2015.243; citation_id=CR26">
    <meta name="citation_reference" content="citation_journal_title=Cancer Discov.; citation_title=An empirical approach leveraging tumorgrafts to dissect the tumor microenvironment in renal cell carcinoma identifies missing link to prognostic inflammatory factors; citation_author=T Wang; citation_volume=8; citation_publication_date=2018; citation_pages=1142-1155; citation_doi=10.1158/2159-8290.CD-17-1246; citation_id=CR27">
    <meta name="citation_reference" content="citation_journal_title=Proc. Natl Acad. Sci. USA; citation_title=Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy; citation_author=R Hassan; citation_volume=116; citation_publication_date=2019; citation_pages=9008-9013; citation_doi=10.1073/pnas.1821510116; citation_id=CR28">
    <meta name="citation_reference" content="citation_journal_title=Nat. Genet.; citation_title=The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma; citation_author=M Bott; citation_volume=43; citation_publication_date=2011; citation_pages=668-672; citation_doi=10.1038/ng.855; citation_id=CR29">
    <meta name="citation_reference" content="citation_journal_title=Nat. Rev. Clin. Oncol.; citation_title=Immunotherapy discontinuation—how, and when? Data from melanoma as a paradigm; citation_author=C Robert; citation_volume=17; citation_publication_date=2020; citation_pages=707-715; citation_doi=10.1038/s41571-020-0399-6; citation_id=CR30">
    <meta name="citation_reference" content="citation_journal_title=Cell; citation_title=Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition; citation_author=K Litchfield; citation_volume=184; citation_publication_date=2021; citation_pages=596-614; citation_doi=10.1016/j.cell.2021.01.002; citation_id=CR31">
    <meta name="citation_reference" content="citation_journal_title=Ann. Oncol.; citation_title=Perspective: APOBEC mutagenesis in drug resistance and immune escape in HIV and cancer evolution; citation_author=S Venkatesan; citation_volume=29; citation_publication_date=2018; citation_pages=563-572; citation_doi=10.1093/annonc/mdy003; citation_id=CR32">
    <meta name="citation_reference" content="citation_journal_title=Nature; citation_title=Neoantigen-directed immune escape in lung cancer evolution; citation_author=R Rosenthal; citation_volume=567; citation_publication_date=2019; citation_pages=479-485; citation_doi=10.1038/s41586-019-1032-7; citation_id=CR33">
    <meta name="citation_reference" content="citation_journal_title=Proc. Natl Acad. Sci. USA; citation_title=High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas; citation_author=AB Bianchi; citation_volume=92; citation_publication_date=1995; citation_pages=10854-10858; citation_doi=10.1073/pnas.92.24.10854; citation_id=CR34">
    <meta name="citation_reference" content="citation_journal_title=Nat. Commun.; citation_title=Clonal architecture in mesothelioma is prognostic and shapes the tumour microenvironment; citation_author=M Zhang; citation_volume=12; citation_publication_date=2021; citation_doi=10.1038/s41467-021-21798-w; citation_id=CR35">
    <meta name="citation_reference" content="citation_journal_title=Science; citation_title=A major chromatin regulator determines resistance of tumor cells to T cell-mediated killing; citation_author=D Pan; citation_volume=359; citation_publication_date=2018; citation_pages=770-775; citation_doi=10.1126/science.aao1710; citation_id=CR36">
    <meta name="citation_reference" content="citation_journal_title=Nat. Med.; citation_title=ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade; citation_author=J Shen; citation_volume=24; citation_publication_date=2018; citation_pages=556-562; citation_doi=10.1038/s41591-018-0012-z; citation_id=CR37">
    <meta name="citation_reference" content="citation_journal_title=J. Thorac. Oncol.; citation_title=High incidence of somatic BAP1 alterations in sporadic malignant mesothelioma; citation_author=M Nasu; citation_volume=10; citation_publication_date=2015; citation_pages=565-576; citation_doi=10.1097/JTO.0000000000000471; citation_id=CR38">
    <meta name="citation_reference" content="citation_journal_title=Carcinogenesis; citation_title=Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival; citation_author=F Baumann; citation_volume=36; citation_publication_date=2015; citation_pages=76-81; citation_doi=10.1093/carcin/bgu227; citation_id=CR39">
    <meta name="citation_reference" content="citation_journal_title=Cancer Discov.; citation_title=Biological mechanisms and clinical significance of BAP1 mutations in human cancer; citation_author=M Carbone; citation_volume=10; citation_publication_date=2020; citation_pages=1103-1120; citation_doi=10.1158/2159-8290.CD-19-1220; citation_id=CR40">
    <meta name="citation_reference" content="citation_journal_title=Nat. Cancer; citation_title=Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy; citation_author=RM Samstein; citation_volume=1; citation_publication_date=2021; citation_pages=1188-1203; citation_doi=10.1038/s43018-020-00139-8; citation_id=CR41">
    <meta name="citation_reference" content="citation_journal_title=Nature; citation_title=STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling; citation_author=H Ishikawa, GN Barber; citation_volume=455; citation_publication_date=2008; citation_pages=674-678; citation_doi=10.1038/nature07317; citation_id=CR42">
    <meta name="citation_reference" content="citation_journal_title=Cancer Discov.; citation_title=Evolution of neoantigen landscape during immune checkpoint blockade in non-small cell lung cancer; citation_author=V Anagnostou; citation_volume=7; citation_publication_date=2017; citation_pages=264-276; citation_doi=10.1158/2159-8290.CD-16-0828; citation_id=CR43">
    <meta name="citation_reference" content="Anagnostou, V. et al. Integrative tumor and immune cell mutli-omic analyses to predict melanoma response to immune checkpoint blockade. Cell Rep. Med. 1, 100139 (2020).">
    <meta name="citation_reference" content="citation_journal_title=Nat. Med.; citation_title=Understanding the tumor immune microenvironment (TIME) for effective therapy; citation_author=M Binnewies; citation_volume=24; citation_publication_date=2018; citation_pages=541-550; citation_doi=10.1038/s41591-018-0014-x; citation_id=CR45">
    <meta name="citation_reference" content="citation_journal_title=Nat. Med.; citation_title=Spatial heterogeneity of the T cell receptor repertoire reflects the mutational landscape in lung cancer; citation_author=K Joshi; citation_volume=25; citation_publication_date=2019; citation_pages=1549-1559; citation_doi=10.1038/s41591-019-0592-2; citation_id=CR46">
    <meta name="citation_reference" content="citation_journal_title=Immunity; citation_title=The immune landscape of cancer; citation_author=V Thorsson; citation_volume=48; citation_publication_date=2018; citation_pages=812-830; citation_doi=10.1016/j.immuni.2018.03.023; citation_id=CR47">
    <meta name="citation_reference" content="citation_journal_title=Cell Syst.; citation_title=Scalable open science approach for mutation calling of tumor exomes using multiple genomic pipelines; citation_author=K Ellrott; citation_volume=6; citation_publication_date=2018; citation_pages=271-281; citation_doi=10.1016/j.cels.2018.03.002; citation_id=CR48">
    <meta name="citation_reference" content="citation_journal_title=Sci. Transl. Med.; citation_title=Personalized genomic analyses for cancer mutation discovery and interpretation; citation_author=S Jones; citation_volume=7; citation_publication_date=2015; citation_pages=283ra253; citation_doi=10.1126/scitranslmed.aaa7161; citation_id=CR49">
    <meta name="citation_reference" content="citation_journal_title=Nat. Cancer; citation_title=Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer; citation_author=V Anagnostou; citation_volume=1; citation_publication_date=2020; citation_pages=99-111; citation_doi=10.1038/s43018-019-0008-8; citation_id=CR50">
    <meta name="citation_reference" content="citation_journal_title=Cancer Immunol. Res.; citation_title=High-throughput prediction of MHC class I and II neoantigens with MHCnuggets; citation_author=XM Shao; citation_volume=8; citation_publication_date=2020; citation_pages=396-408; citation_doi=10.1158/2326-6066.CIR-19-0464; citation_id=CR51">
    <meta name="citation_reference" content="citation_journal_title=Nat. Methods; citation_title=Strelka2: fast and accurate calling of germline and somatic variants; citation_author=S Kim; citation_volume=15; citation_publication_date=2018; citation_pages=591-594; citation_doi=10.1038/s41592-018-0051-x; citation_id=CR52">
    <meta name="citation_reference" content="citation_journal_title=JCO Clin. Cancer Inform.; citation_title=Integrated informatics analysis of cancer-related variants; citation_author=KA Pagel; citation_volume=4; citation_publication_date=2020; citation_pages=310-317; citation_doi=10.1200/CCI.19.00132; citation_id=CR53">
    <meta name="citation_reference" content="citation_journal_title=Nature; citation_title=Signatures of mutational processes in human cancer; citation_author=LB Alexandrov; citation_volume=500; citation_publication_date=2013; citation_pages=415-421; citation_doi=10.1038/nature12477; citation_id=CR54">
    <meta name="citation_reference" content="citation_journal_title=Bioinformatics; citation_title=OptiType: precision HLA typing from next-generation sequencing data; citation_author=A Szolek; citation_volume=30; citation_publication_date=2014; citation_pages=3310-3316; citation_doi=10.1093/bioinformatics/btu548; citation_id=CR55">
    <meta name="citation_reference" content="citation_journal_title=Proc. Natl Acad. Sci. USA; citation_title=Fast and accurate HLA typing from short-read next-generation sequence data with xHLA; citation_author=C Xie; citation_volume=114; citation_publication_date=2017; citation_pages=8059-8064; citation_doi=10.1073/pnas.1707945114; citation_id=CR56">
    <meta name="citation_reference" content="citation_journal_title=PLoS ONE; citation_title=An integrated tool to study MHC region: accurate SNV detection and HLA genes typing in human MHC region using targeted high-throughput sequencing; citation_author=H Cao; citation_volume=8; citation_publication_date=2013; citation_pages=e69388; citation_doi=10.1371/journal.pone.0069388; citation_id=CR57">
    <meta name="citation_reference" content="citation_journal_title=Nat. Biotechnol.; citation_title=Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes; citation_author=SA Shukla; citation_volume=33; citation_publication_date=2015; citation_pages=1152-1158; citation_doi=10.1038/nbt.3344; citation_id=CR58">
    <meta name="citation_reference" content="citation_journal_title=Cell; citation_title=Allele-specific HLA loss and immune escape in lung cancer evolution; citation_author=N McGranahan; citation_volume=171; citation_publication_date=2017; citation_pages=1259-1271; citation_doi=10.1016/j.cell.2017.10.001; citation_id=CR59">
    <meta name="citation_reference" content="citation_journal_title=Nucleic Acids Res.; citation_title=The IPD and IMGT/HLA database: allele variant databases; citation_author=J Robinson; citation_volume=43; citation_publication_date=2015; citation_pages=D423-D431; citation_doi=10.1093/nar/gku1161; citation_id=CR60">
    <meta name="citation_reference" content="citation_journal_title=Nucleic Acids Res.; citation_title=FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing; citation_author=R Shen, VE Seshan; citation_volume=44; citation_publication_date=2016; citation_pages=e131; citation_doi=10.1093/nar/gkw520; citation_id=CR61">
    <meta name="citation_reference" content="citation_journal_title=PLoS Comput. Biol.; citation_title=SubClonal hierarchy inference from somatic mutations: automatic reconstruction of cancer evolutionary trees from multi-region next generation sequencing; citation_author=N Niknafs, V Beleva-Guthrie, DQ Naiman, R Karchin; citation_volume=11; citation_publication_date=2015; citation_pages=e1004416; citation_doi=10.1371/journal.pcbi.1004416; citation_id=CR62">
    <meta name="citation_reference" content="citation_journal_title=NPJ Breast Cancer; citation_title=Migrating the SNP array-based homologous recombination deficiency measures to next generation sequencing data of breast cancer; citation_author=Z Sztupinszki; citation_volume=4; citation_publication_date=2018; citation_doi=10.1038/s41523-018-0066-6; citation_id=CR63">
    <meta name="citation_reference" content="citation_journal_title=Nat. Commun.; citation_title=Using synthetic templates to design an unbiased multiplex PCR assay; citation_author=CS Carlson; citation_volume=4; citation_publication_date=2013; citation_doi=10.1038/ncomms3680; citation_id=CR64">
    <meta name="citation_reference" content="citation_journal_title=Curr. Protoc. Bioinformatics; citation_title=Mapping RNA-seq reads with STAR; citation_author=A Dobin, TR Gingeras; citation_volume=51; citation_publication_date=2015; citation_pages=11 14 11-11 14 19; citation_id=CR65">
    <meta name="citation_reference" content="citation_journal_title=BMC Bioinformatics; citation_title=RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome; citation_author=B Li, CN Dewey; citation_volume=12; citation_publication_date=2011; citation_pages=323; citation_id=CR66">
    <meta name="citation_reference" content="citation_journal_title=Genome Biol.; citation_title=Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2; citation_author=MI Love, W Huber, S Anders; citation_volume=15; citation_publication_date=2014; citation_doi=10.1186/s13059-014-0550-8; citation_id=CR67">
    <meta name="citation_reference" content="citation_journal_title=Cancer Immunol. Res.; citation_title=The mutation-associated neoantigen functional expansion of specific T cells (MANAFEST) assay: a sensitive platform for monitoring antitumor immunity; citation_author=L Danilova; citation_volume=6; citation_publication_date=2018; citation_pages=888-899; citation_doi=10.1158/2326-6066.CIR-18-0129; citation_id=CR68">
    <meta name="citation_reference" content="citation_journal_title=Methods Enzymol.; citation_title=Analysis of TCR β CDR3 sequencing data for tracking anti-tumor immunity; citation_author=J Zhang, Z Ji, KN Smith; citation_volume=629; citation_publication_date=2019; citation_pages=443-464; citation_doi=10.1016/bs.mie.2019.08.006; citation_id=CR69">
    <meta name="citation_author" content="Forde, Patrick M.">
    <meta name="citation_author_institution" content="The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, USA">
    <meta name="citation_author_institution" content="The Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, USA">
    <meta name="citation_author" content="Anagnostou, Valsamo">
    <meta name="citation_author_institution" content="The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, USA">
    <meta name="citation_author_institution" content="The Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, USA">
    <meta name="citation_author" content="Sun, Zhuoxin">
    <meta name="citation_author_institution" content="ECOG-ACRIN Biostatistics Center, Boston, USA">
    <meta name="citation_author_institution" content="Frontier Science Foundation, Boston, USA">
    <meta name="citation_author" content="Dahlberg, Suzanne E.">
    <meta name="citation_author_institution" content="Boston Children’s Hospital, Boston, USA">
    <meta name="citation_author" content="Kindler, Hedy L.">
    <meta name="citation_author_institution" content="University of Chicago Medicine, Chicago, USA">
    <meta name="citation_author" content="Niknafs, Noushin">
    <meta name="citation_author_institution" content="The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, USA">
    <meta name="citation_author" content="Purcell, Thomas">
    <meta name="citation_author_institution" content="University of Washington School of Medicine &amp; Fred Hutchinson Cancer Research Center, Seattle, USA">
    <meta name="citation_author" content="Santana-Davila, Rafael">
    <meta name="citation_author_institution" content="University of Washington School of Medicine &amp; Fred Hutchinson Cancer Research Center, Seattle, USA">
    <meta name="citation_author" content="Dudek, Arkadiusz Z.">
    <meta name="citation_author_institution" content="Metro-Minnesota Community Oncology Research Consortium, St. Louis Park, USA">
    <meta name="citation_author" content="Borghaei, Hossein">
    <meta name="citation_author_institution" content="Fox Chase Cancer Center, Philadelphia, USA">
    <meta name="citation_author" content="Lanis, Mara">
    <meta name="citation_author_institution" content="The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, USA">
    <meta name="citation_author" content="Belcaid, Zineb">
    <meta name="citation_author_institution" content="The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, USA">
    <meta name="citation_author" content="Smith, Kellie N.">
    <meta name="citation_author_institution" content="The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, USA">
    <meta name="citation_author_institution" content="The Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, USA">
    <meta name="citation_author" content="Balan, Archana">
    <meta name="citation_author_institution" content="The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, USA">
    <meta name="citation_author" content="White, James R.">
    <meta name="citation_author_institution" content="The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, USA">
    <meta name="citation_author" content="Cherry, Christopher">
    <meta name="citation_author_institution" content="The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, USA">
    <meta name="citation_author" content="Ashok Sivakumar, I. K.">
    <meta name="citation_author_institution" content="Institute for Computational Medicine, Johns Hopkins University, Baltimore, USA">
    <meta name="citation_author" content="Shao, Xiaoshan M.">
    <meta name="citation_author_institution" content="Institute for Computational Medicine, Johns Hopkins University, Baltimore, USA">
    <meta name="citation_author_institution" content="Department of Biomedical Engineering, Johns Hopkins University, Baltimore, USA">
    <meta name="citation_author" content="Chan, Hok Yee">
    <meta name="citation_author_institution" content="The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, USA">
    <meta name="citation_author_institution" content="The Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, USA">
    <meta name="citation_author" content="Singh, Dipika">
    <meta name="citation_author_institution" content="The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, USA">
    <meta name="citation_author_institution" content="The Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, USA">
    <meta name="citation_author" content="Thapa, Sampriti">
    <meta name="citation_author_institution" content="The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, USA">
    <meta name="citation_author_institution" content="The Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, USA">
    <meta name="citation_author" content="Illei, Peter B.">
    <meta name="citation_author_institution" content="The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, USA">
    <meta name="citation_author_institution" content="Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, USA">
    <meta name="citation_author" content="Pardoll, Drew M.">
    <meta name="citation_author_institution" content="The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, USA">
    <meta name="citation_author_institution" content="The Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, USA">
    <meta name="citation_author" content="Karchin, Rachel">
    <meta name="citation_author_institution" content="The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, USA">
    <meta name="citation_author_institution" content="Institute for Computational Medicine, Johns Hopkins University, Baltimore, USA">
    <meta name="citation_author_institution" content="Department of Biomedical Engineering, Johns Hopkins University, Baltimore, USA">
    <meta name="citation_author" content="Velculescu, Victor E.">
    <meta name="citation_author_institution" content="The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, USA">
    <meta name="citation_author_institution" content="The Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, USA">
    <meta name="citation_author_institution" content="Department of Biomedical Engineering, Johns Hopkins University, Baltimore, USA">
    <meta name="citation_author_institution" content="Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, USA">
    <meta name="citation_author" content="Brahmer, Julie R.">
    <meta name="citation_author_institution" content="The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, USA">
    <meta name="citation_author_institution" content="The Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, USA">
    <meta name="citation_author" content="Ramalingam, Suresh S.">
    <meta name="citation_author_institution" content="Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute, Atlanta, USA">
    <meta name="access_endpoint" content="https://www.nature.com/platform/readcube-access">
    <meta name="twitter:site" content="@naturemedicine">
    <meta name="twitter:card" content="summary_large_image">
    <meta name="twitter:image:alt" content="Content cover image">
    <meta name="twitter:title" content="Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial">
    <meta name="twitter:description" content="Nature Medicine - In a phase 2 trial, the combination of chemotherapy with durvalumab, an anti-PD-L1 antibody, exhibited promising clinical activity in patients with previously untreated,...">
    <meta name="twitter:image" content="https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41591-021-01541-0/MediaObjects/41591_2021_1541_Fig1_HTML.png">
    

    
    
    <meta property="og:url" content="https://www.nature.com/articles/s41591-021-01541-0">
    <meta property="og:type" content="article">
    <meta property="og:site_name" content="Nature">
    <meta property="og:title" content="Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial - Nature Medicine">
    <meta property="og:description" content="In a phase 2 trial, the combination of chemotherapy with durvalumab, an anti-PD-L1 antibody, exhibited promising clinical activity in patients with previously untreated, unresectable mesothelioma, with additional analyses providing insights into genomic and immunologic features potentially associated with response.">
    <meta property="og:image" content="https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41591-021-01541-0/MediaObjects/41591_2021_1541_Fig1_HTML.png">
    

    <script>
        window.eligibleForRa21 = 'false'; 
    </script>
<style type="text/css">.cc-banner{background-color:#01324b;border:none!important;bottom:0;box-sizing:border-box;color:#fff!important;left:0;line-height:1.3;margin:auto 0 0;max-width:100%;outline:0;overflow:visible;padding:0;position:fixed;right:0;width:100%;z-index:99999}.cc-banner::backdrop{background-color:#0000004d}.cc-banner *{color:inherit!important}.cc-banner:focus{box-shadow:none;outline:0}.cc-banner a{color:#fff!important;text-decoration:underline}.cc-banner a:active,.cc-banner a:focus,.cc-banner a:hover{color:inherit;text-decoration:none}.cc-banner a:focus{outline:3px solid #08c!important}.cc-banner h2,.cc-banner h3,.cc-banner h4,.cc-banner h5,.cc-banner h6{font-family:sans-serif;font-style:normal;font-weight:700;margin:0 0 .5em}.cc-banner .cc-h2,.cc-banner h2{font-size:18px}.cc-banner .cc-h3,.cc-banner h3{font-size:16px}.cc-banner .cc-h4,.cc-banner .cc-h5,.cc-banner .cc-h6,.cc-banner h4,.cc-banner h5,.cc-banner h6{font-size:14px}.cc-banner .cc-button{font-size:16px}.cc-banner__content{background-color:#01324b;display:flex;flex-direction:column;margin:0 auto;max-height:90vh;max-width:100%;padding:16px;position:relative}.cc-banner__content:focus{outline:0}@media (min-width:680px){.cc-banner__content{padding:12px}}@media (min-width:980px){.cc-banner__content{max-height:60vh;padding-bottom:20px;padding-top:20px}}@media (min-width:1320px){.cc-banner__content{padding-bottom:40px;padding-top:40px}}.cc-banner__container{display:flex;flex-direction:column;margin:auto;max-width:1320px;overflow:auto}.cc-banner__title{background:none!important;border:0;flex-shrink:0;font-size:18px!important;font-size:22px!important;font-weight:700!important;letter-spacing:normal;margin:0 0 12px!important;padding:0}@media (min-width:680px){.cc-banner__title{font-size:24px!important;margin:0 0 16px!important}}@media (min-width:1320px){.cc-banner__title{font-size:26px!important;margin:0 0 24px!important}}.cc-banner__body{display:flex;flex-direction:column;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif!important;overflow-x:hidden;overflow-y:auto;padding:3px 3px 16px}@media (min-width:980px){.cc-banner__body{flex-direction:row}}.cc-banner__policy p{font-size:16px!important;margin:0;max-width:none;padding:0}.cc-banner__policy p:not(:last-child){margin:0 0 16px}@media (min-width:980px){.cc-banner__policy p:not(:last-child){margin:0 0 24px}}.cc-banner__policy p a{font-size:16px!important;font-weight:700}.cc-banner__footer{box-shadow:none;flex-shrink:0;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif !important!important;margin:0;padding:12px 0 3px 3px;position:relative}@media (min-width:380px){.cc-banner__footer{align-items:stretch;display:flex;flex-wrap:wrap}}@media (min-width:680px){.cc-banner__footer{box-shadow:none;flex-wrap:nowrap;width:40%}}.cc-banner__footer .cc-banner__button{flex:1 1 auto;font-weight:700;overflow:hidden;padding:.5em 1em;width:100%}@media (min-width:680px){.cc-banner__footer .cc-banner__button{max-width:275px}}.cc-banner__footer .cc-banner__button:not(:last-child){margin-bottom:12px}@media (min-width:680px){.cc-banner__footer .cc-banner__button:not(:last-child){margin-bottom:0;margin-right:16px}}@media (min-width:980px){.cc-banner__footer .cc-banner__button:not(:last-child){margin-right:24px}}@media (min-width:680px){html[dir=rtl] .cc-banner__footer .cc-banner__button:not(:last-child){margin-left:16px!important;margin-right:0!important}}@media (min-width:980px){html[dir=rtl] .cc-banner__footer .cc-banner__button:not(:last-child){margin-left:24px!important;margin-right:0!important}}.cc-banner__button-preferences{padding-left:0;padding-right:0}@media (min-width:380px){.cc-banner__button-preferences{flex:0 0 auto;margin:auto}}@media (min-width:680px){.cc-banner__button-preferences{margin:0}}@media (min-width:380px) and (max-width:680px){.cc-banner__button-break{display:block}}@media (min-width:680px){.cc-banner--is-tcf .cc-banner__footer{width:auto}}@media (min-width:980px){.cc-banner--is-tcf .cc-banner__footer{padding-right:48px;width:66%}}.cc-banner--is-tcf .cc-banner__stacks-intro{font-size:16px!important}.cc-banner--is-tcf .cc-banner__stacks{margin:16px 0 0}@media (min-width:980px){.cc-banner--is-tcf .cc-banner__stacks{display:flex;flex:0 0 33%;flex-direction:column;margin:0 0 0 48px;overflow:auto}}.cc-banner--is-tcf .cc-banner__stacks-intro{font-size:16px;margin:0 0 12px}.cc-banner--is-tcf .cc-banner__stacks-details{padding:0 3px}.cc-banner--is-tcf .cc-banner .cc-details{border-color:#fff3!important}.cc-box{border-radius:10px;padding:12px}.cc-box--info{background-color:#eff6fb}.cc-box--light{background-color:#faf9f6}.cc-button{border:2px solid #0000;border-radius:32px!important;color:inherit;cursor:pointer;font-size:14px;font-weight:700!important;left:auto;line-height:1.2;margin:0;padding:.5em 1em;right:auto;text-transform:none!important;transition:all .2s}@media (min-width:680px){.cc-button{font-size:14px;padding:.75em 1em}}.cc-button--sm{font-size:12px;padding:2px 8px!important}.cc-button--primary{background-color:#025e8d!important;border-color:#025e8d!important;color:#fff!important}.cc-button--primary:focus{outline:3px solid #08c}.cc-button--primary:focus,.cc-button--primary:hover,.cc-button--secondary{background-color:#fff!important;border-color:#025e8d!important;color:#025e8d!important}.cc-button--secondary:focus{background-color:#025e8d!important;border-color:#fff!important;color:#fff!important;outline:3px solid #08c!important}.cc-button--secondary:hover{background-color:#025e8d!important;border-color:#025e8d!important;color:#fff!important}.cc-button--secondary:active{border:2px solid #01324b!important}.cc-button--secondary.cc-button--contrast{border-color:#fff!important}.cc-button--secondary.cc-button--contrast:hover{background-color:initial!important;color:#fff!important}.cc-button--tertiary{background-color:#f0f7fc!important;background-image:none;border:2px solid #f0f7fc;color:#025e8d!important;text-decoration:underline!important;text-underline-offset:.25em}.cc-button--tertiary:focus{outline:3px solid #08c!important}.cc-button--tertiary:hover{text-decoration-thickness:.25em}.cc-button--tertiary:active{color:#013c5b}.cc-button--link{background-color:initial!important;border-color:#0000!important;border-radius:0!important;color:inherit!important;padding:0!important;text-decoration:underline!important;width:inherit!important}.cc-button--link:focus{outline:3px solid #08c}.cc-button--link:hover{background-color:initial!important;box-shadow:none;text-decoration:none}.cc-button--text{border-radius:0;padding:0}.cc-button--details{padding-right:24px!important;position:relative;width:auto}.cc-button--details:after,.cc-button--details:before{background-color:currentColor;content:"";position:absolute;transition:transform .25s ease-out}.cc-button--details:before{height:10px;margin-top:-5px;right:12px;top:50%;width:2px}.cc-button--details:after{height:2px;margin-top:-1px;right:8px;top:50%;width:10px}.cc-button--details.cc-active:before{transform:rotate(90deg);transform-origin:center}.cc-button--details.cc-active:after{display:none}.cc-details{border-bottom:1px solid #0000001a;padding:12px 0;position:relative;width:100%}.cc-details__summary{align-items:center;display:flex;font-size:14px;font-weight:700;list-style-type:none}.cc-details__summary:focus,.cc-details__summary:focus-visible{outline:3px solid #08c!important;will-change:auto}.cc-details__title{align-items:baseline;display:flex}.cc-details__title h2,.cc-details__title h3,.cc-details__title h4,.cc-details__title h5{line-height:1.4;margin:0!important;padding:0!important}.cc-details__title svg{flex-shrink:0;height:auto;margin-right:8px;position:relative;top:-1px;transition:all .2s;width:auto}.cc-details[open] .cc-details__title svg{top:2px;transform:rotate(90deg)}.cc-details__switch{margin-left:auto}.cc-details__section{padding:16px 0 0 18px}.cc-details__section p{margin:0}.cc-details__section p:not(:last-child){margin-bottom:12px}details summary::-webkit-details-marker{display:none}.cc-radio{align-items:center;display:flex;position:relative}.cc-radio *{cursor:pointer}.cc-radio__input{height:22px;left:0;position:absolute;top:0;width:22px}.cc-radio__input:focus{outline:none}.cc-radio__label{color:inherit;font-size:14px;font-weight:700;line-height:23px;margin:0;padding-left:28px}.cc-radio__label:after,.cc-radio__label:before{background-color:#fff;content:"";display:block;position:absolute;transition:transform .25s ease-out}.cc-radio__label:before{border:1px solid #777;border-radius:50%;height:22px;left:0;top:0;width:22px}.cc-radio__label:after{border:7px solid #025e8d;border-radius:50%;height:0;left:4px;opacity:0;top:4px;width:0}.cc-radio__input:focus+.cc-radio__label:before{box-shadow:0 0 0 2px #08c;outline:none}.cc-radio__label--hidden{display:none}.cc-radio__input:checked+.cc-radio__label:after{opacity:1}.cc-radio__input:disabled{cursor:default}.cc-radio__input:disabled+.cc-radio__label{cursor:default;opacity:.5}.cc-switch *{cursor:pointer}.cc-switch{align-items:center;display:flex;line-height:1}.cc-switch__label{cursor:pointer;display:inline-block;font-size:14px;font-weight:700;margin:0;-webkit-user-select:none;user-select:none}.cc-switch__input[type=checkbox]{-webkit-appearance:none;appearance:none;background-color:#fff!important;background-image:url("data:image/svg+xml;charset=utf-8,%3Csvg xmlns='http://www.w3.org/2000/svg' viewBox='-4 -4 8 8'%3E%3Ccircle r='3' fill='rgba(0, 0, 0, 0.25)'/%3E%3C/svg%3E")!important;background-position:0!important;background-repeat:no-repeat!important;border:1px solid #777!important;border-radius:16px!important;height:18px!important;margin:0 8px 0 0!important;transition:background-position .2s ease-in-out!important;width:32px!important}.cc-switch__input[type=checkbox]:focus{background-image:url("data:image/svg+xml;charset=utf-8,%3Csvg xmlns='http://www.w3.org/2000/svg' viewBox='-4 -4 8 8'%3E%3Ccircle r='3' fill='%2380b3cc'/%3E%3C/svg%3E")!important}.cc-switch__input[type=checkbox]:checked{background-color:#025e8d!important;background-image:url("data:image/svg+xml;charset=utf-8,%3Csvg xmlns='http://www.w3.org/2000/svg' viewBox='-4 -4 8 8'%3E%3Ccircle r='3' fill='%23fff'/%3E%3C/svg%3E")!important;background-position:100%!important}.cc-switch__input[type=checkbox]:checked~.cc-switch__label>.cc-switch__text-off,.cc-switch__input[type=checkbox]:not(:checked)~.cc-switch__label>.cc-switch__text-on{display:none}.cc-switch__input[type=checkbox]:hover{cursor:pointer;outline:none}.cc-switch__input[type=checkbox]:focus-visible{cursor:pointer;outline:3px solid #fc0}.cc-switch__input[type=checkbox]:checked:before{background-color:none!important;color:#0000!important}html[dir=rtl] .cc-switch__input[type=checkbox]{margin-left:8px!important;margin-right:0!important}.cc-list>ul,ul.cc-list{list-style-type:disc;margin-left:0;padding-left:0}.cc-list>ul>li,ul.cc-list>li{margin-left:1em}.cc-list>ul>li:not(:last-child),ul.cc-list>li:not(:last-child){margin-bottom:4px}.cc-list__title{margin-bottom:8px!important}.cc-list--inline>ul,ul.cc-list--inline{display:flex;flex-wrap:wrap;list-style-type:none}.cc-list--inline>ul>li,ul.cc-list--inline>li{margin:0 .5em .5em 0}.cc-overlay{background-color:#0000004d;z-index:99998}.cc-overlay,.cc-preferences{bottom:0;left:0;position:fixed;right:0;top:0}.cc-preferences{background-color:#050a14f2!important;border:0;box-sizing:border-box;color:#111;font-family:sans-serif!important;line-height:1.4;margin:auto;max-height:100vh;overflow:auto;padding:0;z-index:100000}.cc-preferences:focus{outline:none}.cc-preferences *,.cc-preferences :after,.cc-preferences :before{box-sizing:inherit!important}.cc-preferences h2,.cc-preferences h3,.cc-preferences h4,.cc-preferences h5,.cc-preferences h6{font-family:sans-serif;font-style:normal;font-weight:700;margin:0 0 .5em}.cc-preferences .cc-h2,.cc-preferences h2{font-size:18px}.cc-preferences .cc-h3,.cc-preferences h3{font-size:16px}.cc-preferences .cc-h4,.cc-preferences .cc-h5,.cc-preferences .cc-h6,.cc-preferences h4,.cc-preferences h5,.cc-preferences h6{font-size:14px}.cc-preferences a{color:#025e8d;text-decoration:underline}.cc-preferences a:hover{color:inherit;text-decoration:none}.cc-preferences h3{background:none;color:#111;padding:0;text-transform:none}dialog.cc-preferences{background-color:initial}dialog.cc-preferences::backdrop{background-color:#000000e6}.cc-preferences__dialog{display:flex;flex-direction:column;margin:auto;max-height:100vh;max-width:860px;padding:12px;position:relative}.cc-preferences__dialog>:last-child{border-bottom-left-radius:10px;border-bottom-right-radius:10px}@media (min-width:980px){.cc-preferences__dialog{padding:16px}}.cc-preferences__close{background:#0000!important;border:1px solid #ececec;border-radius:50%;color:#111!important;cursor:pointer;font-family:Times New Roman,serif;font-size:40px;height:40px;left:auto;line-height:1;margin-top:-20px;padding:0!important;position:absolute;right:20px;top:50%;width:40px}.cc-preferences__close:focus{outline:3px solid #08c}.cc-preferences__close-label{border:0;clip:rect(0,0,0,0);height:1px;margin:-100%;overflow:hidden;padding:0;position:absolute!important;width:1px}.cc-preferences__header{background:#fff!important;border-bottom:1px solid #0000001a;border-top-left-radius:10px;border-top-right-radius:10px;padding:16px;position:relative;text-align:center}.cc-preferences__title{background:none!important;color:#111!important;font-family:sans-serif!important;font-size:18px!important;font-weight:700!important;margin:0!important;padding:0 16px 0 0!important}@media (min-width:480px){.cc-preferences__title{padding-right:0!important}}@media (min-width:980px){.cc-preferences__title{font-size:22px!important}}.cc-preferences__body{background:#fff!important;flex:1 1 auto;min-height:200px;overflow-x:hidden;overflow-y:auto;padding:16px}.cc-preferences__footer{background:#fff!important;border-top:1px solid #d0d0d0;box-shadow:0 0 5px 0 #0003;margin-bottom:0;padding:12px;position:relative}@media (min-width:480px){.cc-preferences__footer{align-items:stretch;display:flex}}.cc-preferences__footer>.cc-button{display:block;width:100%}@media (min-width:480px){.cc-preferences__footer>.cc-button{flex:1 1 auto}}@media (min-width:980px){.cc-preferences__footer>.cc-button{flex-basis:auto}}@media (min-width:480px){.cc-preferences__footer>.cc-button:not(:first-child){margin-left:12px}}.cc-preferences__footer>.cc-button:not(:last-child){margin-bottom:8px}@media (min-width:480px){.cc-preferences__footer>.cc-button:not(:last-child){margin-bottom:0}}.cc-preferences__categories{list-style:none;margin:0;padding:0}.cc-preferences__category:not(:last-child){border-bottom:1px solid #0000001a;margin-bottom:12px;padding-bottom:12px}.cc-preferences__category-description{font-size:14px;margin:0 0 8px;padding:0}.cc-preferences__category-footer{align-items:center;display:flex;justify-content:space-between}.cc-preferences__status{border:0;clip:rect(0,0,0,0);height:1px;margin:-100%;overflow:hidden;padding:0;position:absolute!important;width:1px}.cc-preferences__controls{display:flex;margin:0}.cc-preferences__controls>:not(:last-child){margin-right:12px}.cc-preferences__always-on{font-size:14px;font-weight:700;padding-left:26px;position:relative}.cc-preferences__always-on:before{background:#0000!important;border:solid;border-top-color:#0000;border-width:0 0 4px 4px;content:"";display:block;height:10px;left:0;position:absolute;top:2px;transform:rotate(-45deg);width:18px}.cc-preferences__details{background-color:#eff6fb!important;border-radius:10px;font-size:14px;margin:12px 0 0;padding:12px}.cc-preferences__cookie-list,.cc-preferences__provider-list{list-style:none;margin:0;padding:0}.cc-preferences__provider-list{columns:170px}.cc-preferences__cookie-title{font-size:1em;font-style:normal;font-weight:400;margin:0}.cc-preferences__cookie-description{font-size:1em;margin:0 0 8px}.cc-preferences__cookie-domain,.cc-preferences__cookie-lifespan{border-left:1px solid #999;color:#666;margin-left:8px;padding-left:4px}body.cc-has-preferences-open{overflow:hidden;position:relative}.cc-table{border-collapse:collapse;width:100%}.cc-table tbody tr{border-top:1px solid #0000001a}.cc-table td,.cc-table th{font-size:14px;padding:4px 8px;vertical-align:top}.cc-table+.cc-table{margin-top:8px}.cc-table--purposes td:first-child,.cc-table--purposes th:first-child{width:70%}@media (min-width:680px){.cc-table--purposes td:first-child,.cc-table--purposes th:first-child{width:80%}}.cc-table--purposes td:last-child,.cc-table--purposes th:last-child{padding-left:8px;width:40%}@media (min-width:680px){.cc-table--purposes td:last-child,.cc-table--purposes th:last-child{width:30%}}.cc-tabs,.cc-tabs>ul{background-color:#faf9f6;display:flex;list-style:none;margin:0;padding:0}.cc-tabs__panel{border-top:1px solid #ececec;margin-top:-1px}.cc-tabs__button{background-color:initial;border:0;border-left:1px solid #0000;border-right:1px solid #0000;color:#111;font-size:16px;font-weight:700;margin:0;padding:15px 16px 12px;position:relative}.cc-tabs__button:before{background-color:initial;content:"";display:block;height:3px;left:0;position:absolute;top:0;width:100%}.cc-tabs__button.cc-active{background-color:#fff;border-color:#025e8d #ececec #ececec;color:#111}.cc-tabs__button.cc-active:before{background-color:#025e8d}.cc-tabs__content{background-color:#fff;display:none;font-size:14px;padding:16px}.cc-tabs__section:not(:first-child){padding-top:24px}.cc-tcf{font-size:14px;margin-top:16px}.cc-tcf__list{list-style:none;margin:0;padding:0}.cc-vendor-count{color:#666;font-size:16px;margin:0 0 8px}.cc-hide{display:none!important}.cc-show{display:block!important}.cc-external-link{background-color:#ececec;background-image:url("data:image/svg+xml;base64,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");background-position:right 8px center;background-repeat:no-repeat;background-size:10px auto;border-radius:3px;box-shadow:0 1px 0 #0003;color:#111!important;display:inline-block;font-size:12px;padding:4px 26px 4px 8px;text-decoration:none!important}.cc-external-link:hover{text-decoration:underline!important}.cc-m-0{margin:0!important}.cc-grey{color:#666}</style><script async="" type="text/javascript" src="https://injections.readcube.com/nature/inject.fa744f3f.js"></script></head>
<body class="article-page"><dialog class="cc-banner" data-cc-banner="" data-nosnippet="" aria-labelledby="cc-banner-label" open="">
		<div class="cc-banner__content" autofocus="" tabindex="-1">
			<div class="cc-banner__container">
				<div class="cc-banner__header">
					<h2 class="cc-banner__title" id="cc-banner-label">Your privacy, your choice</h2>
				</div>
				<div class="cc-banner__body">
					<div class="cc-banner__policy">
						<p>We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.</p><p>By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.</p><p>See our <a href="https://www.nature.com/info/privacy" data-cc-action="privacy">privacy policy</a> for more information on the use of your personal data.</p><p><button type="button" data-cc-action="preferences" class="cc-button cc-button--link cc-button--text">Manage preferences</button> for further information and to change your choices.</p>
					</div>
					
				</div>
				<div class="cc-banner__footer">
					
			<button data-cc-action="accept" class="cc-button cc-button--secondary cc-button--contrast cc-banner__button cc-banner__button-accept">Accept all cookies</button>
			
		
				</div>
			</div>
		</div>
	</dialog>

<noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-MRVXSHQ"
                  height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>



<div class="position-relative cleared z-index-50 background-white" data-test="top-containers">
    <a class="c-skip-link" href="#content">Skip to main content</a>



<div class="c-grade-c-banner u-hide">
    <div class="c-grade-c-banner__container">
        
        <p>Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
            the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
            Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
            and JavaScript.</p>

    </div>
</div>

    

    

    
    
        <div class="u-hide u-show-following-ad"></div>

    <aside class="c-ad c-ad--728x90" style="display: none !important;">
        <div class="c-ad__inner" data-container-type="banner-advert">
            <p class="c-ad__label">Advertisement</p>
            
        
            
    <div id="div-gpt-ad-top-1" class="div-gpt-ad advert leaderboard js-ad text-center hide-print grade-c-hide" data-ad-type="top" data-test="top-ad" data-pa11y-ignore="" data-gpt="" data-gpt-unitpath="/285/medicine.nature.com/article" data-gpt-sizes="728x90" data-gpt-targeting="type=article;pos=top;artid=s41591-021-01541-0;doi=10.1038/s41591-021-01541-0;subjmeta=1059,109,1641,1941,2325,2779,308,580,67,69,692,699;kwrd=Cancer+genomics,Cancer+immunotherapy,Mesothelioma,Phase+II+trials,Tumour+immunology">
        <noscript>
            <a href="//pubads.g.doubleclick.net/gampad/jump?iu=/285/medicine.nature.com/article&amp;sz=728x90&amp;c=409288482&amp;t=pos%3Dtop%26type%3Darticle%26artid%3Ds41591-021-01541-0%26doi%3D10.1038/s41591-021-01541-0%26subjmeta%3D1059,109,1641,1941,2325,2779,308,580,67,69,692,699%26kwrd%3DCancer+genomics,Cancer+immunotherapy,Mesothelioma,Phase+II+trials,Tumour+immunology">
                <img data-test="gpt-advert-fallback-img"
                     src="//pubads.g.doubleclick.net/gampad/ad?iu=/285/medicine.nature.com/article&amp;sz=728x90&amp;c=409288482&amp;t=pos%3Dtop%26type%3Darticle%26artid%3Ds41591-021-01541-0%26doi%3D10.1038/s41591-021-01541-0%26subjmeta%3D1059,109,1641,1941,2325,2779,308,580,67,69,692,699%26kwrd%3DCancer+genomics,Cancer+immunotherapy,Mesothelioma,Phase+II+trials,Tumour+immunology"
                     alt="Advertisement"
                     width="728"
                     height="90"></a>
        </noscript>
    </div>

        
    
        </div>
    </aside>


    <header class="c-header" id="header" data-header="" data-track-component="nature-150-split-header" style="border-color:#e40428">
        <div class="c-header__row">
            <div class="c-header__container">
                <div class="c-header__split">
                    
                    
                    <div class="c-header__logo-container">
                        
                        <a href="/nm" data-track="click" data-track-action="home" data-track-label="image">
                            <picture class="c-header__logo">
                                <source srcset="https://media.springernature.com/full/nature-cms/uploads/product/nm/header-95e59e63930e5d6009bad2c23a42ab2d.svg" media="(min-width: 875px)">
                                <img src="https://media.springernature.com/full/nature-cms/uploads/product/nm/header-95e59e63930e5d6009bad2c23a42ab2d.svg" height="32" alt="Nature Medicine">
                            </picture>
                        </a>
                    
                    </div>
                    
                    <ul class="c-header__menu c-header__menu--global">
                        <li class="c-header__item c-header__item--padding c-header__item--hide-md-max">
                            <a class="c-header__link" href="https://www.nature.com/siteindex" data-test="siteindex-link" data-track="click" data-track-action="open nature research index" data-track-label="link">
                                <span>View all journals</span>
                            </a>
                        </li>
                        <li class="c-header__item c-header__item--padding c-header__item--pipe">
                            <a class="c-header__link c-header__link--search" href="javascript:;" data-header-expander="" data-test="search-link" data-track="click" data-track-action="open search tray" data-track-label="button" role="button" aria-haspopup="true" aria-expanded="false">
                                <svg role="img" aria-hidden="true" focusable="false" height="22" width="22" viewBox="0 0 18 18" xmlns="http://www.w3.org/2000/svg"><path d="M16.48 15.455c.283.282.29.749.007 1.032a.738.738 0 01-1.032-.007l-3.045-3.044a7 7 0 111.026-1.026zM8 14A6 6 0 108 2a6 6 0 000 12z"></path></svg><span>Search</span>
                            </a><div id="search-menu" class="c-header__dropdown c-header__dropdown--full-width has-tethered u-js-hide" data-track-component="nature-150-split-header" hidden="">
    <div class="c-header__container">
        <h2 class="c-header__visually-hidden">Search</h2>
        <form class="c-header__search-form" action="/search" method="get" role="search" autocomplete="off" data-test="inline-search">
            <label class="c-header__heading" for="keywords">Search articles by subject, keyword or author</label>
            <div class="c-header__search-layout c-header__search-layout--max-width">
                <div>
                    <input type="text" required="" class="c-header__input" id="keywords" name="q" value="">
                </div>
                <div class="c-header__search-layout">
                    <div>
                        <label for="results-from" class="c-header__visually-hidden">Show results from</label>
                        <select id="results-from" name="journal" class="c-header__select">
                            
                                
                                    <option value="" selected="">All journals</option>
                                    <option value="nm">This journal</option>
                                
                            
                        </select>
                    </div>
                    <div>
                        <button type="submit" class="c-header__search-button">Search</button>
                    </div>
                </div>

            </div>
        </form>

        <div class="c-header__flush">
            <a class="c-header__link" href="/search/advanced" data-track="click" data-track-action="advanced search" data-track-label="link">
                Advanced search
            </a>
        </div>

        <h3 class="c-header__heading c-header__heading--keyline">Quick links</h3>
        <ul class="c-header__list">
            <li><a class="c-header__link" href="/subjects" data-track="click" data-track-action="explore articles by subject" data-track-label="link">Explore articles by subject</a></li>
            <li><a class="c-header__link" href="/naturecareers" data-track="click" data-track-action="find a job" data-track-label="link">Find a job</a></li>
            <li><a class="c-header__link" href="/authors/index.html" data-track="click" data-track-action="guide to authors" data-track-label="link">Guide to authors</a></li>
            <li><a class="c-header__link" href="/authors/editorial_policies/" data-track="click" data-track-action="editorial policies" data-track-label="link">Editorial policies</a></li>
        </ul>
    </div>
</div>
                        </li>
                        <li class="c-header__item c-header__item--padding c-header__item--snid-account-widget c-header__item--pipe">
                            
                                <a class="c-header__link eds-c-header__link" id="identity-account-widget" data-track="click_login" data-track-context="header" href="https://idp.nature.com/auth/personal/springernature?redirect_uri=https://www.nature.com/articles/s41591-021-01541-0"><span class="eds-c-header__widget-fragment-title">Log in</span></a>
                            
                        </li>
                    </ul>
                </div>
            </div>
        </div>
        
            <div class="c-header__row">
                <div class="c-header__container" data-test="navigation-row">
                    <div class="c-header__split">
                        <ul class="c-header__menu c-header__menu--journal">
                            
                                <li class="c-header__item c-header__item--dropdown-menu" data-test="explore-content-button">
                                    <a href="javascript:;" class="c-header__link" data-header-expander="" data-test="menu-button--explore" data-track="click" data-track-action="open explore expander" data-track-label="button" role="button" aria-haspopup="true" aria-expanded="false">
                                        <span><span class="c-header__show-text">Explore</span> content</span><svg role="img" aria-hidden="true" focusable="false" height="16" viewBox="0 0 16 16" width="16" xmlns="http://www.w3.org/2000/svg"><path d="m5.58578644 3-3.29289322-3.29289322c-.39052429-.39052429-.39052429-1.02368927 0-1.41421356s1.02368927-.39052429 1.41421356 0l4 4c.39052429.39052429.39052429 1.02368927 0 1.41421356l-4 4c-.39052429.39052429-1.02368927.39052429-1.41421356 0s-.39052429-1.02368927 0-1.41421356z" transform="matrix(0 1 -1 0 11 3)"></path></svg>
                                    </a><nav class="c-header__dropdown has-tethered u-js-hide" aria-labelledby="Explore-content" data-test="Explore-content" id="explore" data-track-component="nature-150-split-header" hidden="">
            <div class="c-header__container">
                <h2 id="Explore-content" class="c-header__heading c-header__heading--js-hide">Explore content</h2>
                <ul class="c-header__list c-header__list--js-stack">
                    
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/research-articles" data-track="click" data-track-action="research articles" data-track-label="link" data-test="explore-nav-item">
                                    Research articles
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/reviews-and-analysis" data-track="click" data-track-action="reviews &amp; analysis" data-track-label="link" data-test="explore-nav-item">
                                    Reviews &amp; Analysis
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/news-and-comment" data-track="click" data-track-action="news &amp; comment" data-track-label="link" data-test="explore-nav-item">
                                    News &amp; Comment
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/podcast" data-track="click" data-track-action="podcasts" data-track-label="link" data-test="explore-nav-item">
                                    Podcasts
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/current-issue" data-track="click" data-track-action="current issue" data-track-label="link" data-test="explore-nav-item">
                                    Current issue
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/collections" data-track="click" data-track-action="collections" data-track-label="link" data-test="explore-nav-item">
                                    Collections
                                </a>
                            </li>
                        
                    
                </ul>
                <ul class="c-header__list c-header__list--js-stack">
                    
                        <li class="c-header__item">
                            <a class="c-header__link" href="https://www.facebook.com/Nature-Medicine-193691346949/" data-track="click" data-track-action="facebook" data-track-label="link">Follow us on Facebook
                            </a>
                        </li>
                    
                    
                        <li class="c-header__item">
                            <a class="c-header__link" href="https://twitter.com/naturemedicine" data-track="click" data-track-action="twitter" data-track-label="link">Follow us on Twitter
                            </a>
                        </li>
                    
                    
                    
                        <li class="c-header__item c-header__item--hide-lg">
                            <a class="c-header__link" href="https://www.nature.com/my-account/alerts/subscribe-journal?list-id=5" rel="nofollow" data-track="nav_sign_up_for_alerts" data-track-action="Sign up for alerts" data-track-external="" data-track-label="link (mobile dropdown)">Sign up for alerts<svg role="img" aria-hidden="true" focusable="false" height="18" viewBox="0 0 18 18" width="18" xmlns="http://www.w3.org/2000/svg"><path d="m4 10h2.5c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-3.08578644l-1.12132034 1.1213203c-.18753638.1875364-.29289322.4418903-.29289322.7071068v.1715729h14v-.1715729c0-.2652165-.1053568-.5195704-.2928932-.7071068l-1.7071068-1.7071067v-3.4142136c0-2.76142375-2.2385763-5-5-5-2.76142375 0-5 2.23857625-5 5zm3 4c0 1.1045695.8954305 2 2 2s2-.8954305 2-2zm-5 0c-.55228475 0-1-.4477153-1-1v-.1715729c0-.530433.21071368-1.0391408.58578644-1.4142135l1.41421356-1.4142136v-3c0-3.3137085 2.6862915-6 6-6s6 2.6862915 6 6v3l1.4142136 1.4142136c.3750727.3750727.5857864.8837805.5857864 1.4142135v.1715729c0 .5522847-.4477153 1-1 1h-4c0 1.6568542-1.3431458 3-3 3-1.65685425 0-3-1.3431458-3-3z" fill="#fff"></path></svg>
                            </a>
                        </li>
                    
                    
                        <li class="c-header__item c-header__item--hide-lg">
                            <a class="c-header__link" href="https://www.nature.com/nm.rss" data-track="click" data-track-action="rss feed" data-track-label="link">
                                <span>RSS feed</span>
                            </a>
                        </li>
                    
                </ul>
            </div>
        </nav>
                                </li>
                            
                            
                                <li class="c-header__item c-header__item--dropdown-menu">
                                    <a href="javascript:;" class="c-header__link" data-header-expander="" data-test="menu-button--about-the-journal" data-track="click" data-track-action="open about the journal expander" data-track-label="button" role="button" aria-haspopup="true" aria-expanded="false">
                                        <span>About <span class="c-header__show-text">the journal</span></span><svg role="img" aria-hidden="true" focusable="false" height="16" viewBox="0 0 16 16" width="16" xmlns="http://www.w3.org/2000/svg"><path d="m5.58578644 3-3.29289322-3.29289322c-.39052429-.39052429-.39052429-1.02368927 0-1.41421356s1.02368927-.39052429 1.41421356 0l4 4c.39052429.39052429.39052429 1.02368927 0 1.41421356l-4 4c-.39052429.39052429-1.02368927.39052429-1.41421356 0s-.39052429-1.02368927 0-1.41421356z" transform="matrix(0 1 -1 0 11 3)"></path></svg>
                                    </a><nav class="c-header__dropdown has-tethered u-js-hide" aria-labelledby="About-the-journal" id="about-the-journal" data-test="about-the-journal" data-track-component="nature-150-split-header" hidden="">
                <div class="c-header__container">
                    <h2 id="About-the-journal" class="c-header__heading c-header__heading--js-hide">About the journal</h2>
                    <ul class="c-header__list c-header__list--js-stack">
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/aims" data-track="click" data-track-action="aims &amp; scope" data-track-label="link">
                                    Aims &amp; Scope
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/journal-information" data-track="click" data-track-action="journal information" data-track-label="link">
                                    Journal Information
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/journal-impact" data-track="click" data-track-action="journal metrics" data-track-label="link">
                                    Journal Metrics
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/editors" data-track="click" data-track-action="about the editors" data-track-label="link">
                                    About the Editors
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/research-cross-journal-editorial-team" data-track="click" data-track-action="research cross-journal editorial team" data-track-label="link">
                                    Research Cross-Journal Editorial Team
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/reviews-cross-journal-editorial-team" data-track="click" data-track-action="reviews cross-journal editorial team" data-track-label="link">
                                    Reviews Cross-Journal Editorial Team
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/statistics-advisory-panel" data-track="click" data-track-action="statistical advisory panel" data-track-label="link">
                                    Statistical Advisory Panel
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/our-publishing-models" data-track="click" data-track-action="our publishing models" data-track-label="link">
                                    Our publishing models
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/editorial-values-statement" data-track="click" data-track-action="editorial values statement" data-track-label="link">
                                    Editorial Values Statement
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/editorial-policies" data-track="click" data-track-action="editorial policies" data-track-label="link">
                                    Editorial Policies
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/content" data-track="click" data-track-action="content types" data-track-label="link">
                                    Content Types
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/web-feeds" data-track="click" data-track-action="web feeds" data-track-label="link">
                                    Web Feeds
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/contact" data-track="click" data-track-action="contact" data-track-label="link">
                                    Contact
                                </a>
                            </li>
                        
                    </ul>
                </div>
            </nav>
                                </li>
                                
                                    <li class="c-header__item c-header__item--dropdown-menu" data-test="publish-with-us-button">
                                        <a href="javascript:;" class="c-header__link c-header__link--dropdown-menu" data-header-expander="" data-test="menu-button--publish" data-track="click" data-track-action="open publish with us expander" data-track-label="button" role="button" aria-haspopup="true" aria-expanded="false">
                                            <span>Publish <span class="c-header__show-text">with us</span></span><svg role="img" aria-hidden="true" focusable="false" height="16" viewBox="0 0 16 16" width="16" xmlns="http://www.w3.org/2000/svg"><path d="m5.58578644 3-3.29289322-3.29289322c-.39052429-.39052429-.39052429-1.02368927 0-1.41421356s1.02368927-.39052429 1.41421356 0l4 4c.39052429.39052429.39052429 1.02368927 0 1.41421356l-4 4c-.39052429.39052429-1.02368927.39052429-1.41421356 0s-.39052429-1.02368927 0-1.41421356z" transform="matrix(0 1 -1 0 11 3)"></path></svg>
                                        </a><nav class="c-header__dropdown has-tethered u-js-hide" aria-labelledby="Publish-with-us-label" id="publish-with-us" data-test="publish-with-us" data-track-component="nature-150-split-header" hidden="">
                <div class="c-header__container">
                    <h2 id="Publish-with-us-label" class="c-header__heading c-header__heading--js-hide">Publish with us</h2>
                    <ul class="c-header__list c-header__list--js-stack">
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/submission-guidelines" data-track="click" data-track-action="submission guidelines" data-track-label="link">
                                    Submission Guidelines
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/for-reviewers" data-track="click" data-track-action="for reviewers" data-track-label="link">
                                    For Reviewers
                                </a>
                            </li>
                        
                        
                            <li class="c-header__item">
                                <a class="c-header__link" data-test="nature-author-services" data-track="nav_language_services" data-track-context="header publish with us dropdown menu" data-track-action="manuscript author services" data-track-label="link manuscript author services" href="https://authorservices.springernature.com/go/sn/?utm_source=For+Authors&amp;utm_medium=Website_Nature&amp;utm_campaign=Platform+Experimentation+2022&amp;utm_id=PE2022">
                                    Language editing services
                                </a>
                            </li>
                        
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/open-access-funding" data-test="funding-eligibility-link" data-track="click_explore_funding" data-track-context="header publish with us" data-track-action="funding eligibility">Open access funding</a>
                            </li>
                        
                        
                            <li class="c-header__item c-header__item--keyline">
                                <a class="c-header__link" href="https://mts-nmed.nature.com/cgi-bin/main.plex" data-track="click_submit_manuscript" data-track-context="submit link in Nature header dropdown menu" data-track-action="submit manuscript" data-track-label="link (publish with us dropdown menu)" data-track-external="" data-gtm-criteo="submit-manuscript">Submit manuscript<svg role="img" aria-hidden="true" focusable="false" height="18" viewBox="0 0 18 18" width="18" xmlns="http://www.w3.org/2000/svg"><path d="m15 0c1.1045695 0 2 .8954305 2 2v5.5c0 .27614237-.2238576.5-.5.5s-.5-.22385763-.5-.5v-5.5c0-.51283584-.3860402-.93550716-.8833789-.99327227l-.1166211-.00672773h-9v3c0 1.1045695-.8954305 2-2 2h-3v10c0 .5128358.38604019.9355072.88337887.9932723l.11662113.0067277h7.5c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-7.5c-1.1045695 0-2-.8954305-2-2v-10.17157288c0-.53043297.21071368-1.0391408.58578644-1.41421356l3.82842712-3.82842712c.37507276-.37507276.88378059-.58578644 1.41421356-.58578644zm-.5442863 8.18867991 3.3545404 3.35454039c.2508994.2508994.2538696.6596433.0035959.909917-.2429543.2429542-.6561449.2462671-.9065387-.0089489l-2.2609825-2.3045251.0010427 7.2231989c0 .3569916-.2898381.6371378-.6473715.6371378-.3470771 0-.6473715-.2852563-.6473715-.6371378l-.0010428-7.2231995-2.2611222 2.3046654c-.2531661.2580415-.6562868.2592444-.9065605.0089707-.24295423-.2429542-.24865597-.6576651.0036132-.9099343l3.3546673-3.35466731c.2509089-.25090888.6612706-.25227691.9135302-.00001728zm-.9557137-3.18867991c.2761424 0 .5.22385763.5.5s-.2238576.5-.5.5h-6c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5zm-8.5-3.587-3.587 3.587h2.587c.55228475 0 1-.44771525 1-1zm8.5 1.587c.2761424 0 .5.22385763.5.5s-.2238576.5-.5.5h-6c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5z" fill="#fff"></path></svg>
                                </a>
                            </li>
                        
                    </ul>
                </div>
            </nav>
                                    </li>
                                
                            
                            
                        </ul>
                        <ul class="c-header__menu c-header__menu--hide-lg-max">
                            
                                <li class="c-header__item" data-test="alert-link">
                                    <a class="c-header__link" href="https://journal-alerts.springernature.com/subscribe?journal_id=41591" rel="nofollow" data-track="nav_sign_up_for_alerts" data-track-action="Sign up for alerts" data-track-label="link (desktop site header)" data-track-external="">
                                        <span>Sign up for alerts</span><svg role="img" aria-hidden="true" focusable="false" height="18" viewBox="0 0 18 18" width="18" xmlns="http://www.w3.org/2000/svg"><path d="m4 10h2.5c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-3.08578644l-1.12132034 1.1213203c-.18753638.1875364-.29289322.4418903-.29289322.7071068v.1715729h14v-.1715729c0-.2652165-.1053568-.5195704-.2928932-.7071068l-1.7071068-1.7071067v-3.4142136c0-2.76142375-2.2385763-5-5-5-2.76142375 0-5 2.23857625-5 5zm3 4c0 1.1045695.8954305 2 2 2s2-.8954305 2-2zm-5 0c-.55228475 0-1-.4477153-1-1v-.1715729c0-.530433.21071368-1.0391408.58578644-1.4142135l1.41421356-1.4142136v-3c0-3.3137085 2.6862915-6 6-6s6 2.6862915 6 6v3l1.4142136 1.4142136c.3750727.3750727.5857864.8837805.5857864 1.4142135v.1715729c0 .5522847-.4477153 1-1 1h-4c0 1.6568542-1.3431458 3-3 3-1.65685425 0-3-1.3431458-3-3z" fill="#222"></path></svg>
                                    </a>
                                </li>
                            
                            
                                <li class="c-header__item c-header__item--pipe">
                                    <a class="c-header__link" href="https://www.nature.com/nm.rss" data-track="click" data-track-action="rss feed" data-track-label="link">
                                            <span>RSS feed</span>
                                    </a>
                                </li>
                            
                        </ul>
                    </div>
                </div>
            </div>
        
    </header>


    
    
        <nav class="u-mb-16" aria-label="breadcrumbs">
            <div class="u-container">
                <ol class="c-breadcrumbs" itemscope="" itemtype="https://schema.org/BreadcrumbList">
                    <li class="c-breadcrumbs__item" id="breadcrumb0" itemprop="itemListElement" itemscope="" itemtype="https://schema.org/ListItem"><a class="c-breadcrumbs__link" href="/" itemprop="item" data-track="click" data-track-action="breadcrumb" data-track-category="header" data-track-label="link:nature"><span itemprop="name">nature</span></a><meta itemprop="position" content="1">
                                    <svg class="c-breadcrumbs__chevron" role="img" aria-hidden="true" focusable="false" height="10" viewBox="0 0 10 10" width="10" xmlns="http://www.w3.org/2000/svg">
                                        <path d="m5.96738168 4.70639573 2.39518594-2.41447274c.37913917-.38219212.98637524-.38972225 1.35419292-.01894278.37750606.38054586.37784436.99719163-.00013556 1.37821513l-4.03074001 4.06319683c-.37758093.38062133-.98937525.38100976-1.367372-.00003075l-4.03091981-4.06337806c-.37759778-.38063832-.38381821-.99150444-.01600053-1.3622839.37750607-.38054587.98772445-.38240057 1.37006824.00302197l2.39538588 2.4146743.96295325.98624457z" fill="#666" fill-rule="evenodd" transform="matrix(0 -1 1 0 0 10)"></path>
                                    </svg>
                                </li><li class="c-breadcrumbs__item" id="breadcrumb1" itemprop="itemListElement" itemscope="" itemtype="https://schema.org/ListItem"><a class="c-breadcrumbs__link" href="/nm" itemprop="item" data-track="click" data-track-action="breadcrumb" data-track-category="header" data-track-label="link:nature medicine"><span itemprop="name">nature medicine</span></a><meta itemprop="position" content="2">
                                    <svg class="c-breadcrumbs__chevron" role="img" aria-hidden="true" focusable="false" height="10" viewBox="0 0 10 10" width="10" xmlns="http://www.w3.org/2000/svg">
                                        <path d="m5.96738168 4.70639573 2.39518594-2.41447274c.37913917-.38219212.98637524-.38972225 1.35419292-.01894278.37750606.38054586.37784436.99719163-.00013556 1.37821513l-4.03074001 4.06319683c-.37758093.38062133-.98937525.38100976-1.367372-.00003075l-4.03091981-4.06337806c-.37759778-.38063832-.38381821-.99150444-.01600053-1.3622839.37750607-.38054587.98772445-.38240057 1.37006824.00302197l2.39538588 2.4146743.96295325.98624457z" fill="#666" fill-rule="evenodd" transform="matrix(0 -1 1 0 0 10)"></path>
                                    </svg>
                                </li><li class="c-breadcrumbs__item" id="breadcrumb2" itemprop="itemListElement" itemscope="" itemtype="https://schema.org/ListItem"><a class="c-breadcrumbs__link" href="/nm/articles?type=article" itemprop="item" data-track="click" data-track-action="breadcrumb" data-track-category="header" data-track-label="link:articles"><span itemprop="name">articles</span></a><meta itemprop="position" content="3">
                                    <svg class="c-breadcrumbs__chevron" role="img" aria-hidden="true" focusable="false" height="10" viewBox="0 0 10 10" width="10" xmlns="http://www.w3.org/2000/svg">
                                        <path d="m5.96738168 4.70639573 2.39518594-2.41447274c.37913917-.38219212.98637524-.38972225 1.35419292-.01894278.37750606.38054586.37784436.99719163-.00013556 1.37821513l-4.03074001 4.06319683c-.37758093.38062133-.98937525.38100976-1.367372-.00003075l-4.03091981-4.06337806c-.37759778-.38063832-.38381821-.99150444-.01600053-1.3622839.37750607-.38054587.98772445-.38240057 1.37006824.00302197l2.39538588 2.4146743.96295325.98624457z" fill="#666" fill-rule="evenodd" transform="matrix(0 -1 1 0 0 10)"></path>
                                    </svg>
                                </li><li class="c-breadcrumbs__item" id="breadcrumb3" itemprop="itemListElement" itemscope="" itemtype="https://schema.org/ListItem">
                                    <span itemprop="name">article</span><meta itemprop="position" content="4"></li>
                </ol>
            </div>
        </nav>
    



    

</div>


<div class="u-container u-mt-32 u-mb-32 u-clearfix" id="content" data-component="article-container" data-container-type="article">
    <main class="c-article-main-column u-float-left js-main-column" data-track-component="article body">
        
            
                <div class="c-context-bar u-hide" id="js-enable-context-bar" data-test="context-bar" data-context-bar="" aria-hidden="true">
                    <div class="c-context-bar__container u-container" data-track-context="sticky banner">
                        <div class="c-context-bar__title">
                            Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial
                        </div>
                        
    
        <div class="c-pdf-download u-clear-both js-pdf-download">
            <a href="/articles/s41591-021-01541-0.pdf" class="u-button u-button--full-width u-button--primary u-justify-content-space-between c-pdf-download__link" data-article-pdf="true" data-readcube-pdf-url="true" data-test="download-pdf" data-draft-ignore="true" data-track="content_download" data-track-type="article pdf download" data-track-action="download pdf" data-track-label="link" data-track-external="" download="">
                <span class="c-pdf-download__text">Download PDF</span>
                <svg aria-hidden="true" focusable="false" width="16" height="16" class="u-icon"><use xlink:href="#icon-download"></use></svg>
            </a>
        </div>
    

                    </div>
                </div>
            
        
        <article lang="en">
            
                <div class="c-pdf-button__container u-mb-16 u-hide-at-lg js-context-bar-sticky-point-mobile">
                    <div class="c-pdf-container" data-track-context="article body">
                        
                            
                                
    
        <div class="c-pdf-download u-clear-both js-pdf-download">
            <a href="/articles/s41591-021-01541-0.pdf" class="u-button u-button--full-width u-button--primary u-justify-content-space-between c-pdf-download__link" data-article-pdf="true" data-readcube-pdf-url="true" data-test="download-pdf" data-draft-ignore="true" data-track="content_download" data-track-type="article pdf download" data-track-action="download pdf" data-track-label="link" data-track-external="" download="">
                <span class="c-pdf-download__text">Download PDF</span>
                <svg aria-hidden="true" focusable="false" width="16" height="16" class="u-icon"><use xlink:href="#icon-download"></use></svg>
            </a>
        </div>
    

                            
                        
                    </div>
                </div>
            
            <div class="c-article-header">
                <header>
                    <ul class="c-article-identifiers" data-test="article-identifier">
                        
        <li class="c-article-identifiers__item" data-test="article-category">Article</li>
    
        <li class="c-article-identifiers__item">
            <a href="https://www.springernature.com/gp/open-research/about/the-fundamentals-of-open-access-and-open-research" data-track="click" data-track-action="open access" data-track-label="link" class="u-color-open-access" data-test="open-access">Open access</a>
        </li>
    
    

                        <li class="c-article-identifiers__item">Published: <time datetime="2021-11-08">08 November 2021</time></li>
                    </ul>

                    <h1 class="c-article-title" data-test="article-title" data-article-title="">Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial</h1>
                    <ul class="c-article-author-list c-article-author-list--long js-no-scroll" data-test="authors-list" data-component-authors-activator="authors-list"><li class="c-article-author-list__item"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Patrick_M_-Forde-Aff1-Aff2" data-author-popup="auth-Patrick_M_-Forde-Aff1-Aff2" data-author-search="Forde, Patrick M." data-corresp-id="c1" data-track-context="researcher popup with no profile" data-track-index="1_27">Patrick M. Forde<svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-mail-medium"></use></svg></a><span class="u-js-hide">&nbsp;
            <a class="js-orcid" href="http://orcid.org/0000-0001-6925-6344"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0001-6925-6344</a></span><sup class="u-js-hide"><a href="#Aff1" tabindex="-1">1</a>,<a href="#Aff2" tabindex="-1">2</a></sup><sup class="u-js-hide">&nbsp;<a href="#na1" tabindex="-1">na1</a></sup>, </li><li class="c-article-author-list__item"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Valsamo-Anagnostou-Aff1-Aff2" data-author-popup="auth-Valsamo-Anagnostou-Aff1-Aff2" data-author-search="Anagnostou, Valsamo" data-corresp-id="c2" data-track-context="researcher popup with no profile" data-track-index="2_27">Valsamo Anagnostou<svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-mail-medium"></use></svg></a><span class="u-js-hide">&nbsp;
            <a class="js-orcid" href="http://orcid.org/0000-0001-9480-3047"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0001-9480-3047</a></span><sup class="u-js-hide"><a href="#Aff1" tabindex="-1">1</a>,<a href="#Aff2" tabindex="-1">2</a></sup><sup class="u-js-hide">&nbsp;<a href="#na1" tabindex="-1">na1</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Zhuoxin-Sun-Aff3-Aff4" data-author-popup="auth-Zhuoxin-Sun-Aff3-Aff4" data-author-search="Sun, Zhuoxin" data-track-context="researcher popup with no profile" data-track-index="3_27">Zhuoxin Sun</a><sup class="u-js-hide"><a href="#Aff3" tabindex="-1">3</a>,<a href="#Aff4" tabindex="-1">4</a></sup><sup class="u-js-hide">&nbsp;<a href="#na1" tabindex="-1">na1</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Suzanne_E_-Dahlberg-Aff5" data-author-popup="auth-Suzanne_E_-Dahlberg-Aff5" data-author-search="Dahlberg, Suzanne E." data-track-context="researcher popup with no profile" data-track-index="4_27">Suzanne E. Dahlberg</a><sup class="u-js-hide"><a href="#Aff5" tabindex="-1">5</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Hedy_L_-Kindler-Aff6" data-author-popup="auth-Hedy_L_-Kindler-Aff6" data-author-search="Kindler, Hedy L." data-track-context="researcher popup with no profile" data-track-index="5_27">Hedy L. Kindler</a><sup class="u-js-hide"><a href="#Aff6" tabindex="-1">6</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Noushin-Niknafs-Aff1" data-author-popup="auth-Noushin-Niknafs-Aff1" data-author-search="Niknafs, Noushin" data-track-context="researcher popup with no profile" data-track-index="6_27">Noushin Niknafs</a><sup class="u-js-hide"><a href="#Aff1" tabindex="-1">1</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Thomas-Purcell-Aff7" data-author-popup="auth-Thomas-Purcell-Aff7" data-author-search="Purcell, Thomas" data-track-context="researcher popup with no profile" data-track-index="7_27">Thomas Purcell</a><sup class="u-js-hide"><a href="#Aff7" tabindex="-1">7</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Rafael-Santana_Davila-Aff7" data-author-popup="auth-Rafael-Santana_Davila-Aff7" data-author-search="Santana-Davila, Rafael" data-track-context="researcher popup with no profile" data-track-index="8_27">Rafael Santana-Davila</a><sup class="u-js-hide"><a href="#Aff7" tabindex="-1">7</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Arkadiusz_Z_-Dudek-Aff8" data-author-popup="auth-Arkadiusz_Z_-Dudek-Aff8" data-author-search="Dudek, Arkadiusz Z." data-track-context="researcher popup with no profile" data-track-index="9_27">Arkadiusz Z. Dudek</a><sup class="u-js-hide"><a href="#Aff8" tabindex="-1">8</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Hossein-Borghaei-Aff9" data-author-popup="auth-Hossein-Borghaei-Aff9" data-author-search="Borghaei, Hossein" data-track-context="researcher popup with no profile" data-track-index="10_27">Hossein Borghaei</a><sup class="u-js-hide"><a href="#Aff9" tabindex="-1">9</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Mara-Lanis-Aff1" data-author-popup="auth-Mara-Lanis-Aff1" data-author-search="Lanis, Mara" data-track-context="researcher popup with no profile" data-track-index="11_27">Mara Lanis</a><sup class="u-js-hide"><a href="#Aff1" tabindex="-1">1</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Zineb-Belcaid-Aff1" data-author-popup="auth-Zineb-Belcaid-Aff1" data-author-search="Belcaid, Zineb" data-track-context="researcher popup with no profile" data-track-index="12_27">Zineb Belcaid</a><sup class="u-js-hide"><a href="#Aff1" tabindex="-1">1</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Kellie_N_-Smith-Aff1-Aff2" data-author-popup="auth-Kellie_N_-Smith-Aff1-Aff2" data-author-search="Smith, Kellie N." data-track-context="researcher popup with no profile" data-track-index="13_27">Kellie N. Smith</a><sup class="u-js-hide"><a href="#Aff1" tabindex="-1">1</a>,<a href="#Aff2" tabindex="-1">2</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Archana-Balan-Aff1" data-author-popup="auth-Archana-Balan-Aff1" data-author-search="Balan, Archana" data-track-context="researcher popup with no profile" data-track-index="14_27">Archana Balan</a><sup class="u-js-hide"><a href="#Aff1" tabindex="-1">1</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-James_R_-White-Aff1" data-author-popup="auth-James_R_-White-Aff1" data-author-search="White, James R." data-track-context="researcher popup with no profile" data-track-index="15_27">James R. White</a><sup class="u-js-hide"><a href="#Aff1" tabindex="-1">1</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Christopher-Cherry-Aff1" data-author-popup="auth-Christopher-Cherry-Aff1" data-author-search="Cherry, Christopher" data-track-context="researcher popup with no profile" data-track-index="16_27">Christopher Cherry</a><sup class="u-js-hide"><a href="#Aff1" tabindex="-1">1</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-I__K_-Ashok_Sivakumar-Aff10" data-author-popup="auth-I__K_-Ashok_Sivakumar-Aff10" data-author-search="Ashok Sivakumar, I. K." data-track-context="researcher popup with no profile" data-track-index="17_27">I. K. Ashok Sivakumar</a><sup class="u-js-hide"><a href="#Aff10" tabindex="-1">10</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Xiaoshan_M_-Shao-Aff10-Aff11" data-author-popup="auth-Xiaoshan_M_-Shao-Aff10-Aff11" data-author-search="Shao, Xiaoshan M." data-track-context="researcher popup with no profile" data-track-index="18_27">Xiaoshan M. Shao</a><span class="u-js-hide">&nbsp;
            <a class="js-orcid" href="http://orcid.org/0000-0003-3190-2288"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0003-3190-2288</a></span><sup class="u-js-hide"><a href="#Aff10" tabindex="-1">10</a>,<a href="#Aff11" tabindex="-1">11</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Hok_Yee-Chan-Aff1-Aff2" data-author-popup="auth-Hok_Yee-Chan-Aff1-Aff2" data-author-search="Chan, Hok Yee" data-track-context="researcher popup with no profile" data-track-index="19_27">Hok Yee Chan</a><sup class="u-js-hide"><a href="#Aff1" tabindex="-1">1</a>,<a href="#Aff2" tabindex="-1">2</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Dipika-Singh-Aff1-Aff2" data-author-popup="auth-Dipika-Singh-Aff1-Aff2" data-author-search="Singh, Dipika" data-track-context="researcher popup with no profile" data-track-index="20_27">Dipika Singh</a><sup class="u-js-hide"><a href="#Aff1" tabindex="-1">1</a>,<a href="#Aff2" tabindex="-1">2</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Sampriti-Thapa-Aff1-Aff2" data-author-popup="auth-Sampriti-Thapa-Aff1-Aff2" data-author-search="Thapa, Sampriti" data-track-context="researcher popup with no profile" data-track-index="21_27">Sampriti Thapa</a><sup class="u-js-hide"><a href="#Aff1" tabindex="-1">1</a>,<a href="#Aff2" tabindex="-1">2</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Peter_B_-Illei-Aff1-Aff12" data-author-popup="auth-Peter_B_-Illei-Aff1-Aff12" data-author-search="Illei, Peter B." data-track-context="researcher popup with no profile" data-track-index="22_27">Peter B. Illei</a><sup class="u-js-hide"><a href="#Aff1" tabindex="-1">1</a>,<a href="#Aff12" tabindex="-1">12</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Drew_M_-Pardoll-Aff1-Aff2" data-author-popup="auth-Drew_M_-Pardoll-Aff1-Aff2" data-author-search="Pardoll, Drew M." data-track-context="researcher popup with no profile" data-track-index="23_27">Drew M. Pardoll</a><sup class="u-js-hide"><a href="#Aff1" tabindex="-1">1</a>,<a href="#Aff2" tabindex="-1">2</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Rachel-Karchin-Aff1-Aff10-Aff11" data-author-popup="auth-Rachel-Karchin-Aff1-Aff10-Aff11" data-author-search="Karchin, Rachel" data-track-context="researcher popup with no profile" data-track-index="24_27">Rachel Karchin</a><span class="u-js-hide">&nbsp;
            <a class="js-orcid" href="http://orcid.org/0000-0002-5069-1239"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0002-5069-1239</a></span><sup class="u-js-hide"><a href="#Aff1" tabindex="-1">1</a>,<a href="#Aff10" tabindex="-1">10</a>,<a href="#Aff11" tabindex="-1">11</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Victor_E_-Velculescu-Aff1-Aff2-Aff11-Aff12" data-author-popup="auth-Victor_E_-Velculescu-Aff1-Aff2-Aff11-Aff12" data-author-search="Velculescu, Victor E." data-track-context="researcher popup with no profile" data-track-index="25_27">Victor E. Velculescu</a><span class="u-js-hide">&nbsp;
            <a class="js-orcid" href="http://orcid.org/0000-0003-1195-438X"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0003-1195-438X</a></span><sup class="u-js-hide"><a href="#Aff1" tabindex="-1">1</a>,<a href="#Aff2" tabindex="-1">2</a>,<a href="#Aff11" tabindex="-1">11</a>,<a href="#Aff12" tabindex="-1">12</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Julie_R_-Brahmer-Aff1-Aff2" data-author-popup="auth-Julie_R_-Brahmer-Aff1-Aff2" data-author-search="Brahmer, Julie R." data-track-context="researcher popup with no profile" data-track-index="26_27">Julie R. Brahmer</a><sup class="u-js-hide"><a href="#Aff1" tabindex="-1">1</a>,<a href="#Aff2" tabindex="-1">2</a></sup> &amp; </li><li class="c-article-author-list__show-more" aria-label="Show all 27 authors for this article" title="Show all 27 authors for this article">…</li><li class="c-article-author-list__item"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Suresh_S_-Ramalingam-Aff13" data-author-popup="auth-Suresh_S_-Ramalingam-Aff13" data-author-search="Ramalingam, Suresh S." data-track-context="researcher popup with no profile" data-track-index="27_27">Suresh S. Ramalingam</a><span class="u-js-hide">&nbsp;
            <a class="js-orcid" href="http://orcid.org/0000-0002-0757-3106"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0002-0757-3106</a></span><sup class="u-js-hide"><a href="#Aff13" tabindex="-1">13</a></sup>&nbsp;</li></ul><button aria-expanded="false" class="c-article-author-list__button"><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-down-medium"></use></svg><span>Show authors</span></button>

                    

                    <p class="c-article-info-details" data-container-section="info">
                        
    <a data-test="journal-link" href="/nm" data-track="click" data-track-action="journal homepage" data-track-category="article body" data-track-label="link"><i data-test="journal-title">Nature Medicine</i></a>

                        <b data-test="journal-volume"><span class="u-visually-hidden">volume</span>&nbsp;27</b>,&nbsp;<span class="u-visually-hidden">pages </span>1910–1920 (<span data-test="article-publication-year">2021</span>)<a href="#citeas" class="c-article-info-details__cite-as u-hide-print" data-track="click" data-track-action="cite this article" data-track-label="link">Cite this article</a>
                    </p>
                    
        <div class="c-article-metrics-bar__wrapper u-clear-both">
            <ul class="c-article-metrics-bar u-list-reset">
                
                    <li class=" c-article-metrics-bar__item" data-test="access-count">
                        <p class="c-article-metrics-bar__count">16k <span class="c-article-metrics-bar__label">Accesses</span></p>
                    </li>
                
                
                    <li class="c-article-metrics-bar__item" data-test="citation-count">
                        <p class="c-article-metrics-bar__count">85 <span class="c-article-metrics-bar__label">Citations</span></p>
                    </li>
                
                
                    
                        <li class="c-article-metrics-bar__item" data-test="altmetric-score">
                            <p class="c-article-metrics-bar__count">170 <span class="c-article-metrics-bar__label">Altmetric</span></p>
                        </li>
                    
                
                <li class="c-article-metrics-bar__item">
                    <p class="c-article-metrics-bar__details"><a href="/articles/s41591-021-01541-0/metrics" data-track="click" data-track-action="view metrics" data-track-label="link" rel="nofollow">Metrics <span class="u-visually-hidden">details</span></a></p>
                </li>
            </ul>
        </div>
    
                    
                </header>

                
    

                
    
    

    
    

                
            </div>

        <div class="c-article-body">
            <section aria-labelledby="Abs1" data-title="Abstract" lang="en"><div class="c-article-section" id="Abs1-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Abs1">Abstract</h2><div class="c-article-section__content" id="Abs1-content"><p>Mesothelioma is a rare and fatal cancer with limited therapeutic options until the recent approval of combination immune checkpoint blockade. Here we report the results of the phase 2 PrE0505 trial (<a href="https://clinicaltrials.gov/ct2/show/NCT02899195">NCT02899195</a>) of the anti-PD-L1 antibody durvalumab plus platinum-pemetrexed chemotherapy for 55 patients with previously untreated, unresectable pleural mesothelioma. The primary endpoint was overall survival compared to historical control with cisplatin and pemetrexed chemotherapy; secondary and exploratory endpoints included safety, progression-free survival and biomarkers of response. The combination of durvalumab with chemotherapy met the pre-specified primary endpoint, reaching a median survival of 20.4 months versus 12.1 months with historical control. Treatment-emergent adverse events were consistent with known side effects of chemotherapy, and all adverse events due to immunotherapy were grade 2 or lower. Integrated genomic and immune cell repertoire analyses revealed that a higher immunogenic mutation burden coupled with a more diverse T cell repertoire was linked to favorable clinical outcome. Structural genome-wide analyses showed a higher degree of genomic instability in responding tumors of epithelioid histology. Patients with germline alterations in cancer predisposing genes, especially those involved in DNA repair, were more likely to achieve long-term survival. Our findings indicate that concurrent durvalumab with platinum-based chemotherapy has promising clinical activity and that responses are driven by the complex genomic background of malignant pleural mesothelioma.</p></div></div></section>

            
                
            

            
                
                    
        
            <section aria-labelledby="inline-recommendations" data-title="Inline Recommendations" class="c-article-recommendations" data-track-component="inline-recommendations">
                <h3 class="c-article-recommendations-title" id="inline-recommendations">Similar content being viewed by others</h3>
                <div class="c-article-recommendations-list">
                    
                        <div class="c-article-recommendations-list__item">
                            <article class="c-article-recommendations-card" itemscope="" itemtype="http://schema.org/ScholarlyArticle">
                                
                                    <div class="c-article-recommendations-card__img"><img src="https://media.springernature.com/w215h120/springer-static/image/art%3A10.1038%2Fs41591-024-02808-y/MediaObjects/41591_2024_2808_Fig1_HTML.png" loading="lazy" alt=""></div>
                                
                                <div class="c-article-recommendations-card__main">
                                    <h3 class="c-article-recommendations-card__heading" itemprop="name headline">
                                        <a class="c-article-recommendations-card__link" itemprop="url" href="https://www.nature.com/articles/s41591-024-02808-y?fromPaywallRec=false" data-track="select_recommendations_1" data-track-context="inline recommendations" data-track-action="click recommendations inline - 1" data-track-label="10.1038/s41591-024-02808-y">Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial
                                        </a>
                                    </h3>
                                    <div class="c-article-meta-recommendations" data-test="recommendation-info">
                                        <span class="c-article-meta-recommendations__item-type">Article</span>
                                         <span class="c-article-meta-recommendations__access-type">Open access</span>
                                         <span class="c-article-meta-recommendations__date">13 February 2024</span>
                                    </div>
                                </div>
                            </article>
                        </div>
                    
                        <div class="c-article-recommendations-list__item">
                            <article class="c-article-recommendations-card" itemscope="" itemtype="http://schema.org/ScholarlyArticle">
                                
                                    <div class="c-article-recommendations-card__img"><img src="https://media.springernature.com/w215h120/springer-static/image/art%3A10.1038%2Fs41571-022-00649-7/MediaObjects/41571_2022_649_Fig1_HTML.png" loading="lazy" alt=""></div>
                                
                                <div class="c-article-recommendations-card__main">
                                    <h3 class="c-article-recommendations-card__heading" itemprop="name headline">
                                        <a class="c-article-recommendations-card__link" itemprop="url" href="https://www.nature.com/articles/s41571-022-00649-7?fromPaywallRec=false" data-track="select_recommendations_2" data-track-context="inline recommendations" data-track-action="click recommendations inline - 2" data-track-label="10.1038/s41571-022-00649-7">Immunotherapy approaches for malignant pleural mesothelioma
                                        </a>
                                    </h3>
                                    <div class="c-article-meta-recommendations" data-test="recommendation-info">
                                        <span class="c-article-meta-recommendations__item-type">Article</span>
                                        
                                         <span class="c-article-meta-recommendations__date">01 July 2022</span>
                                    </div>
                                </div>
                            </article>
                        </div>
                    
                        <div class="c-article-recommendations-list__item">
                            <article class="c-article-recommendations-card" itemscope="" itemtype="http://schema.org/ScholarlyArticle">
                                
                                    <div class="c-article-recommendations-card__img"><img src="https://media.springernature.com/w215h120/springer-static/image/art%3A10.1038%2Fs41467-023-42400-5/MediaObjects/41467_2023_42400_Fig1_HTML.png" loading="lazy" alt=""></div>
                                
                                <div class="c-article-recommendations-card__main">
                                    <h3 class="c-article-recommendations-card__heading" itemprop="name headline">
                                        <a class="c-article-recommendations-card__link" itemprop="url" href="https://www.nature.com/articles/s41467-023-42400-5?fromPaywallRec=false" data-track="select_recommendations_3" data-track-context="inline recommendations" data-track-action="click recommendations inline - 3" data-track-label="10.1038/s41467-023-42400-5">Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trial
                                        </a>
                                    </h3>
                                    <div class="c-article-meta-recommendations" data-test="recommendation-info">
                                        <span class="c-article-meta-recommendations__item-type">Article</span>
                                         <span class="c-article-meta-recommendations__access-type">Open access</span>
                                         <span class="c-article-meta-recommendations__date">24 October 2023</span>
                                    </div>
                                </div>
                            </article>
                        </div>
                    
                </div>
            </section>
        
            <script>
                window.dataLayer = window.dataLayer || [];
                window.dataLayer.push({
                    recommendations: {
                        recommender: 'semantic',
                        model: 'specter',
                        policy_id: 'NA',
                        timestamp: 1749514436,
                        embedded_user: 'null'
                    }
                });
            </script>
        
    
                
                
                <div class="main-content">
                    
                        <section data-title="Main"><div class="c-article-section" id="Sec1-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Sec1">Main</h2><div class="c-article-section__content" id="Sec1-content"><p>Malignant pleural mesothelioma (MPM) affects more than 30,000 people worldwide each year and is fatal in nearly all cases<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 1" title="Odgerel, C. O. et al. Estimation of the global burden of mesothelioma deaths from incomplete national mortality data. Occup. Environ. Med. 74, 851–858 (2017)." href="/articles/s41591-021-01541-0#ref-CR1" id="ref-link-section-d73969948e985">1</a></sup>. Exposure to asbestos and consequent chronic inflammation in the pleural cavity is responsible for most cases, with a typical disease latency of 30–40 years, especially in the context of co-occurring defects in DNA damage repair and germline cancer predisposition syndromes<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Tweedale, G. Asbestos and its lethal legacy. Nat. Rev. Cancer 2, 311–315 (2002)." href="#ref-CR2" id="ref-link-section-d73969948e989">2</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Panou, V. et al. Frequency of germline mutations in cancer susceptibility genes in malignant mesothelioma. J. Clin. Oncol. 36, 2863–2871 (2018)." href="#ref-CR3" id="ref-link-section-d73969948e989_1">3</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 4" title="Carbone, M. et al. Tumour predisposition and cancer syndromes as models to study gene–environment interactions. Nat. Rev. Cancer 20, 533–549 (2020)." href="/articles/s41591-021-01541-0#ref-CR4" id="ref-link-section-d73969948e992">4</a></sup>. For over 15 years, cisplatin and pemetrexed combination chemotherapy was the only approved systemic therapy; this approval was based on a phase 3 study that showed an improvement in survival from 9.3 months with cisplatin alone to 12.1 months with the combination<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 5" title="Vogelzang, N. J. et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J. Clin. Oncol. 21, 2636–2644 (2003)." href="/articles/s41591-021-01541-0#ref-CR5" id="ref-link-section-d73969948e996">5</a></sup>. With the exception of bevacizumab (which has not received regulatory approval in the United States), adding novel agents to platinum doublet chemotherapy has not improved survival<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Krug, L. M. et al. Randomized phase II trial of pemetrexed/cisplatin with or without CBP501 in patients with advanced malignant pleural mesothelioma. Lung Cancer 85, 429–434 (2014)." href="#ref-CR6" id="ref-link-section-d73969948e1000">6</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Scagliotti, G. V. et al. Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet Respir. Med. 7, 569–580 (2019)." href="#ref-CR7" id="ref-link-section-d73969948e1000_1">7</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Tsao, A. S. et al. Phase II trial of cediranib in combination with cisplatin and pemetrexed in chemotherapy-naive patients with unresectable malignant pleural mesothelioma (SWOG S0905). J. Clin. Oncol. 37, 2537–2547 (2019)." href="#ref-CR8" id="ref-link-section-d73969948e1000_2">8</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 9" title="Zalcman, G. et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet 387, 1405–1414 (2016)." href="/articles/s41591-021-01541-0#ref-CR9" id="ref-link-section-d73969948e1003">9</a></sup>. Recently, several phase 2 studies reported on the efficacy of single-agent PD-1 inhibitors in chemotherapy-pretreated MPM<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Alley, E. W. et al. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial. Lancet Oncol. 18, 623–630 (2017)." href="#ref-CR10" id="ref-link-section-d73969948e1007">10</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Quispel-Janssen, J. et al. Programmed death 1 blockade with nivolumab in patients with recurrent malignant pleural mesothelioma. J. Thorac. Oncol. 13, 1569–1576 (2018)." href="#ref-CR11" id="ref-link-section-d73969948e1007_1">11</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Okada, M. et al. Clinical efficacy and safety of nivolumab: results of a multicenter, open-label, single-arm, Japanese phase II study in malignant pleural mesothelioma (MERIT). Clin. Cancer Res. 25, 5485–5492 (2019)." href="#ref-CR12" id="ref-link-section-d73969948e1007_2">12</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 13" title="Fennell, D. A. et al. CONFIRM: a double-blind, placebo-controlled phase III clinical trial investigating the effect of nivolumab in patients with relapsed mesothelioma: study protocol for a randomised controlled trial. Trials 19, 233 (2018)." href="/articles/s41591-021-01541-0#ref-CR13" id="ref-link-section-d73969948e1010">13</a></sup>. Following the non-small-cell lung cancer paradigm, where the combination of first-line chemotherapy with PD-1 pathway blockade has become a standard approach for advanced disease<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 14" title="Gandhi, L. et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N. Engl. J. Med. 378, 2078–2092 (2018)." href="/articles/s41591-021-01541-0#ref-CR14" id="ref-link-section-d73969948e1015">14</a></sup>, chemo-immunotherapy is currently being explored in MPM. In the first-line setting, the phase 2 DREAM study of durvalumab with chemotherapy achieved its primary endpoint of progression-free survival (PFS) at 6 months and showed the regimen to be tolerable and active in this setting<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 15" title="Nowak, A. K. et al. Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in. Lancet Oncol. 21, 1213–1223 (2020)." href="/articles/s41591-021-01541-0#ref-CR15" id="ref-link-section-d73969948e1019">15</a></sup>. Furthermore, the combination of the anti-CTLA-4 antibody ipilimumab with the anti-PD-1 antibody nivolumab was shown to improve survival for previously untreated patients when compared to chemotherapy, with robust efficacy being limited to non-epithelioid histology<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 16" title="Baas, P. et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet 397, 375–386 (2021)." href="/articles/s41591-021-01541-0#ref-CR16" id="ref-link-section-d73969948e1023">16</a></sup>.</p><p>Although several studies have expanded understanding of the genomic landscape of MPM and identified putative actionable alterations, these have not been translated to therapeutic progress<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Hmeljak, J. et al. Integrative molecular characterization of malignant pleural mesothelioma. Cancer Discov. 8, 1548–1565 (2018)." href="#ref-CR17" id="ref-link-section-d73969948e1030">17</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Bueno, R. et al. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat. Genet. 48, 407–416 (2016)." href="#ref-CR18" id="ref-link-section-d73969948e1030_1">18</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 19" title="Mansfield, A. S. et al. Neoantigenic potential of complex chromosomal rearrangements in mesothelioma. J. Thorac. Oncol. 14, 276–287 (2019)." href="/articles/s41591-021-01541-0#ref-CR19" id="ref-link-section-d73969948e1033">19</a></sup>. More than 50% of MPMs carry germline or somatic mutations in genes involved in DNA repair and homologous recombination<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 3" title="Panou, V. et al. Frequency of germline mutations in cancer susceptibility genes in malignant mesothelioma. J. Clin. Oncol. 36, 2863–2871 (2018)." href="/articles/s41591-021-01541-0#ref-CR3" id="ref-link-section-d73969948e1037">3</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 20" title="Panou, V. &amp; Roe, O. D. Inherited genetic mutations and polymorphisms in malignant mesothelioma: a comprehensive review. Int. J. Mol. Sci. 21, 4327 (2020)." href="/articles/s41591-021-01541-0#ref-CR20" id="ref-link-section-d73969948e1040">20</a></sup>. BAP1, a nuclear ubiquitin carboxyterminal hydrolase, has been reported to be frequently mutated in the germline and tumor cells of patients with MPM<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 17" title="Hmeljak, J. et al. Integrative molecular characterization of malignant pleural mesothelioma. Cancer Discov. 8, 1548–1565 (2018)." href="/articles/s41591-021-01541-0#ref-CR17" id="ref-link-section-d73969948e1044">17</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 18" title="Bueno, R. et al. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat. Genet. 48, 407–416 (2016)." href="/articles/s41591-021-01541-0#ref-CR18" id="ref-link-section-d73969948e1047">18</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 20" title="Panou, V. &amp; Roe, O. D. Inherited genetic mutations and polymorphisms in malignant mesothelioma: a comprehensive review. Int. J. Mol. Sci. 21, 4327 (2020)." href="/articles/s41591-021-01541-0#ref-CR20" id="ref-link-section-d73969948e1050">20</a></sup>. Heterozygous germline <i>BAP1</i> alterations predispose to mesothelioma, especially in the context of asbestos exposure<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 21" title="Testa, J. R. et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nat. Genet. 43, 1022–1025 (2011)." href="/articles/s41591-021-01541-0#ref-CR21" id="ref-link-section-d73969948e1057">21</a></sup>, and, similarly, germline <i>BLM</i> mutations might increase susceptibility to asbestos carcinogenesis and emergence of mesothelioma<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 22" title="Bononi, A. et al. Heterozygous germline BLM mutations increase susceptibility to asbestos and mesothelioma. Proc. Natl Acad. Sci. USA 117, 33466–33473 (2020)." href="/articles/s41591-021-01541-0#ref-CR22" id="ref-link-section-d73969948e1065">22</a></sup>. Inactivation of tumor suppressor genes, such as <i>BAP1</i>, <i>NF2</i>, <i>CDKN2A</i>, <i>TP53</i> and <i>SETD2</i>, by sequence or structural alterations, is thought to be the predominant oncogenic mechanism for MPM<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 17" title="Hmeljak, J. et al. Integrative molecular characterization of malignant pleural mesothelioma. Cancer Discov. 8, 1548–1565 (2018)." href="/articles/s41591-021-01541-0#ref-CR17" id="ref-link-section-d73969948e1085">17</a></sup>. Notably, MPM harbors a low tumor mutation burden (TMB) of fewer than two non-synonymous mutations per megabase<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 17" title="Hmeljak, J. et al. Integrative molecular characterization of malignant pleural mesothelioma. Cancer Discov. 8, 1548–1565 (2018)." href="/articles/s41591-021-01541-0#ref-CR17" id="ref-link-section-d73969948e1089">17</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 18" title="Bueno, R. et al. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat. Genet. 48, 407–416 (2016)." href="/articles/s41591-021-01541-0#ref-CR18" id="ref-link-section-d73969948e1092">18</a></sup> and has, therefore, been considered a tumor with low neoantigen-driven immunogenicity. Nevertheless, the promising clinical efficacy of immune checkpoint blockade for MPM calls for in-depth genomic and functional analyses to investigate the mechanisms of therapeutic response and resistance. In this study, we investigated the combination of durvalumab with platinum-based chemotherapy in a phase 2 clinical trial, to establish safety and efficacy and explore genomic and immunologic features of response in patients with unresectable MPM.</p></div></div></section><section data-title="Results"><div class="c-article-section" id="Sec2-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Sec2">Results</h2><div class="c-article-section__content" id="Sec2-content"><h3 class="c-article__sub-heading" id="Sec3">Study design</h3><p>PrE0505, a phase 2, single-arm, multicenter study, enrolled patients with previously untreated, unresectable MPM (<a href="https://clinicaltrials.gov/ct2/show/NCT02899195">NCT02899195</a>; Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01541-0#Fig6">1</a>). Patients received durvalumab (at a fixed dose of 1,120 mg intraveneously) given once every 3 weeks in combination with pemetrexed and cisplatin at their standard doses for up to six cycles. Substitution of carboplatin for cisplatin was permitted on cycle 1 for patients with a glomerular filtration rate (GFR) of ≥45 ml min<sup>−1</sup> but ≤60 ml min<sup>−1</sup>, for patients with another documented contraindication to cisplatin (for example, hearing loss) or because of cisplatin toxicity during treatment. Patients with stable or responding tumors after concurrent therapy continued on maintenance durvalumab for a maximum duration of 1 year from the first study treatment. A protocol-defined safety review was performed after enrollment of the first six and 15 patients. Pre-specified dose-limiting toxicities during the safety run-in period included any immune-mediated adverse event of grade 4 or higher or any non-resolving, immune-mediated adverse event of grade 3 or higher during the first two cycles of therapy.</p><p>The primary endpoint of the study was overall survival (OS), defined as time from study registration to death from any cause. Patients last known to be alive were censored at their date of last follow-up. We assumed a null hypothesis that the median OS with chemo-immunotherapy would be equal to the OS of 12 months with pemetrexed/cisplatin alone (historical control). The total planned enrollment of 55 patients (50 eligible) with 32 events allowed for 90% power to detect a 37% reduction in the OS hazard rate of 0.058–0.037 based on Wald test for the log failure rate parameter using a one-sided type I error rate of 10%. This would correspond to a 58% improvement in the median OS from 12 to 19 months<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 4" title="Carbone, M. et al. Tumour predisposition and cancer syndromes as models to study gene–environment interactions. Nat. Rev. Cancer 20, 533–549 (2020)." href="/articles/s41591-021-01541-0#ref-CR4" id="ref-link-section-d73969948e1125">4</a></sup>. Secondary endpoints included PFS, best objective response and toxicity (<a data-track="click" data-track-label="link" data-track-action="section anchor" href="/articles/s41591-021-01541-0#Sec9">Methods</a>). PFS was defined as the time from study registration to documented disease progression or death from any cause, whichever occurred first. Patients who did not experience an event of interest were censored at the date they were last known to be alive and progression-free. Exploratory endpoints included investigating the genomic and immunologic underpinnings of response to chemo-immunotherapy; to this end, we performed whole exome sequencing (WES), coupled with genome-wide focal and large-scale copy number aberration analysis and sequence deconvolution (<a data-track="click" data-track-label="link" data-track-action="section anchor" href="/articles/s41591-021-01541-0#Sec9">Methods</a>). In parallel, we evaluated the intra-tumoral T cell repertoire and functional neoantigen-specific T cell responses (<a data-track="click" data-track-label="link" data-track-action="section anchor" href="/articles/s41591-021-01541-0#Sec9">Methods</a> and Extended Data Figs. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01541-0#Fig6">1</a> and <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01541-0#Fig7">2</a>).</p><h3 class="c-article__sub-heading" id="Sec4">Participants</h3><p>Between 12 June 2017 and 21 June 2018, PrE0505 enrolled 55 patients at 15 academic and community cancer centers in the United States. Eligible patients were 18 years of age or older and had histologically unselected MPM that was deemed to be surgically unresectable, an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1, adequate organ function including GFR of ≥45 ml min<sup>−1</sup> and measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 modified for pleural mesothelioma<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 23" title="Oken, M. M. et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am. J. Clin. Oncol. 5, 649–655 (1982)." href="/articles/s41591-021-01541-0#ref-CR23" id="ref-link-section-d73969948e1155">23</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 24" title="Tsao, A. S. et al. A practical guide of the Southwest Oncology Group to measure malignant pleural mesothelioma tumors by RECIST and modified RECIST criteria. J. Thorac. Oncol. 6, 598–601 (2011)." href="/articles/s41591-021-01541-0#ref-CR24" id="ref-link-section-d73969948e1158">24</a></sup>. Key exclusion criteria were immunodeficiency, ongoing systemic immunosuppressive therapy, active autoimmune or infectious disease and clinically significant concurrent cancer. Demographics and disease characteristics are summarized in Table <a data-track="click" data-track-label="link" data-track-action="table anchor" href="/articles/s41591-021-01541-0#Tab1">1</a>; median age was 68 years (range, 35–83 years), most patients were male (82%) and 75% of tumors were of epithelioid histology. Patients who had continued clinical benefit by investigator assessment (<i>n</i> = 20) were allowed to continue on treatment past radiographic progression.</p><div class="c-article-table" data-test="inline-table" data-container-section="table" id="table-1"><figure><figcaption class="c-article-table__figcaption"><b id="Tab1" data-test="table-caption">Table 1 Demographic characteristics of study participants</b></figcaption><div class="u-text-right u-hide-print"><a class="c-article__pill-button" data-test="table-link" data-track="click" data-track-action="view table" data-track-label="button" rel="nofollow" href="/articles/s41591-021-01541-0/tables/1" aria-label="Full size table 1"><span>Full size table</span><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-right-small"></use></svg></a></div></figure></div><h3 class="c-article__sub-heading" id="Sec5">Efficacy analyses</h3><p>All patients were included in the eligible population for efficacy analyses. The median follow-up was 24.2 months at the time of this analysis, with 33 death events. The median OS for all patients enrolled was 20.4 months (95% confidence interval (CI): 13.0–28.5, 80% CI: 15.1–27.9) and was significantly longer than the historical control of 12 months (one-sided <i>P</i> = 0.0014; Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01541-0#Fig1">1a</a>), with an observed hazard rate of 0.034. The estimated percentages of patients alive at 6, 12 and 24 months were 87.2%, 70.4% and 44.2%, respectively. Median PFS was 6.7 months (95% CI: 6.1–8.4, 80% CI: 6.3–8.2; Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01541-0#Fig1">1b</a>). The estimated percentages of patients alive and progression-free at 6, 12 and 24 months were 67.3%, 18.2% and 6.1%, respectively. The objective response rate (ORR) was 56.4% (95% CI: 42.3–69.7% and 80% CI: 46.8–65.5%). No patients had a complete response (CR); 31 patients showed partial response (PR); and 20 patients had stable disease (SD). One patient was unevaluable for response owing to missing follow-up disease assessments, and three patients had progressive disease (PD) as best response (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01541-0#Fig1">1c,d</a>). In a non-predefined subgroup analysis, a significant difference in ORR, PFS and OS was noted by histology. Patients with epithelioid tumors had a higher ORR than patients with non-epithelioid tumors (65.9% versus 28.6%, <i>P</i> = 0.03). Similarly, patients with epithelioid MPM had significantly longer median OS (24.3 months versus 9.2 months, hazard ratio (HR) = 0.27, 95% CI: 0.13–0.57, <i>P</i> &lt; 0.001; Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01541-0#Fig1">1e</a>) and PFS (8.2 months versus 4.9 months, HR = 0.30, 95% CI: 0.16–0.58, <i>P</i> &lt; 0.001; Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01541-0#Fig1">1f</a>) compared to patients in the non-epithelioid MPM group.</p><div class="c-article-section__figure js-c-reading-companion-figures-item" data-test="figure" data-container-section="figure" id="figure-1" data-title="Outcomes with chemo-immunotherapy in unresectable MPM."><figure><figcaption><b id="Fig1" class="c-article-section__figure-caption" data-test="figure-caption-text">Fig. 1: Outcomes with chemo-immunotherapy in unresectable MPM.</b></figcaption><div class="c-article-section__figure-content"><div class="c-article-section__figure-item"><a class="c-article-section__figure-link" data-test="img-link" data-track="click" data-track-label="image" data-track-action="view figure" href="/articles/s41591-021-01541-0/figures/1" rel="nofollow"><picture><source type="image/webp" srcset="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-021-01541-0/MediaObjects/41591_2021_1541_Fig1_HTML.png?as=webp"><img aria-describedby="Fig1" src="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-021-01541-0/MediaObjects/41591_2021_1541_Fig1_HTML.png" alt="figure 1" loading="lazy" width="685" height="912"></picture></a></div><div class="c-article-section__figure-description" data-test="bottom-caption" id="figure-1-desc"><p><b>a</b>, Kaplan–Meier curve of OS in patients treated with durvalumab and platinum plus pemetrexed (<i>n</i> = 55). One-sided <i>P</i> value based on the Wald test for the log failure rate parameter is <i>P</i> = 0.0014, indicating significantly longer OS than the historical control of 12 months. <b>b</b>, Kaplan–Meier curve of PFS in patients treated with durvalumab and platinum plus pemetrexed (<i>n</i> = 55). <b>c</b>, Waterfall plot of best change in target lesions to treatment by histological subtype, based on maximal percentage of tumor reduction from baseline (<i>n</i> = 53 patients). Two patients without follow-up measurements in targeted lesions (one with best response unevaluable, the other with best response PD) were excluded. <b>d</b>, Spider plot of change in target lesions over time (<i>n</i> = 53 patients); notably, four patients had continued response or SD at the time of analysis. Two patients without follow-up measurements in targeted lesions (one with best response unevaluable, the other with best response PD) were excluded. <b>e</b>, Kaplan–Meier curves of OS according to histology; two-sided <i>P</i> value with significance level set at 0.05. <b>f</b>, Kaplan–Meier curves of PFS according to histology; two-sided <i>P</i> value with significance level set at 0.05. Epi, epithelioid.</p><p><a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-021-01541-0#MOESM3">Source data</a></p></div></div><div class="u-text-right u-hide-print"><a class="c-article__pill-button" data-test="article-link" data-track="click" data-track-label="button" data-track-action="view figure" href="/articles/s41591-021-01541-0/figures/1" data-track-dest="link:Figure1 Full size image" aria-label="Full size image figure 1" rel="nofollow"><span>Full size image</span><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-right-small"></use></svg></a></div></figure></div><h3 class="c-article__sub-heading" id="Sec6">Safety</h3><p>The study enrolled the full planned cohort of 55 patients after initial safety analysis. The most commonly reported treatment-emergent adverse events (TEAEs) were mostly of low grade and included fatigue (67%), nausea (56%) and anemia (56%) (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01541-0#Fig8">3</a>). Grade 3 or higher TEAEs occurred in 65.5% of patients and included anemia (20%), hyponatremia (9%), fatigue (7%), leucopenia (5%), thrombocytopenia (5%) and hypertension (5%); all other grade 3 or higher TEAEs occurred in fewer than 5% of patients. No grade 5 TEAEs were observed. There were also no unexpected adverse events of special interest (defined as adverse events with a potential immune-mediated mechanism), and those that did occur were grade 2 or lower (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01541-0#Fig8">3</a>). In terms of treatment received, 29 (53%) patients received cisplatin-based chemotherapy from the start of treatment, whereas the rest began with carboplatin, and an additional seven patients in the cisplatin group switched to carboplatin during concurrent treatment. No statistically significant differences in PFS or OS were observed based on which platinum agent was received (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01541-0#Fig8">3</a>). All patients who enrolled in the study received at least one cycle of durvalumab with chemotherapy, and 87.3% (48/55) completed six cycles of concurrent treatment. Ten (18.2%) patients with epithelioid MPM completed the 1-year study treatment, and five (9.1%) patients discontinued the study treatment owing to toxicity. The median dose intensity (of cycles received) was 100% for cisplatin (range, 75–100), 100% for pemetrexed (range, 75–102) and 100% for durvalumab. Two (7%) of 29 patients who received cisplatin received a dose reduction of cisplatin owing to toxicity, and four (12%) of 33 who received carboplatin received a dose reduction of carboplatin owing to toxicity. One (2%) patient received a dose reduction of pemetrexed owing to toxicity, whereas no patients received a dose reduction of durvalumab owing to toxicity (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01541-0#Fig6">1</a>).</p><h3 class="c-article__sub-heading" id="Sec7">Genomic and immunologic exploratory analyses</h3><p>As previously shown<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 17" title="Hmeljak, J. et al. Integrative molecular characterization of malignant pleural mesothelioma. Cancer Discov. 8, 1548–1565 (2018)." href="/articles/s41591-021-01541-0#ref-CR17" id="ref-link-section-d73969948e1599">17</a></sup>, MPMs in this cohort harbored a low TMB, with some tumors harboring a higher than expected TMB in the setting of mutations in DNA damage repair genes (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01541-0#Fig2">2</a>, Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01541-0#Fig9">4</a> and Supplementary Tables <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-021-01541-0#MOESM2">1</a>–<a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-021-01541-0#MOESM2">3</a>). Despite the notion that TMB might not predict response to immunotherapy for MPM, given the low mutation burden, we found that tumors from patients with a radiographic response to chemo-immunotherapy had a higher non-synonymous missense mutation burden and a more clonal mutation repertoire than non-responding tumors (<i>P</i> = 0.086 and <i>P</i> = 0.072, respectively; Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01541-0#Fig10">5</a> and Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-021-01541-0#MOESM2">4</a>), especially in the epithelioid group (<i>P</i> = 0.051 and <i>P</i> = 0.025, respectively; Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01541-0#Fig10">5</a> and Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-021-01541-0#MOESM2">4</a>). Consistent with these findings, an APOBEC mutational signature, reflective of subclonal mutagenesis, was found to be enriched in non-responding epithelioid tumors (<i>P</i> = 0.031; Fig.<a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01541-0#Fig2">2</a> and Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-021-01541-0#MOESM2">4</a>). To place these findings in context with respect to the potential role of TMB in predicting response to standard-of-care treatment versus chemo-immunotherapy, we analyzed tumor WES data from an independent cohort of 82 MPM tumors from The Cancer Genome Atlas (TCGA), which pre-dated the era of immune checkpoint blockade. In the TCGA MPM cohort, TMB-low tumors (TMB less than or equal to the second tertile in the cohort; <a data-track="click" data-track-label="link" data-track-action="section anchor" href="/articles/s41591-021-01541-0#Sec9">Methods</a>) showed a non-significant trend toward a longer PFS, suggesting that the relationship between high TMB and clinical response seen in the PrE0505 cohort might be driven by durvalumab (<a data-track="click" data-track-label="link" data-track-action="section anchor" href="/articles/s41591-021-01541-0#Sec9">Methods</a> and Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01541-0#Fig11">6</a>). In the PrE0505 cohort, a trend toward an enrichment in mutations in chromatin-regulating genes was observed for patients achieving an OS of 12 or more months (<i>P</i> = 0.063).</p><div class="c-article-section__figure js-c-reading-companion-figures-item" data-test="figure" data-container-section="figure" id="figure-2" data-title="Genomic landscape of chemo-immunotherapy-treated mesotheliomas."><figure><figcaption><b id="Fig2" class="c-article-section__figure-caption" data-test="figure-caption-text">Fig. 2: Genomic landscape of chemo-immunotherapy-treated mesotheliomas.</b></figcaption><div class="c-article-section__figure-content"><div class="c-article-section__figure-item"><a class="c-article-section__figure-link" data-test="img-link" data-track="click" data-track-label="image" data-track-action="view figure" href="/articles/s41591-021-01541-0/figures/2" rel="nofollow"><picture><source type="image/webp" srcset="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-021-01541-0/MediaObjects/41591_2021_1541_Fig2_HTML.png?as=webp"><img aria-describedby="Fig2" src="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-021-01541-0/MediaObjects/41591_2021_1541_Fig2_HTML.png" alt="figure 2" loading="lazy" width="685" height="658"></picture></a></div><div class="c-article-section__figure-description" data-test="bottom-caption" id="figure-2-desc"><p>MPMs of patients with a radiographic response harbored a higher number of non-synonymous missense sequence mutations (<i>n</i> = 40 MPM tumors; on average, 23 versus 18 mutations per exome for responding and non-responding tumors, respectively; Mann–Whitney <i>P</i> = 0.086). Epithelioid MPMs responding to therapy harbored a higher number of clonal missense mutations (<i>n</i> = 29 tumors; Mann–Whitney <i>P</i> = 0.051 and <i>P</i> = 0.025 for missense mutation load and clonal mutations, respectively); the numbers of subclonal mutations are shown as yellow inserts. Recurring inactivating alterations in <i>BAP1</i>, <i>CDKN2A</i>, <i>NF2</i>, <i>TP53</i>, <i>SETD2</i> and <i>PBRM1</i> did not differentially cluster with regard to therapeutic responses. Similarly, somatic <i>BAP1</i> sequence alterations and <i>CDKN2A</i> homozygous deletions were detected in 32.5% (13 of 40) and 30% (12 of 40) of MPMs, without a notable enrichment with respect to therapeutic response. Specific genotypes were associated with exceptional therapeutic outcome (PFS ≥12 months and/or OS ≥24 months): patient 178 harbored tumor biallellic inactivation of <i>NF2</i> and the histone methyltransferase <i>SETD2;</i> patient 926 harbored tumor biallellic inactivation of <i>BAP1</i>; and patient 361 harbored tumor homozygous deletions in <i>BAP1</i> and in the SWI/SNF nucleosome remodeling gene <i>PBRM1</i>. An enrichment in mutations in chromatin-regulating genes was observed for patients achieving an OS of 12 or more months (Fisher’s exact <i>P</i> = 0.063). We identified a higher contribution of an HRD mutation signature in responsive tumors (<i>n</i> = 40 patients; average HRD contribution of 9.1% versus 1.6% in responding and non-responding tumors, respectively; Mann–Whitney <i>P</i> = 0.043). Conversely, an APOBEC mutation signature was found to be more enriched in non-responding MPM and epithelioid MPM tumors (Mann–Whitney <i>P</i> = 0.058 and <i>P</i> = 0.031, respectively). Mutations were characterized by consequence (missense, frameshift, nonsense and splice site) and recurrence (hotspots, depicted as solid circles), and loss of the wild-type allele was considered in case of truncating mutations (biallellic inactivation, marked with an ‘x’). Tumor samples from patients 329, 351, 629 and 923 were excluded from analyses of somatic alterations owing to tumor tissue quality and are not shown here; these patients were included in the germline analyses, with patient 629 harboring a deleterious mutation in <i>BAP1</i>. BOR, best overall response; Epi, epithelioid; Sarc, sarcomatoid.</p><p><a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-021-01541-0#MOESM4">Source data</a></p></div></div><div class="u-text-right u-hide-print"><a class="c-article__pill-button" data-test="article-link" data-track="click" data-track-label="button" data-track-action="view figure" href="/articles/s41591-021-01541-0/figures/2" data-track-dest="link:Figure2 Full size image" aria-label="Full size image figure 2" rel="nofollow"><span>Full size image</span><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-right-small"></use></svg></a></div></figure></div><p>We then evaluated non-synonymous sequence alterations associated with putatively immunogenic neoantigens (immunogenic mutations (IMMs); <a data-track="click" data-track-label="link" data-track-action="section anchor" href="/articles/s41591-021-01541-0#Sec9">Methods</a> and Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-021-01541-0#MOESM2">3</a>) and found an enrichment of high major histocompatibility complex (MHC) class I IMM burden (<i>P</i> = 0.064) as well as a higher MHC class II IMM burden (<i>P</i> = 0.023) in responsive tumors (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01541-0#Fig10">5</a> and Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-021-01541-0#MOESM2">4</a>), especially for epithelioid MPM (<i>P</i> = 0.035 and <i>P</i> = 0.038, respectively). Interestingly, consistent with the HLA class I allele divergence hypothesis that points toward a more efficient tumor immune surveillance in the presence of HLA class I functional diversity<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 25" title="Chowell, D. et al. Evolutionary divergence of HLA class I genotype impacts efficacy of cancer immunotherapy. Nat. Med. 25, 1715–1720 (2019)." href="/articles/s41591-021-01541-0#ref-CR25" id="ref-link-section-d73969948e1791">25</a></sup>, maximal germline physiochemical sequence divergence at the HLA-B locus was associated with radiographic response, especially for epithelioid MPM (<i>P</i> = 0.06 and <i>P</i> = 0.003, respectively; Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01541-0#Fig12">7</a> and Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-021-01541-0#MOESM2">5</a>). We subsequently tested autologous T cells for reactivity against IMM-derived neopeptides for two patients who achieved long-term clinical response (<a data-track="click" data-track-label="link" data-track-action="section anchor" href="/articles/s41591-021-01541-0#Sec9">Methods</a>). T cell receptor (TCR) clonotypic expansions for neoantigens derived from the <i>SRPK2</i> p.C234Y and <i>NDUFS2</i> p.V412L mutations were prominent for patient 459 with sarcomatoid MPM and an OS of 33 months (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01541-0#Fig13">8</a>). Similarly, neoantigen-specific TCR expansions were noted for the IMMs <i>SCRN1</i> p.V334A, <i>PSD2</i> p.C307Y, <i>ZNF469</i> p.P3471S and <i>CD72</i> p.T71A for patient 295 with epithelioid MPM and an OS of 21.85 months (patient remained event-free at the time of data lock; Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01541-0#Fig13">8</a>).</p><p>Mesothelioma may arise in the context of germline mutations in cancer susceptibility genes, including <i>BAP1</i>, <i>MLH1</i>, <i>MLH3, BRCA1</i>, <i>BRCA2</i> and <i>BLM</i><sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 20" title="Panou, V. &amp; Roe, O. D. Inherited genetic mutations and polymorphisms in malignant mesothelioma: a comprehensive review. Int. J. Mol. Sci. 21, 4327 (2020)." href="/articles/s41591-021-01541-0#ref-CR20" id="ref-link-section-d73969948e1853">20</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 22" title="Bononi, A. et al. Heterozygous germline BLM mutations increase susceptibility to asbestos and mesothelioma. Proc. Natl Acad. Sci. USA 117, 33466–33473 (2020)." href="/articles/s41591-021-01541-0#ref-CR22" id="ref-link-section-d73969948e1856">22</a></sup>; however, the potential effect of germline MPM-predisposing mutations on response to chemo-immunotherapy has not been previously evaluated. Patients with pathogenic germline loss-of-function mutations in MPM susceptibility genes (<a data-track="click" data-track-label="link" data-track-action="section anchor" href="/articles/s41591-021-01541-0#Sec9">Methods</a>), predominantly those involved in DNA damage repair, had a significantly prolonged survival (log-rank <i>P</i> = 0.05 and <i>P</i> = 0.032 for all patients and epithelioid MPM, respectively; Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01541-0#Fig3">3a–d</a>). Interestingly, patients with sporadic <i>BAP1</i> mutant MPM harboring heterozygous somatic inactivating mutations did not have a better radiographic response or longer OS, potentially suggesting that immune surveillance mechanisms differ in the context of germline BAP1 deficiency<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 26" title="Napolitano, A. et al. Minimal asbestos exposure in germline BAP1 heterozygous mice is associated with deregulated inflammatory response and increased risk of mesothelioma. Oncogene 35, 1996–2002 (2016)." href="/articles/s41591-021-01541-0#ref-CR26" id="ref-link-section-d73969948e1876">26</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 27" title="Wang, T. et al. An empirical approach leveraging tumorgrafts to dissect the tumor microenvironment in renal cell carcinoma identifies missing link to prognostic inflammatory factors. Cancer Discov. 8, 1142–1155 (2018)." href="/articles/s41591-021-01541-0#ref-CR27" id="ref-link-section-d73969948e1879">27</a></sup>. As previously described<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 4" title="Carbone, M. et al. Tumour predisposition and cancer syndromes as models to study gene–environment interactions. Nat. Rev. Cancer 20, 533–549 (2020)." href="/articles/s41591-021-01541-0#ref-CR4" id="ref-link-section-d73969948e1884">4</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 28" title="Hassan, R. et al. Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy. Proc. Natl Acad. Sci. USA 116, 9008–9013 (2019)." href="/articles/s41591-021-01541-0#ref-CR28" id="ref-link-section-d73969948e1887">28</a></sup>, patients with inactivating <i>BAP1</i> germline mutations were younger (<i>P</i> = 0.009)<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 29" title="Bott, M. et al. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat. Genet. 43, 668–672 (2011)." href="/articles/s41591-021-01541-0#ref-CR29" id="ref-link-section-d73969948e1897">29</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 30" title="Robert, C. et al. Immunotherapy discontinuation—how, and when? Data from melanoma as a paradigm. Nat. Rev. Clin. Oncol. 17, 707–715 (2020)." href="/articles/s41591-021-01541-0#ref-CR30" id="ref-link-section-d73969948e1900">30</a></sup>, and tumors with <i>BAP1</i> biallellic inactivation were found to have an enriched DNA mismatch repair deficiency-related mutational signature (<i>P</i> = 0.003). Tumors harboring somatic <i>BAP1</i> inactivating mutations were noted to have a higher clonal TMB as well as a lower fraction of genome with loss of heterozygosity (LOH) (<i>P</i> = 0.033 and <i>P</i> = 0.018, respectively); notably a trend toward a lower degree of LOH was also observed for <i>BAP1</i> mutant mesotheliomas in the TCGA cohort. Interestingly, these findings were not corroborated in cases harboring germline inactivating <i>BAP1</i> mutations, highlighting the differences between germline and somatic genetic backgrounds. Furthermore, we found that epithelioid MPMs harboring somatic <i>BAP1</i> inactivating mutations had a higher intratumoral CD8<sup>+</sup> T cell infiltration (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01541-0#Fig14">9</a>). Analyses of transcriptomic sequence data for six patients with available tissue (four <i>BAP1</i> wild-type and two <i>BAP1</i> mutant) revealed a higher expression level for granzyme B in <i>BAP1</i> mutant tumors, suggesting an active cytotoxic immune response in the microenvironment of <i>BAP1</i> mutant tumors (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01541-0#Fig14">9</a>).</p><div class="c-article-section__figure js-c-reading-companion-figures-item" data-test="figure" data-container-section="figure" id="figure-3" data-title="Effect of germline mutations in cancer susceptibility genes on outcome from combined immuno-chemotherapy."><figure><figcaption><b id="Fig3" class="c-article-section__figure-caption" data-test="figure-caption-text">Fig. 3: Effect of germline mutations in cancer susceptibility genes on outcome from combined immuno-chemotherapy.</b></figcaption><div class="c-article-section__figure-content"><div class="c-article-section__figure-item"><a class="c-article-section__figure-link" data-test="img-link" data-track="click" data-track-label="image" data-track-action="view figure" href="/articles/s41591-021-01541-0/figures/3" rel="nofollow"><picture><source type="image/webp" srcset="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-021-01541-0/MediaObjects/41591_2021_1541_Fig3_HTML.png?as=webp"><img aria-describedby="Fig3" src="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-021-01541-0/MediaObjects/41591_2021_1541_Fig3_HTML.png" alt="figure 3" loading="lazy" width="685" height="554"></picture></a></div><div class="c-article-section__figure-description" data-test="bottom-caption" id="figure-3-desc"><p><b>a</b>, <b>b</b>, Patients harboring known deleterious germline mutations in mesothelioma-predisposing genes (<a data-track="click" data-track-label="link" data-track-action="section anchor" href="/articles/s41591-021-01541-0#Sec9">Methods</a>) had a longer OS (log-rank <i>P</i> = 0.05), especially in the epithelioid MPM group (log-rank <i>P</i> = 0.032). <b>c</b>, <b>d</b>, A focused analysis including deleterious germline mutations in <i>BAP1</i>, <i>BRCA2</i>, <i>MSH6</i> and <i>BLM</i>—all genes involved in DNA damage repair—showed the same trends toward a longer OS for patients harboring germline mutations in DDR genes (log-rank <i>P</i> = 0.12 for all patients and log-rank <i>P</i> = 0.082 for patients with epithelioid tumors). All <i>P</i> values are two sided. DDR; DNA damage repair.</p></div></div><div class="u-text-right u-hide-print"><a class="c-article__pill-button" data-test="article-link" data-track="click" data-track-label="button" data-track-action="view figure" href="/articles/s41591-021-01541-0/figures/3" data-track-dest="link:Figure3 Full size image" aria-label="Full size image figure 3" rel="nofollow"><span>Full size image</span><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-right-small"></use></svg></a></div></figure></div><p>Genomic instability and, particularly, large-scale copy number losses are hallmarks of MPM<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 18" title="Bueno, R. et al. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat. Genet. 48, 407–416 (2016)." href="/articles/s41591-021-01541-0#ref-CR18" id="ref-link-section-d73969948e2017">18</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 29" title="Bott, M. et al. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat. Genet. 43, 668–672 (2011)." href="/articles/s41591-021-01541-0#ref-CR29" id="ref-link-section-d73969948e2020">29</a></sup>, and our large-scale copy number analyses revealed recurrent chromosomal arm losses or LOH of 4p, 4q, 6q, 9p, 10q, 13q, 14q, 18q and 22q as well as LOH/deletion of 3p21.1, where <i>BAP1</i> lies (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01541-0#Fig4">4a</a>, Supplementary Tables <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-021-01541-0#MOESM2">6</a> and <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-021-01541-0#MOESM2">7</a> and Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01541-0#Fig15">10</a>). Regions of recurrent copy loss contained the <i>LATS1</i> (6q), <i>CDKN2A</i> (9p), <i>LATS2</i> (13q) and <i>NF2</i> (22q) loci. We found an enrichment for LOH of chromosomal arm 1p and hemizygous loss of chromosomal arm 6q in tumors that did not achieve a radiographic response (two of 24 in the responder versus six of 16 in the non-responder group, <i>P</i> = 0.04; Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01541-0#Fig4">4a</a>). Interestingly, loss of chromosomal arm 6q, which contains the mesothelioma driver genes <i>LATS1</i>, <i>REV3L</i> and <i>SHPRH</i>, was more prominent in epithelioid tumors without treatment response (two of 21 in the responder group versus four of eight in the non-responder group, <i>P</i> = 0.033). As DNA breaks occur frequently in mesothelioma<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 17" title="Hmeljak, J. et al. Integrative molecular characterization of malignant pleural mesothelioma. Cancer Discov. 8, 1548–1565 (2018)." href="/articles/s41591-021-01541-0#ref-CR17" id="ref-link-section-d73969948e2071">17</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 19" title="Mansfield, A. S. et al. Neoantigenic potential of complex chromosomal rearrangements in mesothelioma. J. Thorac. Oncol. 14, 276–287 (2019)." href="/articles/s41591-021-01541-0#ref-CR19" id="ref-link-section-d73969948e2074">19</a></sup>, we quantified chromosomal instability by estimating the number of copy number breakpoints across the genome (<a data-track="click" data-track-label="link" data-track-action="section anchor" href="/articles/s41591-021-01541-0#Sec9">Methods</a>) and found a higher content of genome-wide breakpoints in epithelioid MPM of patients with an OS of 12 or more months (<i>P</i> = 0.053; Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01541-0#Fig4">4b</a> and Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-021-01541-0#MOESM2">4</a>). Analysis of breakpoints of the TCGA mesothelioma cohort failed to identify such an association with OS (univariate Cox proportional hazards regression analysis, HR = 1.36, <i>P</i> = 0.23). Furthermore, we computed a composite homologous recombination deficiency (HRD) score, incorporating telomeric allelic imbalance, LOH and large-scale state transitions and found that a higher HRD score defined epithelioid tumors from patients with long-term survival (<i>P</i> = 0.014; Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01541-0#Fig4">4c</a> and Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-021-01541-0#MOESM2">4</a>); by contrast, no association was observed between a higher HRD score and outcome in the TCGA mesothelioma cohort (either as a continuous variable (HR = 1.02, <i>P</i> = 0.14) or a binarized variable (HR = 1.58, <i>P</i> = 0.18), using univariate Cox proportional hazards regression analysis). Consistent with these findings, a mutational signature of DNA double-strand break repair deficiency was more enriched in tumors of patients with a radiographic CR or PR (<i>P</i> = 0.043; Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01541-0#Fig2">2</a> and Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-021-01541-0#MOESM2">4</a>). Three cases showed genomic near haploidization, which is a phenomenon where cells lose one copy of nearly all chromosomes followed by duplication of the remaining chromosomes, and, interestingly, all of these patients had an OS of 12 or more months (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01541-0#Fig4">4a</a> and Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01541-0#Fig15">10</a>). It is plausible that mutations and associated neoantigens contained in regions of the genome with a single copy per cancer cell cannot be eliminated under the selective pressure of therapy and, therefore, mediate sustained neoantigen-driven immune responses and long-term clinical benefit. Consistent with this notion, we discovered a higher number of sequence alterations contained in single-copy regions of the genome in tumors from responders compared to non-responders (<i>P</i> = 0.027; Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01541-0#Fig4">4d</a>); notably, the overwhelming majority of these were clonal (71 of 93, 76%; Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-021-01541-0#MOESM2">8</a>). To further support these findings, we investigated the background rate of loss in regions of the genome with a single copy per cell (haploid regions) versus two copies per cell (euploid regions) and analyzed somatic copy number profiles of 1,086 mesothelioma and non-small-cell lung cancer tumors from TCGA (<a data-track="click" data-track-label="link" data-track-action="section anchor" href="/articles/s41591-021-01541-0#Sec9">Methods</a>). These analyses revealed that the rate of loss in haploid regions was consistently lower than that of euploid regions (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01541-0#Fig14">9</a>), supporting the notion that mutations contained in these regions are difficult to eliminate and might drive a sustained anti-tumor immune response.</p><div class="c-article-section__figure js-c-reading-companion-figures-item" data-test="figure" data-container-section="figure" id="figure-4" data-title="Large-scale copy number analyses."><figure><figcaption><b id="Fig4" class="c-article-section__figure-caption" data-test="figure-caption-text">Fig. 4: Large-scale copy number analyses.</b></figcaption><div class="c-article-section__figure-content"><div class="c-article-section__figure-item"><a class="c-article-section__figure-link" data-test="img-link" data-track="click" data-track-label="image" data-track-action="view figure" href="/articles/s41591-021-01541-0/figures/4" rel="nofollow"><picture><source type="image/webp" srcset="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-021-01541-0/MediaObjects/41591_2021_1541_Fig4_HTML.png?as=webp"><img aria-describedby="Fig4" src="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-021-01541-0/MediaObjects/41591_2021_1541_Fig4_HTML.png" alt="figure 4" loading="lazy" width="685" height="652"></picture></a></div><div class="c-article-section__figure-description" data-test="bottom-caption" id="figure-4-desc"><p><b>a</b>, Genome-wide copy number analyses predominantly revealed genomic regions with copy number losses (shown in blue) and were used to determine the extent of copy number breakpoints and fraction of genome with complete allelic imbalance, reflecting genomic instability and tumor aneuploidy. The relative copy ratio (log copy ratio) values quantifying the abundance of each genomic region compared to the average genome ploidy are shown per chromosome after correction for tumor purity. Red and blue shades indicate copy gains and losses, respectively, whereas white marks indicate copy neutral regions. An HRD score was computed, taking into account telomeric allelic imbalance, LOH and large-scale state transitions. Three extreme cases of LOH were noted, with a copy number pattern that was suggestive of genome near-haploidization; these patients had an OS of 12 or more months after chemo-immunotherapy. <b>b</b>, <b>c</b>, A higher number of copy number breakpoints and a higher HRD score distinguished epithelioid MPM from patients with an OS of 12 or more months (<i>n</i> = 28 epithelioid MPM tumors; Mann–Whitney <i>P</i> = 0.0.05 and <i>P</i> = 0.014, respectively). <b>d</b>, Responding tumors harbored a higher number of mutations in single-copy regions of the genome, suggesting that these ‘difficult’ to eliminate alterations and associated neoantigens might be important drivers of the anti-tumor immune response (<i>n</i> = 40 MPM tumors; Mann–Whitney <i>P</i> = 0.027). The center line in the box plots represents the median; the upper limit of the box plots represents the third quantile (75th percentile); the lower limit of the box plots represents the first quantile (25th percentile); the upper whisker is the maximum value of the data that are within 1.5 times the interquartile range over the 75th percentile; and the lower whisker is the minimum value of the data that are within 1.5 times the interquartile range under the 25th percentile. All <i>P</i> values are two sided. Allelic imb. frac., fraction of genome with allelic imbalance; BOR, best overall response; CNA, copy number alteration.</p><p><a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-021-01541-0#MOESM5">Source data</a></p></div></div><div class="u-text-right u-hide-print"><a class="c-article__pill-button" data-test="article-link" data-track="click" data-track-label="button" data-track-action="view figure" href="/articles/s41591-021-01541-0/figures/4" data-track-dest="link:Figure4 Full size image" aria-label="Full size image figure 4" rel="nofollow"><span>Full size image</span><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-right-small"></use></svg></a></div></figure></div><p>As reported previously<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 15" title="Nowak, A. K. et al. Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in. Lancet Oncol. 21, 1213–1223 (2020)." href="/articles/s41591-021-01541-0#ref-CR15" id="ref-link-section-d73969948e2200">15</a></sup>, we did not observe any association between radiographic responses, PFS or OS and PD-L1 expression on tumor cells. In looking at the tumor microenvironment of MPM, the composition of the pre-existing intra-tumoral TCR repertoire tied into the genomic footprint of MPM has not been previously investigated in the context of chemo-immunotherapy. Baseline tumors of patients with an OS of 12 or more months harbored a more diverse TCR repertoire in contrast to tumors of patients with shorter OS, which showed a higher TCR repertoire clonality and a higher proportion of high-frequency TCR clones (<i>P</i> = 0.018 and <i>P</i> = 0.006, respectively; Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01541-0#Fig5">5a–c</a> and Supplementary Tables <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-021-01541-0#MOESM2">4</a> and <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-021-01541-0#MOESM2">9</a>). We investigated the reshaping of the intra-tumoral T cell repertoire for three patients (295, 459 and 926) who had long-term therapeutic responses but eventually developed acquired resistance, by serially sampling tumors before therapy and at the time of acquired resistance. Interestingly, at the time of acquired resistance, significant reshaping signified by TCR clonotypic expansions and regressions was noted, such that the tumor-infiltrating lymphocyte (TIL) repertoire from all three cases was significantly more clonal (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01541-0#Fig5">5d</a>). These findings potentially suggest that an effective anti-tumor immune response is mediated by a polyclonal T cell repertoire, and dependency on fewer TCR effector cells might not be sufficient to mount an effective anti-tumor immune response.</p><div class="c-article-section__figure js-c-reading-companion-figures-item" data-test="figure" data-container-section="figure" id="figure-5" data-title="Baseline TCR repertoire characteristics and dynamic changes at the time of therapeutic resistance."><figure><figcaption><b id="Fig5" class="c-article-section__figure-caption" data-test="figure-caption-text">Fig. 5: Baseline TCR repertoire characteristics and dynamic changes at the time of therapeutic resistance.</b></figcaption><div class="c-article-section__figure-content"><div class="c-article-section__figure-item"><a class="c-article-section__figure-link" data-test="img-link" data-track="click" data-track-label="image" data-track-action="view figure" href="/articles/s41591-021-01541-0/figures/5" rel="nofollow"><picture><source type="image/webp" srcset="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-021-01541-0/MediaObjects/41591_2021_1541_Fig5_HTML.png?as=webp"><img aria-describedby="Fig5" src="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-021-01541-0/MediaObjects/41591_2021_1541_Fig5_HTML.png" alt="figure 5" loading="lazy" width="685" height="624"></picture></a></div><div class="c-article-section__figure-description" data-test="bottom-caption" id="figure-5-desc"><p><b>a</b>, The intratumoral T cell repertoire was interrogated by TCR Vβ sequencing; clonality of the TCR repertoire was computed; and the representation of dominant clones (<a data-track="click" data-track-label="link" data-track-action="section anchor" href="/articles/s41591-021-01541-0#Sec9">Methods</a>) as a proportion of the whole TCR repertoire was determined. CD8<sup>+</sup> T cell density and PD-L1 tumor proportion scores for each evaluable case are shown (missing cases are shown in gray). <b>b</b>, These analyses revealed a less clonal TCR repertoire in tumors from patients achieving an OS of 12 or more months (Mann–Whitney <i>P</i> = 0.018). <b>c</b>, A higher representation of dominant clones was also detected in tumors from patients with a shorter OS (Mann–Whitney <i>P</i> = 0.006). <b>d</b>, Differential abundance analyses of three cases with available tumor samples before therapy initiation (295, 459 and 926) and at the time of acquired resistance revealed TCR clonotypic expansions (labeled as significant positive) and regressions (labeled as significant negative) as shown for patient 926, who had a PR and an OS of 27.8 months. Fold change of intra-tumoral TCR clones is plotted on the <i>x</i> axis (log scale), and the adjusted corresponding Mann–Whitney <i>P</i> value is shown on the <i>y</i> axis (−log scale) of the volcano plot. All <i>P</i> values are two sided. Biph; biphasic; BOR, best overall response; Epi, epithelioid; IHC, immunohistochemistry; NE, non-evaluable; Neg, significantly negative (regressing TCR clones); NS, not significant; Pos, significantly positive (expanding TCR clones); Sarc, sarcomatoid.</p><p><a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-021-01541-0#MOESM6">Source data</a></p></div></div><div class="u-text-right u-hide-print"><a class="c-article__pill-button" data-test="article-link" data-track="click" data-track-label="button" data-track-action="view figure" href="/articles/s41591-021-01541-0/figures/5" data-track-dest="link:Figure5 Full size image" aria-label="Full size image figure 5" rel="nofollow"><span>Full size image</span><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-right-small"></use></svg></a></div></figure></div></div></div></section><section data-title="Discussion"><div class="c-article-section" id="Sec8-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Sec8">Discussion</h2><div class="c-article-section__content" id="Sec8-content"><p>The PrE0505 trial delivered promising rates of response, PFS and OS for patients who received durvalumab with standard chemotherapy as first-line therapy for unresectable MPM. Treatment was well tolerated, and there were low rates of immune-mediated toxicity. The median OS of 20.4 months in the PrE0505 trial is encouraging in the context of several recent phase 2 and 3 clinical trials that enrolled a similarly representative population of treatment-naive patients<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Scagliotti, G. V. et al. Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet Respir. Med. 7, 569–580 (2019)." href="#ref-CR7" id="ref-link-section-d73969948e2291">7</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Tsao, A. S. et al. Phase II trial of cediranib in combination with cisplatin and pemetrexed in chemotherapy-naive patients with unresectable malignant pleural mesothelioma (SWOG S0905). J. Clin. Oncol. 37, 2537–2547 (2019)." href="#ref-CR8" id="ref-link-section-d73969948e2291_1">8</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 9" title="Zalcman, G. et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet 387, 1405–1414 (2016)." href="/articles/s41591-021-01541-0#ref-CR9" id="ref-link-section-d73969948e2294">9</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 16" title="Baas, P. et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet 397, 375–386 (2021)." href="/articles/s41591-021-01541-0#ref-CR16" id="ref-link-section-d73969948e2297">16</a></sup>. Allied to recent results from the DREAM study, these data launched the ongoing phase 3 PrE0506/DREAM3R trial (<a href="https://clinicaltrials.gov/ct2/show/NCT04334759">NCT04334759</a>), which compares durvalumab with chemotherapy to chemotherapy alone<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 15" title="Nowak, A. K. et al. Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in. Lancet Oncol. 21, 1213–1223 (2020)." href="/articles/s41591-021-01541-0#ref-CR15" id="ref-link-section-d73969948e2308">15</a></sup>. Notably, the survival for patients with epithelioid MPM in the PrE0505 trial exceeded 2 years, and several patients with epithelioid MPM continue to be free from tumor progression at the time of this publication. This potential benefit from chemo-immunotherapy for epithelioid MPM is in contrast to the recent CheckMate 743 trial that reported a striking survival advantage favoring ipilimumab–nivolumab over chemotherapy for patients with non-epithelioid histology (18.1 versus 8.8 months); however, no significant survival difference was observed between the two treatment arms for patients with epithelioid MPM (18.7 versus 16.5 months)<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 16" title="Baas, P. et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet 397, 375–386 (2021)." href="/articles/s41591-021-01541-0#ref-CR16" id="ref-link-section-d73969948e2312">16</a></sup>. Given the known chemosensitivity of epithelioid MPM and the relative chemo-resistance of non-epithelioid MPM, it is possible that chemo-immunotherapy confers a synergistic advantage, particularly for patients with epithelioid MPM. As both DREAM and PrE0505 trials mandated that patients conclude durvalumab treatment after one full year of treatment, it is conceivable that some patients would derive additional benefit from maintenance therapy until disease progression, although data on this point are conflicting across tumor types<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 30" title="Robert, C. et al. Immunotherapy discontinuation—how, and when? Data from melanoma as a paradigm. Nat. Rev. Clin. Oncol. 17, 707–715 (2020)." href="/articles/s41591-021-01541-0#ref-CR30" id="ref-link-section-d73969948e2316">30</a></sup>. The investigational arm of the ongoing phase 3 PrE0506/DREAM3R trial includes treatment with maintenance durvalumab until confirmed disease progression, thus addressing this potential concern.</p><p>The clinical efficacy of chemo-immunotherapy shown in the PrE0505 trial challenged the common paradigm of immunotherapy-responsive tumors, as MPM harbors a low non-synonymous TMB that conceptually might limit the number of presented immunogenic neoantigens. Although tumors with TMB in the lower end of the spectrum are historically thought to have TMB-independent mechanisms of response to immunotherapy<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 19" title="Mansfield, A. S. et al. Neoantigenic potential of complex chromosomal rearrangements in mesothelioma. J. Thorac. Oncol. 14, 276–287 (2019)." href="/articles/s41591-021-01541-0#ref-CR19" id="ref-link-section-d73969948e2323">19</a></sup>, we discovered that a higher immunogenic mutation load distinguished responding tumors, particularly in the epithelioid MPM group. Notably, these findings were not corroborated in MPM treated with standard-of-care therapies, suggesting an association with durvalumab. Clonal TMB represents a dominant tumor-intrinsic determinant of clinical response to immunotherapy<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 31" title="Litchfield, K. et al. Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition. Cell 184, 596–614 (2021)." href="/articles/s41591-021-01541-0#ref-CR31" id="ref-link-section-d73969948e2327">31</a></sup>, which is consistent with our findings of clonal TMB predicting radiographic response in epithelioid MPM. Similarly, a high subclonal mutation burden, in part mediated by abnormal activity of the APOBEC enzymes, might enable tumor immune escape<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 32" title="Venkatesan, S. et al. Perspective: APOBEC mutagenesis in drug resistance and immune escape in HIV and cancer evolution. Ann. Oncol. 29, 563–572 (2018)." href="/articles/s41591-021-01541-0#ref-CR32" id="ref-link-section-d73969948e2331">32</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 33" title="Rosenthal, R. et al. Neoantigen-directed immune escape in lung cancer evolution. Nature 567, 479–485 (2019)." href="/articles/s41591-021-01541-0#ref-CR33" id="ref-link-section-d73969948e2334">33</a></sup>. We indeed discovered an inverse association between an APOBEC mutational signature and response to chemo-immunotherapy in epithelioid MPM in the PrE0505 cohort. To substantiate these findings, we pulsed autologous T cells with peptides derived from immunogenic mutations and identified neoantigen-specific TCR expansions in vitro, suggesting that robust neoantigen-specific responses were linked with favorable clinical outcome.</p><p>Consistent with the notion that MPM is driven by inactivating mutations in tumor suppressor genes<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 17" title="Hmeljak, J. et al. Integrative molecular characterization of malignant pleural mesothelioma. Cancer Discov. 8, 1548–1565 (2018)." href="/articles/s41591-021-01541-0#ref-CR17" id="ref-link-section-d73969948e2341">17</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 18" title="Bueno, R. et al. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat. Genet. 48, 407–416 (2016)." href="/articles/s41591-021-01541-0#ref-CR18" id="ref-link-section-d73969948e2344">18</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 29" title="Bott, M. et al. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat. Genet. 43, 668–672 (2011)." href="/articles/s41591-021-01541-0#ref-CR29" id="ref-link-section-d73969948e2347">29</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 34" title="Bianchi, A. B. et al. High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas. Proc. Natl Acad. Sci. USA 92, 10854–10858 (1995)." href="/articles/s41591-021-01541-0#ref-CR34" id="ref-link-section-d73969948e2350">34</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 35" title="Zhang, M. et al. Clonal architecture in mesothelioma is prognostic and shapes the tumour microenvironment. Nat. Commun. 12, 1751 (2021)." href="/articles/s41591-021-01541-0#ref-CR35" id="ref-link-section-d73969948e2353">35</a></sup>, we identified recurring inactivating largely non-overlapping genomic alterations in <i>BAP1</i>, <i>CDKN2A, NF2</i>, <i>SETD2</i>, <i>PBRM1</i> and <i>TP53</i> independent of therapeutic response. Although we did not find an enrichment in alterations of any single gene in tumors from patients with differential responses to chemo-immunotherapy, a trend toward an enrichment in somatic mutations in chromatin-regulating genes was noted in tumors from patients achieving an OS of 12 or more months; these alterations might mediate transcriptional changes of genes involved in immune-related signaling pathways<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 36" title="Pan, D. et al. A major chromatin regulator determines resistance of tumor cells to T cell-mediated killing. Science 359, 770–775 (2018)." href="/articles/s41591-021-01541-0#ref-CR36" id="ref-link-section-d73969948e2373">36</a></sup> or might be linked with a genomic instability phenotype that can predispose to response to immunotherapy<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 37" title="Shen, J. et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat. Med. 24, 556–562 (2018)." href="/articles/s41591-021-01541-0#ref-CR37" id="ref-link-section-d73969948e2377">37</a></sup>.</p><p>Germline genetic susceptibility has been established as a seminal event in MPM tumorigenesis, mostly involving tumor suppressor genes in DNA repair mechanisms<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 20" title="Panou, V. &amp; Roe, O. D. Inherited genetic mutations and polymorphisms in malignant mesothelioma: a comprehensive review. Int. J. Mol. Sci. 21, 4327 (2020)." href="/articles/s41591-021-01541-0#ref-CR20" id="ref-link-section-d73969948e2384">20</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 22" title="Bononi, A. et al. Heterozygous germline BLM mutations increase susceptibility to asbestos and mesothelioma. Proc. Natl Acad. Sci. USA 117, 33466–33473 (2020)." href="/articles/s41591-021-01541-0#ref-CR22" id="ref-link-section-d73969948e2387">22</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 29" title="Bott, M. et al. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat. Genet. 43, 668–672 (2011)." href="/articles/s41591-021-01541-0#ref-CR29" id="ref-link-section-d73969948e2390">29</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 38" title="Nasu, M. et al. High incidence of somatic BAP1 alterations in sporadic malignant mesothelioma. J. Thorac. Oncol. 10, 565–576 (2015)." href="/articles/s41591-021-01541-0#ref-CR38" id="ref-link-section-d73969948e2393">38</a></sup>. The frequency of 32% for <i>BAP1</i> genomic alterations in the PrE0505 cohort is in line with these previously reported analyses<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 17" title="Hmeljak, J. et al. Integrative molecular characterization of malignant pleural mesothelioma. Cancer Discov. 8, 1548–1565 (2018)." href="/articles/s41591-021-01541-0#ref-CR17" id="ref-link-section-d73969948e2400">17</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 29" title="Bott, M. et al. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat. Genet. 43, 668–672 (2011)." href="/articles/s41591-021-01541-0#ref-CR29" id="ref-link-section-d73969948e2403">29</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 39" title="Baumann, F. et al. Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival. Carcinogenesis 36, 76–81 (2015)." href="/articles/s41591-021-01541-0#ref-CR39" id="ref-link-section-d73969948e2406">39</a></sup>. Presence of germline <i>BAP1</i> mutations has been linked with a longer 5-year survival, suggesting a less aggressive phenotype of MPM arising in the context of a <i>BAP1</i> cancer syndrome<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 28" title="Hassan, R. et al. Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy. Proc. Natl Acad. Sci. USA 116, 9008–9013 (2019)." href="/articles/s41591-021-01541-0#ref-CR28" id="ref-link-section-d73969948e2417">28</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 39" title="Baumann, F. et al. Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival. Carcinogenesis 36, 76–81 (2015)." href="/articles/s41591-021-01541-0#ref-CR39" id="ref-link-section-d73969948e2420">39</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 40" title="Carbone, M. et al. Biological mechanisms and clinical significance of BAP1 mutations in human cancer. Cancer Discov. 10, 1103–1120 (2020)." href="/articles/s41591-021-01541-0#ref-CR40" id="ref-link-section-d73969948e2423">40</a></sup>. The underlying etiology of this phenomenon remains unclear, with one potential explanation being that the tumor microenvironment of BAP1 null tumors is more inflammatory<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 27" title="Wang, T. et al. An empirical approach leveraging tumorgrafts to dissect the tumor microenvironment in renal cell carcinoma identifies missing link to prognostic inflammatory factors. Cancer Discov. 8, 1142–1155 (2018)." href="/articles/s41591-021-01541-0#ref-CR27" id="ref-link-section-d73969948e2427">27</a></sup>. Although we did not find a prolonged survival for patients with somatic <i>BAP1</i> mutations, <i>BAP1</i> mutant tumors were found to have a higher degree of CD8<sup>+</sup> T cell infiltration. Notably, patients harboring deleterious germline mutations in MPM-predisposing genes, including, but not limited to, genes involved in DNA homologous recombination, achieved significantly longer PFS and OS with chemo-immunotherapy. Inherited defects in homologous recombination repair, resulting in microdeletions and DNA breaks, might be linked with longer OS after platinum chemotherapy<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 20" title="Panou, V. &amp; Roe, O. D. Inherited genetic mutations and polymorphisms in malignant mesothelioma: a comprehensive review. Int. J. Mol. Sci. 21, 4327 (2020)." href="/articles/s41591-021-01541-0#ref-CR20" id="ref-link-section-d73969948e2439">20</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 28" title="Hassan, R. et al. Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy. Proc. Natl Acad. Sci. USA 116, 9008–9013 (2019)." href="/articles/s41591-021-01541-0#ref-CR28" id="ref-link-section-d73969948e2442">28</a></sup> as well as affect adaptive and innate immunity, ultimately potentiating response to immune checkpoint blockade<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 41" title="Samstein, R. M. et al. Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy. Nat. Cancer 1, 1188–1203 (2021)." href="/articles/s41591-021-01541-0#ref-CR41" id="ref-link-section-d73969948e2447">41</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 42" title="Ishikawa, H. &amp; Barber, G. N. STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. Nature 455, 674–678 (2008)." href="/articles/s41591-021-01541-0#ref-CR42" id="ref-link-section-d73969948e2450">42</a></sup>. Our findings suggest that germline genotypes might affect clinical outcomes after chemo-immunotherapy, and germline testing should be considered for clinical decision-making for patients with mesothelioma.</p><p>Notably, we found that DNA repair deficiency, and defective homologous recombination in particular, determined by both sequence mutational spectra and genome-wide copy number analyses, were hallmarks of responding tumors, especially for epithelioid MPM. Overall, responding epithelioid tumors harbored a higher content of genome-wide copy number breakpoints, suggesting that genomic instability affects therapeutic efficacy for chemo-immunotherapy. Although we did not detect any evidence of oscillating copy number changes within any given chromosome indicative of chromothripsis in the PrE0505 cohort, there were three cases with extensive genome-wide LOH, a phenomenon called genome near-haploidization (GNH), which has been previously reported in five MPM cases<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 17" title="Hmeljak, J. et al. Integrative molecular characterization of malignant pleural mesothelioma. Cancer Discov. 8, 1548–1565 (2018)." href="/articles/s41591-021-01541-0#ref-CR17" id="ref-link-section-d73969948e2458">17</a></sup>. Interestingly, two of the tumors with GNH in our cohort harbored <i>BAP1</i> mutations, and all patients achieved an OS longer than 12 months. As GNH-harboring MPM might comprise a novel molecular subtype of MPM with distinctive clinical behavior<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 17" title="Hmeljak, J. et al. Integrative molecular characterization of malignant pleural mesothelioma. Cancer Discov. 8, 1548–1565 (2018)." href="/articles/s41591-021-01541-0#ref-CR17" id="ref-link-section-d73969948e2465">17</a></sup>, our findings suggest that these unique genomic features might be linked to favorable response to chemo-immunotherapy. Conceptually, immunogenic mutations residing in genomic loci that undergo haploidization cannot be lost under the selective pressure of immunotherapy<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 43" title="Anagnostou, V. et al. Evolution of neoantigen landscape during immune checkpoint blockade in non-small cell lung cancer. Cancer Discov. 7, 264–276 (2017)." href="/articles/s41591-021-01541-0#ref-CR43" id="ref-link-section-d73969948e2469">43</a></sup> and, therefore, might drive a sustained anti-tumor immune response. Consistent with this hypothesis, we discovered that tumors that harbored a higher number of sequence alterations in single-copy regions of the genome responded to combined chemo-immunotherapy.</p><p>The density of the CD8<sup>+</sup> T cell infiltrate has been associated with effective anti-tumor immune responses<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 44" title="Anagnostou, V. et al. Integrative tumor and immune cell mutli-omic analyses to predict melanoma response to immune checkpoint blockade. Cell Rep. Med. 1, 100139 (2020)." href="/articles/s41591-021-01541-0#ref-CR44" id="ref-link-section-d73969948e2478">44</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 45" title="Binnewies, M. et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat. Med. 24, 541–550 (2018)." href="/articles/s41591-021-01541-0#ref-CR45" id="ref-link-section-d73969948e2481">45</a></sup>; however, in the PrE0505 cohort, neither CD8<sup>+</sup> T cell infiltration nor PD-L1 protein expression predicted response to chemo-immunotherapy. Notably, the tumor microenvironment of responding tumors contained a less clonal TCR repertoire that become more polarized at the time of acquired resistance. In contrast to the notion that anti-tumor immune responses in the context of immunotherapy are driven by a clonal T cell repertoire in TMB-high tumors such as melanoma<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 44" title="Anagnostou, V. et al. Integrative tumor and immune cell mutli-omic analyses to predict melanoma response to immune checkpoint blockade. Cell Rep. Med. 1, 100139 (2020)." href="/articles/s41591-021-01541-0#ref-CR44" id="ref-link-section-d73969948e2487">44</a></sup> or non-small-cell lung cancer<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 46" title="Joshi, K. et al. Spatial heterogeneity of the T cell receptor repertoire reflects the mutational landscape in lung cancer. Nat. Med. 25, 1549–1559 (2019)." href="/articles/s41591-021-01541-0#ref-CR46" id="ref-link-section-d73969948e2491">46</a></sup>, our findings suggest that maximal immune cell repertoire diversity is required to mount an effective anti-tumor immune response in MPM. Consistent with this notion, a higher TCR diversity has been previously shown to correlate with improved outcome in bladder cancer, colorectal cancer, hepatocellular carcinoma and uterine cancer<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 47" title="Thorsson, V. et al. The immune landscape of cancer. Immunity 48, 812–830 (2018)." href="/articles/s41591-021-01541-0#ref-CR47" id="ref-link-section-d73969948e2496">47</a></sup>.</p><p>Our study was limited by its small sample size and absence of a non-durvalumab control arm. To interpret our molecular findings with respect to response to chemo-immunotherapy compared to standard-of-care therapy alone, we performed genomic analyses of an independent cohort of 82 mesotheliomas obtained from the TCGA registry. This cohort did not include patients treated with chemo-immunotherapy or immunotherapy, and analyses of the TCGA mesothelioma cohort suggested that the genomic features of response in the PrE0505 trial were driven by durvalumab. Notably, definitively assessing the predictive versus prognostic nature of our findings is needed and planned within the ongoing phase 3 randomized DREAM3R/PrE0506 trial. Furthermore, although the control survival was chosen based on the historical control that led to the approval of pemetrexed with cisplatin<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 5" title="Vogelzang, N. J. et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J. Clin. Oncol. 21, 2636–2644 (2003)." href="/articles/s41591-021-01541-0#ref-CR5" id="ref-link-section-d73969948e2503">5</a></sup>, recent randomized data have shown both shorter and longer survival for the pemetrexed–cisplatin combination<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 8" title="Tsao, A. S. et al. Phase II trial of cediranib in combination with cisplatin and pemetrexed in chemotherapy-naive patients with unresectable malignant pleural mesothelioma (SWOG S0905). J. Clin. Oncol. 37, 2537–2547 (2019)." href="/articles/s41591-021-01541-0#ref-CR8" id="ref-link-section-d73969948e2507">8</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 9" title="Zalcman, G. et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet 387, 1405–1414 (2016)." href="/articles/s41591-021-01541-0#ref-CR9" id="ref-link-section-d73969948e2510">9</a></sup>; it is, therefore, possible that control assumptions might have underestimated the expected survival with chemotherapy alone.</p><p>In summary, we report the favorable clinical efficacy of the PrE0505 study of chemo-immunotherapy for unresectable MPM with in-depth molecular and functional analyses, which provide an understanding of the complex genomic and immune cell features of response to combined chemo-immunotherapy with potential broad clinical implications.</p></div></div></section><section data-title="Methods"><div class="c-article-section" id="Sec9-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Sec9">Methods</h2><div class="c-article-section__content" id="Sec9-content"><h3 class="c-article__sub-heading" id="Sec10">Trial design, endpoints, oversight and samples analyzed</h3><p>The first patient enrollment date was 12 June 2017; the last patient enrollment date 21 June 2018. A detailed outline of the numbers of patients available for analyses is shown in the CONSORT diagram in Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01541-0#Fig6">1</a>. Owing to biospecimen availability and biospecimen quality, germline genomic data were evaluable for 44 patients, and somatic genomic data were evaluable for 40 patients (Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-021-01541-0#MOESM2">1</a> and Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01541-0#Fig6">1</a>). A data safety monitoring board reviewed the study twice a year, and patient consent was provided for sample collection.</p><p>The full list of the inclusion and exclusion criteria is shown below:</p><ul class="u-list-style-bullet">
                  <li>
                    <p>Histologically and/or cytologically confirmed MPM</p>
                  </li>
                  <li>
                    <p>Unresectable disease (defined as the participant not being a candidate for curative surgery)</p>
                  </li>
                  <li>
                    <p>Measurable disease, defined as at least one lesion (measurable) that can be accurately assessed at baseline by computed tomography or magnetic resonance imaging and is suitable for repeated assessment (modified RECIST for pleural mesothelioma)</p>
                  </li>
                  <li>
                    <p>Available unstained archived tumor tissue sample in sufficient quantity to allow for analyses. At least 15 unstained slides or a tumor block (preferred). Note: A fine needle aspiration sample is not sufficient to make the patient eligible for enrollment. Given the complexity of mesothelioma pathological diagnosis and that these will be newly diagnosed patients, it is expected that they will have a core needle biopsy or surgical tumor biopsy as part of their initial diagnostic workup.</p>
                  </li>
                  <li>
                    <p>Age ≥ 18 years</p>
                  </li>
                  <li>
                    <p>ECOG performance status of 0 or 1</p>
                  </li>
                  <li>
                    <p>Ability to understand and willingness to sign institutional review board-approved informed consent</p>
                  </li>
                  <li>
                    <p>Willingness to provide archived tumor tissue and blood samples for research</p>
                  </li>
                  <li>
                    <p>Adequate organ function as measured by the following criteria, obtained at most 2 weeks before registration:</p><ul class="u-list-style-bullet">
                      <li>
                        <p>Absolute neutrophil count ≥1,500 per mm³</p>
                      </li>
                      <li>
                        <p>Hemoglobin &gt;9.0 g dl<sup>−1</sup></p>
                      </li>
                      <li>
                        <p>Platelets &gt;100,000 per mm<sup>3</sup></p>
                      </li>
                      <li>
                        <p>Serum creatinine clearance &gt;60 ml min<sup>−1</sup> by the Cockcroft–Gault formula or by 24-h urine collection for determination of creatinine clearance. Note: Patients with a creatinine clearance ≥45 ml min<sup>−1</sup> but ≤60 ml min<sup>−1</sup> may be considered for enrollment provided they fulfill all other eligibility criteria. These patients will receive pemetrexed carboplatin concurrent with durvalumab during the combination phase of treatment. Patients with a creatinine clearance &lt;45 ml min<sup>−1</sup> should not be enrolled.</p>
                      </li>
                      <li>
                        <p>Albumin ≥2.8 g dl<sup>−1</sup></p>
                      </li>
                      <li>
                        <p>Total bilirubin ≤1.5× the upper limit of normal (ULN)</p>
                      </li>
                      <li>
                        <p>Aspartate aminotransferase/alanine aminotransferas ≤2.5× ULN (≤5× ULN in patients with liver metastases)</p>
                      </li>
                    </ul>
                  </li>
                  <li>
                    <p>Women must either be of non-reproductive potential or have a negative serum pregnancy test upon study entry.</p>
                  </li>
                  <li>
                    <p>Women must not be pregnant or breastfeeding.</p>
                  </li>
                  <li>
                    <p>Patients are willing and able to comply with the protocol for the duration of the study, including undergoing treatment and scheduled visits and examinations, including follow-up.</p>
                  </li>
                  <li>
                    <p>Patients must not have involvement in the planning and/or conduct of the study and no previous enrollment in the present study.</p>
                  </li>
                  <li>
                    <p>Patients must not have participated in another clinical study with an investigational product during the last 4 weeks.</p>
                  </li>
                  <li>
                    <p>Patients must not have received any prior systemic therapy (chemotherapy, immunotherapy, endocrine therapy, targeted therapy, biologic therapy, tumor embolization, monoclonal antibodies or other investigational agent) for mesothelioma.</p>
                  </li>
                  <li>
                    <p>No previous treatment with a PD1 or PD-L1 inhibitor, including durvalumab or any other agent targeting immune checkpoints</p>
                  </li>
                  <li>
                    <p>Patients must not have non-pleural mesothelioma—for example, mesothelioma arising in the peritoneum, tunica vaginalis or any serosal surface other than the pleura.</p>
                  </li>
                  <li>
                    <p>Patients must not have an active second malignancy other than non-melanoma skin cancer or cervical carcinoma in situ.</p>
                  </li>
                  <li>
                    <p>Patients must not have a mean QT interval corrected for heart rate (QTc) ≥470 ms calculated from three electrocardiograms using Frediricia’s correction.</p>
                  </li>
                  <li>
                    <p>Patients must not have symptomatic or uncontrolled brain metastases requiring concurrent treatment, inclusive of, but not limited to, surgery, radiation and/or corticosteroids (prednisone &gt;10 mg or equivalent). Surgery, radiation and/or corticosteroids (any dose &gt;10 mg of prednisone equivalent) must have been completed 2 or more weeks before registration.</p>
                  </li>
                  <li>
                    <p>Patients must not have uncontrolled seizures.</p>
                  </li>
                  <li>
                    <p>Patients must not have current or prior use of immunosuppressive medication within 28 d before the first dose of durvalumab, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg per day of prednisone or an equivalent corticosteroid. Standard steroid premedication given before chemotherapy or as prophylaxis for imaging contrast allergy should not be counted for this criterion.</p>
                  </li>
                  <li>
                    <p>No active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease, diverticulitis with the exception of diverticulosis, celiac disease, irritable bowel disease and Wegner syndrome) within the past 2 years. Patients with vitiligo, alopecia, Grave’s disease or psoriasis not requiring systemic treatment (within the past 3 years) are not excluded.</p>
                  </li>
                  <li>
                    <p>No history of primary immunodeficiency</p>
                  </li>
                  <li>
                    <p>No history of allogeneic organ transplant</p>
                  </li>
                  <li>
                    <p>No history of hypersensitivity to durvalumab, cisplatin, carboplatin, pemetrexed or any of their excipients</p>
                  </li>
                  <li>
                    <p>No uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, active peptic ulcer disease or gastritis and active bleeding diatheses, as well as any patient known to have psychiatric illness/social situations that would limit compliance with study requirements or compromise the ability of the patient to give written informed consent.</p>
                  </li>
                  <li>
                    <p>No active infection, including tuberculosis (clinical evaluation including physical examination findings, radiographic findings and positive purified protein derivative test), hepatitis B virus (HBV) (known positive HBV surface antigen (HBsAg) result) and hepatitis C or HIV (positive HIV 1/2 antibodies as defined by a positive ELISA test). Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody (anti-HBc) and absence of HBsAg) are eligible. Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV RNA. HIV testing is not required in absence of clinical suspicion.</p>
                  </li>
                  <li>
                    <p>No known history of leptomeningeal carcinomatosis</p>
                  </li>
                  <li>
                    <p>Patients must not have received live attenuated vaccination within 30 d before study entry or within 30 d of receiving durvalumab.</p>
                  </li>
                  <li>
                    <p>Patients must not have any condition that, in the opinion of the investigator, would interfere with the evaluation of study treatment or interpretation of patient safety or study results.</p>
                  </li>
                </ul><p>Imaging was performed every 6 weeks during the concurrent phase of treatment and every 9 weeks during maintenance durvalumab. Best objective response was evaluated by RECIST version 1.1 criteria modified for mesothelioma. Toxicity was determined using Common Terminology Criteria for Adverse Events version 4.03.</p><p>Secondary objectives included safety and tolerability of durvalumab and durvalumab in combination with chemotherapy in patients with MPM; percentage of patients who were progression-free at 24 weeks from the time of registration (response coded based on modified RECIST 1.1 criteria for mesothelioma); PFS, measured from the time of study registration until radiologic progression, clinical progression or death; and best objective response rate with evaluation continued for up to 1 year (response coded based on modified RECIST version 1.1 criteria for mesothelioma). Exploratory objectives included assessment of tumor baseline PD-L1 expression, the genomic and neoantigen landscape of tumors, dynamics of circulating cell-free tumor DNA and other blood-based biomarkers.</p><h3 class="c-article__sub-heading" id="Sec11">WES</h3><h4 class="c-article__sub-heading c-article__sub-heading--small" id="Sec12">TCGA mesothelioma cohort</h4><p>We obtained matched tumor-normal exome sequencing data from 82 patients with MPM in TCGA (<a href="http://cancergenome.nih.gov">http://cancergenome.nih.gov</a>), as outlined in TCGA publication guidelines (<a href="http://cancergenome.nih.gov/publications/publicationguidelines">http://cancergenome.nih.gov/publications/publicationguidelines</a>). WES-derived somatic mutation calls from the TCGA PanCancer Atlas MC3 project were retrieved from the National Cancer Institute (NCI) Genomic Data Commons (<a href="https://gdc.cancer.gov/about-data/publications/">https://gdc.cancer.gov/about-data/publications/</a>, mc3-2017). The MC3 mutation call set is the result of application of a uniform analysis pipeline, including a standardized set of six mutation callers and an array of automated filters to all the entire TCGA exome data<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 48" title="Ellrott, K. et al. Scalable open science approach for mutation calling of tumor exomes using multiple genomic pipelines. Cell Syst. 6, 271–281 (2018)." href="/articles/s41591-021-01541-0#ref-CR48" id="ref-link-section-d73969948e2829">48</a></sup>. TMB was calculated as the number of non-synonymous mutations detected by WES.</p><h3 class="c-article__sub-heading" id="Sec13">Tissue sample characteristics and sample preparation</h3><p>Formalin-fixed, paraffin-embedded (FFPE) tumor tissue and matched peripheral blood were collected before therapy initiation. DNA was extracted from patients’ tumors and matched peripheral blood using the Qiagen DNA kit. Fragmented genomic DNA from tumor and normal samples was used for Illumina TruSeq library construction, and exonic regions were captured in solution using the Agilent SureSelect V4 kit according to the manufacturer’s instructions, as previously described<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 43" title="Anagnostou, V. et al. Evolution of neoantigen landscape during immune checkpoint blockade in non-small cell lung cancer. Cancer Discov. 7, 264–276 (2017)." href="/articles/s41591-021-01541-0#ref-CR43" id="ref-link-section-d73969948e2842">43</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 49" title="Jones, S. et al. Personalized genomic analyses for cancer mutation discovery and interpretation. Sci. Transl. Med. 7, 283ra253 (2015)." href="/articles/s41591-021-01541-0#ref-CR49" id="ref-link-section-d73969948e2845">49</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 50" title="Anagnostou, V. et al. Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer. Nat. Cancer 1, 99–111 (2020)." href="/articles/s41591-021-01541-0#ref-CR50" id="ref-link-section-d73969948e2848">50</a></sup>. Paired-end sequencing, resulting in 100 bases from each end of the fragments for the exome libraries, was performed using Illumina HiSeq 2000/2500 instrumentation. The mean depth of total coverage for the pre-treatment tumors and matched normal DNA samples was 220× (166× distinct) and 105× (90× distinct,) respectively (Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-021-01541-0#MOESM2">2</a>). On average, 94% of the bases in the target region had a minimum coverage of 10×; four tumor samples (329, 351, 629 and 923) were determined to be of low purity by mutation and copy number analyses and were excluded from all WES-based analyses of somatic alterations, whereas their matched normal DNA samples were included in the germline analyses.</p><h3 class="c-article__sub-heading" id="Sec14">Somatic mutation calling, immunogenic mutation characterization and neoantigen prediction</h3><p>Somatic mutations, consisting of point mutations, insertions and deletions, across the whole exome were identified using the VariantDx custom software for identifying mutations in matched tumor and normal samples, as previously described<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 43" title="Anagnostou, V. et al. Evolution of neoantigen landscape during immune checkpoint blockade in non-small cell lung cancer. Cancer Discov. 7, 264–276 (2017)." href="/articles/s41591-021-01541-0#ref-CR43" id="ref-link-section-d73969948e2863">43</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 49" title="Jones, S. et al. Personalized genomic analyses for cancer mutation discovery and interpretation. Sci. Transl. Med. 7, 283ra253 (2015)." href="/articles/s41591-021-01541-0#ref-CR49" id="ref-link-section-d73969948e2866">49</a></sup>. Mutations were annotated with the number of tumor samples harboring identical amino acid changes in cosmic database (v91). Somatic sequence alterations are listed in Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-021-01541-0#MOESM2">3</a>. Sequence alterations in DNA damage repair genes were analyzed separately, and the list of DNA damage repair genes considered is shown in Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-021-01541-0#MOESM2">10</a>. MHC class I and II neoantigens were derived from non-synonymous single-base substitutions using MHCnuggets<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 51" title="Shao, X. M. et al. High-throughput prediction of MHC class I and II neoantigens with MHCnuggets. Cancer Immunol. Res. 8, 396–408 (2020)." href="/articles/s41591-021-01541-0#ref-CR51" id="ref-link-section-d73969948e2876">51</a></sup>. Ranks of neopeptides were determined based on their MHC binding affinity compared to 10,000 human proteome peptides per peptide length per binding MHC allele. Sequence alterations resulting in neopeptides ranking in the 1st percentile were considered putatively IMMs (Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-021-01541-0#MOESM2">3</a>).</p><h3 class="c-article__sub-heading" id="Sec15">Germline predisposition characterization</h3><p>A set of cancer susceptibility genes with alterations contributing to germline predisposition to mesothelioma was compiled from the literature<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 3" title="Panou, V. et al. Frequency of germline mutations in cancer susceptibility genes in malignant mesothelioma. J. Clin. Oncol. 36, 2863–2871 (2018)." href="/articles/s41591-021-01541-0#ref-CR3" id="ref-link-section-d73969948e2892">3</a></sup>. Non-synonymous germline alterations in the above set were identified by applying Strelka 2.9.2 (ref. <sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 52" title="Kim, S. et al. Strelka2: fast and accurate calling of germline and somatic variants. Nat. Methods 15, 591–594 (2018)." href="/articles/s41591-021-01541-0#ref-CR52" id="ref-link-section-d73969948e2896">52</a></sup>), and the candidate mutation set was first filtered to include positions where the genotype was of sufficient quality and could be resolved in both normal and tumor samples of each patient. Variants were subsequently annotated using OpenCRAVAT<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 53" title="Pagel, K. A. et al. Integrated informatics analysis of cancer-related variants. JCO Clin. Cancer Inform. 4, 310–317 (2020)." href="/articles/s41591-021-01541-0#ref-CR53" id="ref-link-section-d73969948e2900">53</a></sup>. Confirmed pathogenic variants—hereafter termed germline deleterious mutations—including nonsense, frameshift, splice site and missense variants, in genes with known cancer susceptibility potential, were identified based on annotation in the ClinVar database and published evidence of a damaging effect on protein function.</p><h3 class="c-article__sub-heading" id="Sec16">Mutation signatures</h3><p>Mutation signatures were derived based on the fraction of coding point mutations in each of 96 trinucleotide contexts and estimated the contribution of each signature to each tumor sample using the deconstructSigs R package (v1.8.0) with the default ‘signatures.nature2013’ settings<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 54" title="Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415–421 (2013)." href="/articles/s41591-021-01541-0#ref-CR54" id="ref-link-section-d73969948e2912">54</a></sup> (<a href="https://CRAN.R-project.org/package=deconstructSigs">https://cran.r-project.org/package=deconstructSigs</a>).</p><h3 class="c-article__sub-heading" id="Sec17">HLA germline and somatic analyses</h3><p>OptiType v1.2. was used to determine HLA class I haplotypes<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 55" title="Szolek, A. et al. OptiType: precision HLA typing from next-generation sequencing data. Bioinformatics 30, 3310–3316 (2014)." href="/articles/s41591-021-01541-0#ref-CR55" id="ref-link-section-d73969948e2931">55</a></sup>; xHLA was used to determine HLA class II haplotypes for HLA-DPB1, HLA-DQB1, HLA-DRB1<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 56" title="Xie, C. et al. Fast and accurate HLA typing from short-read next-generation sequence data with xHLA. Proc. Natl Acad. Sci. USA 114, 8059–8064 (2017)." href="/articles/s41591-021-01541-0#ref-CR56" id="ref-link-section-d73969948e2935">56</a></sup>; and SOAP-HLA was used to determined class II haplotypes for HLA-DPA1 and HLA-DQA1 (ref. <sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 57" title="Cao, H. et al. An integrated tool to study MHC region: accurate SNV detection and HLA genes typing in human MHC region using targeted high-throughput sequencing. PLoS ONE 8, e69388 (2013)." href="/articles/s41591-021-01541-0#ref-CR57" id="ref-link-section-d73969948e2939">57</a></sup>). A separate bioinformatic analysis using POLYSOLVER<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 58" title="Shukla, S. A. et al. Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes. Nat. Biotechnol. 33, 1152–1158 (2015)." href="/articles/s41591-021-01541-0#ref-CR58" id="ref-link-section-d73969948e2943">58</a></sup> was used to detect and annotate the somatic mutations in class I HLA genes. We determined HLA class I loss in the tumor by applying LOHHLA<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 59" title="McGranahan, N. et al. Allele-specific HLA loss and immune escape in lung cancer evolution. Cell 171, 1259–1271 (2017)." href="/articles/s41591-021-01541-0#ref-CR59" id="ref-link-section-d73969948e2947">59</a></sup>. We evaluated somatic loss of HLA class II genes by review of allele-specific copy number of these loci, where minor copy number of 0 indicated LOH. The number of unique tumor HLA class I and II alleles was calculated by subtracting the number of heterozygous alleles with somatic LOH from the total number of unique germline alleles. We subsequently computed an HLA evolutionary divergence (HED) score by using Grantham distances between protein sequences of allele pairs for each HLA-A, HLA-B and HLA-C locus<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 25" title="Chowell, D. et al. Evolutionary divergence of HLA class I genotype impacts efficacy of cancer immunotherapy. Nat. Med. 25, 1715–1720 (2019)." href="/articles/s41591-021-01541-0#ref-CR25" id="ref-link-section-d73969948e2952">25</a></sup>. HLA class I allele protein sequences are obtained from the ImMunoGeneTics /HLA database<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 60" title="Robinson, J. et al. The IPD and IMGT/HLA database: allele variant databases. Nucleic Acids Res. 43, D423–D431 (2015)." href="/articles/s41591-021-01541-0#ref-CR60" id="ref-link-section-d73969948e2956">60</a></sup>. A cumulative HED score for each sample was also computed as the arithmetic mean of the three individual divergences, assuming equal contribution from each locus. Germline and somatic HLA class I and II genomic variation is summarized in Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-021-01541-0#MOESM2">5</a>.</p><h3 class="c-article__sub-heading" id="Sec18">Genome-wide copy number analyses</h3><p>We used FACETS 0.6.1 to estimate the purity of each tumor sample, the integer allele-specific copy number profile across the genome and the cellular fraction associated with each aberrant somatic copy number alteration<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 61" title="Shen, R. &amp; Seshan, V. E. FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing. Nucleic Acids Res. 44, e131 (2016)." href="/articles/s41591-021-01541-0#ref-CR61" id="ref-link-section-d73969948e2971">61</a></sup>. The estimated allele-specific copy number profiles were reviewed to ensure quality of fit. In four cases with very low tumor purity (329, 351, 629 and 923), the copy number states and ploidy could not be resolved; these cases were excluded from subsequent copy-number-based analyses. Furthermore, we investigated potential associations between copy-number-derived tumor purity and tumor mutation and IMM load; these analyses revealed a weak association between tumor purity and TMB-derived features when all patients were considered, but no statistically significant association was observed among these features in epithelioid mesotheliomas (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01541-0#Fig15">10</a>). Three cases (225, 926 and 922) harbored extensive LOH across the genome with evidence of GNH (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01541-0#Fig4">4</a> and Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01541-0#Fig14">9</a>). In each tumor sample, the number of sequence alterations overlapping loci with total copy number of 1 was recorded. Focal copy number changes—that is, amplifications and deletions—were determined as genomic regions of a size smaller than 30 Mb where the assigned copy number was 0 (homozygous deletion), or it exceeded three times the ploidy of the tumor sample (amplifications; Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-021-01541-0#MOESM2">7</a>). The estimated ploidy was rounded to the closest integer level and was used as the reference for determining loss, gain or neutral status of each copy number segment. Gain, loss or LOH in each chromosome arm was evaluated if at least 90% of the length of the arm was covered by segments of the given status. The statistical significance of the prevalence of each category of alterations across the arms was evaluated by performing a permutation experiment. In this experiment, each permutation sample was a vector of size 39 where the total number of chromosome arms harboring gain, loss or LOH equaled this value for one of the samples in the main cohort to match the observed level of aneuploidy in the population.</p><h3 class="c-article__sub-heading" id="Sec19">Mutation clonality estimation</h3><p>For each somatic sequence alteration, the observed mutant and total read counts, the tumor purity and the tumor copy number at the mutated locus were integrated using SCHISM<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 62" title="Niknafs, N., Beleva-Guthrie, V., Naiman, D. Q. &amp; Karchin, R. SubClonal hierarchy inference from somatic mutations: automatic reconstruction of cancer evolutionary trees from multi-region next generation sequencing. PLoS Comput. Biol. 11, e1004416 (2015)." href="/articles/s41591-021-01541-0#ref-CR62" id="ref-link-section-d73969948e2995">62</a></sup> and as previously described<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 50" title="Anagnostou, V. et al. Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer. Nat. Cancer 1, 99–111 (2020)." href="/articles/s41591-021-01541-0#ref-CR50" id="ref-link-section-d73969948e2999">50</a></sup> to determine the clonality—that is, the fraction of cancer cells that harbor the alteration (Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-021-01541-0#MOESM2">3</a>).</p><h3 class="c-article__sub-heading" id="Sec20">Aneuploidy assessment</h3><p>Several metrics characterizing the degree of genome aneuploidy were calculated, including the fraction of genome with LOH, the fraction of genome with allelic imbalance, the number of copy number breakpoints and the entropy of the multinomial probability distribution corresponding to the genome representation of different copy number levels (Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-021-01541-0#MOESM2">7</a>)<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 50" title="Anagnostou, V. et al. Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer. Nat. Cancer 1, 99–111 (2020)." href="/articles/s41591-021-01541-0#ref-CR50" id="ref-link-section-d73969948e3017">50</a></sup>. The number of copy number breakpoints was used as a proxy measure for the extent of somatic structural alterations in each tumor.</p><h3 class="c-article__sub-heading" id="Sec21">Homologous recombination deficiency estimation</h3><p>To assess the extent of HRD in tumors, three individual and one combined metric were determined based on the allele-specific copy number profiles by applying the R package scar-HRD 0.1.1 (ref. <sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 63" title="Sztupinszki, Z. et al. Migrating the SNP array-based homologous recombination deficiency measures to next generation sequencing data of breast cancer. NPJ Breast Cancer 4, 16 (2018)." href="/articles/s41591-021-01541-0#ref-CR63" id="ref-link-section-d73969948e3030">63</a></sup>): telomeric allelic imbalance (HRD-TAI score; the count of copy number segments with allelic imbalance that extend of telomeres); loss of heterozygosity profiles (HRD-LOH score; the number of segments with a minimum size of 15 Mb that do not span the entire chromosome); and large-scale state transitions (HRD-LST score; the number of breakpoints between segments with minimum size of 10 Mb where the gap between the segments does not exceed 3 Mb). A combined metric for HRD, termed HRD-sum, was defined as the sum of the three individual metrics (Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-021-01541-0#MOESM2">7</a>).</p><h3 class="c-article__sub-heading" id="Sec22">Evaluation of the background rate of genomic loss</h3><p>To better characterize the background rate of loss in regions of the genome with a single copy per cell (haploid) versus euploid regions (two copies per cell, no LOH), we analyzed somatic copy number profiles of 1,086 mesothelioma and non-small-cell lung cancer tumors from TCGA. In each tumor, we first determined the chromosome arms where at least 75% of the arm length was covered by the copy number state of interest. The set of tumor samples was then narrowed down to those with at least one arm in haploid state (<i>n</i> = 544). Next, across all chromosome arms of a given state, the rate of loss was determined as follows. In the haploid arms, the loss rate was defined as the total number of bases with somatic copy number of 0 within these arms, divided by the total length of arms in haploid state. In the diploid arms, the loss rate was defined as the total number of bases with somatic copy number of 0 within these arms multiplied by 2 added to the number of bases with somatic copy number of 1, and then divided by the total length of arms in euploid state.</p><h3 class="c-article__sub-heading" id="Sec23">TCR sequencing</h3><p>Intra-tumoral TCR clones were evaluated by next-generation sequencing of the baseline tumor as well as matched baseline-resistant tumors for cases 295, 459 and 926. TCR-β CDR3 regions were amplified using the survey ImmunoSeq assay in a multiplex PCR method using 45 forward primers specific to TCR Vβ gene segments and 13 reverse primers specific to TCR Jβ gene segments (Adaptive Biotechnologies)<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 64" title="Carlson, C. S. et al. Using synthetic templates to design an unbiased multiplex PCR assay. Nat. Commun. 4, 2680 (2013)." href="/articles/s41591-021-01541-0#ref-CR64" id="ref-link-section-d73969948e3056">64</a></sup>. Productive TCR sequences were further analyzed, and clone counts were based on CDR3 amino acid sequences (Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-021-01541-0#MOESM2">9</a>). Dominant TCR clones were assessed by estimating the proportion of TCR repertoire constituted by the top 5% of unique clones; for these analyses, TCR repertoires were filtered for clones representing at least 0.01% of the repertoire. For each sample, a clonality metric was estimated to quantitate the extent of mono- or oligo-clonal expansion by measuring the shape of the clone frequency distribution. For differential abundance analysis between baseline and on-therapy tumors, we selected the most expanded and most regressed TCR clonotypes, corresponding to fold changes in productive frequency of TCR clones with a false discovery rate (FDR) &lt; 0.01 (Fisher’s exact test) and requiring at least 0.01% relative repertoire abundance at baseline or resistance time points.</p><h3 class="c-article__sub-heading" id="Sec24">RNA sequencing</h3><p>Total RNA was extracted from 10-µm FFPE sections with the RNeasy FFPE kit (Qiagen). The quality of total RNA was assessed by calculating the DV200 index measured with the RNA 6000 Pico Kit (Agilent Technologies). RNA sequencing (RNA-seq) libraries were generated by ribosomal depletion (Illumina Ribo-Zero Gold rRNA Removal Kit) followed by reverse transcription into strand-specific cDNA libraries (NEBNext Ultra Drectional RNA Library Prep kit for Illumina). Paired-end sequencing, resulting in 150 bases from each end of the fragments, was performed using Illumina NovaSeq 6000 S4, generatig an average of 200 million total reads per library. RNA-seq data were then mapped to the human transcriptome using STAR<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 65" title="Dobin, A. &amp; Gingeras, T. R. Mapping RNA-seq reads with STAR. Curr. Protoc. Bioinformatics 51, 11 14 11–11 14 19 (2015)." href="/articles/s41591-021-01541-0#ref-CR65" id="ref-link-section-d73969948e3071">65</a></sup> followed by RSEM for isoform and gene-level quantification<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 66" title="Li, B. &amp; Dewey, C. N. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics 12, 323 (2011)." href="/articles/s41591-021-01541-0#ref-CR66" id="ref-link-section-d73969948e3075">66</a></sup>. Transcripts associated with RNA genes and mitochondrial genes and with ribosomal proteins were masked. Normalization of raw transcript counts and differential expression analysis was performed using DESeq2 (ref. <sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 67" title="Love, M. I., Huber, W. &amp; Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014)." href="/articles/s41591-021-01541-0#ref-CR67" id="ref-link-section-d73969948e3079">67</a></sup>).</p><h3 class="c-article__sub-heading" id="Sec25">PD-L1 and CD8 immunohistochemistry</h3><p>Immunohistochemistry for CD8/PD-L1 dual detection was performed on FFPE sections on a Ventana Discovery Ultra autostainer (Roche Diagnostics) using a primary mouse anti-human CD8 antibody (1:100 dilution, clone m7103, Dako) and a rabbit anti-human anti-PD-L1 antibody (1:100 dilution, E1L3N clone, Cell Signaling Technologies), as previously described. A minimum of 100 tumor cells were evaluated per specimen, and a PD-L1 tumor proportion score was calculated based on the percentage of tumor cells with PD-L1-positive staining. CD8-positive lymphocyte density was evaluated by the average number of CD8<sup>+</sup> cells in ten representative high-power fields (×40 objective, ×400 magnification).</p><h3 class="c-article__sub-heading" id="Sec26">Functional T cell assays</h3><p>To identify immunogenic, mutation-derived, neopeptide-specific, HLA class I-restricted T cell clones in the peripheral blood, we applied the high-throughput TCR-seq-based platform MANAFEST (Mutation-Associated NeoAntigen Functional Expansion of Specific T Cells), as previously described<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 43" title="Anagnostou, V. et al. Evolution of neoantigen landscape during immune checkpoint blockade in non-small cell lung cancer. Cancer Discov. 7, 264–276 (2017)." href="/articles/s41591-021-01541-0#ref-CR43" id="ref-link-section-d73969948e3101">43</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 68" title="Danilova, L. et al. The mutation-associated neoantigen functional expansion of specific T cells (MANAFEST) assay: a sensitive platform for monitoring antitumor immunity. Cancer Immunol. Res. 6, 888–899 (2018)." href="/articles/s41591-021-01541-0#ref-CR68" id="ref-link-section-d73969948e3104">68</a></sup>. In brief, putative neopeptides identified above (JPT Peptide Technologies; Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-021-01541-0#MOESM2">11</a>) were each used to stimulate 250,000 T cells in vitro for 10 d. On day 0, T cells were isolated from peripheral blood mononuclear cells by negative selection (EasySep, STEMCELL Technologies). The T-cell-negative fraction was co-cultured with an equal number of selected T cells in culture medium (IMDM/5% human serum with 50 μg ml<sup>−1</sup> of gentamicin) with 1 μg ml<sup>−1</sup> of relevant neoantigenic peptide, 1 μg ml<sup>−1</sup> of an MHC class I-restricted CMV, EBV and flu peptide epitope pool (CEFX, JPT Peptide Technologies), 1 μg ml<sup>−1</sup> of pools representing the HIV-1 Gag protein (JPT Peptide Technologies) and no peptide. On day 3, half of the medium was replaced with fresh medium containing cytokines for a final concentration of 50 IU ml<sup>−1</sup> of IL-2 (Chiron), 25 ng ml<sup>−1</sup> of IL-7 (Miltenyi) and 25 ng ml<sup>−1</sup> of IL-15 (PeproTech). On day 7, half of the medium was replaced with fresh culture medium containing cytokines for a final concentration of 100 IU ml<sup>−1</sup> of IL-2 and 25 ng ml<sup>−1</sup> of IL-7 and IL-15. On day 10, cells were harvested and washed twice with PBS, and the CD8<sup>+</sup> fraction was isolated using a CD8<sup>+</sup>-negative enrichment kit (EasySep, STEMCELL Technologies). DNA was extracted from each CD8-enriched culture condition. TCR Vβ CDR3 sequencing was performed by the SKCCC FEST and TCR Immunogenomics Core (FTIC) on genomic DNA from each T cell condition using the Oncomine TCR Beta short-read assay (Illumina). DNA libraries were pooled and sequenced on an Illumina iSeq 100 using unique dual indexes to prevent index hopping, with an estimated recovery of ~50,000 reads per sample. Data pre-processing was performed to eliminate non-productive TCR sequences (sequences that did not translate into a productive protein) and to align and trim the nucleotide sequences to obtain only the CDR3 region. Additionally, for inclusion in our analyses, CDR3 sequences needed to begin with ‘C’, end with ‘F’ or ‘W’ and have at least seven amino acids in the CDR3, which are universally accepted parameters for delineating the CDR3 region<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 69" title="Zhang, J., Ji, Z. &amp; Smith, K. N. Analysis of TCR β CDR3 sequencing data for tracking anti-tumor immunity. Methods Enzymol. 629, 443–464 (2019)." href="/articles/s41591-021-01541-0#ref-CR69" id="ref-link-section-d73969948e3135">69</a></sup>. Productive clonality of each sample and productive frequency of each clone was calculated to reflect the processed data (Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-021-01541-0#MOESM2">12</a>). Resultant processed data files were uploaded to our publicly available MANAFEST analysis web app (<a href="http://www.stat-apps.onc.jhmi.edu">www.stat-apps.onc.jhmi.edu</a>) to bioinformatically identify neoantigen-specific T cell clonotypes. To be considered antigen-specific, a T cell clonotype must have met the following criteria: (1) significant expansion (Fisher’s exact test with Benjamini–Hochberg correction for FDR, <i>P</i> &lt; 0.05) compared to T cells cultured without peptide; (2) significant expansion compared to every other peptide-stimulated culture (FDR &lt; 0.05); (3) an odds ratio greater than 5 compared to all other conditions; (4) at least 30 reads in the ‘positive’ well; and (5) at least 2× higher frequency than background clonotypic expansions as detected in the HIV-negative control condition (Supplementary Tables <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-021-01541-0#MOESM2">13</a> and <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-021-01541-0#MOESM2">14</a>).</p><h3 class="c-article__sub-heading" id="Sec27">Statistical analyses</h3><p>OS and PFS distributions were estimated using the Kaplan–Meier method, and Cox proportional hazard models were used to estimate the HRs among subgroups. The CIs of ORR (defined as the percentage of patients achieving CR or PR) were calculated based on an exact binomial distribution. ORRs were compared among subgroups using Fisher’s exact test. Differences in genomic and molecular features between tumors of responding and non-responding patients were evaluated using the chi-squared test or Fisher’s exact test for categorical variables and the Mann–Whitney test for continuous variables. The Pearson correlation coefficient (<i>R</i>) was used to assess correlations between continuous variables, and the Spearman ρ coefficient was calculated for non-parametric correlations. We investigated potential correlations between the genomic features described, and other than the expected co-linearity between non-synonymous mutation burden and MHC class I and II mutation-associated neoantigens, we did not identify any potential confounding relationships among features (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01541-0#Fig15">10</a>). The median point estimates and 95% CIs for PFS and OS were estimated by the Kaplan–Meier method, and survival curves were compared by using the non-parametric log-rank test. For the survival analyses of the TCGA mesothelioma cohort, progression-free interval was defined as the time interval from diagnosis to progression of disease, local recurrence, distant metastasis or death, whichever was applicable. Statistical analyses were performed using SPSS software (version 25.0.0 for Windows, IBM), SAS (version 9.4) and R version 3.2 and higher (<a href="http://cran.r-project.org">http://cran.r-project.org</a>).</p><h3 class="c-article__sub-heading" id="Sec28">Reporting Summary</h3><p>Further information on research design is available in the <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-021-01541-0#MOESM1">Nature Research Reporting Summary</a> linked to this article.</p></div></div></section>
                    
                </div>
            

            <div class="u-mt-32">
                <section data-title="Data availability"><div class="c-article-section" id="data-availability-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="data-availability">Data availability</h2><div class="c-article-section__content" id="data-availability-content">
              
              <p>All requests for raw and analyzed data and materials are promptly reviewed by PrECOG and Johns Hopkins University to verify if the request is subject to any intellectual property or confidentiality obligations. Patient-related data not included in the paper were generated as part of clinical trials and might be subject to patient confidentiality. All raw sequencing data, used to generate Figs. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01541-0#Fig2">2</a>–<a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01541-0#Fig5">5</a> and Extended Data Figs. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01541-0#Fig9">4</a>–<a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01541-0#Fig15">10</a>, have been deposited in the European Genome-phenome Archive (accession number <a href="https://ega-archive.org/studies/EGAS00001005426">EGAS00001005426</a>). Source data for Figs. <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-021-01541-0#MOESM3">1</a>–<a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-021-01541-0#MOESM6">5</a> and Extended Data Figs. 1–10 are provided with the paper, in the Supplementary Tables and in Source Data files. Source data for the TCGA tumor samples were retrieved from <a href="http://cancergenome.nih.gov">http://cancergenome.nih.gov</a>. WES-derived somatic mutation calls from the TCGA PanCancer Atlas MC3 project were retrieved from the NCI Genomic Data Commons (<a href="https://gdc.cancer.gov/about-data/publications/mc3-2017">https://gdc.cancer.gov/about-data/publications/mc3-2017</a>). <a data-track="click" data-track-label="link" data-track-action="section anchor" href="/articles/s41591-021-01541-0#Sec32">Source data</a> are provided with this paper.</p>
            </div></div></section><div id="MagazineFulltextArticleBodySuffix"><section aria-labelledby="Bib1" data-title="References"><div class="c-article-section" id="Bib1-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Bib1">References</h2><div class="c-article-section__content" id="Bib1-content"><div data-container-section="references"><ol class="c-article-references" data-track-component="outbound reference" data-track-context="references section"><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="1."><p class="c-article-references__text" id="ref-CR1">Odgerel, C. O. et al. Estimation of the global burden of mesothelioma deaths from incomplete national mortality data. <i>Occup. Environ. Med.</i> <b>74</b>, 851–858 (2017).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1136/oemed-2017-104298" data-track-item_id="10.1136/oemed-2017-104298" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1136%2Foemed-2017-104298" aria-label="Article reference 1" data-doi="10.1136/oemed-2017-104298">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=28866609" aria-label="PubMed reference 1">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 1" href="http://scholar.google.com/scholar_lookup?&amp;title=Estimation%20of%20the%20global%20burden%20of%20mesothelioma%20deaths%20from%20incomplete%20national%20mortality%20data&amp;journal=Occup.%20Environ.%20Med.&amp;doi=10.1136%2Foemed-2017-104298&amp;volume=74&amp;pages=851-858&amp;publication_year=2017&amp;author=Odgerel%2CCO">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="2."><p class="c-article-references__text" id="ref-CR2">Tweedale, G. Asbestos and its lethal legacy. <i>Nat. Rev. Cancer</i> <b>2</b>, 311–315 (2002).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/nrc774" data-track-item_id="10.1038/nrc774" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fnrc774" aria-label="Article reference 2" data-doi="10.1038/nrc774">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BD38XivFGqt7Y%3D" aria-label="CAS reference 2">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=12001992" aria-label="PubMed reference 2">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 2" href="http://scholar.google.com/scholar_lookup?&amp;title=Asbestos%20and%20its%20lethal%20legacy&amp;journal=Nat.%20Rev.%20Cancer&amp;doi=10.1038%2Fnrc774&amp;volume=2&amp;pages=311-315&amp;publication_year=2002&amp;author=Tweedale%2CG">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="3."><p class="c-article-references__text" id="ref-CR3">Panou, V. et al. Frequency of germline mutations in cancer susceptibility genes in malignant mesothelioma. <i>J. Clin. Oncol.</i> <b>36</b>, 2863–2871 (2018).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1200/JCO.2018.78.5204" data-track-item_id="10.1200/JCO.2018.78.5204" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1200%2FJCO.2018.78.5204" aria-label="Article reference 3" data-doi="10.1200/JCO.2018.78.5204">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC1MXjs1eju7o%3D" aria-label="CAS reference 3">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30113886" aria-label="PubMed reference 3">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6804864" aria-label="PubMed Central reference 3">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 3" href="http://scholar.google.com/scholar_lookup?&amp;title=Frequency%20of%20germline%20mutations%20in%20cancer%20susceptibility%20genes%20in%20malignant%20mesothelioma&amp;journal=J.%20Clin.%20Oncol.&amp;doi=10.1200%2FJCO.2018.78.5204&amp;volume=36&amp;pages=2863-2871&amp;publication_year=2018&amp;author=Panou%2CV">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="4."><p class="c-article-references__text" id="ref-CR4">Carbone, M. et al. Tumour predisposition and cancer syndromes as models to study gene–environment interactions. <i>Nat. Rev. Cancer</i> <b>20</b>, 533–549 (2020).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/s41568-020-0265-y" data-track-item_id="10.1038/s41568-020-0265-y" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fs41568-020-0265-y" aria-label="Article reference 4" data-doi="10.1038/s41568-020-0265-y">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3cXhtVCltrjI" aria-label="CAS reference 4">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32472073" aria-label="PubMed reference 4">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8104546" aria-label="PubMed Central reference 4">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 4" href="http://scholar.google.com/scholar_lookup?&amp;title=Tumour%20predisposition%20and%20cancer%20syndromes%20as%20models%20to%20study%20gene%E2%80%93environment%20interactions&amp;journal=Nat.%20Rev.%20Cancer&amp;doi=10.1038%2Fs41568-020-0265-y&amp;volume=20&amp;pages=533-549&amp;publication_year=2020&amp;author=Carbone%2CM">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="5."><p class="c-article-references__text" id="ref-CR5">Vogelzang, N. J. et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. <i>J. Clin. Oncol.</i> <b>21</b>, 2636–2644 (2003).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1200/JCO.2003.11.136" data-track-item_id="10.1200/JCO.2003.11.136" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1200%2FJCO.2003.11.136" aria-label="Article reference 5" data-doi="10.1200/JCO.2003.11.136">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BD2cXptlCktL4%3D" aria-label="CAS reference 5">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=12860938" aria-label="PubMed reference 5">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 5" href="http://scholar.google.com/scholar_lookup?&amp;title=Phase%20III%20study%20of%20pemetrexed%20in%20combination%20with%20cisplatin%20versus%20cisplatin%20alone%20in%20patients%20with%20malignant%20pleural%20mesothelioma&amp;journal=J.%20Clin.%20Oncol.&amp;doi=10.1200%2FJCO.2003.11.136&amp;volume=21&amp;pages=2636-2644&amp;publication_year=2003&amp;author=Vogelzang%2CNJ">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="6."><p class="c-article-references__text" id="ref-CR6">Krug, L. M. et al. Randomized phase II trial of pemetrexed/cisplatin with or without CBP501 in patients with advanced malignant pleural mesothelioma. <i>Lung Cancer</i> <b>85</b>, 429–434 (2014).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/j.lungcan.2014.06.008" data-track-item_id="10.1016/j.lungcan.2014.06.008" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.lungcan.2014.06.008" aria-label="Article reference 6" data-doi="10.1016/j.lungcan.2014.06.008">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:STN:280:DC%2BC2cbks1Wgtw%3D%3D" aria-label="CAS reference 6">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=25047675" aria-label="PubMed reference 6">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 6" href="http://scholar.google.com/scholar_lookup?&amp;title=Randomized%20phase%20II%20trial%20of%20pemetrexed%2Fcisplatin%20with%20or%20without%20CBP501%20in%20patients%20with%20advanced%20malignant%20pleural%20mesothelioma&amp;journal=Lung%20Cancer&amp;doi=10.1016%2Fj.lungcan.2014.06.008&amp;volume=85&amp;pages=429-434&amp;publication_year=2014&amp;author=Krug%2CLM">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="7."><p class="c-article-references__text" id="ref-CR7">Scagliotti, G. V. et al. Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial. <i>Lancet Respir. Med.</i> <b>7</b>, 569–580 (2019).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/S2213-2600(19)30139-0" data-track-item_id="10.1016/S2213-2600(19)30139-0" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2FS2213-2600%2819%2930139-0" aria-label="Article reference 7" data-doi="10.1016/S2213-2600(19)30139-0">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC1MXhtVSnt7zF" aria-label="CAS reference 7">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=31103412" aria-label="PubMed reference 7">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 7" href="http://scholar.google.com/scholar_lookup?&amp;title=Nintedanib%20in%20combination%20with%20pemetrexed%20and%20cisplatin%20for%20chemotherapy-naive%20patients%20with%20advanced%20malignant%20pleural%20mesothelioma%20%28LUME-Meso%29%3A%20a%20double-blind%2C%20randomised%2C%20placebo-controlled%20phase%203%20trial&amp;journal=Lancet%20Respir.%20Med.&amp;doi=10.1016%2FS2213-2600%2819%2930139-0&amp;volume=7&amp;pages=569-580&amp;publication_year=2019&amp;author=Scagliotti%2CGV">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="8."><p class="c-article-references__text" id="ref-CR8">Tsao, A. S. et al. Phase II trial of cediranib in combination with cisplatin and pemetrexed in chemotherapy-naive patients with unresectable malignant pleural mesothelioma (SWOG S0905). <i>J. Clin. Oncol.</i> <b>37</b>, 2537–2547 (2019).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1200/JCO.19.00269" data-track-item_id="10.1200/JCO.19.00269" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1200%2FJCO.19.00269" aria-label="Article reference 8" data-doi="10.1200/JCO.19.00269">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3cXlsVCgsbo%3D" aria-label="CAS reference 8">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=31386610" aria-label="PubMed reference 8">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7001793" aria-label="PubMed Central reference 8">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 8" href="http://scholar.google.com/scholar_lookup?&amp;title=Phase%20II%20trial%20of%20cediranib%20in%20combination%20with%20cisplatin%20and%20pemetrexed%20in%20chemotherapy-naive%20patients%20with%20unresectable%20malignant%20pleural%20mesothelioma%20%28SWOG%20S0905%29&amp;journal=J.%20Clin.%20Oncol.&amp;doi=10.1200%2FJCO.19.00269&amp;volume=37&amp;pages=2537-2547&amp;publication_year=2019&amp;author=Tsao%2CAS">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="9."><p class="c-article-references__text" id="ref-CR9">Zalcman, G. et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. <i>Lancet</i> <b>387</b>, 1405–1414 (2016).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/S0140-6736(15)01238-6" data-track-item_id="10.1016/S0140-6736(15)01238-6" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2FS0140-6736%2815%2901238-6" aria-label="Article reference 9" data-doi="10.1016/S0140-6736(15)01238-6">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC2MXitVyqsLzM" aria-label="CAS reference 9">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=26719230" aria-label="PubMed reference 9">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 9" href="http://scholar.google.com/scholar_lookup?&amp;title=Bevacizumab%20for%20newly%20diagnosed%20pleural%20mesothelioma%20in%20the%20Mesothelioma%20Avastin%20Cisplatin%20Pemetrexed%20Study%20%28MAPS%29%3A%20a%20randomised%2C%20controlled%2C%20open-label%2C%20phase%203%20trial&amp;journal=Lancet&amp;doi=10.1016%2FS0140-6736%2815%2901238-6&amp;volume=387&amp;pages=1405-1414&amp;publication_year=2016&amp;author=Zalcman%2CG">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="10."><p class="c-article-references__text" id="ref-CR10">Alley, E. W. et al. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial. <i>Lancet Oncol.</i> <b>18</b>, 623–630 (2017).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/S1470-2045(17)30169-9" data-track-item_id="10.1016/S1470-2045(17)30169-9" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2FS1470-2045%2817%2930169-9" aria-label="Article reference 10" data-doi="10.1016/S1470-2045(17)30169-9">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC2sXkt1Ohurw%3D" aria-label="CAS reference 10">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=28291584" aria-label="PubMed reference 10">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 10" href="http://scholar.google.com/scholar_lookup?&amp;title=Clinical%20safety%20and%20activity%20of%20pembrolizumab%20in%20patients%20with%20malignant%20pleural%20mesothelioma%20%28KEYNOTE-028%29%3A%20preliminary%20results%20from%20a%20non-randomised%2C%20open-label%2C%20phase%201b%20trial&amp;journal=Lancet%20Oncol.&amp;doi=10.1016%2FS1470-2045%2817%2930169-9&amp;volume=18&amp;pages=623-630&amp;publication_year=2017&amp;author=Alley%2CEW">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="11."><p class="c-article-references__text" id="ref-CR11">Quispel-Janssen, J. et al. Programmed death 1 blockade with nivolumab in patients with recurrent malignant pleural mesothelioma. <i>J. Thorac. Oncol.</i> <b>13</b>, 1569–1576 (2018).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/j.jtho.2018.05.038" data-track-item_id="10.1016/j.jtho.2018.05.038" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.jtho.2018.05.038" aria-label="Article reference 11" data-doi="10.1016/j.jtho.2018.05.038">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29908324" aria-label="PubMed reference 11">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 11" href="http://scholar.google.com/scholar_lookup?&amp;title=Programmed%20death%201%20blockade%20with%20nivolumab%20in%20patients%20with%20recurrent%20malignant%20pleural%20mesothelioma&amp;journal=J.%20Thorac.%20Oncol.&amp;doi=10.1016%2Fj.jtho.2018.05.038&amp;volume=13&amp;pages=1569-1576&amp;publication_year=2018&amp;author=Quispel-Janssen%2CJ">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="12."><p class="c-article-references__text" id="ref-CR12">Okada, M. et al. Clinical efficacy and safety of nivolumab: results of a multicenter, open-label, single-arm, Japanese phase II study in malignant pleural mesothelioma (MERIT). <i>Clin. Cancer Res.</i> <b>25</b>, 5485–5492 (2019).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1158/1078-0432.CCR-19-0103" data-track-item_id="10.1158/1078-0432.CCR-19-0103" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1158%2F1078-0432.CCR-19-0103" aria-label="Article reference 12" data-doi="10.1158/1078-0432.CCR-19-0103">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3cXlvF2rtrg%3D" aria-label="CAS reference 12">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=31164373" aria-label="PubMed reference 12">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 12" href="http://scholar.google.com/scholar_lookup?&amp;title=Clinical%20efficacy%20and%20safety%20of%20nivolumab%3A%20results%20of%20a%20multicenter%2C%20open-label%2C%20single-arm%2C%20Japanese%20phase%20II%20study%20in%20malignant%20pleural%20mesothelioma%20%28MERIT%29&amp;journal=Clin.%20Cancer%20Res.&amp;doi=10.1158%2F1078-0432.CCR-19-0103&amp;volume=25&amp;pages=5485-5492&amp;publication_year=2019&amp;author=Okada%2CM">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="13."><p class="c-article-references__text" id="ref-CR13">Fennell, D. A. et al. CONFIRM: a double-blind, placebo-controlled phase III clinical trial investigating the effect of nivolumab in patients with relapsed mesothelioma: study protocol for a randomised controlled trial. <i>Trials</i> <b>19</b>, 233 (2018).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="noopener" data-track-label="10.1186/s13063-018-2602-y" data-track-item_id="10.1186/s13063-018-2602-y" data-track-value="article reference" data-track-action="article reference" href="https://link.springer.com/doi/10.1186/s13063-018-2602-y" aria-label="Article reference 13" data-doi="10.1186/s13063-018-2602-y">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29669604" aria-label="PubMed reference 13">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5907297" aria-label="PubMed Central reference 13">PubMed Central</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC1MXjs1ers7Y%3D" aria-label="CAS reference 13">CAS</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 13" href="http://scholar.google.com/scholar_lookup?&amp;title=CONFIRM%3A%20a%20double-blind%2C%20placebo-controlled%20phase%20III%20clinical%20trial%20investigating%20the%20effect%20of%20nivolumab%20in%20patients%20with%20relapsed%20mesothelioma%3A%20study%20protocol%20for%20a%20randomised%20controlled%20trial&amp;journal=Trials&amp;doi=10.1186%2Fs13063-018-2602-y&amp;volume=19&amp;publication_year=2018&amp;author=Fennell%2CDA">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="14."><p class="c-article-references__text" id="ref-CR14">Gandhi, L. et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. <i>N. Engl. J. Med.</i> <b>378</b>, 2078–2092 (2018).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1056/NEJMoa1801005" data-track-item_id="10.1056/NEJMoa1801005" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1056%2FNEJMoa1801005" aria-label="Article reference 14" data-doi="10.1056/NEJMoa1801005">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC1cXhtV2rtrjL" aria-label="CAS reference 14">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29658856" aria-label="PubMed reference 14">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 14" href="http://scholar.google.com/scholar_lookup?&amp;title=Pembrolizumab%20plus%20chemotherapy%20in%20metastatic%20non-small-cell%20lung%20cancer&amp;journal=N.%20Engl.%20J.%20Med.&amp;doi=10.1056%2FNEJMoa1801005&amp;volume=378&amp;pages=2078-2092&amp;publication_year=2018&amp;author=Gandhi%2CL">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="15."><p class="c-article-references__text" id="ref-CR15">Nowak, A. K. et al. Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in. <i>Lancet Oncol.</i> <b>21</b>, 1213–1223 (2020).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/S1470-2045(20)30462-9" data-track-item_id="10.1016/S1470-2045(20)30462-9" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2FS1470-2045%2820%2930462-9" aria-label="Article reference 15" data-doi="10.1016/S1470-2045(20)30462-9">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3cXhslKhtrfK" aria-label="CAS reference 15">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32888453" aria-label="PubMed reference 15">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 15" href="http://scholar.google.com/scholar_lookup?&amp;title=Durvalumab%20with%20first-line%20chemotherapy%20in%20previously%20untreated%20malignant%20pleural%20mesothelioma%20%28DREAM%29%3A%20a%20multicentre%2C%20single-arm%2C%20phase%202%20trial%20with%20a%20safety%20run-in&amp;journal=Lancet%20Oncol.&amp;doi=10.1016%2FS1470-2045%2820%2930462-9&amp;volume=21&amp;pages=1213-1223&amp;publication_year=2020&amp;author=Nowak%2CAK">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="16."><p class="c-article-references__text" id="ref-CR16">Baas, P. et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. <i>Lancet</i> <b>397</b>, 375–386 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/S0140-6736(20)32714-8" data-track-item_id="10.1016/S0140-6736(20)32714-8" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2FS0140-6736%2820%2932714-8" aria-label="Article reference 16" data-doi="10.1016/S0140-6736(20)32714-8">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3MXltFaqsbk%3D" aria-label="CAS reference 16">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33485464" aria-label="PubMed reference 16">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 16" href="http://scholar.google.com/scholar_lookup?&amp;title=First-line%20nivolumab%20plus%20ipilimumab%20in%20unresectable%20malignant%20pleural%20mesothelioma%20%28CheckMate%20743%29%3A%20a%20multicentre%2C%20randomised%2C%20open-label%2C%20phase%203%20trial&amp;journal=Lancet&amp;doi=10.1016%2FS0140-6736%2820%2932714-8&amp;volume=397&amp;pages=375-386&amp;publication_year=2021&amp;author=Baas%2CP">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="17."><p class="c-article-references__text" id="ref-CR17">Hmeljak, J. et al. Integrative molecular characterization of malignant pleural mesothelioma. <i>Cancer Discov.</i> <b>8</b>, 1548–1565 (2018).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1158/2159-8290.CD-18-0804" data-track-item_id="10.1158/2159-8290.CD-18-0804" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1158%2F2159-8290.CD-18-0804" aria-label="Article reference 17" data-doi="10.1158/2159-8290.CD-18-0804">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3cXhtFOms73J" aria-label="CAS reference 17">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30322867" aria-label="PubMed reference 17">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6310008" aria-label="PubMed Central reference 17">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 17" href="http://scholar.google.com/scholar_lookup?&amp;title=Integrative%20molecular%20characterization%20of%20malignant%20pleural%20mesothelioma&amp;journal=Cancer%20Discov.&amp;doi=10.1158%2F2159-8290.CD-18-0804&amp;volume=8&amp;pages=1548-1565&amp;publication_year=2018&amp;author=Hmeljak%2CJ">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="18."><p class="c-article-references__text" id="ref-CR18">Bueno, R. et al. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. <i>Nat. Genet.</i> <b>48</b>, 407–416 (2016).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/ng.3520" data-track-item_id="10.1038/ng.3520" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fng.3520" aria-label="Article reference 18" data-doi="10.1038/ng.3520">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC28XivFKgtb8%3D" aria-label="CAS reference 18">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=26928227" aria-label="PubMed reference 18">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 18" href="http://scholar.google.com/scholar_lookup?&amp;title=Comprehensive%20genomic%20analysis%20of%20malignant%20pleural%20mesothelioma%20identifies%20recurrent%20mutations%2C%20gene%20fusions%20and%20splicing%20alterations&amp;journal=Nat.%20Genet.&amp;doi=10.1038%2Fng.3520&amp;volume=48&amp;pages=407-416&amp;publication_year=2016&amp;author=Bueno%2CR">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="19."><p class="c-article-references__text" id="ref-CR19">Mansfield, A. S. et al. Neoantigenic potential of complex chromosomal rearrangements in mesothelioma. <i>J. Thorac. Oncol.</i> <b>14</b>, 276–287 (2019).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/j.jtho.2018.10.001" data-track-item_id="10.1016/j.jtho.2018.10.001" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.jtho.2018.10.001" aria-label="Article reference 19" data-doi="10.1016/j.jtho.2018.10.001">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC1MXitFemtLjJ" aria-label="CAS reference 19">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30316012" aria-label="PubMed reference 19">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 19" href="http://scholar.google.com/scholar_lookup?&amp;title=Neoantigenic%20potential%20of%20complex%20chromosomal%20rearrangements%20in%20mesothelioma&amp;journal=J.%20Thorac.%20Oncol.&amp;doi=10.1016%2Fj.jtho.2018.10.001&amp;volume=14&amp;pages=276-287&amp;publication_year=2019&amp;author=Mansfield%2CAS">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="20."><p class="c-article-references__text" id="ref-CR20">Panou, V. &amp; Roe, O. D. Inherited genetic mutations and polymorphisms in malignant mesothelioma: a comprehensive review. <i>Int. J. Mol. Sci.</i> <b>21</b>, 4327 (2020).</p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="21."><p class="c-article-references__text" id="ref-CR21">Testa, J. R. et al. Germline <i>BAP1</i> mutations predispose to malignant mesothelioma. <i>Nat. Genet.</i> <b>43</b>, 1022–1025 (2011).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/ng.912" data-track-item_id="10.1038/ng.912" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fng.912" aria-label="Article reference 21" data-doi="10.1038/ng.912">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC3MXhtV2gt7vJ" aria-label="CAS reference 21">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21874000" aria-label="PubMed reference 21">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3184199" aria-label="PubMed Central reference 21">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 21" href="http://scholar.google.com/scholar_lookup?&amp;title=Germline%20BAP1%20mutations%20predispose%20to%20malignant%20mesothelioma&amp;journal=Nat.%20Genet.&amp;doi=10.1038%2Fng.912&amp;volume=43&amp;pages=1022-1025&amp;publication_year=2011&amp;author=Testa%2CJR">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="22."><p class="c-article-references__text" id="ref-CR22">Bononi, A. et al. Heterozygous germline <i>BLM</i> mutations increase susceptibility to asbestos and mesothelioma. <i>Proc. Natl Acad. Sci. USA</i> <b>117</b>, 33466–33473 (2020).</p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="23."><p class="c-article-references__text" id="ref-CR23">Oken, M. M. et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. <i>Am. J. Clin. Oncol.</i> <b>5</b>, 649–655 (1982).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1097/00000421-198212000-00014" data-track-item_id="10.1097/00000421-198212000-00014" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1097%2F00000421-198212000-00014" aria-label="Article reference 23" data-doi="10.1097/00000421-198212000-00014">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:STN:280:DyaL3s7kvFOgsw%3D%3D" aria-label="CAS reference 23">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=7165009" aria-label="PubMed reference 23">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 23" href="http://scholar.google.com/scholar_lookup?&amp;title=Toxicity%20and%20response%20criteria%20of%20the%20Eastern%20Cooperative%20Oncology%20Group&amp;journal=Am.%20J.%20Clin.%20Oncol.&amp;doi=10.1097%2F00000421-198212000-00014&amp;volume=5&amp;pages=649-655&amp;publication_year=1982&amp;author=Oken%2CMM">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="24."><p class="c-article-references__text" id="ref-CR24">Tsao, A. S. et al. A practical guide of the Southwest Oncology Group to measure malignant pleural mesothelioma tumors by RECIST and modified RECIST criteria. <i>J. Thorac. Oncol.</i> <b>6</b>, 598–601 (2011).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1097/JTO.0b013e318208c83d" data-track-item_id="10.1097/JTO.0b013e318208c83d" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1097%2FJTO.0b013e318208c83d" aria-label="Article reference 24" data-doi="10.1097/JTO.0b013e318208c83d">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21270668" aria-label="PubMed reference 24">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3643692" aria-label="PubMed Central reference 24">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 24" href="http://scholar.google.com/scholar_lookup?&amp;title=A%20practical%20guide%20of%20the%20Southwest%20Oncology%20Group%20to%20measure%20malignant%20pleural%20mesothelioma%20tumors%20by%20RECIST%20and%20modified%20RECIST%20criteria&amp;journal=J.%20Thorac.%20Oncol.&amp;doi=10.1097%2FJTO.0b013e318208c83d&amp;volume=6&amp;pages=598-601&amp;publication_year=2011&amp;author=Tsao%2CAS">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="25."><p class="c-article-references__text" id="ref-CR25">Chowell, D. et al. Evolutionary divergence of HLA class I genotype impacts efficacy of cancer immunotherapy. <i>Nat. Med.</i> <b>25</b>, 1715–1720 (2019).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/s41591-019-0639-4" data-track-item_id="10.1038/s41591-019-0639-4" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fs41591-019-0639-4" aria-label="Article reference 25" data-doi="10.1038/s41591-019-0639-4">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC1MXitFaktLbL" aria-label="CAS reference 25">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=31700181" aria-label="PubMed reference 25">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7938381" aria-label="PubMed Central reference 25">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 25" href="http://scholar.google.com/scholar_lookup?&amp;title=Evolutionary%20divergence%20of%20HLA%20class%20I%20genotype%20impacts%20efficacy%20of%20cancer%20immunotherapy&amp;journal=Nat.%20Med.&amp;doi=10.1038%2Fs41591-019-0639-4&amp;volume=25&amp;pages=1715-1720&amp;publication_year=2019&amp;author=Chowell%2CD">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="26."><p class="c-article-references__text" id="ref-CR26">Napolitano, A. et al. Minimal asbestos exposure in germline <i>BAP1</i> heterozygous mice is associated with deregulated inflammatory response and increased risk of mesothelioma. <i>Oncogene</i> <b>35</b>, 1996–2002 (2016).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/onc.2015.243" data-track-item_id="10.1038/onc.2015.243" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fonc.2015.243" aria-label="Article reference 26" data-doi="10.1038/onc.2015.243">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC2MXhtFaitrzJ" aria-label="CAS reference 26">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=26119930" aria-label="PubMed reference 26">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 26" href="http://scholar.google.com/scholar_lookup?&amp;title=Minimal%20asbestos%20exposure%20in%20germline%20BAP1%20heterozygous%20mice%20is%20associated%20with%20deregulated%20inflammatory%20response%20and%20increased%20risk%20of%20mesothelioma&amp;journal=Oncogene&amp;doi=10.1038%2Fonc.2015.243&amp;volume=35&amp;pages=1996-2002&amp;publication_year=2016&amp;author=Napolitano%2CA">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="27."><p class="c-article-references__text" id="ref-CR27">Wang, T. et al. An empirical approach leveraging tumorgrafts to dissect the tumor microenvironment in renal cell carcinoma identifies missing link to prognostic inflammatory factors. <i>Cancer Discov.</i> <b>8</b>, 1142–1155 (2018).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1158/2159-8290.CD-17-1246" data-track-item_id="10.1158/2159-8290.CD-17-1246" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1158%2F2159-8290.CD-17-1246" aria-label="Article reference 27" data-doi="10.1158/2159-8290.CD-17-1246">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC1MXlvFyitL4%3D" aria-label="CAS reference 27">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29884728" aria-label="PubMed reference 27">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6125163" aria-label="PubMed Central reference 27">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 27" href="http://scholar.google.com/scholar_lookup?&amp;title=An%20empirical%20approach%20leveraging%20tumorgrafts%20to%20dissect%20the%20tumor%20microenvironment%20in%20renal%20cell%20carcinoma%20identifies%20missing%20link%20to%20prognostic%20inflammatory%20factors&amp;journal=Cancer%20Discov.&amp;doi=10.1158%2F2159-8290.CD-17-1246&amp;volume=8&amp;pages=1142-1155&amp;publication_year=2018&amp;author=Wang%2CT">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="28."><p class="c-article-references__text" id="ref-CR28">Hassan, R. et al. Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy. <i>Proc. Natl Acad. Sci. USA</i> <b>116</b>, 9008–9013 (2019).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1073/pnas.1821510116" data-track-item_id="10.1073/pnas.1821510116" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1073%2Fpnas.1821510116" aria-label="Article reference 28" data-doi="10.1073/pnas.1821510116">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC1MXos1Sht78%3D" aria-label="CAS reference 28">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30975761" aria-label="PubMed reference 28">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6500142" aria-label="PubMed Central reference 28">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 28" href="http://scholar.google.com/scholar_lookup?&amp;title=Inherited%20predisposition%20to%20malignant%20mesothelioma%20and%20overall%20survival%20following%20platinum%20chemotherapy&amp;journal=Proc.%20Natl%20Acad.%20Sci.%20USA&amp;doi=10.1073%2Fpnas.1821510116&amp;volume=116&amp;pages=9008-9013&amp;publication_year=2019&amp;author=Hassan%2CR">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="29."><p class="c-article-references__text" id="ref-CR29">Bott, M. et al. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. <i>Nat. Genet.</i> <b>43</b>, 668–672 (2011).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/ng.855" data-track-item_id="10.1038/ng.855" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fng.855" aria-label="Article reference 29" data-doi="10.1038/ng.855">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC3MXntV2rsLg%3D" aria-label="CAS reference 29">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21642991" aria-label="PubMed reference 29">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4643098" aria-label="PubMed Central reference 29">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 29" href="http://scholar.google.com/scholar_lookup?&amp;title=The%20nuclear%20deubiquitinase%20BAP1%20is%20commonly%20inactivated%20by%20somatic%20mutations%20and%203p21.1%20losses%20in%20malignant%20pleural%20mesothelioma&amp;journal=Nat.%20Genet.&amp;doi=10.1038%2Fng.855&amp;volume=43&amp;pages=668-672&amp;publication_year=2011&amp;author=Bott%2CM">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="30."><p class="c-article-references__text" id="ref-CR30">Robert, C. et al. Immunotherapy discontinuation—how, and when? Data from melanoma as a paradigm. <i>Nat. Rev. Clin. Oncol.</i> <b>17</b>, 707–715 (2020).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/s41571-020-0399-6" data-track-item_id="10.1038/s41571-020-0399-6" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fs41571-020-0399-6" aria-label="Article reference 30" data-doi="10.1038/s41571-020-0399-6">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3cXhtlCqt7%2FO" aria-label="CAS reference 30">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32636502" aria-label="PubMed reference 30">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 30" href="http://scholar.google.com/scholar_lookup?&amp;title=Immunotherapy%20discontinuation%E2%80%94how%2C%20and%20when%3F%20Data%20from%20melanoma%20as%20a%20paradigm&amp;journal=Nat.%20Rev.%20Clin.%20Oncol.&amp;doi=10.1038%2Fs41571-020-0399-6&amp;volume=17&amp;pages=707-715&amp;publication_year=2020&amp;author=Robert%2CC">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="31."><p class="c-article-references__text" id="ref-CR31">Litchfield, K. et al. Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition. <i>Cell</i> <b>184</b>, 596–614 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/j.cell.2021.01.002" data-track-item_id="10.1016/j.cell.2021.01.002" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.cell.2021.01.002" aria-label="Article reference 31" data-doi="10.1016/j.cell.2021.01.002">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3MXitlGgsLc%3D" aria-label="CAS reference 31">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33508232" aria-label="PubMed reference 31">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7933824" aria-label="PubMed Central reference 31">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 31" href="http://scholar.google.com/scholar_lookup?&amp;title=Meta-analysis%20of%20tumor-%20and%20T%20cell-intrinsic%20mechanisms%20of%20sensitization%20to%20checkpoint%20inhibition&amp;journal=Cell&amp;doi=10.1016%2Fj.cell.2021.01.002&amp;volume=184&amp;pages=596-614&amp;publication_year=2021&amp;author=Litchfield%2CK">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="32."><p class="c-article-references__text" id="ref-CR32">Venkatesan, S. et al. Perspective: APOBEC mutagenesis in drug resistance and immune escape in HIV and cancer evolution. <i>Ann. Oncol.</i> <b>29</b>, 563–572 (2018).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1093/annonc/mdy003" data-track-item_id="10.1093/annonc/mdy003" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1093%2Fannonc%2Fmdy003" aria-label="Article reference 32" data-doi="10.1093/annonc/mdy003">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:STN:280:DC%2BC1MzpvVeitw%3D%3D" aria-label="CAS reference 32">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29324969" aria-label="PubMed reference 32">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5888943" aria-label="PubMed Central reference 32">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 32" href="http://scholar.google.com/scholar_lookup?&amp;title=Perspective%3A%20APOBEC%20mutagenesis%20in%20drug%20resistance%20and%20immune%20escape%20in%20HIV%20and%20cancer%20evolution&amp;journal=Ann.%20Oncol.&amp;doi=10.1093%2Fannonc%2Fmdy003&amp;volume=29&amp;pages=563-572&amp;publication_year=2018&amp;author=Venkatesan%2CS">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="33."><p class="c-article-references__text" id="ref-CR33">Rosenthal, R. et al. Neoantigen-directed immune escape in lung cancer evolution. <i>Nature</i> <b>567</b>, 479–485 (2019).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/s41586-019-1032-7" data-track-item_id="10.1038/s41586-019-1032-7" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fs41586-019-1032-7" aria-label="Article reference 33" data-doi="10.1038/s41586-019-1032-7">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC1MXmslKntrY%3D" aria-label="CAS reference 33">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30894752" aria-label="PubMed reference 33">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6954100" aria-label="PubMed Central reference 33">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 33" href="http://scholar.google.com/scholar_lookup?&amp;title=Neoantigen-directed%20immune%20escape%20in%20lung%20cancer%20evolution&amp;journal=Nature&amp;doi=10.1038%2Fs41586-019-1032-7&amp;volume=567&amp;pages=479-485&amp;publication_year=2019&amp;author=Rosenthal%2CR">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="34."><p class="c-article-references__text" id="ref-CR34">Bianchi, A. B. et al. High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas. <i>Proc. Natl Acad. Sci. USA</i> <b>92</b>, 10854–10858 (1995).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1073/pnas.92.24.10854" data-track-item_id="10.1073/pnas.92.24.10854" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1073%2Fpnas.92.24.10854" aria-label="Article reference 34" data-doi="10.1073/pnas.92.24.10854">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DyaK2MXps1amtbk%3D" aria-label="CAS reference 34">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=7479897" aria-label="PubMed reference 34">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC40529" aria-label="PubMed Central reference 34">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 34" href="http://scholar.google.com/scholar_lookup?&amp;title=High%20frequency%20of%20inactivating%20mutations%20in%20the%20neurofibromatosis%20type%202%20gene%20%28NF2%29%20in%20primary%20malignant%20mesotheliomas&amp;journal=Proc.%20Natl%20Acad.%20Sci.%20USA&amp;doi=10.1073%2Fpnas.92.24.10854&amp;volume=92&amp;pages=10854-10858&amp;publication_year=1995&amp;author=Bianchi%2CAB">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="35."><p class="c-article-references__text" id="ref-CR35">Zhang, M. et al. Clonal architecture in mesothelioma is prognostic and shapes the tumour microenvironment. <i>Nat. Commun.</i> <b>12</b>, 1751 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/s41467-021-21798-w" data-track-item_id="10.1038/s41467-021-21798-w" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fs41467-021-21798-w" aria-label="Article reference 35" data-doi="10.1038/s41467-021-21798-w">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3MXntl2kurw%3D" aria-label="CAS reference 35">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33741915" aria-label="PubMed reference 35">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7979861" aria-label="PubMed Central reference 35">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 35" href="http://scholar.google.com/scholar_lookup?&amp;title=Clonal%20architecture%20in%20mesothelioma%20is%20prognostic%20and%20shapes%20the%20tumour%20microenvironment&amp;journal=Nat.%20Commun.&amp;doi=10.1038%2Fs41467-021-21798-w&amp;volume=12&amp;publication_year=2021&amp;author=Zhang%2CM">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="36."><p class="c-article-references__text" id="ref-CR36">Pan, D. et al. A major chromatin regulator determines resistance of tumor cells to T cell-mediated killing. <i>Science</i> <b>359</b>, 770–775 (2018).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1126/science.aao1710" data-track-item_id="10.1126/science.aao1710" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1126%2Fscience.aao1710" aria-label="Article reference 36" data-doi="10.1126/science.aao1710">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC1cXivVaitr4%3D" aria-label="CAS reference 36">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29301958" aria-label="PubMed reference 36">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5953516" aria-label="PubMed Central reference 36">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 36" href="http://scholar.google.com/scholar_lookup?&amp;title=A%20major%20chromatin%20regulator%20determines%20resistance%20of%20tumor%20cells%20to%20T%20cell-mediated%20killing&amp;journal=Science&amp;doi=10.1126%2Fscience.aao1710&amp;volume=359&amp;pages=770-775&amp;publication_year=2018&amp;author=Pan%2CD">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="37."><p class="c-article-references__text" id="ref-CR37">Shen, J. et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. <i>Nat. Med.</i> <b>24</b>, 556–562 (2018).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/s41591-018-0012-z" data-track-item_id="10.1038/s41591-018-0012-z" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fs41591-018-0012-z" aria-label="Article reference 37" data-doi="10.1038/s41591-018-0012-z">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC1cXpt1Gksrc%3D" aria-label="CAS reference 37">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29736026" aria-label="PubMed reference 37">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6076433" aria-label="PubMed Central reference 37">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 37" href="http://scholar.google.com/scholar_lookup?&amp;title=ARID1A%20deficiency%20promotes%20mutability%20and%20potentiates%20therapeutic%20antitumor%20immunity%20unleashed%20by%20immune%20checkpoint%20blockade&amp;journal=Nat.%20Med.&amp;doi=10.1038%2Fs41591-018-0012-z&amp;volume=24&amp;pages=556-562&amp;publication_year=2018&amp;author=Shen%2CJ">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="38."><p class="c-article-references__text" id="ref-CR38">Nasu, M. et al. High incidence of somatic BAP1 alterations in sporadic malignant mesothelioma. <i>J. Thorac. Oncol.</i> <b>10</b>, 565–576 (2015).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1097/JTO.0000000000000471" data-track-item_id="10.1097/JTO.0000000000000471" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1097%2FJTO.0000000000000471" aria-label="Article reference 38" data-doi="10.1097/JTO.0000000000000471">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC2MXltFSqs74%3D" aria-label="CAS reference 38">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=25658628" aria-label="PubMed reference 38">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4408084" aria-label="PubMed Central reference 38">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 38" href="http://scholar.google.com/scholar_lookup?&amp;title=High%20incidence%20of%20somatic%20BAP1%20alterations%20in%20sporadic%20malignant%20mesothelioma&amp;journal=J.%20Thorac.%20Oncol.&amp;doi=10.1097%2FJTO.0000000000000471&amp;volume=10&amp;pages=565-576&amp;publication_year=2015&amp;author=Nasu%2CM">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="39."><p class="c-article-references__text" id="ref-CR39">Baumann, F. et al. Mesothelioma patients with germline <i>BAP1</i> mutations have 7-fold improved long-term survival. <i>Carcinogenesis</i> <b>36</b>, 76–81 (2015).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1093/carcin/bgu227" data-track-item_id="10.1093/carcin/bgu227" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1093%2Fcarcin%2Fbgu227" aria-label="Article reference 39" data-doi="10.1093/carcin/bgu227">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC28XhtF2ltrfJ" aria-label="CAS reference 39">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=25380601" aria-label="PubMed reference 39">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 39" href="http://scholar.google.com/scholar_lookup?&amp;title=Mesothelioma%20patients%20with%20germline%20BAP1%20mutations%20have%207-fold%20improved%20long-term%20survival&amp;journal=Carcinogenesis&amp;doi=10.1093%2Fcarcin%2Fbgu227&amp;volume=36&amp;pages=76-81&amp;publication_year=2015&amp;author=Baumann%2CF">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="40."><p class="c-article-references__text" id="ref-CR40">Carbone, M. et al. Biological mechanisms and clinical significance of <i>BAP1</i> mutations in human cancer. <i>Cancer Discov.</i> <b>10</b>, 1103–1120 (2020).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1158/2159-8290.CD-19-1220" data-track-item_id="10.1158/2159-8290.CD-19-1220" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1158%2F2159-8290.CD-19-1220" aria-label="Article reference 40" data-doi="10.1158/2159-8290.CD-19-1220">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3cXit1ehsb7N" aria-label="CAS reference 40">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32690542" aria-label="PubMed reference 40">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8006752" aria-label="PubMed Central reference 40">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 40" href="http://scholar.google.com/scholar_lookup?&amp;title=Biological%20mechanisms%20and%20clinical%20significance%20of%20BAP1%20mutations%20in%20human%20cancer&amp;journal=Cancer%20Discov.&amp;doi=10.1158%2F2159-8290.CD-19-1220&amp;volume=10&amp;pages=1103-1120&amp;publication_year=2020&amp;author=Carbone%2CM">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="41."><p class="c-article-references__text" id="ref-CR41">Samstein, R. M. et al. Mutations in <i>BRCA1</i> and <i>BRCA2</i> differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy. <i>Nat. Cancer</i> <b>1</b>, 1188–1203 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/s43018-020-00139-8" data-track-item_id="10.1038/s43018-020-00139-8" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fs43018-020-00139-8" aria-label="Article reference 41" data-doi="10.1038/s43018-020-00139-8">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33834176" aria-label="PubMed reference 41">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB38XjsVOmtrs%3D" aria-label="CAS reference 41">CAS</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 41" href="http://scholar.google.com/scholar_lookup?&amp;title=Mutations%20in%20BRCA1%20and%20BRCA2%20differentially%20affect%20the%20tumor%20microenvironment%20and%20response%20to%20checkpoint%20blockade%20immunotherapy&amp;journal=Nat.%20Cancer&amp;doi=10.1038%2Fs43018-020-00139-8&amp;volume=1&amp;pages=1188-1203&amp;publication_year=2021&amp;author=Samstein%2CRM">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="42."><p class="c-article-references__text" id="ref-CR42">Ishikawa, H. &amp; Barber, G. N. STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. <i>Nature</i> <b>455</b>, 674–678 (2008).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/nature07317" data-track-item_id="10.1038/nature07317" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fnature07317" aria-label="Article reference 42" data-doi="10.1038/nature07317">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BD1cXhtF2hsbzL" aria-label="CAS reference 42">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=18724357" aria-label="PubMed reference 42">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2804933" aria-label="PubMed Central reference 42">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 42" href="http://scholar.google.com/scholar_lookup?&amp;title=STING%20is%20an%20endoplasmic%20reticulum%20adaptor%20that%20facilitates%20innate%20immune%20signalling&amp;journal=Nature&amp;doi=10.1038%2Fnature07317&amp;volume=455&amp;pages=674-678&amp;publication_year=2008&amp;author=Ishikawa%2CH&amp;author=Barber%2CGN">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="43."><p class="c-article-references__text" id="ref-CR43">Anagnostou, V. et al. Evolution of neoantigen landscape during immune checkpoint blockade in non-small cell lung cancer. <i>Cancer Discov.</i> <b>7</b>, 264–276 (2017).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1158/2159-8290.CD-16-0828" data-track-item_id="10.1158/2159-8290.CD-16-0828" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1158%2F2159-8290.CD-16-0828" aria-label="Article reference 43" data-doi="10.1158/2159-8290.CD-16-0828">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC2sXjs1Klsb0%3D" aria-label="CAS reference 43">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=28031159" aria-label="PubMed reference 43">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 43" href="http://scholar.google.com/scholar_lookup?&amp;title=Evolution%20of%20neoantigen%20landscape%20during%20immune%20checkpoint%20blockade%20in%20non-small%20cell%20lung%20cancer&amp;journal=Cancer%20Discov.&amp;doi=10.1158%2F2159-8290.CD-16-0828&amp;volume=7&amp;pages=264-276&amp;publication_year=2017&amp;author=Anagnostou%2CV">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="44."><p class="c-article-references__text" id="ref-CR44">Anagnostou, V. et al. Integrative tumor and immune cell mutli-omic analyses to predict melanoma response to immune checkpoint blockade. <i>Cell Rep. Med.</i> <b>1</b>, 100139 (2020).</p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="45."><p class="c-article-references__text" id="ref-CR45">Binnewies, M. et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. <i>Nat. Med.</i> <b>24</b>, 541–550 (2018).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/s41591-018-0014-x" data-track-item_id="10.1038/s41591-018-0014-x" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fs41591-018-0014-x" aria-label="Article reference 45" data-doi="10.1038/s41591-018-0014-x">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC1cXosVCnsLk%3D" aria-label="CAS reference 45">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29686425" aria-label="PubMed reference 45">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5998822" aria-label="PubMed Central reference 45">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 45" href="http://scholar.google.com/scholar_lookup?&amp;title=Understanding%20the%20tumor%20immune%20microenvironment%20%28TIME%29%20for%20effective%20therapy&amp;journal=Nat.%20Med.&amp;doi=10.1038%2Fs41591-018-0014-x&amp;volume=24&amp;pages=541-550&amp;publication_year=2018&amp;author=Binnewies%2CM">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="46."><p class="c-article-references__text" id="ref-CR46">Joshi, K. et al. Spatial heterogeneity of the T cell receptor repertoire reflects the mutational landscape in lung cancer. <i>Nat. Med.</i> <b>25</b>, 1549–1559 (2019).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/s41591-019-0592-2" data-track-item_id="10.1038/s41591-019-0592-2" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fs41591-019-0592-2" aria-label="Article reference 46" data-doi="10.1038/s41591-019-0592-2">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC1MXhvFaksbnF" aria-label="CAS reference 46">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=31591606" aria-label="PubMed reference 46">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6890490" aria-label="PubMed Central reference 46">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 46" href="http://scholar.google.com/scholar_lookup?&amp;title=Spatial%20heterogeneity%20of%20the%20T%20cell%20receptor%20repertoire%20reflects%20the%20mutational%20landscape%20in%20lung%20cancer&amp;journal=Nat.%20Med.&amp;doi=10.1038%2Fs41591-019-0592-2&amp;volume=25&amp;pages=1549-1559&amp;publication_year=2019&amp;author=Joshi%2CK">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="47."><p class="c-article-references__text" id="ref-CR47">Thorsson, V. et al. The immune landscape of cancer. <i>Immunity</i> <b>48</b>, 812–830 (2018).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/j.immuni.2018.03.023" data-track-item_id="10.1016/j.immuni.2018.03.023" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.immuni.2018.03.023" aria-label="Article reference 47" data-doi="10.1016/j.immuni.2018.03.023">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC1cXntFSjt7o%3D" aria-label="CAS reference 47">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29628290" aria-label="PubMed reference 47">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5982584" aria-label="PubMed Central reference 47">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 47" href="http://scholar.google.com/scholar_lookup?&amp;title=The%20immune%20landscape%20of%20cancer&amp;journal=Immunity&amp;doi=10.1016%2Fj.immuni.2018.03.023&amp;volume=48&amp;pages=812-830&amp;publication_year=2018&amp;author=Thorsson%2CV">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="48."><p class="c-article-references__text" id="ref-CR48">Ellrott, K. et al. Scalable open science approach for mutation calling of tumor exomes using multiple genomic pipelines. <i>Cell Syst.</i> <b>6</b>, 271–281 (2018).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/j.cels.2018.03.002" data-track-item_id="10.1016/j.cels.2018.03.002" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.cels.2018.03.002" aria-label="Article reference 48" data-doi="10.1016/j.cels.2018.03.002">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC1cXpslOktr0%3D" aria-label="CAS reference 48">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29596782" aria-label="PubMed reference 48">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6075717" aria-label="PubMed Central reference 48">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 48" href="http://scholar.google.com/scholar_lookup?&amp;title=Scalable%20open%20science%20approach%20for%20mutation%20calling%20of%20tumor%20exomes%20using%20multiple%20genomic%20pipelines&amp;journal=Cell%20Syst.&amp;doi=10.1016%2Fj.cels.2018.03.002&amp;volume=6&amp;pages=271-281&amp;publication_year=2018&amp;author=Ellrott%2CK">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="49."><p class="c-article-references__text" id="ref-CR49">Jones, S. et al. Personalized genomic analyses for cancer mutation discovery and interpretation. <i>Sci. Transl. Med.</i> <b>7</b>, 283ra253 (2015).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1126/scitranslmed.aaa7161" data-track-item_id="10.1126/scitranslmed.aaa7161" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1126%2Fscitranslmed.aaa7161" aria-label="Article reference 49" data-doi="10.1126/scitranslmed.aaa7161">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC2MXnvFKnt7Y%3D" aria-label="CAS reference 49">CAS</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 49" href="http://scholar.google.com/scholar_lookup?&amp;title=Personalized%20genomic%20analyses%20for%20cancer%20mutation%20discovery%20and%20interpretation&amp;journal=Sci.%20Transl.%20Med.&amp;doi=10.1126%2Fscitranslmed.aaa7161&amp;volume=7&amp;publication_year=2015&amp;author=Jones%2CS">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="50."><p class="c-article-references__text" id="ref-CR50">Anagnostou, V. et al. Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer. <i>Nat. Cancer</i> <b>1</b>, 99–111 (2020).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/s43018-019-0008-8" data-track-item_id="10.1038/s43018-019-0008-8" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fs43018-019-0008-8" aria-label="Article reference 50" data-doi="10.1038/s43018-019-0008-8">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32984843" aria-label="PubMed reference 50">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7514475" aria-label="PubMed Central reference 50">PubMed Central</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB38XjsFeitrk%3D" aria-label="CAS reference 50">CAS</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 50" href="http://scholar.google.com/scholar_lookup?&amp;title=Multimodal%20genomic%20features%20predict%20outcome%20of%20immune%20checkpoint%20blockade%20in%20non-small-cell%20lung%20cancer&amp;journal=Nat.%20Cancer&amp;doi=10.1038%2Fs43018-019-0008-8&amp;volume=1&amp;pages=99-111&amp;publication_year=2020&amp;author=Anagnostou%2CV">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="51."><p class="c-article-references__text" id="ref-CR51">Shao, X. M. et al. High-throughput prediction of MHC class I and II neoantigens with MHCnuggets. <i>Cancer Immunol. Res.</i> <b>8</b>, 396–408 (2020).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1158/2326-6066.CIR-19-0464" data-track-item_id="10.1158/2326-6066.CIR-19-0464" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1158%2F2326-6066.CIR-19-0464" aria-label="Article reference 51" data-doi="10.1158/2326-6066.CIR-19-0464">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3cXitVOgur%2FF" aria-label="CAS reference 51">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=31871119" aria-label="PubMed reference 51">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 51" href="http://scholar.google.com/scholar_lookup?&amp;title=High-throughput%20prediction%20of%20MHC%20class%20I%20and%20II%20neoantigens%20with%20MHCnuggets&amp;journal=Cancer%20Immunol.%20Res.&amp;doi=10.1158%2F2326-6066.CIR-19-0464&amp;volume=8&amp;pages=396-408&amp;publication_year=2020&amp;author=Shao%2CXM">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="52."><p class="c-article-references__text" id="ref-CR52">Kim, S. et al. Strelka2: fast and accurate calling of germline and somatic variants. <i>Nat. Methods</i> <b>15</b>, 591–594 (2018).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/s41592-018-0051-x" data-track-item_id="10.1038/s41592-018-0051-x" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fs41592-018-0051-x" aria-label="Article reference 52" data-doi="10.1038/s41592-018-0051-x">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC1cXhtlCmt7%2FF" aria-label="CAS reference 52">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30013048" aria-label="PubMed reference 52">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 52" href="http://scholar.google.com/scholar_lookup?&amp;title=Strelka2%3A%20fast%20and%20accurate%20calling%20of%20germline%20and%20somatic%20variants&amp;journal=Nat.%20Methods&amp;doi=10.1038%2Fs41592-018-0051-x&amp;volume=15&amp;pages=591-594&amp;publication_year=2018&amp;author=Kim%2CS">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="53."><p class="c-article-references__text" id="ref-CR53">Pagel, K. A. et al. Integrated informatics analysis of cancer-related variants. <i>JCO Clin. Cancer Inform.</i> <b>4</b>, 310–317 (2020).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1200/CCI.19.00132" data-track-item_id="10.1200/CCI.19.00132" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1200%2FCCI.19.00132" aria-label="Article reference 53" data-doi="10.1200/CCI.19.00132">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32228266" aria-label="PubMed reference 53">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 53" href="http://scholar.google.com/scholar_lookup?&amp;title=Integrated%20informatics%20analysis%20of%20cancer-related%20variants&amp;journal=JCO%20Clin.%20Cancer%20Inform.&amp;doi=10.1200%2FCCI.19.00132&amp;volume=4&amp;pages=310-317&amp;publication_year=2020&amp;author=Pagel%2CKA">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="54."><p class="c-article-references__text" id="ref-CR54">Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. <i>Nature</i> <b>500</b>, 415–421 (2013).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/nature12477" data-track-item_id="10.1038/nature12477" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fnature12477" aria-label="Article reference 54" data-doi="10.1038/nature12477">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC3sXhtlWjur7M" aria-label="CAS reference 54">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=23945592" aria-label="PubMed reference 54">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3776390" aria-label="PubMed Central reference 54">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 54" href="http://scholar.google.com/scholar_lookup?&amp;title=Signatures%20of%20mutational%20processes%20in%20human%20cancer&amp;journal=Nature&amp;doi=10.1038%2Fnature12477&amp;volume=500&amp;pages=415-421&amp;publication_year=2013&amp;author=Alexandrov%2CLB">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="55."><p class="c-article-references__text" id="ref-CR55">Szolek, A. et al. OptiType: precision HLA typing from next-generation sequencing data. <i>Bioinformatics</i> <b>30</b>, 3310–3316 (2014).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1093/bioinformatics/btu548" data-track-item_id="10.1093/bioinformatics/btu548" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1093%2Fbioinformatics%2Fbtu548" aria-label="Article reference 55" data-doi="10.1093/bioinformatics/btu548">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC2MXisFalt7Y%3D" aria-label="CAS reference 55">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=25143287" aria-label="PubMed reference 55">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4441069" aria-label="PubMed Central reference 55">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 55" href="http://scholar.google.com/scholar_lookup?&amp;title=OptiType%3A%20precision%20HLA%20typing%20from%20next-generation%20sequencing%20data&amp;journal=Bioinformatics&amp;doi=10.1093%2Fbioinformatics%2Fbtu548&amp;volume=30&amp;pages=3310-3316&amp;publication_year=2014&amp;author=Szolek%2CA">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="56."><p class="c-article-references__text" id="ref-CR56">Xie, C. et al. Fast and accurate HLA typing from short-read next-generation sequence data with xHLA. <i>Proc. Natl Acad. Sci. USA</i> <b>114</b>, 8059–8064 (2017).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1073/pnas.1707945114" data-track-item_id="10.1073/pnas.1707945114" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1073%2Fpnas.1707945114" aria-label="Article reference 56" data-doi="10.1073/pnas.1707945114">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC2sXhtFSmtrfJ" aria-label="CAS reference 56">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=28674023" aria-label="PubMed reference 56">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5544337" aria-label="PubMed Central reference 56">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 56" href="http://scholar.google.com/scholar_lookup?&amp;title=Fast%20and%20accurate%20HLA%20typing%20from%20short-read%20next-generation%20sequence%20data%20with%20xHLA&amp;journal=Proc.%20Natl%20Acad.%20Sci.%20USA&amp;doi=10.1073%2Fpnas.1707945114&amp;volume=114&amp;pages=8059-8064&amp;publication_year=2017&amp;author=Xie%2CC">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="57."><p class="c-article-references__text" id="ref-CR57">Cao, H. et al. An integrated tool to study MHC region: accurate SNV detection and HLA genes typing in human MHC region using targeted high-throughput sequencing. <i>PLoS ONE</i> <b>8</b>, e69388 (2013).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1371/journal.pone.0069388" data-track-item_id="10.1371/journal.pone.0069388" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1371%2Fjournal.pone.0069388" aria-label="Article reference 57" data-doi="10.1371/journal.pone.0069388">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC3sXht1ert7zL" aria-label="CAS reference 57">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=23894464" aria-label="PubMed reference 57">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3722289" aria-label="PubMed Central reference 57">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 57" href="http://scholar.google.com/scholar_lookup?&amp;title=An%20integrated%20tool%20to%20study%20MHC%20region%3A%20accurate%20SNV%20detection%20and%20HLA%20genes%20typing%20in%20human%20MHC%20region%20using%20targeted%20high-throughput%20sequencing&amp;journal=PLoS%20ONE&amp;doi=10.1371%2Fjournal.pone.0069388&amp;volume=8&amp;publication_year=2013&amp;author=Cao%2CH">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="58."><p class="c-article-references__text" id="ref-CR58">Shukla, S. A. et al. Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes. <i>Nat. Biotechnol.</i> <b>33</b>, 1152–1158 (2015).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/nbt.3344" data-track-item_id="10.1038/nbt.3344" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fnbt.3344" aria-label="Article reference 58" data-doi="10.1038/nbt.3344">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC2MXhsFWht7nO" aria-label="CAS reference 58">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=26372948" aria-label="PubMed reference 58">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4747795" aria-label="PubMed Central reference 58">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 58" href="http://scholar.google.com/scholar_lookup?&amp;title=Comprehensive%20analysis%20of%20cancer-associated%20somatic%20mutations%20in%20class%20I%20HLA%20genes&amp;journal=Nat.%20Biotechnol.&amp;doi=10.1038%2Fnbt.3344&amp;volume=33&amp;pages=1152-1158&amp;publication_year=2015&amp;author=Shukla%2CSA">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="59."><p class="c-article-references__text" id="ref-CR59">McGranahan, N. et al. Allele-specific HLA loss and immune escape in lung cancer evolution. <i>Cell</i> <b>171</b>, 1259–1271 (2017).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/j.cell.2017.10.001" data-track-item_id="10.1016/j.cell.2017.10.001" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.cell.2017.10.001" aria-label="Article reference 59" data-doi="10.1016/j.cell.2017.10.001">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC2sXhslehs7nL" aria-label="CAS reference 59">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29107330" aria-label="PubMed reference 59">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5720478" aria-label="PubMed Central reference 59">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 59" href="http://scholar.google.com/scholar_lookup?&amp;title=Allele-specific%20HLA%20loss%20and%20immune%20escape%20in%20lung%20cancer%20evolution&amp;journal=Cell&amp;doi=10.1016%2Fj.cell.2017.10.001&amp;volume=171&amp;pages=1259-1271&amp;publication_year=2017&amp;author=McGranahan%2CN">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="60."><p class="c-article-references__text" id="ref-CR60">Robinson, J. et al. The IPD and IMGT/HLA database: allele variant databases. <i>Nucleic Acids Res.</i> <b>43</b>, D423–D431 (2015).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1093/nar/gku1161" data-track-item_id="10.1093/nar/gku1161" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1093%2Fnar%2Fgku1161" aria-label="Article reference 60" data-doi="10.1093/nar/gku1161">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC2sXhtVymtrbF" aria-label="CAS reference 60">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=25414341" aria-label="PubMed reference 60">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 60" href="http://scholar.google.com/scholar_lookup?&amp;title=The%20IPD%20and%20IMGT%2FHLA%20database%3A%20allele%20variant%20databases&amp;journal=Nucleic%20Acids%20Res.&amp;doi=10.1093%2Fnar%2Fgku1161&amp;volume=43&amp;pages=D423-D431&amp;publication_year=2015&amp;author=Robinson%2CJ">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="61."><p class="c-article-references__text" id="ref-CR61">Shen, R. &amp; Seshan, V. E. FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing. <i>Nucleic Acids Res.</i> <b>44</b>, e131 (2016).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1093/nar/gkw520" data-track-item_id="10.1093/nar/gkw520" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1093%2Fnar%2Fgkw520" aria-label="Article reference 61" data-doi="10.1093/nar/gkw520">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=27270079" aria-label="PubMed reference 61">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5027494" aria-label="PubMed Central reference 61">PubMed Central</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC28XhvVKmsrvE" aria-label="CAS reference 61">CAS</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 61" href="http://scholar.google.com/scholar_lookup?&amp;title=FACETS%3A%20allele-specific%20copy%20number%20and%20clonal%20heterogeneity%20analysis%20tool%20for%20high-throughput%20DNA%20sequencing&amp;journal=Nucleic%20Acids%20Res.&amp;doi=10.1093%2Fnar%2Fgkw520&amp;volume=44&amp;publication_year=2016&amp;author=Shen%2CR&amp;author=Seshan%2CVE">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="62."><p class="c-article-references__text" id="ref-CR62">Niknafs, N., Beleva-Guthrie, V., Naiman, D. Q. &amp; Karchin, R. SubClonal hierarchy inference from somatic mutations: automatic reconstruction of cancer evolutionary trees from multi-region next generation sequencing. <i>PLoS Comput. Biol.</i> <b>11</b>, e1004416 (2015).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1371/journal.pcbi.1004416" data-track-item_id="10.1371/journal.pcbi.1004416" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1371%2Fjournal.pcbi.1004416" aria-label="Article reference 62" data-doi="10.1371/journal.pcbi.1004416">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=26436540" aria-label="PubMed reference 62">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4593588" aria-label="PubMed Central reference 62">PubMed Central</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC28XkvVOltrY%3D" aria-label="CAS reference 62">CAS</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 62" href="http://scholar.google.com/scholar_lookup?&amp;title=SubClonal%20hierarchy%20inference%20from%20somatic%20mutations%3A%20automatic%20reconstruction%20of%20cancer%20evolutionary%20trees%20from%20multi-region%20next%20generation%20sequencing&amp;journal=PLoS%20Comput.%20Biol.&amp;doi=10.1371%2Fjournal.pcbi.1004416&amp;volume=11&amp;publication_year=2015&amp;author=Niknafs%2CN&amp;author=Beleva-Guthrie%2CV&amp;author=Naiman%2CDQ&amp;author=Karchin%2CR">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="63."><p class="c-article-references__text" id="ref-CR63">Sztupinszki, Z. et al. Migrating the SNP array-based homologous recombination deficiency measures to next generation sequencing data of breast cancer. <i>NPJ Breast Cancer</i> <b>4</b>, 16 (2018).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/s41523-018-0066-6" data-track-item_id="10.1038/s41523-018-0066-6" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fs41523-018-0066-6" aria-label="Article reference 63" data-doi="10.1038/s41523-018-0066-6">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29978035" aria-label="PubMed reference 63">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6028448" aria-label="PubMed Central reference 63">PubMed Central</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC1cXht1OjsLzI" aria-label="CAS reference 63">CAS</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 63" href="http://scholar.google.com/scholar_lookup?&amp;title=Migrating%20the%20SNP%20array-based%20homologous%20recombination%20deficiency%20measures%20to%20next%20generation%20sequencing%20data%20of%20breast%20cancer&amp;journal=NPJ%20Breast%20Cancer&amp;doi=10.1038%2Fs41523-018-0066-6&amp;volume=4&amp;publication_year=2018&amp;author=Sztupinszki%2CZ">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="64."><p class="c-article-references__text" id="ref-CR64">Carlson, C. S. et al. Using synthetic templates to design an unbiased multiplex PCR assay. <i>Nat. Commun.</i> <b>4</b>, 2680 (2013).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/ncomms3680" data-track-item_id="10.1038/ncomms3680" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fncomms3680" aria-label="Article reference 64" data-doi="10.1038/ncomms3680">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=24157944" aria-label="PubMed reference 64">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC2cXhtVGmsrw%3D" aria-label="CAS reference 64">CAS</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 64" href="http://scholar.google.com/scholar_lookup?&amp;title=Using%20synthetic%20templates%20to%20design%20an%20unbiased%20multiplex%20PCR%20assay&amp;journal=Nat.%20Commun.&amp;doi=10.1038%2Fncomms3680&amp;volume=4&amp;publication_year=2013&amp;author=Carlson%2CCS">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="65."><p class="c-article-references__text" id="ref-CR65">Dobin, A. &amp; Gingeras, T. R. Mapping RNA-seq reads with STAR. <i>Curr. Protoc. Bioinformatics</i> <b>51</b>, 11 14 11–11 14 19 (2015).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=26334920" aria-label="PubMed reference 65">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 65" href="http://scholar.google.com/scholar_lookup?&amp;title=Mapping%20RNA-seq%20reads%20with%20STAR&amp;journal=Curr.%20Protoc.%20Bioinformatics&amp;volume=51&amp;pages=11%2014%2011-11%2014%2019&amp;publication_year=2015&amp;author=Dobin%2CA&amp;author=Gingeras%2CTR">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="66."><p class="c-article-references__text" id="ref-CR66">Li, B. &amp; Dewey, C. N. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. <i>BMC Bioinformatics</i> <b>12</b>, 323 (2011).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC3MXhtFajtLvM" aria-label="CAS reference 66">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21816040" aria-label="PubMed reference 66">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3163565" aria-label="PubMed Central reference 66">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 66" href="http://scholar.google.com/scholar_lookup?&amp;title=RSEM%3A%20accurate%20transcript%20quantification%20from%20RNA-Seq%20data%20with%20or%20without%20a%20reference%20genome&amp;journal=BMC%20Bioinformatics&amp;volume=12&amp;publication_year=2011&amp;author=Li%2CB&amp;author=Dewey%2CCN">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="67."><p class="c-article-references__text" id="ref-CR67">Love, M. I., Huber, W. &amp; Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. <i>Genome Biol.</i> <b>15</b>, 550 (2014).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="noopener" data-track-label="10.1186/s13059-014-0550-8" data-track-item_id="10.1186/s13059-014-0550-8" data-track-value="article reference" data-track-action="article reference" href="https://link.springer.com/doi/10.1186/s13059-014-0550-8" aria-label="Article reference 67" data-doi="10.1186/s13059-014-0550-8">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=25516281" aria-label="PubMed reference 67">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4302049" aria-label="PubMed Central reference 67">PubMed Central</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC2MXjtVCrsL8%3D" aria-label="CAS reference 67">CAS</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 67" href="http://scholar.google.com/scholar_lookup?&amp;title=Moderated%20estimation%20of%20fold%20change%20and%20dispersion%20for%20RNA-seq%20data%20with%20DESeq2&amp;journal=Genome%20Biol.&amp;doi=10.1186%2Fs13059-014-0550-8&amp;volume=15&amp;publication_year=2014&amp;author=Love%2CMI&amp;author=Huber%2CW&amp;author=Anders%2CS">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="68."><p class="c-article-references__text" id="ref-CR68">Danilova, L. et al. The mutation-associated neoantigen functional expansion of specific T cells (MANAFEST) assay: a sensitive platform for monitoring antitumor immunity. <i>Cancer Immunol. Res.</i> <b>6</b>, 888–899 (2018).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1158/2326-6066.CIR-18-0129" data-track-item_id="10.1158/2326-6066.CIR-18-0129" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1158%2F2326-6066.CIR-18-0129" aria-label="Article reference 68" data-doi="10.1158/2326-6066.CIR-18-0129">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC1cXhsVWrsbbI" aria-label="CAS reference 68">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29895573" aria-label="PubMed reference 68">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6072595" aria-label="PubMed Central reference 68">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 68" href="http://scholar.google.com/scholar_lookup?&amp;title=The%20mutation-associated%20neoantigen%20functional%20expansion%20of%20specific%20T%20cells%20%28MANAFEST%29%20assay%3A%20a%20sensitive%20platform%20for%20monitoring%20antitumor%20immunity&amp;journal=Cancer%20Immunol.%20Res.&amp;doi=10.1158%2F2326-6066.CIR-18-0129&amp;volume=6&amp;pages=888-899&amp;publication_year=2018&amp;author=Danilova%2CL">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="69."><p class="c-article-references__text" id="ref-CR69">Zhang, J., Ji, Z. &amp; Smith, K. N. Analysis of TCR β CDR3 sequencing data for tracking anti-tumor immunity. <i>Methods Enzymol.</i> <b>629</b>, 443–464 (2019).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/bs.mie.2019.08.006" data-track-item_id="10.1016/bs.mie.2019.08.006" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2Fbs.mie.2019.08.006" aria-label="Article reference 69" data-doi="10.1016/bs.mie.2019.08.006">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3cXisVyrtL7P" aria-label="CAS reference 69">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=31727253" aria-label="PubMed reference 69">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 69" href="http://scholar.google.com/scholar_lookup?&amp;title=Analysis%20of%20TCR%20%CE%B2%20CDR3%20sequencing%20data%20for%20tracking%20anti-tumor%20immunity&amp;journal=Methods%20Enzymol.&amp;doi=10.1016%2Fbs.mie.2019.08.006&amp;volume=629&amp;pages=443-464&amp;publication_year=2019&amp;author=Zhang%2CJ&amp;author=Ji%2CZ&amp;author=Smith%2CKN">
                    Google Scholar</a>&nbsp;
                </p></li></ol><p class="c-article-references__download u-hide-print"><a data-track="click" data-track-action="download citation references" data-track-label="link" rel="nofollow" href="https://citation-needed.springer.com/v2/references/10.1038/s41591-021-01541-0?format=refman&amp;flavour=references">Download references<svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-download-medium"></use></svg></a></p></div></div></div></section></div><section data-title="Acknowledgements"><div class="c-article-section" id="Ack1-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Ack1">Acknowledgements</h2><div class="c-article-section__content" id="Ack1-content"><p>We would like to thank G. Pereira and A. Curry in the Upper Aerodigestive Biorepository for sample procurement and members of the SKCCC FEST and TCR Immunogenomics Core Facility for assistance with the MANAFEST assays. The PrE0505 clinical trial was sponsored by AstraZeneca and PrECOG. This work was supported, in part, by Johns Hopkins SKCCC core grant NCI CCSG P30 CA006973, Department of Defense Congressionally Directed Medical Research Programs grant CA190755 (V.A. and P.M.F.), National Institutes of Health grants CA121113 (V.A. and V.V.), CA006973 (V.V.) and R37CA251447 (K.N.S.), ECOG-ACRIN Thoracic Malignancies Integrated Translational Science Center grant UG1CA233259 (V.A., V.V., Z.S. and S.R.), the Bloomberg-Kimmel Institute for Cancer Immunotherapy (V.A, P.M.F. and K.N.S.), the V Foundation (V.A. and V.V.), the IASLC Foundation (K.N.S), the Lung Cancer Foundation of America (K.N.S.), Swim Across America (V.A. and K.N.S.), the Florence Lomax Eley Fund (V.A., P.M.F. and J.B.) and the LUNGevity Foundation (V.A., V.V. and K.N.S.).</p></div></div></section><section aria-labelledby="author-information" data-title="Author information"><div class="c-article-section" id="author-information-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="author-information">Author information</h2><div class="c-article-section__content" id="author-information-content"><span class="c-article-author-information__subtitle u-visually-hidden" id="author-notes">Author notes</span><ol class="c-article-author-information__list"><li class="c-article-author-information__item" id="na1"><p>These authors contributed equally: Patrick M. Forde, Valsamo Anagnostou, Zhuoxin Sun.</p></li></ol><h3 class="c-article__sub-heading" id="affiliations">Authors and Affiliations</h3><ol class="c-article-author-affiliation__list"><li id="Aff1"><p class="c-article-author-affiliation__address">The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA</p><p class="c-article-author-affiliation__authors-list">Patrick M. Forde,&nbsp;Valsamo Anagnostou,&nbsp;Noushin Niknafs,&nbsp;Mara Lanis,&nbsp;Zineb Belcaid,&nbsp;Kellie N. Smith,&nbsp;Archana Balan,&nbsp;James R. White,&nbsp;Christopher Cherry,&nbsp;Hok Yee Chan,&nbsp;Dipika Singh,&nbsp;Sampriti Thapa,&nbsp;Peter B. Illei,&nbsp;Drew M. Pardoll,&nbsp;Rachel Karchin,&nbsp;Victor E. Velculescu&nbsp;&amp;&nbsp;Julie R. Brahmer</p></li><li id="Aff2"><p class="c-article-author-affiliation__address">The Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, MD, USA</p><p class="c-article-author-affiliation__authors-list">Patrick M. Forde,&nbsp;Valsamo Anagnostou,&nbsp;Kellie N. Smith,&nbsp;Hok Yee Chan,&nbsp;Dipika Singh,&nbsp;Sampriti Thapa,&nbsp;Drew M. Pardoll,&nbsp;Victor E. Velculescu&nbsp;&amp;&nbsp;Julie R. Brahmer</p></li><li id="Aff3"><p class="c-article-author-affiliation__address">ECOG-ACRIN Biostatistics Center, Boston, MA, USA</p><p class="c-article-author-affiliation__authors-list">Zhuoxin Sun</p></li><li id="Aff4"><p class="c-article-author-affiliation__address">Frontier Science Foundation, Boston, MA, USA</p><p class="c-article-author-affiliation__authors-list">Zhuoxin Sun</p></li><li id="Aff5"><p class="c-article-author-affiliation__address">Boston Children’s Hospital, Boston, MA, USA</p><p class="c-article-author-affiliation__authors-list">Suzanne E. Dahlberg</p></li><li id="Aff6"><p class="c-article-author-affiliation__address">University of Chicago Medicine, Chicago, IL, USA</p><p class="c-article-author-affiliation__authors-list">Hedy L. Kindler</p></li><li id="Aff7"><p class="c-article-author-affiliation__address">University of Washington School of Medicine &amp; Fred Hutchinson Cancer Research Center, Seattle, WA, USA</p><p class="c-article-author-affiliation__authors-list">Thomas Purcell&nbsp;&amp;&nbsp;Rafael Santana-Davila</p></li><li id="Aff8"><p class="c-article-author-affiliation__address">Metro-Minnesota Community Oncology Research Consortium, St. Louis Park, MN, USA</p><p class="c-article-author-affiliation__authors-list">Arkadiusz Z. Dudek</p></li><li id="Aff9"><p class="c-article-author-affiliation__address">Fox Chase Cancer Center, Philadelphia, PA, USA</p><p class="c-article-author-affiliation__authors-list">Hossein Borghaei</p></li><li id="Aff10"><p class="c-article-author-affiliation__address">Institute for Computational Medicine, Johns Hopkins University, Baltimore, MD, USA</p><p class="c-article-author-affiliation__authors-list">I. K. Ashok Sivakumar,&nbsp;Xiaoshan M. Shao&nbsp;&amp;&nbsp;Rachel Karchin</p></li><li id="Aff11"><p class="c-article-author-affiliation__address">Department of Biomedical Engineering, Johns Hopkins University, Baltimore, MD, USA</p><p class="c-article-author-affiliation__authors-list">Xiaoshan M. Shao,&nbsp;Rachel Karchin&nbsp;&amp;&nbsp;Victor E. Velculescu</p></li><li id="Aff12"><p class="c-article-author-affiliation__address">Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA</p><p class="c-article-author-affiliation__authors-list">Peter B. Illei&nbsp;&amp;&nbsp;Victor E. Velculescu</p></li><li id="Aff13"><p class="c-article-author-affiliation__address">Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute, Atlanta, GA, USA</p><p class="c-article-author-affiliation__authors-list">Suresh S. Ramalingam</p></li></ol><div class="u-js-hide u-hide-print" data-test="author-info"><span class="c-article__sub-heading">Authors</span><ol class="c-article-authors-search u-list-reset"><li id="auth-Patrick_M_-Forde-Aff1-Aff2"><span class="c-article-authors-search__title u-h3 js-search-name">Patrick M. Forde</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Patrick%20M.%20Forde" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Patrick%20M.%20Forde" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Patrick%20M.%20Forde%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Valsamo-Anagnostou-Aff1-Aff2"><span class="c-article-authors-search__title u-h3 js-search-name">Valsamo Anagnostou</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Valsamo%20Anagnostou" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Valsamo%20Anagnostou" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Valsamo%20Anagnostou%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Zhuoxin-Sun-Aff3-Aff4"><span class="c-article-authors-search__title u-h3 js-search-name">Zhuoxin Sun</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Zhuoxin%20Sun" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Zhuoxin%20Sun" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Zhuoxin%20Sun%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Suzanne_E_-Dahlberg-Aff5"><span class="c-article-authors-search__title u-h3 js-search-name">Suzanne E. Dahlberg</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Suzanne%20E.%20Dahlberg" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Suzanne%20E.%20Dahlberg" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Suzanne%20E.%20Dahlberg%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Hedy_L_-Kindler-Aff6"><span class="c-article-authors-search__title u-h3 js-search-name">Hedy L. Kindler</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Hedy%20L.%20Kindler" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Hedy%20L.%20Kindler" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Hedy%20L.%20Kindler%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Noushin-Niknafs-Aff1"><span class="c-article-authors-search__title u-h3 js-search-name">Noushin Niknafs</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Noushin%20Niknafs" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Noushin%20Niknafs" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Noushin%20Niknafs%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Thomas-Purcell-Aff7"><span class="c-article-authors-search__title u-h3 js-search-name">Thomas Purcell</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Thomas%20Purcell" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Thomas%20Purcell" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Thomas%20Purcell%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Rafael-Santana_Davila-Aff7"><span class="c-article-authors-search__title u-h3 js-search-name">Rafael Santana-Davila</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Rafael%20Santana-Davila" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Rafael%20Santana-Davila" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Rafael%20Santana-Davila%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Arkadiusz_Z_-Dudek-Aff8"><span class="c-article-authors-search__title u-h3 js-search-name">Arkadiusz Z. Dudek</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Arkadiusz%20Z.%20Dudek" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Arkadiusz%20Z.%20Dudek" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Arkadiusz%20Z.%20Dudek%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Hossein-Borghaei-Aff9"><span class="c-article-authors-search__title u-h3 js-search-name">Hossein Borghaei</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Hossein%20Borghaei" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Hossein%20Borghaei" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Hossein%20Borghaei%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Mara-Lanis-Aff1"><span class="c-article-authors-search__title u-h3 js-search-name">Mara Lanis</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Mara%20Lanis" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Mara%20Lanis" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Mara%20Lanis%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Zineb-Belcaid-Aff1"><span class="c-article-authors-search__title u-h3 js-search-name">Zineb Belcaid</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Zineb%20Belcaid" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Zineb%20Belcaid" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Zineb%20Belcaid%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Kellie_N_-Smith-Aff1-Aff2"><span class="c-article-authors-search__title u-h3 js-search-name">Kellie N. Smith</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Kellie%20N.%20Smith" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Kellie%20N.%20Smith" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Kellie%20N.%20Smith%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Archana-Balan-Aff1"><span class="c-article-authors-search__title u-h3 js-search-name">Archana Balan</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Archana%20Balan" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Archana%20Balan" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Archana%20Balan%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-James_R_-White-Aff1"><span class="c-article-authors-search__title u-h3 js-search-name">James R. White</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=James%20R.%20White" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=James%20R.%20White" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22James%20R.%20White%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Christopher-Cherry-Aff1"><span class="c-article-authors-search__title u-h3 js-search-name">Christopher Cherry</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Christopher%20Cherry" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Christopher%20Cherry" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Christopher%20Cherry%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-I__K_-Ashok_Sivakumar-Aff10"><span class="c-article-authors-search__title u-h3 js-search-name">I. K. Ashok Sivakumar</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=I.%20K.%20Ashok%20Sivakumar" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=I.%20K.%20Ashok%20Sivakumar" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22I.%20K.%20Ashok%20Sivakumar%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Xiaoshan_M_-Shao-Aff10-Aff11"><span class="c-article-authors-search__title u-h3 js-search-name">Xiaoshan M. Shao</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Xiaoshan%20M.%20Shao" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Xiaoshan%20M.%20Shao" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Xiaoshan%20M.%20Shao%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Hok_Yee-Chan-Aff1-Aff2"><span class="c-article-authors-search__title u-h3 js-search-name">Hok Yee Chan</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Hok%20Yee%20Chan" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Hok%20Yee%20Chan" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Hok%20Yee%20Chan%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Dipika-Singh-Aff1-Aff2"><span class="c-article-authors-search__title u-h3 js-search-name">Dipika Singh</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Dipika%20Singh" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Dipika%20Singh" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Dipika%20Singh%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Sampriti-Thapa-Aff1-Aff2"><span class="c-article-authors-search__title u-h3 js-search-name">Sampriti Thapa</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Sampriti%20Thapa" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Sampriti%20Thapa" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Sampriti%20Thapa%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Peter_B_-Illei-Aff1-Aff12"><span class="c-article-authors-search__title u-h3 js-search-name">Peter B. Illei</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Peter%20B.%20Illei" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Peter%20B.%20Illei" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Peter%20B.%20Illei%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Drew_M_-Pardoll-Aff1-Aff2"><span class="c-article-authors-search__title u-h3 js-search-name">Drew M. Pardoll</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Drew%20M.%20Pardoll" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Drew%20M.%20Pardoll" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Drew%20M.%20Pardoll%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Rachel-Karchin-Aff1-Aff10-Aff11"><span class="c-article-authors-search__title u-h3 js-search-name">Rachel Karchin</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Rachel%20Karchin" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Rachel%20Karchin" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Rachel%20Karchin%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Victor_E_-Velculescu-Aff1-Aff2-Aff11-Aff12"><span class="c-article-authors-search__title u-h3 js-search-name">Victor E. Velculescu</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Victor%20E.%20Velculescu" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Victor%20E.%20Velculescu" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Victor%20E.%20Velculescu%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Julie_R_-Brahmer-Aff1-Aff2"><span class="c-article-authors-search__title u-h3 js-search-name">Julie R. Brahmer</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Julie%20R.%20Brahmer" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Julie%20R.%20Brahmer" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Julie%20R.%20Brahmer%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Suresh_S_-Ramalingam-Aff13"><span class="c-article-authors-search__title u-h3 js-search-name">Suresh S. Ramalingam</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Suresh%20S.%20Ramalingam" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Suresh%20S.%20Ramalingam" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Suresh%20S.%20Ramalingam%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li></ol></div><h3 class="c-article__sub-heading" id="contributions">Contributions</h3><p>V.A, P.M.F., J.R.B. and S.S.R. conceived the study and contributed to the study design, data analysis, interpretation and writing. Z.S. and S.E.D. contributed to the study design and data analysis. H.L.K., T.P., R.S.-D, A.Z.D. and H.B. contributed to data collection and edited the manuscript. N.N., Z.B., K.N.S., A.B., J.R.W., C.C., I.K.A.S., X.M.S., H.Y.C., D.S., T.S., P.B.I., D.M.P., V.E.V. and R.C. contributed to data analysis and interpretation and manuscript editing.</p><h3 class="c-article__sub-heading" id="corresponding-author">Corresponding authors</h3><p id="corresponding-author-list">Correspondence to
                <a id="corresp-c1" href="mailto:pforde1@jhmi.edu">Patrick M. Forde</a> or <a id="corresp-c2" href="mailto:vanagno1@jhmi.edu">Valsamo Anagnostou</a>.</p></div></div></section><section data-title="Ethics declarations"><div class="c-article-section" id="ethics-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="ethics">Ethics declarations</h2><div class="c-article-section__content" id="ethics-content">
              
                <h3 class="c-article__sub-heading" id="FPar3">Competing interests</h3>
                <p>V.A. receives research funding to her institution from Bristol Myers Squibb and AstraZeneca. P.M.F. has received research funding to his institution from AstraZeneca, Bristol Myers Squibb, Novartis, Corvus and Kyowa. He has also served as a consultant for Amgen, AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Iteos, Janssen, Mirati, Novartis and Sanofi and as a data and safety monitoring board member for Polaris and Flame Therapeutics. A.D. is Chief Medical Officer and Chief Executive Officer at TTC Oncology, Chief Medical Officer at Luminary Therapeutics, Chief Medical Officer at IGF Oncology, Chief Medical Officer at Squarex and an advisor to the Martell Diagnostic Laboratory. K.N.S. receives research funding to her institution from Bristol Myers Squibb, AstraZeneca and Enara Bio and holds founder’s equity in ManaT Bio. V.E.V. is a founder of Delfi Diagnostics and Personal Genome Diagnostics, serves on the board of directors and as a consultant for both organizations and owns Delfi Diagnostics and Personal Genome Diagnostics stock, which are subject to certain restrictions under university policy. Additionally, Johns Hopkins University owns equity in Delfi Diagnostics and Personal Genome Diagnostics. V.E.V. is an inventor of multiple licensed patents related to technologies from Johns Hopkins University. Some of these licenses and relationships are associated with equity or royalty payments directly to Johns Hopkins and V.E.V. V.E.V. is an advisor to Bristol Myers Squibb, Danaher, Genentech and Takeda Pharmaceuticals. Within the last 5 years, V.E.V. has been an advisor to Merck and Ignyta. These arrangements have been reviewed and approved by Johns Hopkins University in accordance with its conflict of interest policies. D.P. is a consultant for Aduro Biotech, Amgen, Bayer, Dynavax, Enara, FLX Bio, Immunomic Therapeutics, Janssen, Merck, Rock Springs Capitol, Tizona and Trieza; is on the Board of Directors of DNAtrix; is on the scientific advisory board of Immununica, WindMil, Dracen, Camden Partners and Astellas; receives research support from Bristol Myers Squibb and Compugen; and is a founder of ManaT Bio. C.C. is the founder of CM Cherry Consulting. J.W. is a consultant for Personal Genome Diagnostics, is the founder and owner of Resphera Biosciences and holds patents, royalties or other intellectual property from Personal Genomic Diagnostics. R.S.-D. is a consultant for Genentech/Roche, Bayer, Bristol Myers Squibb, Eli Lilly, AstraZeneca, NGM Biopharmaceuticals and Takeda Science Foundation. H.B. receives research support from Millennium, Merck, Celgene, Bristol Myers Squibb and Eli Lilly; is on the advisory board and/or a consultant for Bristol Myers Squibb, Eli Lilly, Genentech, Celgene, Pfizer, Merck, EMD-Serono, Boehringer-Ingelheim, AstraZeneca, Novartis, Genmab, Regeneron, BioNTech, Cantargia AB, Amgen, Abbvie, Axiom, PharmaMar, Takeda, Huya Bio, Mirati and Daiichi Sankyo; is on the data and safety monitoring board of the University of Pennsylvania, CAR T Program, Takeda and Incyte; is on the scientific advisory board for Sonnetbio (stock options), Rgenix (stock options) and Nucleai (stock options); receives honoraria from Amgen, Pfizer and Daiichi Sankyo; and receives travel support from Amgen, Bristol Myers Squibb, Merck, Eli Lilly, EMD-Serono and Genentech. J.B. is on the advisory board and/or a consultant for Amgen, AstraZeneca, Bristol Myers Squibb, Genentech/Roche, Eli Lilly, GlaxoSmithKline, Merck, Sanofi and Regeneron; receives grant research funding from AstraZeneca, Bristol Myers Squibb, Genentech/Roche, Merck, RAPT Therapeutics and Revolution Medicines; and is on the data and safety monitoring board/committees of GlaxoSmithKline, Sanofi and Janssen. H.L.K. reports personal fees from Aldeyra Therapeutics, AstraZeneca, Bayer, Boehringer-Ingelheim, Bristol Myers Squibb, Kyowa, Merck, Paredox Therapeutics, Deciphera, Inhibrx and Inventiva; and non-financial support from AstraZeneca, Boehringer-Ingelheim, Merck, Paredox Therapeutics and Inventiva. H.L.K. also reports funds given to support clinical trials at her institution from Aduro, AstraZeneca, Bayer, Bristol Myers Squibb, Deciphera, GlaxoSmithKline, Eli Lilly, Merck, Polaris, Verastem, Blueprint, Tesaro and Inhibrx. S.R. is a consultant for Amgen, Bristol Myers Squibb, Genentech/Roche, Merck, AstraZeneca, Takeda, Eisai, Daiichi Sankyo, Sanofi, GlaxoSmithKline and Eli Lilly and receives grants from Tesaro, Merck, AstraZeneca, Advaxis, Bristol Myers Squibb, Amgen, Takeda, Genmab and GlaxoSmithKline. All other authors declare no competing interests.</p>
              
            </div></div></section><section data-title="Additional information"><div class="c-article-section" id="additional-information-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="additional-information">Additional information</h2><div class="c-article-section__content" id="additional-information-content"><p><b>Peer review information</b> <i>Nature Medicine</i> thanks Paul Baas, Dean Fennell, Linghua Wang and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Saheli Sadanand was the primary editor on this article and managed its editorial process and peer review in collaboration with the rest of the editorial team.</p><p><b>Publisher’s note</b> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></div></div></section><section data-title="Extended data"><div class="c-article-section" id="Sec30-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Sec30">Extended data</h2><div class="c-article-section__content" id="Sec30-content"><div data-test="supplementary-info"><div id="figshareContainer" class="c-article-figshare-container" data-test="figshare-container"></div><div class="c-article-supplementary__item js-c-reading-companion-figures-item" data-test="supp-item" id="Fig6"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="extended data fig. 1 consort trial diagram for the" href="/articles/s41591-021-01541-0/figures/6" data-supp-info-image="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01541-0/MediaObjects/41591_2021_1541_Fig6_ESM.jpg">Extended Data Fig. 1 CONSORT trial diagram for the PrE0505 study.</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>Outline of number of patients available for analyses.</p></div></div><div class="c-article-supplementary__item js-c-reading-companion-figures-item" data-test="supp-item" id="Fig7"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="extended data fig. 2 analyses overview." href="/articles/s41591-021-01541-0/figures/7" data-supp-info-image="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01541-0/MediaObjects/41591_2021_1541_Fig7_ESM.jpg">Extended Data Fig. 2 Analyses Overview.</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>Whole exome sequencing data were analyzed to determine somatic sequence and focal copy number changes as well as germline variants in cancer predisposing genes and HLA class I and II haplotypes. Mutational spectra and enrichment in individual genes and gene sets were assessed. Genome-wide copy number analyses were performed to estimate genome aneuploidy, number of copy number breakpoints, homologous recombination deficiency as well as utilized to compute mutation cellular fractions. Computational predictions of mutation-associated neoantigens and immunogenic mutations were coupled with analyses of the intratumoral T cell repertoire and functional analyses of neopeptides-stimulated autologous peripheral T cells. PD-L1 and CD8+T cell expression was assessed by immunohistochemistry. This figure was developed using BioRender under a full license.</p></div></div><div class="c-article-supplementary__item js-c-reading-companion-figures-item" data-test="supp-item" id="Fig8"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="extended data fig. 3 treatment emergent adverse ev" href="/articles/s41591-021-01541-0/figures/8" data-supp-info-image="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01541-0/MediaObjects/41591_2021_1541_Fig8_ESM.jpg">Extended Data Fig. 3 Treatment emergent adverse events and outcome by platinum agent used.</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>(<b>a</b>) All grades and grade 3/4 treatment emergent adverse events; events reported in greater than 20% subjects or grade 3/4 events reported in greater than 5% of patients, worst grade reported per patient (CTCAE Version 4.03) (<b>b</b>) Adverse events of special interest, investigator reported assessment and attribution as possibly, probably, or related for selected events, worst grade overall as reported for each patient. (<b>c</b>) Kaplan-Meier curves of OS according to the platinum agent used at the start of the treatment. (<b>d</b>) Kaplan-Meier curves of PFS according to the platinum agent used at the start of the treatment. There was no significant difference in OS or PFS for carboplatin vs. cisplatin-based chemotherapy (log rank p = 0.18 and p = 0.4 respectively). All p values are two-sided.</p><p><a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-021-01541-0#MOESM7">Source data</a></p></div></div><div class="c-article-supplementary__item js-c-reading-companion-figures-item" data-test="supp-item" id="Fig9"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="extended data fig. 4 distribution of mutations in " href="/articles/s41591-021-01541-0/figures/9" data-supp-info-image="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01541-0/MediaObjects/41591_2021_1541_Fig9_ESM.jpg">Extended Data Fig. 4 Distribution of mutations in genes involved in DNA damage repair.</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>We investigated co-occurrence of mutations in DNA damage repair (DDR) genes involved in base excision repair, DNA damage sensoring, the Fanconi anemia pathway, homologous recombination, mismatch repair, nucleotide excision repair, non-homologous end joining and translesion DNA synthesis. Mutations were characterized by consequence (missense, frameshift, nonsense, splice site, in-frame) and recurrence (hotspots) and loss of the wild type allele was considered in case of truncating mutations (biallellic inactivation, marked with an ‘x’). There were no significant differences in somatic genomic alterations in the DDR gene set between tumors from responders and non-responders. When confirmed pathogenic germline mutations in DDR genes were considered, 5 patients harboring such alterations (629-BAP1 c.1717del, 295-BRCA2 c.6730 A&gt;T, 628-BAP1 c.581-1 G &gt; T, 976-MSH6 c.3261dup and 506-BLM c.968 A&gt;G) had a longer overall survival as shown in Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01541-0#Fig2">2</a>. Abbreviations: TMB; tumor mutation burden, BOR; best overall response, CR; complete response, PR; partial response, SD; stable disease, PD; progressive disease, LOH; loss of heterozygosity, HRD; homologous recombination defect, CNA; copy number aberration.</p></div></div><div class="c-article-supplementary__item js-c-reading-companion-figures-item" data-test="supp-item" id="Fig10"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="extended data fig. 5 immunogenic mutation load may" href="/articles/s41591-021-01541-0/figures/10" data-supp-info-image="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01541-0/MediaObjects/41591_2021_1541_Fig10_ESM.jpg">Extended Data Fig. 5 Immunogenic mutation load may be linked with functional neopeptide-specific anti-tumor immune response and therapeutic response.</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>(<b>a</b>) Patients with MPM harboring a high non synonymous mutation load were more likely to achieve a radiographic response to chemo-immunotherapy (n = 40 MPM tumors, Mann Whitney p = 0.086). (<b>b</b>) MPMs responsive to chemo-immunotherapy also harbored a more clonal TMB (n = 40 MPM tumors, Mann Whitney p = 0.076). (<b>c</b>-<b>d</b>) These findings were more prominent in the epithelioid MPM group (n = 29 epithelioid MPM tumors, Mann Whitney p = 0.051 for non synonymous mutation load and Mann Whitney p = 0.025 for clonal mutation burden). (<b>e</b>,<b>f</b>) Immunogenic mutations associated with HLA class I and II neoantigens (<a data-track="click" data-track-label="link" data-track-action="section anchor" href="/articles/s41591-021-01541-0#Sec9">Methods</a>) better distinguished responders from non responders (n = 40 MPM tumors, Mann Whitney p = 0.064 for class I IMMs and Mann Whitney p = 0.023 for class II IMMs). (<b>g</b>,<b>h</b>) These findings were more pronounced for patients with epithelioid MPM (n = 29 epithelioid MPM tumors, Mann Whitney p = 0.035 for class I IMMs and Mann Whitney p = 0.038 for class II IMMs). The center line in the boxplots represents the median, the upper limit of the boxplots represents the third quantile (75th percentile), the lower limit of the boxplots represents the first quantile (25th percentile), the upper whiskers is the maximum value of the data that is within 1.5 times the interquartile range over the 75th percentile, and the lower whisker is the minimum value of the data that is within 1.5 times the interquartile range under the 25th percentile. (<b>i</b>) Survival analyses did not reveal any significant differences in overall survival between MPM tumors in the TCGA cohort with high TMB vs. those harboring a low TMB (log rank p = 0.21). (<b>j</b>) Analyses of progression-free survival revealed a trend towards longer PFS for patients with MPM tumors in the TCGA cohort harboring a low TMB (log rank p = 0.05). The TMB-high and low groups were defined using the 2nd quartile of TMB in the TCGA mesothelioma cohort, which corresponds to a non-synonymous mutation burden ≥33 alterations/exome. All p values are two-sided. Abbreviations: IMM; immunogenic mutation, CR; complete response, PR; partial response, SD; stable disease, PD; progressive disease.</p></div></div><div class="c-article-supplementary__item js-c-reading-companion-figures-item" data-test="supp-item" id="Fig11"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="extended data fig. 6 germline and tumor hla class " href="/articles/s41591-021-01541-0/figures/11" data-supp-info-image="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01541-0/MediaObjects/41591_2021_1541_Fig11_ESM.jpg">Extended Data Fig. 6 Germline and tumor HLA class I and II genetic variation.</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>(<b>a</b>) Tumors from responders harbored a higher load of HLA class I and II immunogenic mutations (<a data-track="click" data-track-label="link" data-track-action="section anchor" href="/articles/s41591-021-01541-0#Sec9">Methods</a>, Mann Whitney p = 0.064 and 0.023 respectively) especially in the epithelioid MPM group (Mann-Whitney p = 0.035 and p = 0.038 respectively). There were no differences in the degree of germline homozygosity found between responders and non-responders. HLA class I and II germline zygosity and somatic LOH events were combined to calculate the unique number of HLA class I and class II alleles on cancer cells, which did not differ between responders and non responders. Similarly, there was no evidence of biallellic inactivation of β2-microglobulin or differential abundance of β2-microglobulin LOH events with respect to therapeutic response. (<b>b</b>) When sequence divergence of the allele’s peptide-binding domains was computed for HLA class I alleles, patients with high pairwise divergence between HLA alleles and in particular in HLA-B achieved a radiographic response (Mann Whitney p = 0.06), suggesting that in high HLA divergence may be linked with an increased diversity of the neopeptide repertoire presented and reflective of a more potent-antitumor immune response. (<b>c</b>) While there were no differences in mean HLA class I divergence for patients with epithelioid MPM (Mann Whitney p = 0.3), (<b>d</b>) a higher HLA-B divergence was linked with radiographic response (Mann Whitney p = 0.003). All p values are two-sided and unadjusted for multiple comparisons. Abbreviations: IMM; immunogenic mutation, B2M; β2-microglobulin, LOH; loss of heterozygosity.</p></div></div><div class="c-article-supplementary__item js-c-reading-companion-figures-item" data-test="supp-item" id="Fig12"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="extended data fig. 7 tcr clonotypic expansions to " href="/articles/s41591-021-01541-0/figures/12" data-supp-info-image="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01541-0/MediaObjects/41591_2021_1541_Fig12_ESM.jpg">Extended Data Fig. 7 TCR clonotypic expansions to neopeptides derived from immunogenic mutations.</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>(<b>a</b>) We used the MANAFEST assay, which detects memory T cell responses and identifies antigen-specific T cell receptors to test neoantigen-specific TCR reactivity. Neopeptides derived from class I immunogenic mutations were tested in vitro in autologous T cell cultures from peripheral blood of patient 459 that achieved an overall survival of 32.88 months after chemo-immunotherapy. Neopeptide-specific TCR clonotypic expansions were identified post stimulation with peptides derived from the SRPK2 p.C234Y and NDUFS2 p.V412L immunogenic mutations (orange bars, y axis denotes TCR productive frequencies of CD8+ T cells after the 10-day culture). (<b>b</b>) Neontigen-specific TCR clonotypic expansions were noted in autologous CD8+ T cell cultures from the peripheral blood for patient 295 that achieved an overall survival of 21.85 months and remained event-free at the time of data lock. TCR clonotypic expansions for peptides derived from the immunogenic mutations SCRN1 p.V334A, PSD2 p.C307Y, ZNF469 p.P3471S and CD72 p.T71A (orange bars, y axis denotes TCR productive frequencies of CD8+ T cells after the 10-day culture). Peptide pools of known HLA class I-restricted viral antigens (<a data-track="click" data-track-label="link" data-track-action="section anchor" href="/articles/s41591-021-01541-0#Sec9">Methods</a>) were utilized as positive controls and are shown in blue bars for both cases.</p></div></div><div class="c-article-supplementary__item js-c-reading-companion-figures-item" data-test="supp-item" id="Fig13"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="extended data fig. 8 differences in cd8+t cell inf" href="/articles/s41591-021-01541-0/figures/13" data-supp-info-image="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01541-0/MediaObjects/41591_2021_1541_Fig13_ESM.jpg">Extended Data Fig. 8 Differences in CD8+T cell infiltration in <i>BAP1</i> mutant tumors.</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>(<b>a</b>) Epithelioid MPMs harboring somatic <i>BAP1</i> inactivating mutations had a higher intratumoral CD8+ T cell infiltration (n = 33 epithelioid MPM tumors, Mann Whitney p = 0.036). (<b>b</b>) RNA sequencing of tumor samples with adequate tissue (n = 6, 4 <i>BAP1</i> wild type and 2 <i>BAP1</i> mutant) revealed a higher expression level for GranzymeB in <i>BAP1</i> mutant tumors (n = 6 MPM tumors, Mann Whitney p = 0.0094). The center line in the boxplots represents the median, the upper limit of the boxplots represents the third quantile (75th percentile), the lower limit of the boxplots represents the first quantile (25th percentile), the upper whiskers is the maximum value of the data that is within 1.5 times the interquartile range over the 75th percentile, and the lower whisker is the minimum value of the data that is within 1.5 times the interquartile range under the 25th percentile. All p values are two-sided.</p><p><a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-021-01541-0#MOESM8">Source data</a></p></div></div><div class="c-article-supplementary__item js-c-reading-companion-figures-item" data-test="supp-item" id="Fig14"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="extended data fig. 9 genome-wide loss of heterozyg" href="/articles/s41591-021-01541-0/figures/14" data-supp-info-image="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01541-0/MediaObjects/41591_2021_1541_Fig14_ESM.jpg">Extended Data Fig. 9 Genome-wide loss of heterozygosity and genome near haploidization.</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>(<b>a</b>) MPM tumors exhibited various levels of genome-wide loss of heterozygosity. LOH in chromosomal arms 4p, 4q, 6q, 13q (containing the <i>BRCA2</i>, <i>ERCC5</i> and <i>LATS2</i> loci), 14q (containing the <i>FANCM</i>, <i>MLH3</i> and <i>XRCC3</i> loci), and 22q (containing the <i>CHECK2</i>, <i>NF2</i> and <i>XRCC6</i> loci) was observed at a significantly higher rate compared to background. In three tumors (cases 506, 628, 976), LOH was widespread throughout the genome consistent with the genome near haploidization phenotype. (<b>b</b>) Genome-wide copy number (top) and B-allele frequency (bottom) profiles of a tumor with GNH (976), depicting a hyper-diploid state and LOH in all chromosomes observed at normal copy number state. Abbreviations: LOH; loss of heterozygosity, GNH; genome near haploidization. (<b>c</b>-<b>e</b>) Comparison of the background rate of genomic loss in 1,086 mesothelioma and non-small cell lung cancer cases from TCGA showing that haploid regions of the genome consistently harbored a lower background rate of genomic loss compared to diploid regions (Mann Whitney p = 1e-09, p &lt; 2.2e-16 and p &lt; 2.2e-16 for mesothelioma, lung adenocarcinoma and lung squamous cell carcinomas respectively). (<b>f)</b> Patients in the PrE0505 study with a radiographic response harbored a higher number of clonal mutations within the haploid regions of their genomes (n = 40 MPM tumors, Mann Whitney p = 0.043). The center line in the boxplots represents the median, the upper limit of the boxplots represents the third quantile (75th percentile), the lower limit of the boxplots represents the first quantile (25th percentile), the upper whiskers is the maximum value of the data that is within 1.5 times the interquartile range over the 75th percentile, and the lower whisker is the minimum value of the data that is within 1.5 times the interquartile range under the 25th percentile. All p values are two-sided and unadjusted for multiple comparisons. Abbreviations: MESO; mesothelioma, LUAD; lung adenocarcinoma, LUSC; lung squamous cell carcinoma, CR; complete response, PR; partial response, SD; stable disease, PD; disease progression.</p><p><a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-021-01541-0#MOESM9">Source data</a></p></div></div><div class="c-article-supplementary__item js-c-reading-companion-figures-item" data-test="supp-item" id="Fig15"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="extended data fig. 10 correlations between genomic" href="/articles/s41591-021-01541-0/figures/15" data-supp-info-image="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01541-0/MediaObjects/41591_2021_1541_Fig15_ESM.jpg">Extended Data Fig. 10 Correlations between genomic and molecular features.</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>Non parametric correlations between sequence and structural genomic and TCR features for all patients (<b>a</b>) and patients with epithelioid mesothelioma (<b>b</b>). Correlations between tumor purity and non-synonymous missense mutation burden and associated neoantigens were noted for all patients but not for the epithelioid mesothelioma group. An asterix indicates a p value less than 0.05.</p></div></div></div></div></div></section><section data-title="Supplementary information"><div class="c-article-section" id="Sec31-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Sec31">Supplementary information</h2><div class="c-article-section__content" id="Sec31-content"><div data-test="supplementary-info"><div class="c-article-supplementary__item" data-test="supp-item" id="MOESM1"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="reporting summary" href="https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-021-01541-0/MediaObjects/41591_2021_1541_MOESM1_ESM.pdf" data-supp-info-image="">Reporting Summary</a></h3></div><div class="c-article-supplementary__item" data-test="supp-item" id="MOESM2"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="supplementary tables" href="https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-021-01541-0/MediaObjects/41591_2021_1541_MOESM2_ESM.xlsx" data-supp-info-image="">Supplementary Tables</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>Supplementary Table 1. Summary of clinical features of samples analyzed. Supplementary Table 2. Summary of WES characteristics. Supplementary Table 3. Summary of somatic sequence alterations. Supplementary Table 4. Differential enrichment analysis for genomic and TCR features for all patients and patients with epithelioid MPM. Supplementary Table 5. HLA class I and II germline and somatic diversity. Supplementary Table 6. Summary of somatic focal copy number alterations. Supplementary Table 7. Genome-wide aneuploidy characteristics. Supplementary Table 8. Mutation cellularity of mutations in haploid regions for mesotheliomas in the PrE0505 cohort. Supplementary Table 9. TCR sequencing characteristics. Supplementary Table 10. List of genes involved in DNA damage response assessed in the study. Supplementary Table 11. Neopeptides tested for patients 295 and 459. Supplementary Table 12. TCR sequencing characteristics for the MANAFEST assays. Supplementary Table 13. Frequency of neopeptide-specific TCR clonotypes in each experimental condition for patient 295. Supplementary Table 14. Frequency of neopeptide-specific TCR clonotypes in each experimental condition for patient 459.</p></div></div></div></div></div></section><section data-title="Source data"><div class="c-article-section" id="Sec32-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Sec32">Source data</h2><div class="c-article-section__content" id="Sec32-content"><div data-test="supplementary-info"><div class="c-article-supplementary__item" data-test="supp-item" id="MOESM3"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="source data fig. 1" href="https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-021-01541-0/MediaObjects/41591_2021_1541_MOESM3_ESM.xlsx" data-supp-info-image="">Source Data Fig. 1</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>Statistical Source Data</p></div></div><div class="c-article-supplementary__item" data-test="supp-item" id="MOESM4"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="source data fig. 2" href="https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-021-01541-0/MediaObjects/41591_2021_1541_MOESM4_ESM.xlsx" data-supp-info-image="">Source Data Fig. 2</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>Statistical Source Data</p></div></div><div class="c-article-supplementary__item" data-test="supp-item" id="MOESM5"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="source data fig. 4" href="https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-021-01541-0/MediaObjects/41591_2021_1541_MOESM5_ESM.xlsx" data-supp-info-image="">Source Data Fig. 4</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>Statistical Source Data.</p></div></div><div class="c-article-supplementary__item" data-test="supp-item" id="MOESM6"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="source data fig. 5" href="https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-021-01541-0/MediaObjects/41591_2021_1541_MOESM6_ESM.xlsx" data-supp-info-image="">Source Data Fig. 5</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>Statistical Source Data.</p></div></div><div class="c-article-supplementary__item" data-test="supp-item" id="MOESM7"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="source data extended data fig. 3" href="https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-021-01541-0/MediaObjects/41591_2021_1541_MOESM7_ESM.xlsx" data-supp-info-image="">Source Data Extended Data Fig. 3</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>Statistical Source Data</p></div></div><div class="c-article-supplementary__item" data-test="supp-item" id="MOESM8"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="source data extended data fig. 8" href="https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-021-01541-0/MediaObjects/41591_2021_1541_MOESM8_ESM.xlsx" data-supp-info-image="">Source Data Extended Data Fig. 8</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>Statistical Source Data</p></div></div><div class="c-article-supplementary__item" data-test="supp-item" id="MOESM9"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="source data extended data fig. 9" href="https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-021-01541-0/MediaObjects/41591_2021_1541_MOESM9_ESM.xlsx" data-supp-info-image="">Source Data Extended Data Fig. 9</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>Statistical Source Data</p></div></div></div></div></div></section><section data-title="Rights and permissions"><div class="c-article-section" id="rightslink-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="rightslink">Rights and permissions</h2><div class="c-article-section__content" id="rightslink-content">
                <p><b>Open Access</b>  This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <a href="http://creativecommons.org/licenses/by/4.0/" rel="license">http://creativecommons.org/licenses/by/4.0/</a>.</p>
              <p class="c-article-rights"><a data-track="click" data-track-action="view rights and permissions" data-track-label="link" href="https://s100.copyright.com/AppDispatchServlet?title=Durvalumab%20with%20platinum-pemetrexed%20for%20unresectable%20pleural%20mesothelioma%3A%20survival%2C%20genomic%20and%20immunologic%20analyses%20from%20the%20phase%202%20PrE0505%20trial&amp;author=Patrick%20M.%20Forde%20et%20al&amp;contentID=10.1038%2Fs41591-021-01541-0&amp;copyright=The%20Author%28s%29&amp;publication=1078-8956&amp;publicationDate=2021-11-08&amp;publisherName=SpringerNature&amp;orderBeanReset=true&amp;oa=CC%20BY">Reprints and permissions</a></p></div></div></section><section aria-labelledby="article-info" data-title="About this article"><div class="c-article-section" id="article-info-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="article-info">About this article</h2><div class="c-article-section__content" id="article-info-content"><div class="c-bibliographic-information"><div class="u-hide-print c-bibliographic-information__column c-bibliographic-information__column--border"><a data-crossmark="10.1038/s41591-021-01541-0" target="_blank" rel="noopener" href="https://crossmark.crossref.org/dialog/?doi=10.1038/s41591-021-01541-0" data-track="click" data-track-action="Click Crossmark" data-track-label="link" data-test="crossmark"><img loading="lazy" width="57" height="81" alt="Check for updates. Verify currency and authenticity via CrossMark" src="data:image/svg+xml;base64,<svg height="81" width="57" xmlns="http://www.w3.org/2000/svg"><g fill="none" fill-rule="evenodd"><path d="m17.35 35.45 21.3-14.2v-17.03h-21.3" fill="#989898"/><path d="m38.65 35.45-21.3-14.2v-17.03h21.3" fill="#747474"/><path d="m28 .5c-12.98 0-23.5 10.52-23.5 23.5s10.52 23.5 23.5 23.5 23.5-10.52 23.5-23.5c0-6.23-2.48-12.21-6.88-16.62-4.41-4.4-10.39-6.88-16.62-6.88zm0 41.25c-9.8 0-17.75-7.95-17.75-17.75s7.95-17.75 17.75-17.75 17.75 7.95 17.75 17.75c0 4.71-1.87 9.22-5.2 12.55s-7.84 5.2-12.55 5.2z" fill="#535353"/><path d="m41 36c-5.81 6.23-15.23 7.45-22.43 2.9-7.21-4.55-10.16-13.57-7.03-21.5l-4.92-3.11c-4.95 10.7-1.19 23.42 8.78 29.71 9.97 6.3 23.07 4.22 30.6-4.86z" fill="#9c9c9c"/><path d="m.2 58.45c0-.75.11-1.42.33-2.01s.52-1.09.91-1.5c.38-.41.83-.73 1.34-.94.51-.22 1.06-.32 1.65-.32.56 0 1.06.11 1.51.35.44.23.81.5 1.1.81l-.91 1.01c-.24-.24-.49-.42-.75-.56-.27-.13-.58-.2-.93-.2-.39 0-.73.08-1.05.23-.31.16-.58.37-.81.66-.23.28-.41.63-.53 1.04-.13.41-.19.88-.19 1.39 0 1.04.23 1.86.68 2.46.45.59 1.06.88 1.84.88.41 0 .77-.07 1.07-.23s.59-.39.85-.68l.91 1c-.38.43-.8.76-1.28.99-.47.22-1 .34-1.58.34-.59 0-1.13-.1-1.64-.31-.5-.2-.94-.51-1.31-.91-.38-.4-.67-.9-.88-1.48-.22-.59-.33-1.26-.33-2.02zm8.4-5.33h1.61v2.54l-.05 1.33c.29-.27.61-.51.96-.72s.76-.31 1.24-.31c.73 0 1.27.23 1.61.71.33.47.5 1.14.5 2.02v4.31h-1.61v-4.1c0-.57-.08-.97-.25-1.21-.17-.23-.45-.35-.83-.35-.3 0-.56.08-.79.22-.23.15-.49.36-.78.64v4.8h-1.61zm7.37 6.45c0-.56.09-1.06.26-1.51.18-.45.42-.83.71-1.14.29-.3.63-.54 1.01-.71.39-.17.78-.25 1.18-.25.47 0 .88.08 1.23.24.36.16.65.38.89.67s.42.63.54 1.03c.12.41.18.84.18 1.32 0 .32-.02.57-.07.76h-4.36c.07.62.29 1.1.65 1.44.36.33.82.5 1.38.5.29 0 .57-.04.83-.13s.51-.21.76-.37l.55 1.01c-.33.21-.69.39-1.09.53-.41.14-.83.21-1.26.21-.48 0-.92-.08-1.34-.25-.41-.16-.76-.4-1.07-.7-.31-.31-.55-.69-.72-1.13-.18-.44-.26-.95-.26-1.52zm4.6-.62c0-.55-.11-.98-.34-1.28-.23-.31-.58-.47-1.06-.47-.41 0-.77.15-1.07.45-.31.29-.5.73-.58 1.3zm2.5.62c0-.57.09-1.08.28-1.53.18-.44.43-.82.75-1.13s.69-.54 1.1-.71c.42-.16.85-.24 1.31-.24.45 0 .84.08 1.17.23s.61.34.85.57l-.77 1.02c-.19-.16-.38-.28-.56-.37-.19-.09-.39-.14-.61-.14-.56 0-1.01.21-1.35.63-.35.41-.52.97-.52 1.67 0 .69.17 1.24.51 1.66.34.41.78.62 1.32.62.28 0 .54-.06.78-.17.24-.12.45-.26.64-.42l.67 1.03c-.33.29-.69.51-1.08.65-.39.15-.78.23-1.18.23-.46 0-.9-.08-1.31-.24-.4-.16-.75-.39-1.05-.7s-.53-.69-.7-1.13c-.17-.45-.25-.96-.25-1.53zm6.91-6.45h1.58v6.17h.05l2.54-3.16h1.77l-2.35 2.8 2.59 4.07h-1.75l-1.77-2.98-1.08 1.23v1.75h-1.58zm13.69 1.27c-.25-.11-.5-.17-.75-.17-.58 0-.87.39-.87 1.16v.75h1.34v1.27h-1.34v5.6h-1.61v-5.6h-.92v-1.2l.92-.07v-.72c0-.35.04-.68.13-.98.08-.31.21-.57.4-.79s.42-.39.71-.51c.28-.12.63-.18 1.04-.18.24 0 .48.02.69.07.22.05.41.1.57.17zm.48 5.18c0-.57.09-1.08.27-1.53.17-.44.41-.82.72-1.13.3-.31.65-.54 1.04-.71.39-.16.8-.24 1.23-.24s.84.08 1.24.24c.4.17.74.4 1.04.71s.54.69.72 1.13c.19.45.28.96.28 1.53s-.09 1.08-.28 1.53c-.18.44-.42.82-.72 1.13s-.64.54-1.04.7-.81.24-1.24.24-.84-.08-1.23-.24-.74-.39-1.04-.7c-.31-.31-.55-.69-.72-1.13-.18-.45-.27-.96-.27-1.53zm1.65 0c0 .69.14 1.24.43 1.66.28.41.68.62 1.18.62.51 0 .9-.21 1.19-.62.29-.42.44-.97.44-1.66 0-.7-.15-1.26-.44-1.67-.29-.42-.68-.63-1.19-.63-.5 0-.9.21-1.18.63-.29.41-.43.97-.43 1.67zm6.48-3.44h1.33l.12 1.21h.05c.24-.44.54-.79.88-1.02.35-.24.7-.36 1.07-.36.32 0 .59.05.78.14l-.28 1.4-.33-.09c-.11-.01-.23-.02-.38-.02-.27 0-.56.1-.86.31s-.55.58-.77 1.1v4.2h-1.61zm-47.87 15h1.61v4.1c0 .57.08.97.25 1.2.17.24.44.35.81.35.3 0 .57-.07.8-.22.22-.15.47-.39.73-.73v-4.7h1.61v6.87h-1.32l-.12-1.01h-.04c-.3.36-.63.64-.98.86-.35.21-.76.32-1.24.32-.73 0-1.27-.24-1.61-.71-.33-.47-.5-1.14-.5-2.02zm9.46 7.43v2.16h-1.61v-9.59h1.33l.12.72h.05c.29-.24.61-.45.97-.63.35-.17.72-.26 1.1-.26.43 0 .81.08 1.15.24.33.17.61.4.84.71.24.31.41.68.53 1.11.13.42.19.91.19 1.44 0 .59-.09 1.11-.25 1.57-.16.47-.38.85-.65 1.16-.27.32-.58.56-.94.73-.35.16-.72.25-1.1.25-.3 0-.6-.07-.9-.2s-.59-.31-.87-.56zm0-2.3c.26.22.5.37.73.45.24.09.46.13.66.13.46 0 .84-.2 1.15-.6.31-.39.46-.98.46-1.77 0-.69-.12-1.22-.35-1.61-.23-.38-.61-.57-1.13-.57-.49 0-.99.26-1.52.77zm5.87-1.69c0-.56.08-1.06.25-1.51.16-.45.37-.83.65-1.14.27-.3.58-.54.93-.71s.71-.25 1.08-.25c.39 0 .73.07 1 .2.27.14.54.32.81.55l-.06-1.1v-2.49h1.61v9.88h-1.33l-.11-.74h-.06c-.25.25-.54.46-.88.64-.33.18-.69.27-1.06.27-.87 0-1.56-.32-2.07-.95s-.76-1.51-.76-2.65zm1.67-.01c0 .74.13 1.31.4 1.7.26.38.65.58 1.15.58.51 0 .99-.26 1.44-.77v-3.21c-.24-.21-.48-.36-.7-.45-.23-.08-.46-.12-.7-.12-.45 0-.82.19-1.13.59-.31.39-.46.95-.46 1.68zm6.35 1.59c0-.73.32-1.3.97-1.71.64-.4 1.67-.68 3.08-.84 0-.17-.02-.34-.07-.51-.05-.16-.12-.3-.22-.43s-.22-.22-.38-.3c-.15-.06-.34-.1-.58-.1-.34 0-.68.07-1 .2s-.63.29-.93.47l-.59-1.08c.39-.24.81-.45 1.28-.63.47-.17.99-.26 1.54-.26.86 0 1.51.25 1.93.76s.63 1.25.63 2.21v4.07h-1.32l-.12-.76h-.05c-.3.27-.63.48-.98.66s-.73.27-1.14.27c-.61 0-1.1-.19-1.48-.56-.38-.36-.57-.85-.57-1.46zm1.57-.12c0 .3.09.53.27.67.19.14.42.21.71.21.28 0 .54-.07.77-.2s.48-.31.73-.56v-1.54c-.47.06-.86.13-1.18.23-.31.09-.57.19-.76.31s-.33.25-.41.4c-.09.15-.13.31-.13.48zm6.29-3.63h-.98v-1.2l1.06-.07.2-1.88h1.34v1.88h1.75v1.27h-1.75v3.28c0 .8.32 1.2.97 1.2.12 0 .24-.01.37-.04.12-.03.24-.07.34-.11l.28 1.19c-.19.06-.4.12-.64.17-.23.05-.49.08-.76.08-.4 0-.74-.06-1.02-.18-.27-.13-.49-.3-.67-.52-.17-.21-.3-.48-.37-.78-.08-.3-.12-.64-.12-1.01zm4.36 2.17c0-.56.09-1.06.27-1.51s.41-.83.71-1.14c.29-.3.63-.54 1.01-.71.39-.17.78-.25 1.18-.25.47 0 .88.08 1.23.24.36.16.65.38.89.67s.42.63.54 1.03c.12.41.18.84.18 1.32 0 .32-.02.57-.07.76h-4.37c.08.62.29 1.1.65 1.44.36.33.82.5 1.38.5.3 0 .58-.04.84-.13.25-.09.51-.21.76-.37l.54 1.01c-.32.21-.69.39-1.09.53s-.82.21-1.26.21c-.47 0-.92-.08-1.33-.25-.41-.16-.77-.4-1.08-.7-.3-.31-.54-.69-.72-1.13-.17-.44-.26-.95-.26-1.52zm4.61-.62c0-.55-.11-.98-.34-1.28-.23-.31-.58-.47-1.06-.47-.41 0-.77.15-1.08.45-.31.29-.5.73-.57 1.3zm3.01 2.23c.31.24.61.43.92.57.3.13.63.2.98.2.38 0 .65-.08.83-.23s.27-.35.27-.6c0-.14-.05-.26-.13-.37-.08-.1-.2-.2-.34-.28-.14-.09-.29-.16-.47-.23l-.53-.22c-.23-.09-.46-.18-.69-.3-.23-.11-.44-.24-.62-.4s-.33-.35-.45-.55c-.12-.21-.18-.46-.18-.75 0-.61.23-1.1.68-1.49.44-.38 1.06-.57 1.83-.57.48 0 .91.08 1.29.25s.71.36.99.57l-.74.98c-.24-.17-.49-.32-.73-.42-.25-.11-.51-.16-.78-.16-.35 0-.6.07-.76.21-.17.15-.25.33-.25.54 0 .14.04.26.12.36s.18.18.31.26c.14.07.29.14.46.21l.54.19c.23.09.47.18.7.29s.44.24.64.4c.19.16.34.35.46.58.11.23.17.5.17.82 0 .3-.06.58-.17.83-.12.26-.29.48-.51.68-.23.19-.51.34-.84.45-.34.11-.72.17-1.15.17-.48 0-.95-.09-1.41-.27-.46-.19-.86-.41-1.2-.68z" fill="#535353"/></g></svg>"></a></div><div class="c-bibliographic-information__column"><h3 class="c-article__sub-heading" id="citeas">Cite this article</h3><p class="c-bibliographic-information__citation">Forde, P.M., Anagnostou, V., Sun, Z. <i>et al.</i> Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial.
                    <i>Nat Med</i> <b>27</b>, 1910–1920 (2021). https://doi.org/10.1038/s41591-021-01541-0</p><p class="c-bibliographic-information__download-citation u-hide-print"><a data-test="citation-link" data-track="click" data-track-action="download article citation" data-track-label="link" data-track-external="" rel="nofollow" href="https://citation-needed.springer.com/v2/references/10.1038/s41591-021-01541-0?format=refman&amp;flavour=citation">Download citation<svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-download-medium"></use></svg></a></p><ul class="c-bibliographic-information__list" data-test="publication-history"><li class="c-bibliographic-information__list-item"><p>Received<span class="u-hide">: </span><span class="c-bibliographic-information__value"><time datetime="2021-05-14">14 May 2021</time></span></p></li><li class="c-bibliographic-information__list-item"><p>Accepted<span class="u-hide">: </span><span class="c-bibliographic-information__value"><time datetime="2021-09-15">15 September 2021</time></span></p></li><li class="c-bibliographic-information__list-item"><p>Published<span class="u-hide">: </span><span class="c-bibliographic-information__value"><time datetime="2021-11-08">08 November 2021</time></span></p></li><li class="c-bibliographic-information__list-item"><p>Issue Date<span class="u-hide">: </span><span class="c-bibliographic-information__value"><time datetime="2021-11">November 2021</time></span></p></li><li class="c-bibliographic-information__list-item c-bibliographic-information__list-item--full-width"><p><abbr title="Digital Object Identifier">DOI</abbr><span class="u-hide">: </span><span class="c-bibliographic-information__value">https://doi.org/10.1038/s41591-021-01541-0</span></p></li></ul><div data-component="share-box"><div class="c-article-share-box u-display-block"><h3 class="c-article__sub-heading">Share this article</h3><p class="c-article-share-box__description">Anyone you share the following link with will be able to read this content:</p><button class="js-get-share-url c-article-share-box__button" type="button" id="get-share-url" data-track="click" data-track-label="button" data-track-external="" data-track-action="get shareable link">Get shareable link</button><div class="js-no-share-url-container u-display-none" hidden=""><p class="js-c-article-share-box__no-sharelink-info c-article-share-box__no-sharelink-info">Sorry, a shareable link is not currently available for this article.</p></div><div class="js-share-url-container u-display-none" hidden=""><p class="js-share-url c-article-share-box__only-read-input" id="share-url" data-track="click" data-track-label="button" data-track-action="select share url"></p><button class="js-copy-share-url c-article-share-box__button--link-like" type="button" id="copy-share-url" data-track="click" data-track-label="button" data-track-action="copy share url" data-track-external="">Copy to clipboard</button></div><p class="js-c-article-share-box__additional-info c-article-share-box__additional-info">
                            Provided by the Springer Nature SharedIt content-sharing initiative
                        </p></div></div><div data-component="article-info-list">
        <h3 class="c-article__sub-heading">Subjects</h3>
        <ul class="c-article-subject-list">
            <li class="c-article-subject-list__subject"><a href="/subjects/cancer-genomics" data-track="click" data-track-action="view subject" data-track-label="link">Cancer genomics</a></li><li class="c-article-subject-list__subject"><a href="/subjects/cancer-immunotherapy" data-track="click" data-track-action="view subject" data-track-label="link">Cancer immunotherapy</a></li><li class="c-article-subject-list__subject"><a href="/subjects/mesothelioma" data-track="click" data-track-action="view subject" data-track-label="link">Mesothelioma</a></li><li class="c-article-subject-list__subject"><a href="/subjects/phase-ii-trials" data-track="click" data-track-action="view subject" data-track-label="link">Phase II trials</a></li><li class="c-article-subject-list__subject"><a href="/subjects/tumour-immunology" data-track="click" data-track-action="view subject" data-track-label="link">Tumour immunology</a></li>
        </ul>
    </div></div></div></div></div></section>
            </div>

            
        <section>
            <div class="c-article-section js-article-section" id="further-reading-section" data-test="further-reading-section">
                <h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="further-reading">This article is cited by</h2>
                <div class="c-article-section__content js-collapsible-section" id="further-reading-content">
                    <ul class="c-article-further-reading__list" id="further-reading-list">
                        
                            <li class="c-article-further-reading__item js-ref-item">
                            
                                <h3 class="c-article-further-reading__title" data-test="article-title">
                                    <a class="print-link" data-track="click" data-track-action="view further reading article" data-track-label="link:Emerging Radiopharmaceuticals in Pet Imaging for Mesothelioma: A Review of [18F]FDG Alternatives" href="https://doi.org/10.1007/s40291-024-00756-4">
                                        Emerging Radiopharmaceuticals in Pet Imaging for Mesothelioma: A Review of [18F]FDG Alternatives
                                    </a>
                                </h3>
                            
                                
                                    <ul data-test="author-list" class="app-author-list app-author-list--compact app-author-list--truncated u-sans-serif u-mb-4 u-mt-auto">
                                        <li>Priscilla Guglielmo</li><li>Cinzia Crivellaro</li><li>Laura Evangelista</li>
                                    </ul>
                                
                                <p class="c-article-further-reading__journal-title"><i>Molecular Diagnosis &amp; Therapy</i> (2025)</p>
                            </li>
                        
                            <li class="c-article-further-reading__item js-ref-item">
                            
                                <h3 class="c-article-further-reading__title" data-test="article-title">
                                    <a class="print-link" data-track="click" data-track-action="view further reading article" data-track-label="link:Tumour mutational burden: clinical utility, challenges and emerging improvements" href="https://doi.org/10.1038/s41571-024-00932-9">
                                        Tumour mutational burden: clinical utility, challenges and emerging improvements
                                    </a>
                                </h3>
                            
                                
                                    <ul data-test="author-list" class="app-author-list app-author-list--compact app-author-list--truncated u-sans-serif u-mb-4 u-mt-auto">
                                        <li>Jan Budczies</li><li>Daniel Kazdal</li><li>Albrecht Stenzinger</li>
                                    </ul>
                                
                                <p class="c-article-further-reading__journal-title"><i>Nature Reviews Clinical Oncology</i> (2024)</p>
                            </li>
                        
                            <li class="c-article-further-reading__item js-ref-item">
                            
                                <h3 class="c-article-further-reading__title" data-test="article-title">
                                    <a class="print-link" data-track="click" data-track-action="view further reading article" data-track-label="link:A gut microbiota rheostat forecasts responsiveness to PD-L1 and VEGF blockade in mesothelioma" href="https://doi.org/10.1038/s41467-024-49842-5">
                                        A gut microbiota rheostat forecasts responsiveness to PD-L1 and VEGF blockade in mesothelioma
                                    </a>
                                </h3>
                            
                                
                                    <ul data-test="author-list" class="app-author-list app-author-list--compact app-author-list--truncated u-sans-serif u-mb-4 u-mt-auto">
                                        <li>Min Zhang</li><li>Aleksandra Bzura</li><li>Dean A. Fennell</li>
                                    </ul>
                                
                                <p class="c-article-further-reading__journal-title"><i>Nature Communications</i> (2024)</p>
                            </li>
                        
                            <li class="c-article-further-reading__item js-ref-item">
                            
                                <h3 class="c-article-further-reading__title" data-test="article-title">
                                    <a class="print-link" data-track="click" data-track-action="view further reading article" data-track-label="link:Immunotherapies in rare cancers" href="https://doi.org/10.1186/s12943-023-01720-2">
                                        Immunotherapies in rare cancers
                                    </a>
                                </h3>
                            
                                
                                    <ul data-test="author-list" class="app-author-list app-author-list--compact app-author-list--truncated u-sans-serif u-mb-4 u-mt-auto">
                                        <li>Sneha Vivekanandhan</li><li>Deborah Bahr</li><li>Emmanuel Gabriel</li>
                                    </ul>
                                
                                <p class="c-article-further-reading__journal-title"><i>Molecular Cancer</i> (2023)</p>
                            </li>
                        
                            <li class="c-article-further-reading__item js-ref-item">
                            
                                <h3 class="c-article-further-reading__title" data-test="article-title">
                                    <a class="print-link" data-track="click" data-track-action="view further reading article" data-track-label="link:Persistent mutation burden drives sustained anti-tumor immune responses" href="https://doi.org/10.1038/s41591-022-02163-w">
                                        Persistent mutation burden drives sustained anti-tumor immune responses
                                    </a>
                                </h3>
                            
                                
                                    <ul data-test="author-list" class="app-author-list app-author-list--compact app-author-list--truncated u-sans-serif u-mb-4 u-mt-auto">
                                        <li>Noushin Niknafs</li><li>Archana Balan</li><li>Valsamo Anagnostou</li>
                                    </ul>
                                
                                <p class="c-article-further-reading__journal-title"><i>Nature Medicine</i> (2023)</p>
                            </li>
                        
                    </ul>
                </div>
            </div>
        </section>
    

        </div>
</article>
</main>

<aside class="c-article-extras u-hide-print" aria-label="Article navigation" data-component-reading-companion="" data-container-type="reading-companion" data-track-component="reading companion">
    <div class="js-context-bar-sticky-point-desktop" data-track-context="reading companion">
        

        
            
                
                    
    
        <div class="c-pdf-download u-clear-both js-pdf-download">
            <a href="/articles/s41591-021-01541-0.pdf" class="u-button u-button--full-width u-button--primary u-justify-content-space-between c-pdf-download__link" data-article-pdf="true" data-readcube-pdf-url="true" data-test="download-pdf" data-draft-ignore="true" data-track="content_download" data-track-type="article pdf download" data-track-action="download pdf" data-track-label="link" data-track-external="" download="">
                <span class="c-pdf-download__text">Download PDF</span>
                <svg aria-hidden="true" focusable="false" width="16" height="16" class="u-icon"><use xlink:href="#icon-download"></use></svg>
            </a>
        </div>
    

                
            
        
    </div>

    
        
    

    
    

    <div class="c-reading-companion">
        <div class="c-reading-companion__sticky" data-component="reading-companion-sticky" data-test="reading-companion-sticky" style="top: 40px;">
            <ul class="c-reading-companion__tabs" role="tablist"><li role="presentation"><button data-tab-target="sections" role="tab" id="tab-sections" aria-controls="tabpanel-sections" aria-selected="true" class="c-reading-companion__tab c-reading-companion__tab--active" data-track="click" data-track-action="sections tab" data-track-label="tab">Sections</button></li><li role="presentation"><button data-tab-target="figures" role="tab" id="tab-figures" aria-controls="tabpanel-figures" aria-selected="false" tabindex="-1" class="c-reading-companion__tab" data-track="click" data-track-action="figures tab" data-track-label="tab">Figures</button></li><li role="presentation"><button data-tab-target="references" role="tab" id="tab-references" aria-controls="tabpanel-references" aria-selected="false" tabindex="-1" class="c-reading-companion__tab" data-track="click" data-track-action="references tab" data-track-label="tab">References</button></li></ul><div class="c-reading-companion__panel c-reading-companion__sections c-reading-companion__panel--active" id="tabpanel-sections" aria-labelledby="tab-sections" role="tabpanel"><div class="c-reading-companion__scroll-pane" style="max-height: 409.45px;"><ul class="c-reading-companion__sections-list"><li id="rc-sec-Abs1" class="c-reading-companion__section-item"><a href="#Abs1" data-track="click" data-track-action="section anchor" data-track-label="link:Abstract">Abstract</a></li><li id="rc-sec-Sec1" class="c-reading-companion__section-item"><a href="#Sec1" data-track="click" data-track-action="section anchor" data-track-label="link:Main">Main</a></li><li id="rc-sec-Sec2" class="c-reading-companion__section-item"><a href="#Sec2" data-track="click" data-track-action="section anchor" data-track-label="link:Results">Results</a></li><li id="rc-sec-Sec8" class="c-reading-companion__section-item"><a href="#Sec8" data-track="click" data-track-action="section anchor" data-track-label="link:Discussion">Discussion</a></li><li id="rc-sec-Sec9" class="c-reading-companion__section-item"><a href="#Sec9" data-track="click" data-track-action="section anchor" data-track-label="link:Methods">Methods</a></li><li id="rc-sec-data-availability" class="c-reading-companion__section-item"><a href="#data-availability" data-track="click" data-track-action="section anchor" data-track-label="link:Data availability">Data availability</a></li><li id="rc-sec-Bib1" class="c-reading-companion__section-item"><a href="#Bib1" data-track="click" data-track-action="section anchor" data-track-label="link:References">References</a></li><li id="rc-sec-Ack1" class="c-reading-companion__section-item"><a href="#Ack1" data-track="click" data-track-action="section anchor" data-track-label="link:Acknowledgements">Acknowledgements</a></li><li id="rc-sec-author-information" class="c-reading-companion__section-item"><a href="#author-information" data-track="click" data-track-action="section anchor" data-track-label="link:Author information">Author information</a></li><li id="rc-sec-ethics" class="c-reading-companion__section-item"><a href="#ethics" data-track="click" data-track-action="section anchor" data-track-label="link:Ethics declarations">Ethics declarations</a></li><li id="rc-sec-additional-information" class="c-reading-companion__section-item"><a href="#additional-information" data-track="click" data-track-action="section anchor" data-track-label="link:Additional information">Additional information</a></li><li id="rc-sec-Sec30" class="c-reading-companion__section-item"><a href="#Sec30" data-track="click" data-track-action="section anchor" data-track-label="link:Extended data">Extended data</a></li><li id="rc-sec-Sec31" class="c-reading-companion__section-item"><a href="#Sec31" data-track="click" data-track-action="section anchor" data-track-label="link:Supplementary information">Supplementary information</a></li><li id="rc-sec-Sec32" class="c-reading-companion__section-item"><a href="#Sec32" data-track="click" data-track-action="section anchor" data-track-label="link:Source data">Source data</a></li><li id="rc-sec-rightslink" class="c-reading-companion__section-item"><a href="#rightslink" data-track="click" data-track-action="section anchor" data-track-label="link:Rights and permissions">Rights and permissions</a></li><li id="rc-sec-article-info" class="c-reading-companion__section-item"><a href="#article-info" data-track="click" data-track-action="section anchor" data-track-label="link:About this article">About this article</a></li><li id="rc-sec-further-reading" class="c-reading-companion__section-item"><a href="#further-reading" data-track="click" data-track-action="section anchor" data-track-label="link:This article is cited by">This article is cited by</a></li></ul></div>
                <div class="u-lazy-ad-wrapper u-mt-16 u-show" data-component-mpu="" style="display: none !important;">
                    <div class="c-ad c-ad--300x250">
                        <div class="c-ad__inner">
                            <p class="c-ad__label">Advertisement</p>
                            
    <div id="div-gpt-ad-right-2" class="div-gpt-ad advert medium-rectangle js-ad text-center hide-print grade-c-hide" data-ad-type="right" data-test="right-ad" data-pa11y-ignore="" data-gpt="" data-gpt-unitpath="/285/medicine.nature.com/article" data-gpt-sizes="300x250" data-gpt-targeting="type=article;pos=right;artid=s41591-021-01541-0;doi=10.1038/s41591-021-01541-0;subjmeta=1059,109,1641,1941,2325,2779,308,580,67,69,692,699;kwrd=Cancer+genomics,Cancer+immunotherapy,Mesothelioma,Phase+II+trials,Tumour+immunology">
        <noscript>
            <a href="//pubads.g.doubleclick.net/gampad/jump?iu=/285/medicine.nature.com/article&amp;sz=300x250&amp;c=1521897228&amp;t=pos%3Dright%26type%3Darticle%26artid%3Ds41591-021-01541-0%26doi%3D10.1038/s41591-021-01541-0%26subjmeta%3D1059,109,1641,1941,2325,2779,308,580,67,69,692,699%26kwrd%3DCancer+genomics,Cancer+immunotherapy,Mesothelioma,Phase+II+trials,Tumour+immunology">
                <img data-test="gpt-advert-fallback-img"
                     src="//pubads.g.doubleclick.net/gampad/ad?iu=/285/medicine.nature.com/article&amp;sz=300x250&amp;c=1521897228&amp;t=pos%3Dright%26type%3Darticle%26artid%3Ds41591-021-01541-0%26doi%3D10.1038/s41591-021-01541-0%26subjmeta%3D1059,109,1641,1941,2325,2779,308,580,67,69,692,699%26kwrd%3DCancer+genomics,Cancer+immunotherapy,Mesothelioma,Phase+II+trials,Tumour+immunology"
                     alt="Advertisement"
                     width="300"
                     height="250"></a>
        </noscript>
    </div>

                        </div>
                    </div>
                </div>
            </div>
            <div class="c-reading-companion__panel c-reading-companion__figures c-reading-companion__panel--full-width" id="tabpanel-figures" aria-labelledby="tab-figures" role="tabpanel"><div class="c-reading-companion__scroll-pane"><ul class="c-reading-companion__figures-list"><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig1">Fig. 1: Outcomes with chemo-immunotherapy in unresectable MPM.</b></figcaption><picture><source data-srcset="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-021-01541-0/MediaObjects/41591_2021_1541_Fig1_HTML.png?"><img data-src="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-021-01541-0/MediaObjects/41591_2021_1541_Fig1_HTML.png" alt="figure 1" aria-describedby="rc-Fig1"></picture><p class="c-reading-companion__figure-links"><a href="#Fig1" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-021-01541-0/figures/1" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig2">Fig. 2: Genomic landscape of chemo-immunotherapy-treated mesotheliomas.</b></figcaption><picture><source data-srcset="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-021-01541-0/MediaObjects/41591_2021_1541_Fig2_HTML.png?"><img data-src="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-021-01541-0/MediaObjects/41591_2021_1541_Fig2_HTML.png" alt="figure 2" aria-describedby="rc-Fig2"></picture><p class="c-reading-companion__figure-links"><a href="#Fig2" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-021-01541-0/figures/2" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig3">Fig. 3: Effect of germline mutations in cancer susceptibility genes on outcome from combined immuno-chemotherapy.</b></figcaption><picture><source data-srcset="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-021-01541-0/MediaObjects/41591_2021_1541_Fig3_HTML.png?"><img data-src="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-021-01541-0/MediaObjects/41591_2021_1541_Fig3_HTML.png" alt="figure 3" aria-describedby="rc-Fig3"></picture><p class="c-reading-companion__figure-links"><a href="#Fig3" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-021-01541-0/figures/3" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig4">Fig. 4: Large-scale copy number analyses.</b></figcaption><picture><source data-srcset="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-021-01541-0/MediaObjects/41591_2021_1541_Fig4_HTML.png?"><img data-src="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-021-01541-0/MediaObjects/41591_2021_1541_Fig4_HTML.png" alt="figure 4" aria-describedby="rc-Fig4"></picture><p class="c-reading-companion__figure-links"><a href="#Fig4" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-021-01541-0/figures/4" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig5">Fig. 5: Baseline TCR repertoire characteristics and dynamic changes at the time of therapeutic resistance.</b></figcaption><picture><source data-srcset="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-021-01541-0/MediaObjects/41591_2021_1541_Fig5_HTML.png?"><img data-src="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-021-01541-0/MediaObjects/41591_2021_1541_Fig5_HTML.png" alt="figure 5" aria-describedby="rc-Fig5"></picture><p class="c-reading-companion__figure-links"><a href="#Fig5" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-021-01541-0/figures/5" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig6">Extended Data Fig. 1 CONSORT trial diagram for the PrE0505 study.</b></figcaption><picture><source data-srcset="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01541-0/MediaObjects/41591_2021_1541_Fig6_ESM.jpg?"><img data-src="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01541-0/MediaObjects/41591_2021_1541_Fig6_ESM.jpg" alt="extended data figure 6" aria-describedby="rc-Fig6"></picture><p class="c-reading-companion__figure-links"><a href="#Fig6" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-021-01541-0/figures/6" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig7">Extended Data Fig. 2 Analyses Overview.</b></figcaption><picture><source data-srcset="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01541-0/MediaObjects/41591_2021_1541_Fig7_ESM.jpg?"><img data-src="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01541-0/MediaObjects/41591_2021_1541_Fig7_ESM.jpg" alt="extended data figure 7" aria-describedby="rc-Fig7"></picture><p class="c-reading-companion__figure-links"><a href="#Fig7" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-021-01541-0/figures/7" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig8">Extended Data Fig. 3 Treatment emergent adverse events and outcome by platinum agent used.</b></figcaption><picture><source data-srcset="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01541-0/MediaObjects/41591_2021_1541_Fig8_ESM.jpg?"><img data-src="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01541-0/MediaObjects/41591_2021_1541_Fig8_ESM.jpg" alt="extended data figure 8" aria-describedby="rc-Fig8"></picture><p class="c-reading-companion__figure-links"><a href="#Fig8" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-021-01541-0/figures/8" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig9">Extended Data Fig. 4 Distribution of mutations in genes involved in DNA damage repair.</b></figcaption><picture><source data-srcset="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01541-0/MediaObjects/41591_2021_1541_Fig9_ESM.jpg?"><img data-src="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01541-0/MediaObjects/41591_2021_1541_Fig9_ESM.jpg" alt="extended data figure 9" aria-describedby="rc-Fig9"></picture><p class="c-reading-companion__figure-links"><a href="#Fig9" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-021-01541-0/figures/9" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig10">Extended Data Fig. 5 Immunogenic mutation load may be linked with functional neopeptide-specific anti-tumor immune response and therapeutic response.</b></figcaption><picture><source data-srcset="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01541-0/MediaObjects/41591_2021_1541_Fig10_ESM.jpg?"><img data-src="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01541-0/MediaObjects/41591_2021_1541_Fig10_ESM.jpg" alt="extended data figure 10" aria-describedby="rc-Fig10"></picture><p class="c-reading-companion__figure-links"><a href="#Fig10" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-021-01541-0/figures/10" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig11">Extended Data Fig. 6 Germline and tumor HLA class I and II genetic variation.</b></figcaption><picture><source data-srcset="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01541-0/MediaObjects/41591_2021_1541_Fig11_ESM.jpg?"><img data-src="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01541-0/MediaObjects/41591_2021_1541_Fig11_ESM.jpg" alt="extended data figure 11" aria-describedby="rc-Fig11"></picture><p class="c-reading-companion__figure-links"><a href="#Fig11" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-021-01541-0/figures/11" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig12">Extended Data Fig. 7 TCR clonotypic expansions to neopeptides derived from immunogenic mutations.</b></figcaption><picture><source data-srcset="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01541-0/MediaObjects/41591_2021_1541_Fig12_ESM.jpg?"><img data-src="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01541-0/MediaObjects/41591_2021_1541_Fig12_ESM.jpg" alt="extended data figure 12" aria-describedby="rc-Fig12"></picture><p class="c-reading-companion__figure-links"><a href="#Fig12" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-021-01541-0/figures/12" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig13">Extended Data Fig. 8 Differences in CD8+T cell infiltration in <i>BAP1</i> mutant tumors.</b></figcaption><picture><source data-srcset="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01541-0/MediaObjects/41591_2021_1541_Fig13_ESM.jpg?"><img data-src="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01541-0/MediaObjects/41591_2021_1541_Fig13_ESM.jpg" alt="extended data figure 13" aria-describedby="rc-Fig13"></picture><p class="c-reading-companion__figure-links"><a href="#Fig13" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-021-01541-0/figures/13" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig14">Extended Data Fig. 9 Genome-wide loss of heterozygosity and genome near haploidization.</b></figcaption><picture><source data-srcset="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01541-0/MediaObjects/41591_2021_1541_Fig14_ESM.jpg?"><img data-src="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01541-0/MediaObjects/41591_2021_1541_Fig14_ESM.jpg" alt="extended data figure 14" aria-describedby="rc-Fig14"></picture><p class="c-reading-companion__figure-links"><a href="#Fig14" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-021-01541-0/figures/14" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig15">Extended Data Fig. 10 Correlations between genomic and molecular features.</b></figcaption><picture><source data-srcset="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01541-0/MediaObjects/41591_2021_1541_Fig15_ESM.jpg?"><img data-src="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01541-0/MediaObjects/41591_2021_1541_Fig15_ESM.jpg" alt="extended data figure 15" aria-describedby="rc-Fig15"></picture><p class="c-reading-companion__figure-links"><a href="#Fig15" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-021-01541-0/figures/15" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li></ul></div></div>
            <div class="c-reading-companion__panel c-reading-companion__references c-reading-companion__panel--full-width" id="tabpanel-references" aria-labelledby="tab-references" role="tabpanel"><div class="c-reading-companion__scroll-pane"><ol class="c-reading-companion__references-list c-reading-companion__references-list--numeric" data-track-context="article references sidebar"><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR1">Odgerel, C. O. et al. Estimation of the global burden of mesothelioma deaths from incomplete national mortality data. <i>Occup. Environ. Med.</i> <b>74</b>, 851–858 (2017).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1136%2Foemed-2017-104298" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1136/oemed-2017-104298" data-track-item_id="10.1136/oemed-2017-104298">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=28866609" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Estimation%20of%20the%20global%20burden%20of%20mesothelioma%20deaths%20from%20incomplete%20national%20mortality%20data&amp;journal=Occup.%20Environ.%20Med.&amp;doi=10.1136%2Foemed-2017-104298&amp;volume=74&amp;pages=851-858&amp;publication_year=2017&amp;author=Odgerel%2CCO" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR2">Tweedale, G. Asbestos and its lethal legacy. <i>Nat. Rev. Cancer</i> <b>2</b>, 311–315 (2002).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1038%2Fnrc774" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1038/nrc774" data-track-item_id="10.1038/nrc774">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD38XivFGqt7Y%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=12001992" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Asbestos%20and%20its%20lethal%20legacy&amp;journal=Nat.%20Rev.%20Cancer&amp;doi=10.1038%2Fnrc774&amp;volume=2&amp;pages=311-315&amp;publication_year=2002&amp;author=Tweedale%2CG" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR3">Panou, V. et al. Frequency of germline mutations in cancer susceptibility genes in malignant mesothelioma. <i>J. Clin. Oncol.</i> <b>36</b>, 2863–2871 (2018).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1200%2FJCO.2018.78.5204" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1200/JCO.2018.78.5204" data-track-item_id="10.1200/JCO.2018.78.5204">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1MXjs1eju7o%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30113886" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6804864" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Frequency%20of%20germline%20mutations%20in%20cancer%20susceptibility%20genes%20in%20malignant%20mesothelioma&amp;journal=J.%20Clin.%20Oncol.&amp;doi=10.1200%2FJCO.2018.78.5204&amp;volume=36&amp;pages=2863-2871&amp;publication_year=2018&amp;author=Panou%2CV" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR4">Carbone, M. et al. Tumour predisposition and cancer syndromes as models to study gene–environment interactions. <i>Nat. Rev. Cancer</i> <b>20</b>, 533–549 (2020).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1038%2Fs41568-020-0265-y" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1038/s41568-020-0265-y" data-track-item_id="10.1038/s41568-020-0265-y">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXhtVCltrjI" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32472073" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8104546" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Tumour%20predisposition%20and%20cancer%20syndromes%20as%20models%20to%20study%20gene%E2%80%93environment%20interactions&amp;journal=Nat.%20Rev.%20Cancer&amp;doi=10.1038%2Fs41568-020-0265-y&amp;volume=20&amp;pages=533-549&amp;publication_year=2020&amp;author=Carbone%2CM" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR5">Vogelzang, N. J. et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. <i>J. Clin. Oncol.</i> <b>21</b>, 2636–2644 (2003).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1200%2FJCO.2003.11.136" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1200/JCO.2003.11.136" data-track-item_id="10.1200/JCO.2003.11.136">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD2cXptlCktL4%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=12860938" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Phase%20III%20study%20of%20pemetrexed%20in%20combination%20with%20cisplatin%20versus%20cisplatin%20alone%20in%20patients%20with%20malignant%20pleural%20mesothelioma&amp;journal=J.%20Clin.%20Oncol.&amp;doi=10.1200%2FJCO.2003.11.136&amp;volume=21&amp;pages=2636-2644&amp;publication_year=2003&amp;author=Vogelzang%2CNJ" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR6">Krug, L. M. et al. Randomized phase II trial of pemetrexed/cisplatin with or without CBP501 in patients with advanced malignant pleural mesothelioma. <i>Lung Cancer</i> <b>85</b>, 429–434 (2014).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1016%2Fj.lungcan.2014.06.008" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1016/j.lungcan.2014.06.008" data-track-item_id="10.1016/j.lungcan.2014.06.008">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:STN:280:DC%2BC2cbks1Wgtw%3D%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=25047675" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Randomized%20phase%20II%20trial%20of%20pemetrexed%2Fcisplatin%20with%20or%20without%20CBP501%20in%20patients%20with%20advanced%20malignant%20pleural%20mesothelioma&amp;journal=Lung%20Cancer&amp;doi=10.1016%2Fj.lungcan.2014.06.008&amp;volume=85&amp;pages=429-434&amp;publication_year=2014&amp;author=Krug%2CLM" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR7">Scagliotti, G. V. et al. Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial. <i>Lancet Respir. Med.</i> <b>7</b>, 569–580 (2019).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1016%2FS2213-2600%2819%2930139-0" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1016/S2213-2600(19)30139-0" data-track-item_id="10.1016/S2213-2600(19)30139-0">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1MXhtVSnt7zF" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=31103412" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Nintedanib%20in%20combination%20with%20pemetrexed%20and%20cisplatin%20for%20chemotherapy-naive%20patients%20with%20advanced%20malignant%20pleural%20mesothelioma%20%28LUME-Meso%29%3A%20a%20double-blind%2C%20randomised%2C%20placebo-controlled%20phase%203%20trial&amp;journal=Lancet%20Respir.%20Med.&amp;doi=10.1016%2FS2213-2600%2819%2930139-0&amp;volume=7&amp;pages=569-580&amp;publication_year=2019&amp;author=Scagliotti%2CGV" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR8">Tsao, A. S. et al. Phase II trial of cediranib in combination with cisplatin and pemetrexed in chemotherapy-naive patients with unresectable malignant pleural mesothelioma (SWOG S0905). <i>J. Clin. Oncol.</i> <b>37</b>, 2537–2547 (2019).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1200%2FJCO.19.00269" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1200/JCO.19.00269" data-track-item_id="10.1200/JCO.19.00269">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXlsVCgsbo%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=31386610" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7001793" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Phase%20II%20trial%20of%20cediranib%20in%20combination%20with%20cisplatin%20and%20pemetrexed%20in%20chemotherapy-naive%20patients%20with%20unresectable%20malignant%20pleural%20mesothelioma%20%28SWOG%20S0905%29&amp;journal=J.%20Clin.%20Oncol.&amp;doi=10.1200%2FJCO.19.00269&amp;volume=37&amp;pages=2537-2547&amp;publication_year=2019&amp;author=Tsao%2CAS" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR9">Zalcman, G. et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. <i>Lancet</i> <b>387</b>, 1405–1414 (2016).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1016%2FS0140-6736%2815%2901238-6" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1016/S0140-6736(15)01238-6" data-track-item_id="10.1016/S0140-6736(15)01238-6">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2MXitVyqsLzM" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=26719230" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Bevacizumab%20for%20newly%20diagnosed%20pleural%20mesothelioma%20in%20the%20Mesothelioma%20Avastin%20Cisplatin%20Pemetrexed%20Study%20%28MAPS%29%3A%20a%20randomised%2C%20controlled%2C%20open-label%2C%20phase%203%20trial&amp;journal=Lancet&amp;doi=10.1016%2FS0140-6736%2815%2901238-6&amp;volume=387&amp;pages=1405-1414&amp;publication_year=2016&amp;author=Zalcman%2CG" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR10">Alley, E. W. et al. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial. <i>Lancet Oncol.</i> <b>18</b>, 623–630 (2017).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1016%2FS1470-2045%2817%2930169-9" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1016/S1470-2045(17)30169-9" data-track-item_id="10.1016/S1470-2045(17)30169-9">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2sXkt1Ohurw%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=28291584" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Clinical%20safety%20and%20activity%20of%20pembrolizumab%20in%20patients%20with%20malignant%20pleural%20mesothelioma%20%28KEYNOTE-028%29%3A%20preliminary%20results%20from%20a%20non-randomised%2C%20open-label%2C%20phase%201b%20trial&amp;journal=Lancet%20Oncol.&amp;doi=10.1016%2FS1470-2045%2817%2930169-9&amp;volume=18&amp;pages=623-630&amp;publication_year=2017&amp;author=Alley%2CEW" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR11">Quispel-Janssen, J. et al. Programmed death 1 blockade with nivolumab in patients with recurrent malignant pleural mesothelioma. <i>J. Thorac. Oncol.</i> <b>13</b>, 1569–1576 (2018).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1016%2Fj.jtho.2018.05.038" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1016/j.jtho.2018.05.038" data-track-item_id="10.1016/j.jtho.2018.05.038">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29908324" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Programmed%20death%201%20blockade%20with%20nivolumab%20in%20patients%20with%20recurrent%20malignant%20pleural%20mesothelioma&amp;journal=J.%20Thorac.%20Oncol.&amp;doi=10.1016%2Fj.jtho.2018.05.038&amp;volume=13&amp;pages=1569-1576&amp;publication_year=2018&amp;author=Quispel-Janssen%2CJ" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR12">Okada, M. et al. Clinical efficacy and safety of nivolumab: results of a multicenter, open-label, single-arm, Japanese phase II study in malignant pleural mesothelioma (MERIT). <i>Clin. Cancer Res.</i> <b>25</b>, 5485–5492 (2019).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1158%2F1078-0432.CCR-19-0103" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1158/1078-0432.CCR-19-0103" data-track-item_id="10.1158/1078-0432.CCR-19-0103">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXlvF2rtrg%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=31164373" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Clinical%20efficacy%20and%20safety%20of%20nivolumab%3A%20results%20of%20a%20multicenter%2C%20open-label%2C%20single-arm%2C%20Japanese%20phase%20II%20study%20in%20malignant%20pleural%20mesothelioma%20%28MERIT%29&amp;journal=Clin.%20Cancer%20Res.&amp;doi=10.1158%2F1078-0432.CCR-19-0103&amp;volume=25&amp;pages=5485-5492&amp;publication_year=2019&amp;author=Okada%2CM" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR13">Fennell, D. A. et al. CONFIRM: a double-blind, placebo-controlled phase III clinical trial investigating the effect of nivolumab in patients with relapsed mesothelioma: study protocol for a randomised controlled trial. <i>Trials</i> <b>19</b>, 233 (2018).</p><p class="c-reading-companion__reference-links"><a href="https://link.springer.com/doi/10.1186/s13063-018-2602-y" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1186/s13063-018-2602-y" data-track-item_id="10.1186/s13063-018-2602-y">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29669604" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5907297" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1MXjs1ers7Y%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=CONFIRM%3A%20a%20double-blind%2C%20placebo-controlled%20phase%20III%20clinical%20trial%20investigating%20the%20effect%20of%20nivolumab%20in%20patients%20with%20relapsed%20mesothelioma%3A%20study%20protocol%20for%20a%20randomised%20controlled%20trial&amp;journal=Trials&amp;doi=10.1186%2Fs13063-018-2602-y&amp;volume=19&amp;publication_year=2018&amp;author=Fennell%2CDA" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR14">Gandhi, L. et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. <i>N. Engl. J. Med.</i> <b>378</b>, 2078–2092 (2018).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1056%2FNEJMoa1801005" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1056/NEJMoa1801005" data-track-item_id="10.1056/NEJMoa1801005">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1cXhtV2rtrjL" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29658856" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Pembrolizumab%20plus%20chemotherapy%20in%20metastatic%20non-small-cell%20lung%20cancer&amp;journal=N.%20Engl.%20J.%20Med.&amp;doi=10.1056%2FNEJMoa1801005&amp;volume=378&amp;pages=2078-2092&amp;publication_year=2018&amp;author=Gandhi%2CL" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR15">Nowak, A. K. et al. Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in. <i>Lancet Oncol.</i> <b>21</b>, 1213–1223 (2020).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1016%2FS1470-2045%2820%2930462-9" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1016/S1470-2045(20)30462-9" data-track-item_id="10.1016/S1470-2045(20)30462-9">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXhslKhtrfK" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32888453" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Durvalumab%20with%20first-line%20chemotherapy%20in%20previously%20untreated%20malignant%20pleural%20mesothelioma%20%28DREAM%29%3A%20a%20multicentre%2C%20single-arm%2C%20phase%202%20trial%20with%20a%20safety%20run-in&amp;journal=Lancet%20Oncol.&amp;doi=10.1016%2FS1470-2045%2820%2930462-9&amp;volume=21&amp;pages=1213-1223&amp;publication_year=2020&amp;author=Nowak%2CAK" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR16">Baas, P. et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. <i>Lancet</i> <b>397</b>, 375–386 (2021).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1016%2FS0140-6736%2820%2932714-8" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1016/S0140-6736(20)32714-8" data-track-item_id="10.1016/S0140-6736(20)32714-8">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3MXltFaqsbk%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33485464" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=First-line%20nivolumab%20plus%20ipilimumab%20in%20unresectable%20malignant%20pleural%20mesothelioma%20%28CheckMate%20743%29%3A%20a%20multicentre%2C%20randomised%2C%20open-label%2C%20phase%203%20trial&amp;journal=Lancet&amp;doi=10.1016%2FS0140-6736%2820%2932714-8&amp;volume=397&amp;pages=375-386&amp;publication_year=2021&amp;author=Baas%2CP" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR17">Hmeljak, J. et al. Integrative molecular characterization of malignant pleural mesothelioma. <i>Cancer Discov.</i> <b>8</b>, 1548–1565 (2018).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1158%2F2159-8290.CD-18-0804" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1158/2159-8290.CD-18-0804" data-track-item_id="10.1158/2159-8290.CD-18-0804">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXhtFOms73J" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30322867" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6310008" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Integrative%20molecular%20characterization%20of%20malignant%20pleural%20mesothelioma&amp;journal=Cancer%20Discov.&amp;doi=10.1158%2F2159-8290.CD-18-0804&amp;volume=8&amp;pages=1548-1565&amp;publication_year=2018&amp;author=Hmeljak%2CJ" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR18">Bueno, R. et al. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. <i>Nat. Genet.</i> <b>48</b>, 407–416 (2016).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1038%2Fng.3520" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1038/ng.3520" data-track-item_id="10.1038/ng.3520">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC28XivFKgtb8%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=26928227" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Comprehensive%20genomic%20analysis%20of%20malignant%20pleural%20mesothelioma%20identifies%20recurrent%20mutations%2C%20gene%20fusions%20and%20splicing%20alterations&amp;journal=Nat.%20Genet.&amp;doi=10.1038%2Fng.3520&amp;volume=48&amp;pages=407-416&amp;publication_year=2016&amp;author=Bueno%2CR" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR19">Mansfield, A. S. et al. Neoantigenic potential of complex chromosomal rearrangements in mesothelioma. <i>J. Thorac. Oncol.</i> <b>14</b>, 276–287 (2019).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1016%2Fj.jtho.2018.10.001" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1016/j.jtho.2018.10.001" data-track-item_id="10.1016/j.jtho.2018.10.001">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1MXitFemtLjJ" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30316012" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Neoantigenic%20potential%20of%20complex%20chromosomal%20rearrangements%20in%20mesothelioma&amp;journal=J.%20Thorac.%20Oncol.&amp;doi=10.1016%2Fj.jtho.2018.10.001&amp;volume=14&amp;pages=276-287&amp;publication_year=2019&amp;author=Mansfield%2CAS" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR20">Panou, V. &amp; Roe, O. D. Inherited genetic mutations and polymorphisms in malignant mesothelioma: a comprehensive review. <i>Int. J. Mol. Sci.</i> <b>21</b>, 4327 (2020).</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR21">Testa, J. R. et al. Germline <i>BAP1</i> mutations predispose to malignant mesothelioma. <i>Nat. Genet.</i> <b>43</b>, 1022–1025 (2011).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1038%2Fng.912" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1038/ng.912" data-track-item_id="10.1038/ng.912">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC3MXhtV2gt7vJ" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21874000" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3184199" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Germline%20BAP1%20mutations%20predispose%20to%20malignant%20mesothelioma&amp;journal=Nat.%20Genet.&amp;doi=10.1038%2Fng.912&amp;volume=43&amp;pages=1022-1025&amp;publication_year=2011&amp;author=Testa%2CJR" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR22">Bononi, A. et al. Heterozygous germline <i>BLM</i> mutations increase susceptibility to asbestos and mesothelioma. <i>Proc. Natl Acad. Sci. USA</i> <b>117</b>, 33466–33473 (2020).</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR23">Oken, M. M. et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. <i>Am. J. Clin. Oncol.</i> <b>5</b>, 649–655 (1982).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1097%2F00000421-198212000-00014" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1097/00000421-198212000-00014" data-track-item_id="10.1097/00000421-198212000-00014">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:STN:280:DyaL3s7kvFOgsw%3D%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=7165009" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Toxicity%20and%20response%20criteria%20of%20the%20Eastern%20Cooperative%20Oncology%20Group&amp;journal=Am.%20J.%20Clin.%20Oncol.&amp;doi=10.1097%2F00000421-198212000-00014&amp;volume=5&amp;pages=649-655&amp;publication_year=1982&amp;author=Oken%2CMM" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR24">Tsao, A. S. et al. A practical guide of the Southwest Oncology Group to measure malignant pleural mesothelioma tumors by RECIST and modified RECIST criteria. <i>J. Thorac. Oncol.</i> <b>6</b>, 598–601 (2011).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1097%2FJTO.0b013e318208c83d" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1097/JTO.0b013e318208c83d" data-track-item_id="10.1097/JTO.0b013e318208c83d">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21270668" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3643692" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=A%20practical%20guide%20of%20the%20Southwest%20Oncology%20Group%20to%20measure%20malignant%20pleural%20mesothelioma%20tumors%20by%20RECIST%20and%20modified%20RECIST%20criteria&amp;journal=J.%20Thorac.%20Oncol.&amp;doi=10.1097%2FJTO.0b013e318208c83d&amp;volume=6&amp;pages=598-601&amp;publication_year=2011&amp;author=Tsao%2CAS" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR25">Chowell, D. et al. Evolutionary divergence of HLA class I genotype impacts efficacy of cancer immunotherapy. <i>Nat. Med.</i> <b>25</b>, 1715–1720 (2019).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1038%2Fs41591-019-0639-4" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1038/s41591-019-0639-4" data-track-item_id="10.1038/s41591-019-0639-4">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1MXitFaktLbL" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=31700181" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7938381" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Evolutionary%20divergence%20of%20HLA%20class%20I%20genotype%20impacts%20efficacy%20of%20cancer%20immunotherapy&amp;journal=Nat.%20Med.&amp;doi=10.1038%2Fs41591-019-0639-4&amp;volume=25&amp;pages=1715-1720&amp;publication_year=2019&amp;author=Chowell%2CD" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR26">Napolitano, A. et al. Minimal asbestos exposure in germline <i>BAP1</i> heterozygous mice is associated with deregulated inflammatory response and increased risk of mesothelioma. <i>Oncogene</i> <b>35</b>, 1996–2002 (2016).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1038%2Fonc.2015.243" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1038/onc.2015.243" data-track-item_id="10.1038/onc.2015.243">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2MXhtFaitrzJ" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=26119930" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Minimal%20asbestos%20exposure%20in%20germline%20BAP1%20heterozygous%20mice%20is%20associated%20with%20deregulated%20inflammatory%20response%20and%20increased%20risk%20of%20mesothelioma&amp;journal=Oncogene&amp;doi=10.1038%2Fonc.2015.243&amp;volume=35&amp;pages=1996-2002&amp;publication_year=2016&amp;author=Napolitano%2CA" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR27">Wang, T. et al. An empirical approach leveraging tumorgrafts to dissect the tumor microenvironment in renal cell carcinoma identifies missing link to prognostic inflammatory factors. <i>Cancer Discov.</i> <b>8</b>, 1142–1155 (2018).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1158%2F2159-8290.CD-17-1246" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1158/2159-8290.CD-17-1246" data-track-item_id="10.1158/2159-8290.CD-17-1246">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1MXlvFyitL4%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29884728" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6125163" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=An%20empirical%20approach%20leveraging%20tumorgrafts%20to%20dissect%20the%20tumor%20microenvironment%20in%20renal%20cell%20carcinoma%20identifies%20missing%20link%20to%20prognostic%20inflammatory%20factors&amp;journal=Cancer%20Discov.&amp;doi=10.1158%2F2159-8290.CD-17-1246&amp;volume=8&amp;pages=1142-1155&amp;publication_year=2018&amp;author=Wang%2CT" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR28">Hassan, R. et al. Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy. <i>Proc. Natl Acad. Sci. USA</i> <b>116</b>, 9008–9013 (2019).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1073%2Fpnas.1821510116" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1073/pnas.1821510116" data-track-item_id="10.1073/pnas.1821510116">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1MXos1Sht78%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30975761" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6500142" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Inherited%20predisposition%20to%20malignant%20mesothelioma%20and%20overall%20survival%20following%20platinum%20chemotherapy&amp;journal=Proc.%20Natl%20Acad.%20Sci.%20USA&amp;doi=10.1073%2Fpnas.1821510116&amp;volume=116&amp;pages=9008-9013&amp;publication_year=2019&amp;author=Hassan%2CR" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR29">Bott, M. et al. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. <i>Nat. Genet.</i> <b>43</b>, 668–672 (2011).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1038%2Fng.855" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1038/ng.855" data-track-item_id="10.1038/ng.855">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC3MXntV2rsLg%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21642991" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4643098" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=The%20nuclear%20deubiquitinase%20BAP1%20is%20commonly%20inactivated%20by%20somatic%20mutations%20and%203p21.1%20losses%20in%20malignant%20pleural%20mesothelioma&amp;journal=Nat.%20Genet.&amp;doi=10.1038%2Fng.855&amp;volume=43&amp;pages=668-672&amp;publication_year=2011&amp;author=Bott%2CM" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR30">Robert, C. et al. Immunotherapy discontinuation—how, and when? Data from melanoma as a paradigm. <i>Nat. Rev. Clin. Oncol.</i> <b>17</b>, 707–715 (2020).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1038%2Fs41571-020-0399-6" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1038/s41571-020-0399-6" data-track-item_id="10.1038/s41571-020-0399-6">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXhtlCqt7%2FO" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32636502" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Immunotherapy%20discontinuation%E2%80%94how%2C%20and%20when%3F%20Data%20from%20melanoma%20as%20a%20paradigm&amp;journal=Nat.%20Rev.%20Clin.%20Oncol.&amp;doi=10.1038%2Fs41571-020-0399-6&amp;volume=17&amp;pages=707-715&amp;publication_year=2020&amp;author=Robert%2CC" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR31">Litchfield, K. et al. Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition. <i>Cell</i> <b>184</b>, 596–614 (2021).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1016%2Fj.cell.2021.01.002" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1016/j.cell.2021.01.002" data-track-item_id="10.1016/j.cell.2021.01.002">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3MXitlGgsLc%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33508232" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7933824" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Meta-analysis%20of%20tumor-%20and%20T%20cell-intrinsic%20mechanisms%20of%20sensitization%20to%20checkpoint%20inhibition&amp;journal=Cell&amp;doi=10.1016%2Fj.cell.2021.01.002&amp;volume=184&amp;pages=596-614&amp;publication_year=2021&amp;author=Litchfield%2CK" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR32">Venkatesan, S. et al. Perspective: APOBEC mutagenesis in drug resistance and immune escape in HIV and cancer evolution. <i>Ann. Oncol.</i> <b>29</b>, 563–572 (2018).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1093%2Fannonc%2Fmdy003" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1093/annonc/mdy003" data-track-item_id="10.1093/annonc/mdy003">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:STN:280:DC%2BC1MzpvVeitw%3D%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29324969" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5888943" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Perspective%3A%20APOBEC%20mutagenesis%20in%20drug%20resistance%20and%20immune%20escape%20in%20HIV%20and%20cancer%20evolution&amp;journal=Ann.%20Oncol.&amp;doi=10.1093%2Fannonc%2Fmdy003&amp;volume=29&amp;pages=563-572&amp;publication_year=2018&amp;author=Venkatesan%2CS" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR33">Rosenthal, R. et al. Neoantigen-directed immune escape in lung cancer evolution. <i>Nature</i> <b>567</b>, 479–485 (2019).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1038%2Fs41586-019-1032-7" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1038/s41586-019-1032-7" data-track-item_id="10.1038/s41586-019-1032-7">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1MXmslKntrY%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30894752" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6954100" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Neoantigen-directed%20immune%20escape%20in%20lung%20cancer%20evolution&amp;journal=Nature&amp;doi=10.1038%2Fs41586-019-1032-7&amp;volume=567&amp;pages=479-485&amp;publication_year=2019&amp;author=Rosenthal%2CR" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR34">Bianchi, A. B. et al. High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas. <i>Proc. Natl Acad. Sci. USA</i> <b>92</b>, 10854–10858 (1995).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1073%2Fpnas.92.24.10854" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1073/pnas.92.24.10854" data-track-item_id="10.1073/pnas.92.24.10854">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DyaK2MXps1amtbk%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=7479897" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC40529" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=High%20frequency%20of%20inactivating%20mutations%20in%20the%20neurofibromatosis%20type%202%20gene%20%28NF2%29%20in%20primary%20malignant%20mesotheliomas&amp;journal=Proc.%20Natl%20Acad.%20Sci.%20USA&amp;doi=10.1073%2Fpnas.92.24.10854&amp;volume=92&amp;pages=10854-10858&amp;publication_year=1995&amp;author=Bianchi%2CAB" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR35">Zhang, M. et al. Clonal architecture in mesothelioma is prognostic and shapes the tumour microenvironment. <i>Nat. Commun.</i> <b>12</b>, 1751 (2021).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1038%2Fs41467-021-21798-w" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1038/s41467-021-21798-w" data-track-item_id="10.1038/s41467-021-21798-w">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3MXntl2kurw%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33741915" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7979861" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Clonal%20architecture%20in%20mesothelioma%20is%20prognostic%20and%20shapes%20the%20tumour%20microenvironment&amp;journal=Nat.%20Commun.&amp;doi=10.1038%2Fs41467-021-21798-w&amp;volume=12&amp;publication_year=2021&amp;author=Zhang%2CM" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR36">Pan, D. et al. A major chromatin regulator determines resistance of tumor cells to T cell-mediated killing. <i>Science</i> <b>359</b>, 770–775 (2018).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1126%2Fscience.aao1710" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1126/science.aao1710" data-track-item_id="10.1126/science.aao1710">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1cXivVaitr4%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29301958" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5953516" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=A%20major%20chromatin%20regulator%20determines%20resistance%20of%20tumor%20cells%20to%20T%20cell-mediated%20killing&amp;journal=Science&amp;doi=10.1126%2Fscience.aao1710&amp;volume=359&amp;pages=770-775&amp;publication_year=2018&amp;author=Pan%2CD" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR37">Shen, J. et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. <i>Nat. Med.</i> <b>24</b>, 556–562 (2018).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1038%2Fs41591-018-0012-z" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1038/s41591-018-0012-z" data-track-item_id="10.1038/s41591-018-0012-z">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1cXpt1Gksrc%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29736026" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6076433" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=ARID1A%20deficiency%20promotes%20mutability%20and%20potentiates%20therapeutic%20antitumor%20immunity%20unleashed%20by%20immune%20checkpoint%20blockade&amp;journal=Nat.%20Med.&amp;doi=10.1038%2Fs41591-018-0012-z&amp;volume=24&amp;pages=556-562&amp;publication_year=2018&amp;author=Shen%2CJ" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR38">Nasu, M. et al. High incidence of somatic BAP1 alterations in sporadic malignant mesothelioma. <i>J. Thorac. Oncol.</i> <b>10</b>, 565–576 (2015).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1097%2FJTO.0000000000000471" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1097/JTO.0000000000000471" data-track-item_id="10.1097/JTO.0000000000000471">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2MXltFSqs74%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=25658628" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4408084" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=High%20incidence%20of%20somatic%20BAP1%20alterations%20in%20sporadic%20malignant%20mesothelioma&amp;journal=J.%20Thorac.%20Oncol.&amp;doi=10.1097%2FJTO.0000000000000471&amp;volume=10&amp;pages=565-576&amp;publication_year=2015&amp;author=Nasu%2CM" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR39">Baumann, F. et al. Mesothelioma patients with germline <i>BAP1</i> mutations have 7-fold improved long-term survival. <i>Carcinogenesis</i> <b>36</b>, 76–81 (2015).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1093%2Fcarcin%2Fbgu227" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1093/carcin/bgu227" data-track-item_id="10.1093/carcin/bgu227">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC28XhtF2ltrfJ" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=25380601" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Mesothelioma%20patients%20with%20germline%20BAP1%20mutations%20have%207-fold%20improved%20long-term%20survival&amp;journal=Carcinogenesis&amp;doi=10.1093%2Fcarcin%2Fbgu227&amp;volume=36&amp;pages=76-81&amp;publication_year=2015&amp;author=Baumann%2CF" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR40">Carbone, M. et al. Biological mechanisms and clinical significance of <i>BAP1</i> mutations in human cancer. <i>Cancer Discov.</i> <b>10</b>, 1103–1120 (2020).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1158%2F2159-8290.CD-19-1220" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1158/2159-8290.CD-19-1220" data-track-item_id="10.1158/2159-8290.CD-19-1220">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXit1ehsb7N" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32690542" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8006752" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Biological%20mechanisms%20and%20clinical%20significance%20of%20BAP1%20mutations%20in%20human%20cancer&amp;journal=Cancer%20Discov.&amp;doi=10.1158%2F2159-8290.CD-19-1220&amp;volume=10&amp;pages=1103-1120&amp;publication_year=2020&amp;author=Carbone%2CM" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR41">Samstein, R. M. et al. Mutations in <i>BRCA1</i> and <i>BRCA2</i> differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy. <i>Nat. Cancer</i> <b>1</b>, 1188–1203 (2021).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1038%2Fs43018-020-00139-8" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1038/s43018-020-00139-8" data-track-item_id="10.1038/s43018-020-00139-8">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33834176" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB38XjsVOmtrs%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Mutations%20in%20BRCA1%20and%20BRCA2%20differentially%20affect%20the%20tumor%20microenvironment%20and%20response%20to%20checkpoint%20blockade%20immunotherapy&amp;journal=Nat.%20Cancer&amp;doi=10.1038%2Fs43018-020-00139-8&amp;volume=1&amp;pages=1188-1203&amp;publication_year=2021&amp;author=Samstein%2CRM" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR42">Ishikawa, H. &amp; Barber, G. N. STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. <i>Nature</i> <b>455</b>, 674–678 (2008).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1038%2Fnature07317" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1038/nature07317" data-track-item_id="10.1038/nature07317">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD1cXhtF2hsbzL" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=18724357" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2804933" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=STING%20is%20an%20endoplasmic%20reticulum%20adaptor%20that%20facilitates%20innate%20immune%20signalling&amp;journal=Nature&amp;doi=10.1038%2Fnature07317&amp;volume=455&amp;pages=674-678&amp;publication_year=2008&amp;author=Ishikawa%2CH&amp;author=Barber%2CGN" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR43">Anagnostou, V. et al. Evolution of neoantigen landscape during immune checkpoint blockade in non-small cell lung cancer. <i>Cancer Discov.</i> <b>7</b>, 264–276 (2017).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1158%2F2159-8290.CD-16-0828" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1158/2159-8290.CD-16-0828" data-track-item_id="10.1158/2159-8290.CD-16-0828">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2sXjs1Klsb0%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=28031159" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Evolution%20of%20neoantigen%20landscape%20during%20immune%20checkpoint%20blockade%20in%20non-small%20cell%20lung%20cancer&amp;journal=Cancer%20Discov.&amp;doi=10.1158%2F2159-8290.CD-16-0828&amp;volume=7&amp;pages=264-276&amp;publication_year=2017&amp;author=Anagnostou%2CV" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR44">Anagnostou, V. et al. Integrative tumor and immune cell mutli-omic analyses to predict melanoma response to immune checkpoint blockade. <i>Cell Rep. Med.</i> <b>1</b>, 100139 (2020).</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR45">Binnewies, M. et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. <i>Nat. Med.</i> <b>24</b>, 541–550 (2018).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1038%2Fs41591-018-0014-x" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1038/s41591-018-0014-x" data-track-item_id="10.1038/s41591-018-0014-x">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1cXosVCnsLk%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29686425" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5998822" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Understanding%20the%20tumor%20immune%20microenvironment%20%28TIME%29%20for%20effective%20therapy&amp;journal=Nat.%20Med.&amp;doi=10.1038%2Fs41591-018-0014-x&amp;volume=24&amp;pages=541-550&amp;publication_year=2018&amp;author=Binnewies%2CM" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR46">Joshi, K. et al. Spatial heterogeneity of the T cell receptor repertoire reflects the mutational landscape in lung cancer. <i>Nat. Med.</i> <b>25</b>, 1549–1559 (2019).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1038%2Fs41591-019-0592-2" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1038/s41591-019-0592-2" data-track-item_id="10.1038/s41591-019-0592-2">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1MXhvFaksbnF" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=31591606" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6890490" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Spatial%20heterogeneity%20of%20the%20T%20cell%20receptor%20repertoire%20reflects%20the%20mutational%20landscape%20in%20lung%20cancer&amp;journal=Nat.%20Med.&amp;doi=10.1038%2Fs41591-019-0592-2&amp;volume=25&amp;pages=1549-1559&amp;publication_year=2019&amp;author=Joshi%2CK" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR47">Thorsson, V. et al. The immune landscape of cancer. <i>Immunity</i> <b>48</b>, 812–830 (2018).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1016%2Fj.immuni.2018.03.023" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1016/j.immuni.2018.03.023" data-track-item_id="10.1016/j.immuni.2018.03.023">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1cXntFSjt7o%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29628290" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5982584" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=The%20immune%20landscape%20of%20cancer&amp;journal=Immunity&amp;doi=10.1016%2Fj.immuni.2018.03.023&amp;volume=48&amp;pages=812-830&amp;publication_year=2018&amp;author=Thorsson%2CV" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR48">Ellrott, K. et al. Scalable open science approach for mutation calling of tumor exomes using multiple genomic pipelines. <i>Cell Syst.</i> <b>6</b>, 271–281 (2018).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1016%2Fj.cels.2018.03.002" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1016/j.cels.2018.03.002" data-track-item_id="10.1016/j.cels.2018.03.002">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1cXpslOktr0%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29596782" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6075717" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Scalable%20open%20science%20approach%20for%20mutation%20calling%20of%20tumor%20exomes%20using%20multiple%20genomic%20pipelines&amp;journal=Cell%20Syst.&amp;doi=10.1016%2Fj.cels.2018.03.002&amp;volume=6&amp;pages=271-281&amp;publication_year=2018&amp;author=Ellrott%2CK" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR49">Jones, S. et al. Personalized genomic analyses for cancer mutation discovery and interpretation. <i>Sci. Transl. Med.</i> <b>7</b>, 283ra253 (2015).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1126%2Fscitranslmed.aaa7161" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1126/scitranslmed.aaa7161" data-track-item_id="10.1126/scitranslmed.aaa7161">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2MXnvFKnt7Y%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Personalized%20genomic%20analyses%20for%20cancer%20mutation%20discovery%20and%20interpretation&amp;journal=Sci.%20Transl.%20Med.&amp;doi=10.1126%2Fscitranslmed.aaa7161&amp;volume=7&amp;publication_year=2015&amp;author=Jones%2CS" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR50">Anagnostou, V. et al. Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer. <i>Nat. Cancer</i> <b>1</b>, 99–111 (2020).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1038%2Fs43018-019-0008-8" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1038/s43018-019-0008-8" data-track-item_id="10.1038/s43018-019-0008-8">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32984843" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7514475" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB38XjsFeitrk%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Multimodal%20genomic%20features%20predict%20outcome%20of%20immune%20checkpoint%20blockade%20in%20non-small-cell%20lung%20cancer&amp;journal=Nat.%20Cancer&amp;doi=10.1038%2Fs43018-019-0008-8&amp;volume=1&amp;pages=99-111&amp;publication_year=2020&amp;author=Anagnostou%2CV" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR51">Shao, X. M. et al. High-throughput prediction of MHC class I and II neoantigens with MHCnuggets. <i>Cancer Immunol. Res.</i> <b>8</b>, 396–408 (2020).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1158%2F2326-6066.CIR-19-0464" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1158/2326-6066.CIR-19-0464" data-track-item_id="10.1158/2326-6066.CIR-19-0464">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXitVOgur%2FF" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=31871119" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=High-throughput%20prediction%20of%20MHC%20class%20I%20and%20II%20neoantigens%20with%20MHCnuggets&amp;journal=Cancer%20Immunol.%20Res.&amp;doi=10.1158%2F2326-6066.CIR-19-0464&amp;volume=8&amp;pages=396-408&amp;publication_year=2020&amp;author=Shao%2CXM" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR52">Kim, S. et al. Strelka2: fast and accurate calling of germline and somatic variants. <i>Nat. Methods</i> <b>15</b>, 591–594 (2018).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1038%2Fs41592-018-0051-x" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1038/s41592-018-0051-x" data-track-item_id="10.1038/s41592-018-0051-x">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1cXhtlCmt7%2FF" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30013048" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Strelka2%3A%20fast%20and%20accurate%20calling%20of%20germline%20and%20somatic%20variants&amp;journal=Nat.%20Methods&amp;doi=10.1038%2Fs41592-018-0051-x&amp;volume=15&amp;pages=591-594&amp;publication_year=2018&amp;author=Kim%2CS" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR53">Pagel, K. A. et al. Integrated informatics analysis of cancer-related variants. <i>JCO Clin. Cancer Inform.</i> <b>4</b>, 310–317 (2020).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1200%2FCCI.19.00132" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1200/CCI.19.00132" data-track-item_id="10.1200/CCI.19.00132">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32228266" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Integrated%20informatics%20analysis%20of%20cancer-related%20variants&amp;journal=JCO%20Clin.%20Cancer%20Inform.&amp;doi=10.1200%2FCCI.19.00132&amp;volume=4&amp;pages=310-317&amp;publication_year=2020&amp;author=Pagel%2CKA" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR54">Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. <i>Nature</i> <b>500</b>, 415–421 (2013).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1038%2Fnature12477" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1038/nature12477" data-track-item_id="10.1038/nature12477">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC3sXhtlWjur7M" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=23945592" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3776390" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Signatures%20of%20mutational%20processes%20in%20human%20cancer&amp;journal=Nature&amp;doi=10.1038%2Fnature12477&amp;volume=500&amp;pages=415-421&amp;publication_year=2013&amp;author=Alexandrov%2CLB" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR55">Szolek, A. et al. OptiType: precision HLA typing from next-generation sequencing data. <i>Bioinformatics</i> <b>30</b>, 3310–3316 (2014).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1093%2Fbioinformatics%2Fbtu548" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1093/bioinformatics/btu548" data-track-item_id="10.1093/bioinformatics/btu548">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2MXisFalt7Y%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=25143287" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4441069" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=OptiType%3A%20precision%20HLA%20typing%20from%20next-generation%20sequencing%20data&amp;journal=Bioinformatics&amp;doi=10.1093%2Fbioinformatics%2Fbtu548&amp;volume=30&amp;pages=3310-3316&amp;publication_year=2014&amp;author=Szolek%2CA" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR56">Xie, C. et al. Fast and accurate HLA typing from short-read next-generation sequence data with xHLA. <i>Proc. Natl Acad. Sci. USA</i> <b>114</b>, 8059–8064 (2017).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1073%2Fpnas.1707945114" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1073/pnas.1707945114" data-track-item_id="10.1073/pnas.1707945114">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2sXhtFSmtrfJ" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=28674023" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5544337" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Fast%20and%20accurate%20HLA%20typing%20from%20short-read%20next-generation%20sequence%20data%20with%20xHLA&amp;journal=Proc.%20Natl%20Acad.%20Sci.%20USA&amp;doi=10.1073%2Fpnas.1707945114&amp;volume=114&amp;pages=8059-8064&amp;publication_year=2017&amp;author=Xie%2CC" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR57">Cao, H. et al. An integrated tool to study MHC region: accurate SNV detection and HLA genes typing in human MHC region using targeted high-throughput sequencing. <i>PLoS ONE</i> <b>8</b>, e69388 (2013).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1371%2Fjournal.pone.0069388" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1371/journal.pone.0069388" data-track-item_id="10.1371/journal.pone.0069388">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC3sXht1ert7zL" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=23894464" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3722289" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=An%20integrated%20tool%20to%20study%20MHC%20region%3A%20accurate%20SNV%20detection%20and%20HLA%20genes%20typing%20in%20human%20MHC%20region%20using%20targeted%20high-throughput%20sequencing&amp;journal=PLoS%20ONE&amp;doi=10.1371%2Fjournal.pone.0069388&amp;volume=8&amp;publication_year=2013&amp;author=Cao%2CH" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR58">Shukla, S. A. et al. Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes. <i>Nat. Biotechnol.</i> <b>33</b>, 1152–1158 (2015).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1038%2Fnbt.3344" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1038/nbt.3344" data-track-item_id="10.1038/nbt.3344">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2MXhsFWht7nO" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=26372948" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4747795" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Comprehensive%20analysis%20of%20cancer-associated%20somatic%20mutations%20in%20class%20I%20HLA%20genes&amp;journal=Nat.%20Biotechnol.&amp;doi=10.1038%2Fnbt.3344&amp;volume=33&amp;pages=1152-1158&amp;publication_year=2015&amp;author=Shukla%2CSA" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR59">McGranahan, N. et al. Allele-specific HLA loss and immune escape in lung cancer evolution. <i>Cell</i> <b>171</b>, 1259–1271 (2017).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1016%2Fj.cell.2017.10.001" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1016/j.cell.2017.10.001" data-track-item_id="10.1016/j.cell.2017.10.001">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2sXhslehs7nL" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29107330" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5720478" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Allele-specific%20HLA%20loss%20and%20immune%20escape%20in%20lung%20cancer%20evolution&amp;journal=Cell&amp;doi=10.1016%2Fj.cell.2017.10.001&amp;volume=171&amp;pages=1259-1271&amp;publication_year=2017&amp;author=McGranahan%2CN" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR60">Robinson, J. et al. The IPD and IMGT/HLA database: allele variant databases. <i>Nucleic Acids Res.</i> <b>43</b>, D423–D431 (2015).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1093%2Fnar%2Fgku1161" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1093/nar/gku1161" data-track-item_id="10.1093/nar/gku1161">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2sXhtVymtrbF" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=25414341" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=The%20IPD%20and%20IMGT%2FHLA%20database%3A%20allele%20variant%20databases&amp;journal=Nucleic%20Acids%20Res.&amp;doi=10.1093%2Fnar%2Fgku1161&amp;volume=43&amp;pages=D423-D431&amp;publication_year=2015&amp;author=Robinson%2CJ" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR61">Shen, R. &amp; Seshan, V. E. FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing. <i>Nucleic Acids Res.</i> <b>44</b>, e131 (2016).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1093%2Fnar%2Fgkw520" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1093/nar/gkw520" data-track-item_id="10.1093/nar/gkw520">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=27270079" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5027494" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC28XhvVKmsrvE" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=FACETS%3A%20allele-specific%20copy%20number%20and%20clonal%20heterogeneity%20analysis%20tool%20for%20high-throughput%20DNA%20sequencing&amp;journal=Nucleic%20Acids%20Res.&amp;doi=10.1093%2Fnar%2Fgkw520&amp;volume=44&amp;publication_year=2016&amp;author=Shen%2CR&amp;author=Seshan%2CVE" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR62">Niknafs, N., Beleva-Guthrie, V., Naiman, D. Q. &amp; Karchin, R. SubClonal hierarchy inference from somatic mutations: automatic reconstruction of cancer evolutionary trees from multi-region next generation sequencing. <i>PLoS Comput. Biol.</i> <b>11</b>, e1004416 (2015).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1371%2Fjournal.pcbi.1004416" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1371/journal.pcbi.1004416" data-track-item_id="10.1371/journal.pcbi.1004416">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=26436540" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4593588" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC28XkvVOltrY%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=SubClonal%20hierarchy%20inference%20from%20somatic%20mutations%3A%20automatic%20reconstruction%20of%20cancer%20evolutionary%20trees%20from%20multi-region%20next%20generation%20sequencing&amp;journal=PLoS%20Comput.%20Biol.&amp;doi=10.1371%2Fjournal.pcbi.1004416&amp;volume=11&amp;publication_year=2015&amp;author=Niknafs%2CN&amp;author=Beleva-Guthrie%2CV&amp;author=Naiman%2CDQ&amp;author=Karchin%2CR" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR63">Sztupinszki, Z. et al. Migrating the SNP array-based homologous recombination deficiency measures to next generation sequencing data of breast cancer. <i>NPJ Breast Cancer</i> <b>4</b>, 16 (2018).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1038%2Fs41523-018-0066-6" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1038/s41523-018-0066-6" data-track-item_id="10.1038/s41523-018-0066-6">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29978035" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6028448" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1cXht1OjsLzI" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Migrating%20the%20SNP%20array-based%20homologous%20recombination%20deficiency%20measures%20to%20next%20generation%20sequencing%20data%20of%20breast%20cancer&amp;journal=NPJ%20Breast%20Cancer&amp;doi=10.1038%2Fs41523-018-0066-6&amp;volume=4&amp;publication_year=2018&amp;author=Sztupinszki%2CZ" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR64">Carlson, C. S. et al. Using synthetic templates to design an unbiased multiplex PCR assay. <i>Nat. Commun.</i> <b>4</b>, 2680 (2013).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1038%2Fncomms3680" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1038/ncomms3680" data-track-item_id="10.1038/ncomms3680">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=24157944" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2cXhtVGmsrw%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Using%20synthetic%20templates%20to%20design%20an%20unbiased%20multiplex%20PCR%20assay&amp;journal=Nat.%20Commun.&amp;doi=10.1038%2Fncomms3680&amp;volume=4&amp;publication_year=2013&amp;author=Carlson%2CCS" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR65">Dobin, A. &amp; Gingeras, T. R. Mapping RNA-seq reads with STAR. <i>Curr. Protoc. Bioinformatics</i> <b>51</b>, 11 14 11–11 14 19 (2015).</p><p class="c-reading-companion__reference-links"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=26334920" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Mapping%20RNA-seq%20reads%20with%20STAR&amp;journal=Curr.%20Protoc.%20Bioinformatics&amp;volume=51&amp;pages=11%2014%2011-11%2014%2019&amp;publication_year=2015&amp;author=Dobin%2CA&amp;author=Gingeras%2CTR" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR66">Li, B. &amp; Dewey, C. N. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. <i>BMC Bioinformatics</i> <b>12</b>, 323 (2011).</p><p class="c-reading-companion__reference-links"><a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC3MXhtFajtLvM" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21816040" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3163565" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=RSEM%3A%20accurate%20transcript%20quantification%20from%20RNA-Seq%20data%20with%20or%20without%20a%20reference%20genome&amp;journal=BMC%20Bioinformatics&amp;volume=12&amp;publication_year=2011&amp;author=Li%2CB&amp;author=Dewey%2CCN" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR67">Love, M. I., Huber, W. &amp; Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. <i>Genome Biol.</i> <b>15</b>, 550 (2014).</p><p class="c-reading-companion__reference-links"><a href="https://link.springer.com/doi/10.1186/s13059-014-0550-8" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1186/s13059-014-0550-8" data-track-item_id="10.1186/s13059-014-0550-8">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=25516281" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4302049" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2MXjtVCrsL8%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Moderated%20estimation%20of%20fold%20change%20and%20dispersion%20for%20RNA-seq%20data%20with%20DESeq2&amp;journal=Genome%20Biol.&amp;doi=10.1186%2Fs13059-014-0550-8&amp;volume=15&amp;publication_year=2014&amp;author=Love%2CMI&amp;author=Huber%2CW&amp;author=Anders%2CS" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR68">Danilova, L. et al. The mutation-associated neoantigen functional expansion of specific T cells (MANAFEST) assay: a sensitive platform for monitoring antitumor immunity. <i>Cancer Immunol. Res.</i> <b>6</b>, 888–899 (2018).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1158%2F2326-6066.CIR-18-0129" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1158/2326-6066.CIR-18-0129" data-track-item_id="10.1158/2326-6066.CIR-18-0129">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1cXhsVWrsbbI" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29895573" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6072595" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=The%20mutation-associated%20neoantigen%20functional%20expansion%20of%20specific%20T%20cells%20%28MANAFEST%29%20assay%3A%20a%20sensitive%20platform%20for%20monitoring%20antitumor%20immunity&amp;journal=Cancer%20Immunol.%20Res.&amp;doi=10.1158%2F2326-6066.CIR-18-0129&amp;volume=6&amp;pages=888-899&amp;publication_year=2018&amp;author=Danilova%2CL" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR69">Zhang, J., Ji, Z. &amp; Smith, K. N. Analysis of TCR β CDR3 sequencing data for tracking anti-tumor immunity. <i>Methods Enzymol.</i> <b>629</b>, 443–464 (2019).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1016%2Fbs.mie.2019.08.006" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1016/bs.mie.2019.08.006" data-track-item_id="10.1016/bs.mie.2019.08.006">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXisVyrtL7P" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=31727253" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Analysis%20of%20TCR%20%CE%B2%20CDR3%20sequencing%20data%20for%20tracking%20anti-tumor%20immunity&amp;journal=Methods%20Enzymol.&amp;doi=10.1016%2Fbs.mie.2019.08.006&amp;volume=629&amp;pages=443-464&amp;publication_year=2019&amp;author=Zhang%2CJ&amp;author=Ji%2CZ&amp;author=Smith%2CKN" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li></ol></div></div>
        </div>
    </div>
</aside>
</div>


    
        
    
    
        
            
        

        
            
        
    
    <script>
        window.dataLayer = window.dataLayer || [];
        window.dataLayer.push({
            page: {
                content: {
                    fundingWidget: "true",
                        }
                    }
                });
    </script>




<footer class="composite-layer" itemscope="" itemtype="http://schema.org/Periodical">
        <meta itemprop="publisher" content="Springer Nature">
        

        <div class="u-mt-16 u-mb-16">
    <div class="u-container">
        <div class="u-display-flex u-flex-wrap u-justify-content-space-between">
            

            <div class="c-meta u-ma-0 u-flex-shrink">
                <p class="c-meta__item c-meta__type u-mt-0">
                    <span itemprop="name">
                        Nature Medicine
                    </span>
                    (<i itemprop="alternateName">Nat Med</i>)
                </p>
                
    
        <p class="c-meta__item u-mt-0">
            <abbr title="International Standard Serial Number">ISSN</abbr> <span itemprop="issn">1546-170X</span> (online)
        </p>
    

                
    
        <p class="c-meta__item u-mt-0">
            <abbr title="International Standard Serial Number">ISSN</abbr> <span itemprop="issn">1078-8956</span> (print)
        </p>
    

            </div>
        </div>
    </div>
</div>

    <div class="c-footer">
        <div class="u-hide-print" data-track-component="footer">
    <h2 class="u-visually-hidden">nature.com sitemap</h2>
    <div class="c-footer__container">
        <div class="c-footer__grid c-footer__group--separator">
            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">About Nature Portfolio</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/npg_/company_info/index.html" data-track="click" data-track-action="about us" data-track-label="link">About us</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/npg_/press_room/press_releases.html" data-track="click" data-track-action="press releases" data-track-label="link">Press releases</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://press.nature.com/" data-track="click" data-track-action="press office" data-track-label="link">Press office</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://support.nature.com/support/home" data-track="click" data-track-action="contact us" data-track-label="link">Contact us</a></li>
                </ul>
            </div>

            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">Discover content</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/siteindex" data-track="click" data-track-action="journals a-z" data-track-label="link">Journals A-Z</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/subjects" data-track="click" data-track-action="article by subject" data-track-label="link">Articles by subject</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.protocols.io/" data-track="click" data-track-action="protocols.io" data-track-label="link">protocols.io</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.natureindex.com/" data-track="click" data-track-action="nature index" data-track-label="link">Nature Index</a></li>
                </ul>
            </div>

            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">Publishing policies</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/authors/editorial_policies" data-track="click" data-track-action="Nature portfolio policies" data-track-label="link">Nature portfolio policies</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/nature-research/open-access" data-track="click" data-track-action="open access" data-track-label="link">Open access</a></li>
                </ul>
            </div>

            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">Author &amp; Researcher services</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/reprints" data-track="click" data-track-action="reprints and permissions" data-track-label="link">Reprints &amp; permissions</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.springernature.com/gp/authors/research-data" data-track="click" data-track-action="data research service" data-track-label="link">Research data</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://authorservices.springernature.com/language-editing/" data-track="click" data-track-action="language editing" data-track-label="link">Language editing</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://authorservices.springernature.com/scientific-editing/" data-track="click" data-track-action="scientific editing" data-track-label="link">Scientific editing</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://masterclasses.nature.com/" data-track="click" data-track-action="nature masterclasses" data-track-label="link">Nature Masterclasses</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://solutions.springernature.com/" data-track="click" data-track-action="research solutions" data-track-label="link">Research Solutions</a></li>
                </ul>
            </div>

            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">Libraries &amp; institutions</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.springernature.com/gp/librarians/tools-services" data-track="click" data-track-action="librarian service and tools" data-track-label="link">Librarian service &amp; tools</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.springernature.com/gp/librarians/manage-your-account/librarianportal" data-track="click" data-track-action="librarian portal" data-track-label="link">Librarian portal</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/openresearch/about-open-access/information-for-institutions" data-track="click" data-track-action="open research" data-track-label="link">Open research</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.springernature.com/gp/librarians/recommend-to-your-library" data-track="click" data-track-action="Recommend to library" data-track-label="link">Recommend to library</a></li>
                </ul>
            </div>

            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">Advertising &amp; partnerships</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link" href="https://partnerships.nature.com/product/digital-advertising/" data-track="click" data-track-action="advertising" data-track-label="link">Advertising</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://partnerships.nature.com/" data-track="click" data-track-action="partnerships and services" data-track-label="link">Partnerships &amp; Services</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://partnerships.nature.com/media-kits/" data-track="click" data-track-action="media kits" data-track-label="link">Media kits</a>
                    </li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://partnerships.nature.com/product/branded-content-native-advertising/" data-track-action="branded content" data-track-label="link">Branded
                        content</a></li>
                </ul>
            </div>

            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">Professional development</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/naturecareers/" data-track="click" data-track-action="nature careers" data-track-label="link">Nature Careers</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://conferences.nature.com" data-track="click" data-track-action="nature conferences" data-track-label="link">Nature<span class="u-visually-hidden"> </span>
                        Conferences</a></li>
                </ul>
            </div>

            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">Regional websites</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/natafrica" data-track="click" data-track-action="nature africa" data-track-label="link">Nature Africa</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="http://www.naturechina.com" data-track="click" data-track-action="nature china" data-track-label="link">Nature China</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/nindia" data-track="click" data-track-action="nature india" data-track-label="link">Nature India</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/natitaly" data-track="click" data-track-action="nature Italy" data-track-label="link">Nature Italy</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.natureasia.com/ja-jp" data-track="click" data-track-action="nature japan" data-track-label="link">Nature Japan</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/nmiddleeast" data-track="click" data-track-action="nature middle east" data-track-label="link">Nature Middle East</a></li>
                </ul>
            </div>

        </div>
    </div>
    <div class="c-footer__container">
        <ul class="c-footer__links">
            <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/info/privacy" data-track="click" data-track-action="privacy policy" data-track-label="link">Privacy
                Policy</a></li>
            <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/info/cookies" data-track="click" data-track-action="use of cookies" data-track-label="link">Use
                of cookies</a></li>
            <li class="c-footer__item">
                <button class="optanon-toggle-display c-footer__link" onclick="javascript:;" data-cc-action="preferences" data-track="click" data-track-action="manage cookies" data-track-label="link">Your privacy choices/Manage cookies
                </button>
            </li>
            <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/info/legal-notice" data-track="click" data-track-action="legal notice" data-track-label="link">Legal
                notice</a></li>
            <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/info/accessibility-statement" data-track="click" data-track-action="accessibility statement" data-track-label="link">Accessibility
                statement</a></li>
            <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/info/terms-and-conditions" data-track="click" data-track-action="terms and conditions" data-track-label="link">Terms &amp; Conditions</a></li>
            <li class="c-footer__item"><a class="c-footer__link" href="https://www.springernature.com/ccpa" data-track="click" data-track-action="california privacy statement" data-track-label="link">Your US state privacy rights</a></li>
            
        </ul>
    </div>
</div>


        <div class="c-footer__container">
    <a href="https://www.springernature.com/" class="c-footer__link">
        <img src="/static/images/logos/sn-logo-white-ea63208b81.svg" alt="Springer Nature" loading="lazy" width="200" height="20">
    </a>
    <p class="c-footer__legal" data-test="copyright">© 2025 Springer Nature Limited</p>
</div>

    </div>
    <div class="u-visually-hidden" aria-hidden="true">
    
    <!--?xml version="1.0" encoding="UTF-8"?--><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink"><defs><path id="a" d="M0 .74h56.72v55.24H0z"></path></defs><symbol id="icon-access" viewBox="0 0 18 18"><path d="m14 8c.5522847 0 1 .44771525 1 1v7h2.5c.2761424 0 .5.2238576.5.5v1.5h-18v-1.5c0-.2761424.22385763-.5.5-.5h2.5v-7c0-.55228475.44771525-1 1-1s1 .44771525 1 1v6.9996556h8v-6.9996556c0-.55228475.4477153-1 1-1zm-8 0 2 1v5l-2 1zm6 0v7l-2-1v-5zm-2.42653766-7.59857636 7.03554716 4.92488299c.4162533.29137735.5174853.86502537.226108 1.28127873-.1721584.24594054-.4534847.39241464-.7536934.39241464h-14.16284822c-.50810197 0-.92-.41189803-.92-.92 0-.30020869.1464741-.58153499.39241464-.75369337l7.03554714-4.92488299c.34432015-.2410241.80260453-.2410241 1.14692468 0zm-.57346234 2.03988748-3.65526982 2.55868888h7.31053962z" fill-rule="evenodd"></path></symbol><symbol id="icon-account" viewBox="0 0 18 18"><path d="m10.2379028 16.9048051c1.3083556-.2032362 2.5118471-.7235183 3.5294683-1.4798399-.8731327-2.5141501-2.0638925-3.935978-3.7673711-4.3188248v-1.27684611c1.1651924-.41183641 2-1.52307546 2-2.82929429 0-1.65685425-1.3431458-3-3-3-1.65685425 0-3 1.34314575-3 3 0 1.30621883.83480763 2.41745788 2 2.82929429v1.27684611c-1.70347856.3828468-2.89423845 1.8046747-3.76737114 4.3188248 1.01762123.7563216 2.22111275 1.2766037 3.52946833 1.4798399.40563808.0629726.81921174.0951949 1.23790281.0951949s.83226473-.0322223 1.2379028-.0951949zm4.3421782-2.1721994c1.4927655-1.4532925 2.419919-3.484675 2.419919-5.7326057 0-4.418278-3.581722-8-8-8s-8 3.581722-8 8c0 2.2479307.92715352 4.2793132 2.41991895 5.7326057.75688473-2.0164459 1.83949951-3.6071894 3.48926591-4.3218837-1.14534283-.70360829-1.90918486-1.96796271-1.90918486-3.410722 0-2.209139 1.790861-4 4-4s4 1.790861 4 4c0 1.44275929-.763842 2.70711371-1.9091849 3.410722 1.6497664.7146943 2.7323812 2.3054378 3.4892659 4.3218837zm-5.580081 3.2673943c-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9 4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9z" fill-rule="evenodd"></path></symbol><symbol id="icon-alert" viewBox="0 0 18 18"><path d="m4 10h2.5c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-3.08578644l-1.12132034 1.1213203c-.18753638.1875364-.29289322.4418903-.29289322.7071068v.1715729h14v-.1715729c0-.2652165-.1053568-.5195704-.2928932-.7071068l-1.7071068-1.7071067v-3.4142136c0-2.76142375-2.2385763-5-5-5-2.76142375 0-5 2.23857625-5 5zm3 4c0 1.1045695.8954305 2 2 2s2-.8954305 2-2zm-5 0c-.55228475 0-1-.4477153-1-1v-.1715729c0-.530433.21071368-1.0391408.58578644-1.4142135l1.41421356-1.4142136v-3c0-3.3137085 2.6862915-6 6-6s6 2.6862915 6 6v3l1.4142136 1.4142136c.3750727.3750727.5857864.8837805.5857864 1.4142135v.1715729c0 .5522847-.4477153 1-1 1h-4c0 1.6568542-1.3431458 3-3 3-1.65685425 0-3-1.3431458-3-3z" fill-rule="evenodd"></path></symbol><symbol id="icon-arrow-broad" viewBox="0 0 16 16"><path d="m6.10307866 2.97190702v7.69043288l2.44965196-2.44676915c.38776071-.38730439 1.0088052-.39493524 1.38498697-.01919617.38609051.38563612.38643641 1.01053024-.00013864 1.39665039l-4.12239817 4.11754683c-.38616704.3857126-1.01187344.3861062-1.39846576-.0000311l-4.12258206-4.11773056c-.38618426-.38572979-.39254614-1.00476697-.01636437-1.38050605.38609047-.38563611 1.01018509-.38751562 1.4012233.00306241l2.44985644 2.4469734v-8.67638639c0-.54139983.43698413-.98042709.98493125-.98159081l7.89910522-.0043627c.5451687 0 .9871152.44142642.9871152.98595351s-.4419465.98595351-.9871152.98595351z" fill-rule="evenodd" transform="matrix(-1 0 0 -1 14 15)"></path></symbol><symbol id="icon-arrow-down" viewBox="0 0 16 16"><path d="m3.28337502 11.5302405 4.03074001 4.176208c.37758093.3912076.98937525.3916069 1.367372-.0000316l4.03091977-4.1763942c.3775978-.3912252.3838182-1.0190815.0160006-1.4001736-.3775061-.39113013-.9877245-.39303641-1.3700683.003106l-2.39538585 2.4818345v-11.6147896l-.00649339-.11662112c-.055753-.49733869-.46370161-.88337888-.95867408-.88337888-.49497246 0-.90292107.38604019-.95867408.88337888l-.00649338.11662112v11.6147896l-2.39518594-2.4816273c-.37913917-.39282218-.98637524-.40056175-1.35419292-.0194697-.37750607.3911302-.37784433 1.0249269.00013556 1.4165479z" fill-rule="evenodd"></path></symbol><symbol id="icon-arrow-left" viewBox="0 0 16 16"><path d="m4.46975946 3.28337502-4.17620792 4.03074001c-.39120768.37758093-.39160691.98937525.0000316 1.367372l4.1763942 4.03091977c.39122514.3775978 1.01908149.3838182 1.40017357.0160006.39113012-.3775061.3930364-.9877245-.00310603-1.3700683l-2.48183446-2.39538585h11.61478958l.1166211-.00649339c.4973387-.055753.8833789-.46370161.8833789-.95867408 0-.49497246-.3860402-.90292107-.8833789-.95867408l-.1166211-.00649338h-11.61478958l2.4816273-2.39518594c.39282216-.37913917.40056173-.98637524.01946965-1.35419292-.39113012-.37750607-1.02492687-.37784433-1.41654791.00013556z" fill-rule="evenodd"></path></symbol><symbol id="icon-arrow-right" viewBox="0 0 16 16"><path d="m11.5302405 12.716625 4.176208-4.03074003c.3912076-.37758093.3916069-.98937525-.0000316-1.367372l-4.1763942-4.03091981c-.3912252-.37759778-1.0190815-.38381821-1.4001736-.01600053-.39113013.37750607-.39303641.98772445.003106 1.37006824l2.4818345 2.39538588h-11.6147896l-.11662112.00649339c-.49733869.055753-.88337888.46370161-.88337888.95867408 0 .49497246.38604019.90292107.88337888.95867408l.11662112.00649338h11.6147896l-2.4816273 2.39518592c-.39282218.3791392-.40056175.9863753-.0194697 1.3541929.3911302.3775061 1.0249269.3778444 1.4165479-.0001355z" fill-rule="evenodd"></path></symbol><symbol id="icon-arrow-sub" viewBox="0 0 16 16"><path d="m7.89692134 4.97190702v7.69043288l-2.44965196-2.4467692c-.38776071-.38730434-1.0088052-.39493519-1.38498697-.0191961-.38609047.3856361-.38643643 1.0105302.00013864 1.3966504l4.12239817 4.1175468c.38616704.3857126 1.01187344.3861062 1.39846576-.0000311l4.12258202-4.1177306c.3861843-.3857298.3925462-1.0047669.0163644-1.380506-.3860905-.38563612-1.0101851-.38751563-1.4012233.0030624l-2.44985643 2.4469734v-8.67638639c0-.54139983-.43698413-.98042709-.98493125-.98159081l-7.89910525-.0043627c-.54516866 0-.98711517.44142642-.98711517.98595351s.44194651.98595351.98711517.98595351z" fill-rule="evenodd"></path></symbol><symbol id="icon-arrow-up" viewBox="0 0 16 16"><path d="m12.716625 4.46975946-4.03074003-4.17620792c-.37758093-.39120768-.98937525-.39160691-1.367372.0000316l-4.03091981 4.1763942c-.37759778.39122514-.38381821 1.01908149-.01600053 1.40017357.37750607.39113012.98772445.3930364 1.37006824-.00310603l2.39538588-2.48183446v11.61478958l.00649339.1166211c.055753.4973387.46370161.8833789.95867408.8833789.49497246 0 .90292107-.3860402.95867408-.8833789l.00649338-.1166211v-11.61478958l2.39518592 2.4816273c.3791392.39282216.9863753.40056173 1.3541929.01946965.3775061-.39113012.3778444-1.02492687-.0001355-1.41654791z" fill-rule="evenodd"></path></symbol><symbol id="icon-article" viewBox="0 0 18 18"><path d="m13 15v-12.9906311c0-.0073595-.0019884-.0093689.0014977-.0093689l-11.00158888.00087166v13.00506804c0 .5482678.44615281.9940603.99415146.9940603h10.27350412c-.1701701-.2941734-.2675644-.6357129-.2675644-1zm-12 .0059397v-13.00506804c0-.5562408.44704472-1.00087166.99850233-1.00087166h11.00299537c.5510129 0 .9985023.45190985.9985023 1.0093689v2.9906311h3v9.9914698c0 1.1065798-.8927712 2.0085302-1.9940603 2.0085302h-12.01187942c-1.09954652 0-1.99406028-.8927712-1.99406028-1.9940603zm13-9.0059397v9c0 .5522847.4477153 1 1 1s1-.4477153 1-1v-9zm-10-2h7v4h-7zm1 1v2h5v-2zm-1 4h7v1h-7zm0 2h7v1h-7zm0 2h7v1h-7z" fill-rule="evenodd"></path></symbol><symbol id="icon-audio" viewBox="0 0 18 18"><path d="m13.0957477 13.5588459c-.195279.1937043-.5119137.193729-.7072234.0000551-.1953098-.193674-.1953346-.5077061-.0000556-.7014104 1.0251004-1.0168342 1.6108711-2.3905226 1.6108711-3.85745208 0-1.46604976-.5850634-2.83898246-1.6090736-3.85566829-.1951894-.19379323-.1950192-.50782531.0003802-.70141028.1953993-.19358497.512034-.19341614.7072234.00037709 1.2094886 1.20083761 1.901635 2.8250555 1.901635 4.55670148 0 1.73268608-.6929822 3.35779608-1.9037571 4.55880738zm2.1233994 2.1025159c-.195234.193749-.5118687.1938462-.7072235.0002171-.1953548-.1936292-.1954528-.5076613-.0002189-.7014104 1.5832215-1.5711805 2.4881302-3.6939808 2.4881302-5.96012998 0-2.26581266-.9046382-4.3883241-2.487443-5.95944795-.1952117-.19377107-.1950777-.50780316.0002993-.70141031s.5120117-.19347426.7072234.00029682c1.7683321 1.75528196 2.7800854 4.12911258 2.7800854 6.66056144 0 2.53182498-1.0120556 4.90597838-2.7808529 6.66132328zm-14.21898205-3.6854911c-.5523759 0-1.00016505-.4441085-1.00016505-.991944v-3.96777631c0-.54783558.44778915-.99194407 1.00016505-.99194407h2.0003301l5.41965617-3.8393633c.44948677-.31842296 1.07413994-.21516983 1.39520191.23062232.12116339.16823446.18629727.36981184.18629727.57655577v12.01603479c0 .5478356-.44778914.9919441-1.00016505.9919441-.20845738 0-.41170538-.0645985-.58133413-.184766l-5.41965617-3.8393633zm0-.991944h2.32084805l5.68047235 4.0241292v-12.01603479l-5.68047235 4.02412928h-2.32084805z" fill-rule="evenodd"></path></symbol><symbol id="icon-block" viewBox="0 0 24 24"><path d="m0 0h24v24h-24z" fill-rule="evenodd"></path></symbol><symbol id="icon-book" viewBox="0 0 18 18"><path d="m4 13v-11h1v11h11v-11h-13c-.55228475 0-1 .44771525-1 1v10.2675644c.29417337-.1701701.63571286-.2675644 1-.2675644zm12 1h-13c-.55228475 0-1 .4477153-1 1s.44771525 1 1 1h13zm0 3h-13c-1.1045695 0-2-.8954305-2-2v-12c0-1.1045695.8954305-2 2-2h13c.5522847 0 1 .44771525 1 1v14c0 .5522847-.4477153 1-1 1zm-8.5-13h6c.2761424 0 .5.22385763.5.5s-.2238576.5-.5.5h-6c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5zm1 2h4c.2761424 0 .5.22385763.5.5s-.2238576.5-.5.5h-4c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5z" fill-rule="evenodd"></path></symbol><symbol id="icon-broad" viewBox="0 0 24 24"><path d="m9.18274226 7.81v7.7999954l2.48162734-2.4816273c.3928221-.3928221 1.0219731-.4005617 1.4030652-.0194696.3911301.3911301.3914806 1.0249268-.0001404 1.4165479l-4.17620796 4.1762079c-.39120769.3912077-1.02508144.3916069-1.41671995-.0000316l-4.1763942-4.1763942c-.39122514-.3912251-.39767006-1.0190815-.01657798-1.4001736.39113012-.3911301 1.02337106-.3930364 1.41951349.0031061l2.48183446 2.4818344v-8.7999954c0-.54911294.4426881-.99439484.99778758-.99557515l8.00221246-.00442485c.5522847 0 1 .44771525 1 1s-.4477153 1-1 1z" fill-rule="evenodd" transform="matrix(-1 0 0 -1 20.182742 24.805206)"></path></symbol><symbol id="icon-calendar" viewBox="0 0 18 18"><path d="m12.5 0c.2761424 0 .5.21505737.5.49047852v.50952148h2c1.1072288 0 2 .89451376 2 2v12c0 1.1072288-.8945138 2-2 2h-12c-1.1072288 0-2-.8945138-2-2v-12c0-1.1072288.89451376-2 2-2h1v1h-1c-.55393837 0-1 .44579254-1 1v3h14v-3c0-.55393837-.4457925-1-1-1h-2v1.50952148c0 .27088381-.2319336.49047852-.5.49047852-.2761424 0-.5-.21505737-.5-.49047852v-3.01904296c0-.27088381.2319336-.49047852.5-.49047852zm3.5 7h-14v8c0 .5539384.44579254 1 1 1h12c.5539384 0 1-.4457925 1-1zm-11 6v1h-1v-1zm3 0v1h-1v-1zm3 0v1h-1v-1zm-6-2v1h-1v-1zm3 0v1h-1v-1zm6 0v1h-1v-1zm-3 0v1h-1v-1zm-3-2v1h-1v-1zm6 0v1h-1v-1zm-3 0v1h-1v-1zm-5.5-9c.27614237 0 .5.21505737.5.49047852v.50952148h5v1h-5v1.50952148c0 .27088381-.23193359.49047852-.5.49047852-.27614237 0-.5-.21505737-.5-.49047852v-3.01904296c0-.27088381.23193359-.49047852.5-.49047852z" fill-rule="evenodd"></path></symbol><symbol id="icon-cart" viewBox="0 0 18 18"><path d="m5 14c1.1045695 0 2 .8954305 2 2s-.8954305 2-2 2-2-.8954305-2-2 .8954305-2 2-2zm10 0c1.1045695 0 2 .8954305 2 2s-.8954305 2-2 2-2-.8954305-2-2 .8954305-2 2-2zm-10 1c-.55228475 0-1 .4477153-1 1s.44771525 1 1 1 1-.4477153 1-1-.44771525-1-1-1zm10 0c-.5522847 0-1 .4477153-1 1s.4477153 1 1 1 1-.4477153 1-1-.4477153-1-1-1zm-12.82032249-15c.47691417 0 .88746157.33678127.98070211.80449199l.23823144 1.19501025 13.36277974.00045554c.5522847.00001882.9999659.44774934.9999659 1.00004222 0 .07084994-.0075361.14150708-.022474.2107727l-1.2908094 5.98534344c-.1007861.46742419-.5432548.80388386-1.0571651.80388386h-10.24805106c-.59173366 0-1.07142857.4477153-1.07142857 1 0 .5128358.41361449.9355072.94647737.9932723l.1249512.0067277h10.35933776c.2749512 0 .4979349.2228539.4979349.4978051 0 .2749417-.2227336.4978951-.4976753.4980063l-10.35959736.0041886c-1.18346732 0-2.14285714-.8954305-2.14285714-2 0-.6625717.34520317-1.24989198.87690425-1.61383592l-1.63768102-8.19004794c-.01312273-.06561364-.01950005-.131011-.0196107-.19547395l-1.71961253-.00064219c-.27614237 0-.5-.22385762-.5-.5 0-.27614237.22385763-.5.5-.5zm14.53193359 2.99950224h-13.11300004l1.20580469 6.02530174c.11024034-.0163252.22327998-.02480398.33844139-.02480398h10.27064786z"></path></symbol><symbol id="icon-chevron-less" viewBox="0 0 10 10"><path d="m5.58578644 4-3.29289322-3.29289322c-.39052429-.39052429-.39052429-1.02368927 0-1.41421356s1.02368927-.39052429 1.41421356 0l4 4c.39052429.39052429.39052429 1.02368927 0 1.41421356l-4 4c-.39052429.39052429-1.02368927.39052429-1.41421356 0s-.39052429-1.02368927 0-1.41421356z" fill-rule="evenodd" transform="matrix(0 -1 -1 0 9 9)"></path></symbol><symbol id="icon-chevron-more" viewBox="0 0 10 10"><path d="m5.58578644 6-3.29289322-3.29289322c-.39052429-.39052429-.39052429-1.02368927 0-1.41421356s1.02368927-.39052429 1.41421356 0l4 4c.39052429.39052429.39052429 1.02368927 0 1.41421356l-4 4.00000002c-.39052429.3905243-1.02368927.3905243-1.41421356 0s-.39052429-1.02368929 0-1.41421358z" fill-rule="evenodd" transform="matrix(0 1 -1 0 11 1)"></path></symbol><symbol id="icon-chevron-right" viewBox="0 0 10 10"><path d="m5.96738168 4.70639573 2.39518594-2.41447274c.37913917-.38219212.98637524-.38972225 1.35419292-.01894278.37750606.38054586.37784436.99719163-.00013556 1.37821513l-4.03074001 4.06319683c-.37758093.38062133-.98937525.38100976-1.367372-.00003075l-4.03091981-4.06337806c-.37759778-.38063832-.38381821-.99150444-.01600053-1.3622839.37750607-.38054587.98772445-.38240057 1.37006824.00302197l2.39538588 2.4146743.96295325.98624457z" fill-rule="evenodd" transform="matrix(0 -1 1 0 0 10)"></path></symbol><symbol id="icon-circle-fill" viewBox="0 0 16 16"><path d="m8 14c-3.3137085 0-6-2.6862915-6-6s2.6862915-6 6-6 6 2.6862915 6 6-2.6862915 6-6 6z" fill-rule="evenodd"></path></symbol><symbol id="icon-circle" viewBox="0 0 16 16"><path d="m8 12c2.209139 0 4-1.790861 4-4s-1.790861-4-4-4-4 1.790861-4 4 1.790861 4 4 4zm0 2c-3.3137085 0-6-2.6862915-6-6s2.6862915-6 6-6 6 2.6862915 6 6-2.6862915 6-6 6z" fill-rule="evenodd"></path></symbol><symbol id="icon-citation" viewBox="0 0 18 18"><path d="m8.63593473 5.99995183c2.20913897 0 3.99999997 1.79084375 3.99999997 3.99996146 0 1.40730761-.7267788 2.64486871-1.8254829 3.35783281 1.6240224.6764218 2.8754442 2.0093871 3.4610603 3.6412466l-1.0763845.000006c-.5310008-1.2078237-1.5108121-2.1940153-2.7691712-2.7181346l-.79002167-.329052v-1.023992l.63016577-.4089232c.8482885-.5504661 1.3698342-1.4895187 1.3698342-2.51898361 0-1.65683828-1.3431457-2.99996146-2.99999997-2.99996146-1.65685425 0-3 1.34312318-3 2.99996146 0 1.02946491.52154569 1.96851751 1.36983419 2.51898361l.63016581.4089232v1.023992l-.79002171.329052c-1.25835905.5241193-2.23817037 1.5103109-2.76917113 2.7181346l-1.07638453-.000006c.58561612-1.6318595 1.8370379-2.9648248 3.46106024-3.6412466-1.09870405-.7129641-1.82548287-1.9505252-1.82548287-3.35783281 0-2.20911771 1.790861-3.99996146 4-3.99996146zm7.36897597-4.99995183c1.1018574 0 1.9950893.89353404 1.9950893 2.00274083v5.994422c0 1.10608317-.8926228 2.00274087-1.9950893 2.00274087l-3.0049107-.0009037v-1l3.0049107.00091329c.5490631 0 .9950893-.44783123.9950893-1.00275046v-5.994422c0-.55646537-.4450595-1.00275046-.9950893-1.00275046h-14.00982141c-.54906309 0-.99508929.44783123-.99508929 1.00275046v5.9971821c0 .66666024.33333333.99999036 1 .99999036l2-.00091329v1l-2 .0009037c-1 0-2-.99999041-2-1.99998077v-5.9971821c0-1.10608322.8926228-2.00274083 1.99508929-2.00274083zm-8.5049107 2.9999711c.27614237 0 .5.22385547.5.5 0 .2761349-.22385763.5-.5.5h-4c-.27614237 0-.5-.2238651-.5-.5 0-.27614453.22385763-.5.5-.5zm3 0c.2761424 0 .5.22385547.5.5 0 .2761349-.2238576.5-.5.5h-1c-.27614237 0-.5-.2238651-.5-.5 0-.27614453.22385763-.5.5-.5zm4 0c.2761424 0 .5.22385547.5.5 0 .2761349-.2238576.5-.5.5h-2c-.2761424 0-.5-.2238651-.5-.5 0-.27614453.2238576-.5.5-.5z" fill-rule="evenodd"></path></symbol><symbol id="icon-close" viewBox="0 0 16 16"><path d="m2.29679575 12.2772478c-.39658757.3965876-.39438847 1.0328109-.00062148 1.4265779.39651227.3965123 1.03246768.3934888 1.42657791-.0006214l4.27724782-4.27724787 4.2772478 4.27724787c.3965876.3965875 1.0328109.3943884 1.4265779.0006214.3965123-.3965122.3934888-1.0324677-.0006214-1.4265779l-4.27724787-4.2772478 4.27724787-4.27724782c.3965875-.39658757.3943884-1.03281091.0006214-1.42657791-.3965122-.39651226-1.0324677-.39348875-1.4265779.00062148l-4.2772478 4.27724782-4.27724782-4.27724782c-.39658757-.39658757-1.03281091-.39438847-1.42657791-.00062148-.39651226.39651227-.39348875 1.03246768.00062148 1.42657791l4.27724782 4.27724782z" fill-rule="evenodd"></path></symbol><symbol id="icon-collections" viewBox="0 0 18 18"><path d="m15 4c1.1045695 0 2 .8954305 2 2v9c0 1.1045695-.8954305 2-2 2h-8c-1.1045695 0-2-.8954305-2-2h1c0 .5128358.38604019.9355072.88337887.9932723l.11662113.0067277h8c.5128358 0 .9355072-.3860402.9932723-.8833789l.0067277-.1166211v-9c0-.51283584-.3860402-.93550716-.8833789-.99327227l-.1166211-.00672773h-1v-1zm-4-3c1.1045695 0 2 .8954305 2 2v9c0 1.1045695-.8954305 2-2 2h-8c-1.1045695 0-2-.8954305-2-2v-9c0-1.1045695.8954305-2 2-2zm0 1h-8c-.51283584 0-.93550716.38604019-.99327227.88337887l-.00672773.11662113v9c0 .5128358.38604019.9355072.88337887.9932723l.11662113.0067277h8c.5128358 0 .9355072-.3860402.9932723-.8833789l.0067277-.1166211v-9c0-.51283584-.3860402-.93550716-.8833789-.99327227zm-1.5 7c.27614237 0 .5.22385763.5.5s-.22385763.5-.5.5h-5c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5zm0-2c.27614237 0 .5.22385763.5.5s-.22385763.5-.5.5h-5c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5zm0-2c.27614237 0 .5.22385763.5.5s-.22385763.5-.5.5h-5c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5z" fill-rule="evenodd"></path></symbol><symbol id="icon-compare" viewBox="0 0 18 18"><path d="m12 3c3.3137085 0 6 2.6862915 6 6s-2.6862915 6-6 6c-1.0928452 0-2.11744941-.2921742-2.99996061-.8026704-.88181407.5102749-1.90678042.8026704-3.00003939.8026704-3.3137085 0-6-2.6862915-6-6s2.6862915-6 6-6c1.09325897 0 2.11822532.29239547 3.00096303.80325037.88158756-.51107621 1.90619177-.80325037 2.99903697-.80325037zm-6 1c-2.76142375 0-5 2.23857625-5 5 0 2.7614237 2.23857625 5 5 5 .74397391 0 1.44999672-.162488 2.08451611-.4539116-1.27652344-1.1000812-2.08451611-2.7287264-2.08451611-4.5460884s.80799267-3.44600721 2.08434391-4.5463015c-.63434719-.29121054-1.34037-.4536985-2.08434391-.4536985zm6 0c-.7439739 0-1.4499967.16248796-2.08451611.45391156 1.27652341 1.10008123 2.08451611 2.72872644 2.08451611 4.54608844s-.8079927 3.4460072-2.08434391 4.5463015c.63434721.2912105 1.34037001.4536985 2.08434391.4536985 2.7614237 0 5-2.2385763 5-5 0-2.76142375-2.2385763-5-5-5zm-1.4162763 7.0005324h-3.16744736c.15614659.3572676.35283837.6927622.58425872 1.0006671h1.99892988c.23142036-.3079049.42811216-.6433995.58425876-1.0006671zm.4162763-2.0005324h-4c0 .34288501.0345146.67770871.10025909 1.0011864h3.79948181c.0657445-.32347769.1002591-.65830139.1002591-1.0011864zm-.4158423-1.99953894h-3.16831543c-.13859957.31730812-.24521946.651783-.31578599.99935097h3.79988742c-.0705665-.34756797-.1771864-.68204285-.315786-.99935097zm-1.58295822-1.999926-.08316107.06199199c-.34550042.27081213-.65446126.58611297-.91825862.93727862h2.00044041c-.28418626-.37830727-.6207872-.71499149-.99902072-.99927061z" fill-rule="evenodd"></path></symbol><symbol id="icon-download-file" viewBox="0 0 18 18"><path d="m10.0046024 0c.5497429 0 1.3179837.32258606 1.707238.71184039l4.5763192 4.57631922c.3931386.39313859.7118404 1.16760135.7118404 1.71431368v8.98899651c0 1.1092806-.8945138 2.0085302-1.9940603 2.0085302h-12.01187942c-1.10128908 0-1.99406028-.8926228-1.99406028-1.9950893v-14.00982141c0-1.10185739.88743329-1.99508929 1.99961498-1.99508929zm0 1h-7.00498742c-.55709576 0-.99961498.44271433-.99961498.99508929v14.00982141c0 .5500396.44491393.9950893.99406028.9950893h12.01187942c.5463747 0 .9940603-.4506622.9940603-1.0085302v-8.98899651c0-.28393444-.2150684-.80332809-.4189472-1.0072069l-4.5763192-4.57631922c-.2038461-.20384606-.718603-.41894717-1.0001312-.41894717zm-1.5046024 4c.27614237 0 .5.21637201.5.49209595v6.14827645l1.7462789-1.77990922c.1933927-.1971171.5125222-.19455839.7001689-.0069117.1932998.19329992.1910058.50899492-.0027774.70277812l-2.59089271 2.5908927c-.19483374.1948337-.51177825.1937771-.70556873-.0000133l-2.59099079-2.5909908c-.19484111-.1948411-.19043735-.5151448-.00279066-.70279146.19329987-.19329987.50465175-.19237083.70018565.00692852l1.74638684 1.78001764v-6.14827695c0-.27177709.23193359-.49209595.5-.49209595z" fill-rule="evenodd"></path></symbol><symbol id="icon-download" viewBox="0 0 16 16"><path d="m12.9975267 12.999368c.5467123 0 1.0024733.4478567 1.0024733 1.000316 0 .5563109-.4488226 1.000316-1.0024733 1.000316h-9.99505341c-.54671233 0-1.00247329-.4478567-1.00247329-1.000316 0-.5563109.44882258-1.000316 1.00247329-1.000316zm-4.9975267-11.999368c.55228475 0 1 .44497754 1 .99589209v6.80214418l2.4816273-2.48241149c.3928222-.39294628 1.0219732-.4006883 1.4030652-.01947579.3911302.39125371.3914806 1.02525073-.0001404 1.41699553l-4.17620792 4.17752758c-.39120769.3913313-1.02508144.3917306-1.41671995-.0000316l-4.17639421-4.17771394c-.39122513-.39134876-.39767006-1.01940351-.01657797-1.40061601.39113012-.39125372 1.02337105-.3931606 1.41951349.00310701l2.48183446 2.48261871v-6.80214418c0-.55001601.44386482-.99589209 1-.99589209z" fill-rule="evenodd"></path></symbol><symbol id="icon-editors" viewBox="0 0 18 18"><path d="m8.72592184 2.54588137c-.48811714-.34391207-1.08343326-.54588137-1.72592184-.54588137-1.65685425 0-3 1.34314575-3 3 0 1.02947485.5215457 1.96853646 1.3698342 2.51900785l.6301658.40892721v1.02400182l-.79002171.32905522c-1.93395773.8055207-3.20997829 2.7024791-3.20997829 4.8180274v.9009805h-1v-.9009805c0-2.5479714 1.54557359-4.79153984 3.82548288-5.7411543-1.09870406-.71297106-1.82548288-1.95054399-1.82548288-3.3578652 0-2.209139 1.790861-4 4-4 1.09079823 0 2.07961816.43662103 2.80122451 1.1446278-.37707584.09278571-.7373238.22835063-1.07530267.40125357zm-2.72592184 14.45411863h-1v-.9009805c0-2.5479714 1.54557359-4.7915398 3.82548288-5.7411543-1.09870406-.71297106-1.82548288-1.95054399-1.82548288-3.3578652 0-2.209139 1.790861-4 4-4s4 1.790861 4 4c0 1.40732121-.7267788 2.64489414-1.8254829 3.3578652 2.2799093.9496145 3.8254829 3.1931829 3.8254829 5.7411543v.9009805h-1v-.9009805c0-2.1155483-1.2760206-4.0125067-3.2099783-4.8180274l-.7900217-.3290552v-1.02400184l.6301658-.40892721c.8482885-.55047139 1.3698342-1.489533 1.3698342-2.51900785 0-1.65685425-1.3431458-3-3-3-1.65685425 0-3 1.34314575-3 3 0 1.02947485.5215457 1.96853646 1.3698342 2.51900785l.6301658.40892721v1.02400184l-.79002171.3290552c-1.93395773.8055207-3.20997829 2.7024791-3.20997829 4.8180274z" fill-rule="evenodd"></path></symbol><symbol id="icon-email" viewBox="0 0 18 18"><path d="m16.0049107 2c1.1018574 0 1.9950893.89706013 1.9950893 2.00585866v9.98828264c0 1.1078052-.8926228 2.0058587-1.9950893 2.0058587h-14.00982141c-1.10185739 0-1.99508929-.8970601-1.99508929-2.0058587v-9.98828264c0-1.10780515.8926228-2.00585866 1.99508929-2.00585866zm0 1h-14.00982141c-.54871518 0-.99508929.44887827-.99508929 1.00585866v9.98828264c0 .5572961.44630695 1.0058587.99508929 1.0058587h14.00982141c.5487152 0 .9950893-.4488783.9950893-1.0058587v-9.98828264c0-.55729607-.446307-1.00585866-.9950893-1.00585866zm-.0049107 2.55749512v1.44250488l-7 4-7-4v-1.44250488l7 4z" fill-rule="evenodd"></path></symbol><symbol id="icon-error" viewBox="0 0 18 18"><path d="m9 0c4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9zm2.8630343 4.71100931-2.8630343 2.86303426-2.86303426-2.86303426c-.39658757-.39658757-1.03281091-.39438847-1.4265779-.00062147-.39651227.39651226-.39348876 1.03246767.00062147 1.4265779l2.86303426 2.86303426-2.86303426 2.8630343c-.39658757.3965875-.39438847 1.0328109-.00062147 1.4265779.39651226.3965122 1.03246767.3934887 1.4265779-.0006215l2.86303426-2.8630343 2.8630343 2.8630343c.3965875.3965876 1.0328109.3943885 1.4265779.0006215.3965122-.3965123.3934887-1.0324677-.0006215-1.4265779l-2.8630343-2.8630343 2.8630343-2.86303426c.3965876-.39658757.3943885-1.03281091.0006215-1.4265779-.3965123-.39651227-1.0324677-.39348876-1.4265779.00062147z" fill-rule="evenodd"></path></symbol><symbol id="icon-ethics" viewBox="0 0 18 18"><path d="m6.76384967 1.41421356.83301651-.8330165c.77492941-.77492941 2.03133823-.77492941 2.80626762 0l.8330165.8330165c.3750728.37507276.8837806.58578644 1.4142136.58578644h1.3496361c1.1045695 0 2 .8954305 2 2v1.34963611c0 .53043298.2107137 1.03914081.5857864 1.41421356l.8330165.83301651c.7749295.77492941.7749295 2.03133823 0 2.80626762l-.8330165.8330165c-.3750727.3750728-.5857864.8837806-.5857864 1.4142136v1.3496361c0 1.1045695-.8954305 2-2 2h-1.3496361c-.530433 0-1.0391408.2107137-1.4142136.5857864l-.8330165.8330165c-.77492939.7749295-2.03133821.7749295-2.80626762 0l-.83301651-.8330165c-.37507275-.3750727-.88378058-.5857864-1.41421356-.5857864h-1.34963611c-1.1045695 0-2-.8954305-2-2v-1.3496361c0-.530433-.21071368-1.0391408-.58578644-1.4142136l-.8330165-.8330165c-.77492941-.77492939-.77492941-2.03133821 0-2.80626762l.8330165-.83301651c.37507276-.37507275.58578644-.88378058.58578644-1.41421356v-1.34963611c0-1.1045695.8954305-2 2-2h1.34963611c.53043298 0 1.03914081-.21071368 1.41421356-.58578644zm-1.41421356 1.58578644h-1.34963611c-.55228475 0-1 .44771525-1 1v1.34963611c0 .79564947-.31607052 1.55871121-.87867966 2.12132034l-.8330165.83301651c-.38440512.38440512-.38440512 1.00764896 0 1.39205408l.8330165.83301646c.56260914.5626092.87867966 1.3256709.87867966 2.1213204v1.3496361c0 .5522847.44771525 1 1 1h1.34963611c.79564947 0 1.55871121.3160705 2.12132034.8786797l.83301651.8330165c.38440512.3844051 1.00764896.3844051 1.39205408 0l.83301646-.8330165c.5626092-.5626092 1.3256709-.8786797 2.1213204-.8786797h1.3496361c.5522847 0 1-.4477153 1-1v-1.3496361c0-.7956495.3160705-1.5587112.8786797-2.1213204l.8330165-.83301646c.3844051-.38440512.3844051-1.00764896 0-1.39205408l-.8330165-.83301651c-.5626092-.56260913-.8786797-1.32567087-.8786797-2.12132034v-1.34963611c0-.55228475-.4477153-1-1-1h-1.3496361c-.7956495 0-1.5587112-.31607052-2.1213204-.87867966l-.83301646-.8330165c-.38440512-.38440512-1.00764896-.38440512-1.39205408 0l-.83301651.8330165c-.56260913.56260914-1.32567087.87867966-2.12132034.87867966zm3.58698944 11.4960218c-.02081224.002155-.04199226.0030286-.06345763.002542-.98766446-.0223875-1.93408568-.3063547-2.75885125-.8155622-.23496767-.1450683-.30784554-.4531483-.16277726-.688116.14506827-.2349677.45314827-.3078455.68811595-.1627773.67447084.4164161 1.44758575.6483839 2.25617384.6667123.01759529.0003988.03495764.0017019.05204365.0038639.01713363-.0017748.03452416-.0026845.05212715-.0026845 2.4852814 0 4.5-2.0147186 4.5-4.5 0-1.04888973-.3593547-2.04134635-1.0074477-2.83787157-.1742817-.21419731-.1419238-.5291218.0722736-.70340353.2141973-.17428173.5291218-.14192375.7034035.07227357.7919032.97327203 1.2317706 2.18808682 1.2317706 3.46900153 0 3.0375661-2.4624339 5.5-5.5 5.5-.02146768 0-.04261937-.0013529-.06337445-.0039782zm1.57975095-10.78419583c.2654788.07599731.419084.35281842.3430867.61829728-.0759973.26547885-.3528185.419084-.6182973.3430867-.37560116-.10752146-.76586237-.16587951-1.15568824-.17249193-2.5587807-.00064534-4.58547766 2.00216524-4.58547766 4.49928198 0 .62691557.12797645 1.23496.37274865 1.7964426.11035133.2531347-.0053975.5477984-.25853224.6581497-.25313473.1103514-.54779841-.0053975-.65814974-.2585322-.29947131-.6869568-.45606667-1.43097603-.45606667-2.1960601 0-3.05211432 2.47714695-5.50006595 5.59399617-5.49921198.48576182.00815502.96289603.0795037 1.42238033.21103795zm-1.9766658 6.41091303 2.69835-2.94655317c.1788432-.21040373.4943901-.23598862.7047939-.05714545.2104037.17884318.2359886.49439014.0571454.70479387l-3.01637681 3.34277395c-.18039088.1999106-.48669547.2210637-.69285412.0478478l-1.93095347-1.62240047c-.21213845-.17678204-.24080048-.49206439-.06401844-.70420284.17678204-.21213844.49206439-.24080048.70420284-.06401844z" fill-rule="evenodd"></path></symbol><symbol id="icon-expand"><path d="M7.498 11.918a.997.997 0 0 0-.003-1.411.995.995 0 0 0-1.412-.003l-4.102 4.102v-3.51A1 1 0 0 0 .98 10.09.992.992 0 0 0 0 11.092V17c0 .554.448 1.002 1.002 1.002h5.907c.554 0 1.002-.45 1.002-1.003 0-.539-.45-.978-1.006-.978h-3.51zm3.005-5.835a.997.997 0 0 0 .003 1.412.995.995 0 0 0 1.411.003l4.103-4.103v3.51a1 1 0 0 0 1.001 1.006A.992.992 0 0 0 18 6.91V1.002A1 1 0 0 0 17 0h-5.907a1.003 1.003 0 0 0-1.002 1.003c0 .539.45.978 1.006.978h3.51z" fill-rule="evenodd"></path></symbol><symbol id="icon-explore" viewBox="0 0 18 18"><path d="m9 17c4.418278 0 8-3.581722 8-8s-3.581722-8-8-8-8 3.581722-8 8 3.581722 8 8 8zm0 1c-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9 4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9zm0-2.5c-.27614237 0-.5-.2238576-.5-.5s.22385763-.5.5-.5c2.969509 0 5.400504-2.3575119 5.497023-5.31714844.0090007-.27599565.2400359-.49243782.5160315-.48343711.2759957.0090007.4924378.2400359.4834371.51603155-.114093 3.4985237-2.9869632 6.284554-6.4964916 6.284554zm-.29090657-12.99359748c.27587424-.01216621.50937715.20161139.52154336.47748563.01216621.27587423-.20161139.50937715-.47748563.52154336-2.93195733.12930094-5.25315116 2.54886451-5.25315116 5.49456849 0 .27614237-.22385763.5-.5.5s-.5-.22385763-.5-.5c0-3.48142406 2.74307146-6.34074398 6.20909343-6.49359748zm1.13784138 8.04763908-1.2004882-1.20048821c-.19526215-.19526215-.19526215-.51184463 0-.70710678s.51184463-.19526215.70710678 0l1.20048821 1.2004882 1.6006509-4.00162734-4.50670359 1.80268144-1.80268144 4.50670359zm4.10281269-6.50378907-2.6692597 6.67314927c-.1016411.2541026-.3029834.4554449-.557086.557086l-6.67314927 2.6692597 2.66925969-6.67314926c.10164107-.25410266.30298336-.45544495.55708602-.55708602z" fill-rule="evenodd"></path></symbol><symbol id="icon-filter" viewBox="0 0 16 16"><path d="m14.9738641 0c.5667192 0 1.0261359.4477136 1.0261359 1 0 .24221858-.0902161.47620768-.2538899.65849851l-5.6938314 6.34147206v5.49997973c0 .3147562-.1520673.6111434-.4104543.7999971l-2.05227171 1.4999945c-.45337535.3313696-1.09655869.2418269-1.4365902-.1999993-.13321514-.1730955-.20522717-.3836284-.20522717-.5999978v-6.99997423l-5.69383133-6.34147206c-.3731872-.41563511-.32996891-1.0473954.09653074-1.41107611.18705584-.15950448.42716133-.2474224.67571519-.2474224zm-5.9218641 8.5h-2.105v6.491l.01238459.0070843.02053271.0015705.01955278-.0070558 2.0532976-1.4990996zm-8.02585008-7.5-.01564945.00240169 5.83249953 6.49759831h2.313l5.836-6.499z"></path></symbol><symbol id="icon-home" viewBox="0 0 18 18"><path d="m9 5-6 6v5h4v-4h4v4h4v-5zm7 6.5857864v4.4142136c0 .5522847-.4477153 1-1 1h-5v-4h-2v4h-5c-.55228475 0-1-.4477153-1-1v-4.4142136c-.25592232 0-.51184464-.097631-.70710678-.2928932l-.58578644-.5857864c-.39052429-.3905243-.39052429-1.02368929 0-1.41421358l8.29289322-8.29289322 8.2928932 8.29289322c.3905243.39052429.3905243 1.02368928 0 1.41421358l-.5857864.5857864c-.1952622.1952622-.4511845.2928932-.7071068.2928932zm-7-9.17157284-7.58578644 7.58578644.58578644.5857864 7-6.99999996 7 6.99999996.5857864-.5857864z" fill-rule="evenodd"></path></symbol><symbol id="icon-image" viewBox="0 0 18 18"><path d="m10.0046024 0c.5497429 0 1.3179837.32258606 1.707238.71184039l4.5763192 4.57631922c.3931386.39313859.7118404 1.16760135.7118404 1.71431368v8.98899651c0 1.1092806-.8945138 2.0085302-1.9940603 2.0085302h-12.01187942c-1.10128908 0-1.99406028-.8926228-1.99406028-1.9950893v-14.00982141c0-1.10185739.88743329-1.99508929 1.99961498-1.99508929zm-3.49645283 10.1752453-3.89407257 6.7495552c.11705545.048464.24538859.0751995.37998328.0751995h10.60290092l-2.4329715-4.2154691-1.57494129 2.7288098zm8.49779013 6.8247547c.5463747 0 .9940603-.4506622.9940603-1.0085302v-8.98899651c0-.28393444-.2150684-.80332809-.4189472-1.0072069l-4.5763192-4.57631922c-.2038461-.20384606-.718603-.41894717-1.0001312-.41894717h-7.00498742c-.55709576 0-.99961498.44271433-.99961498.99508929v13.98991071l4.50814957-7.81026689 3.08089884 5.33809539 1.57494129-2.7288097 3.5875735 6.2159812zm-3.0059397-11c1.1045695 0 2 .8954305 2 2s-.8954305 2-2 2-2-.8954305-2-2 .8954305-2 2-2zm0 1c-.5522847 0-1 .44771525-1 1s.4477153 1 1 1 1-.44771525 1-1-.4477153-1-1-1z" fill-rule="evenodd"></path></symbol><symbol id="icon-info" viewBox="0 0 18 18"><path d="m9 0c4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9zm0 7h-1.5l-.11662113.00672773c-.49733868.05776511-.88337887.48043643-.88337887.99327227 0 .47338693.32893365.86994729.77070917.97358929l.1126697.01968298.11662113.00672773h.5v3h-.5l-.11662113.0067277c-.42082504.0488782-.76196299.3590206-.85696816.7639815l-.01968298.1126697-.00672773.1166211.00672773.1166211c.04887817.4208251.35902055.761963.76398144.8569682l.1126697.019683.11662113.0067277h3l.1166211-.0067277c.4973387-.0577651.8833789-.4804365.8833789-.9932723 0-.4733869-.3289337-.8699473-.7707092-.9735893l-.1126697-.019683-.1166211-.0067277h-.5v-4l-.00672773-.11662113c-.04887817-.42082504-.35902055-.76196299-.76398144-.85696816l-.1126697-.01968298zm0-3.25c-.69035594 0-1.25.55964406-1.25 1.25s.55964406 1.25 1.25 1.25 1.25-.55964406 1.25-1.25-.55964406-1.25-1.25-1.25z" fill-rule="evenodd"></path></symbol><symbol id="icon-institution" viewBox="0 0 18 18"><path d="m7 16.9998189v-2.0003623h4v2.0003623h2v-3.0005434h-8v3.0005434zm-3-10.00181122h-1.52632364c-.27614237 0-.5-.22389817-.5-.50009056 0-.13995446.05863589-.27350497.16166338-.36820841l1.23156713-1.13206327h-2.36690687v12.00217346h3v-2.0003623h-3v-1.0001811h3v-1.0001811h1v-4.00072448h-1zm10 0v2.00036224h-1v4.00072448h1v1.0001811h3v1.0001811h-3v2.0003623h3v-12.00217346h-2.3695309l1.2315671 1.13206327c.2033191.186892.2166633.50325042.0298051.70660631-.0946863.10304615-.2282126.16169266-.3681417.16169266zm3-3.00054336c.5522847 0 1 .44779634 1 1.00018112v13.00235456h-18v-13.00235456c0-.55238478.44771525-1.00018112 1-1.00018112h3.45499992l4.20535144-3.86558216c.19129876-.17584288.48537447-.17584288.67667324 0l4.2053514 3.86558216zm-4 3.00054336h-8v1.00018112h8zm-2 6.00108672h1v-4.00072448h-1zm-1 0v-4.00072448h-2v4.00072448zm-3 0v-4.00072448h-1v4.00072448zm8-4.00072448c.5522847 0 1 .44779634 1 1.00018112v2.00036226h-2v-2.00036226c0-.55238478.4477153-1.00018112 1-1.00018112zm-12 0c.55228475 0 1 .44779634 1 1.00018112v2.00036226h-2v-2.00036226c0-.55238478.44771525-1.00018112 1-1.00018112zm5.99868798-7.81907007-5.24205601 4.81852671h10.48411203zm.00131202 3.81834559c-.55228475 0-1-.44779634-1-1.00018112s.44771525-1.00018112 1-1.00018112 1 .44779634 1 1.00018112-.44771525 1.00018112-1 1.00018112zm-1 11.00199236v1.0001811h2v-1.0001811z" fill-rule="evenodd"></path></symbol><symbol id="icon-location" viewBox="0 0 18 18"><path d="m9.39521328 16.2688008c.79596342-.7770119 1.59208152-1.6299956 2.33285652-2.5295081 1.4020032-1.7024324 2.4323601-3.3624519 2.9354918-4.871847.2228715-.66861448.3364384-1.29323246.3364384-1.8674457 0-3.3137085-2.6862915-6-6-6-3.36356866 0-6 2.60156856-6 6 0 .57421324.11356691 1.19883122.3364384 1.8674457.50313169 1.5093951 1.53348863 3.1694146 2.93549184 4.871847.74077492.8995125 1.53689309 1.7524962 2.33285648 2.5295081.13694479.1336842.26895677.2602648.39521328.3793207.12625651-.1190559.25826849-.2456365.39521328-.3793207zm-.39521328 1.7311992s-7-6-7-11c0-4 3.13400675-7 7-7 3.8659932 0 7 3.13400675 7 7 0 5-7 11-7 11zm0-8c-1.65685425 0-3-1.34314575-3-3s1.34314575-3 3-3c1.6568542 0 3 1.34314575 3 3s-1.3431458 3-3 3zm0-1c1.1045695 0 2-.8954305 2-2s-.8954305-2-2-2-2 .8954305-2 2 .8954305 2 2 2z" fill-rule="evenodd"></path></symbol><symbol id="icon-minus" viewBox="0 0 16 16"><path d="m2.00087166 7h11.99825664c.5527662 0 1.0008717.44386482 1.0008717 1 0 .55228475-.4446309 1-1.0008717 1h-11.99825664c-.55276616 0-1.00087166-.44386482-1.00087166-1 0-.55228475.44463086-1 1.00087166-1z" fill-rule="evenodd"></path></symbol><symbol id="icon-newsletter" viewBox="0 0 18 18"><path d="m9 11.8482489 2-1.1428571v-1.7053918h-4v1.7053918zm-3-1.7142857v-2.1339632h6v2.1339632l3-1.71428574v-6.41967746h-12v6.41967746zm10-5.3839632 1.5299989.95624934c.2923814.18273835.4700011.50320827.4700011.8479983v8.44575236c0 1.1045695-.8954305 2-2 2h-14c-1.1045695 0-2-.8954305-2-2v-8.44575236c0-.34479003.1776197-.66525995.47000106-.8479983l1.52999894-.95624934v-2.75c0-.55228475.44771525-1 1-1h12c.5522847 0 1 .44771525 1 1zm0 1.17924764v3.07075236l-7 4-7-4v-3.07075236l-1 .625v8.44575236c0 .5522847.44771525 1 1 1h14c.5522847 0 1-.4477153 1-1v-8.44575236zm-10-1.92924764h6v1h-6zm-1 2h8v1h-8z" fill-rule="evenodd"></path></symbol><symbol id="icon-orcid" viewBox="0 0 18 18"><path d="m9 1c4.418278 0 8 3.581722 8 8s-3.581722 8-8 8-8-3.581722-8-8 3.581722-8 8-8zm-2.90107518 5.2732337h-1.41865256v7.1712107h1.41865256zm4.55867178.02508949h-2.99247027v7.14612121h2.91062487c.7673039 0 1.4476365-.1483432 2.0410182-.445034s1.0511995-.7152915 1.3734671-1.2558144c.3222677-.540523.4833991-1.1603247.4833991-1.85942385 0-.68545815-.1602789-1.30270225-.4808414-1.85175082-.3205625-.54904856-.7707074-.97532211-1.3504481-1.27883343-.5797408-.30351132-1.2413173-.45526471-1.9847495-.45526471zm-.1892674 1.07933542c.7877654 0 1.4143875.22336734 1.8798852.67010873.4654977.44674138.698243 1.05546001.698243 1.82617415 0 .74343221-.2310402 1.34447791-.6931277 1.80315511-.4620874.4586773-1.0750688.6880124-1.8389625.6880124h-1.46810075v-4.98745039zm-5.08652545-3.71099194c-.21825533 0-.410525.08444276-.57681478.25333081-.16628977.16888806-.24943341.36245684-.24943341.58071218 0 .22345188.08314364.41961891.24943341.58850696.16628978.16888806.35855945.25333082.57681478.25333082.233845 0 .43390938-.08314364.60019916-.24943342.16628978-.16628977.24943342-.36375592.24943342-.59240436 0-.233845-.08314364-.43131115-.24943342-.59240437s-.36635416-.24163862-.60019916-.24163862z" fill-rule="evenodd"></path></symbol><symbol id="icon-plus" viewBox="0 0 16 16"><path d="m2.00087166 7h4.99912834v-4.99912834c0-.55276616.44386482-1.00087166 1-1.00087166.55228475 0 1 .44463086 1 1.00087166v4.99912834h4.9991283c.5527662 0 1.0008717.44386482 1.0008717 1 0 .55228475-.4446309 1-1.0008717 1h-4.9991283v4.9991283c0 .5527662-.44386482 1.0008717-1 1.0008717-.55228475 0-1-.4446309-1-1.0008717v-4.9991283h-4.99912834c-.55276616 0-1.00087166-.44386482-1.00087166-1 0-.55228475.44463086-1 1.00087166-1z" fill-rule="evenodd"></path></symbol><symbol id="icon-print" viewBox="0 0 18 18"><path d="m16.0049107 5h-14.00982141c-.54941618 0-.99508929.4467783-.99508929.99961498v6.00077002c0 .5570958.44271433.999615.99508929.999615h1.00491071v-3h12v3h1.0049107c.5494162 0 .9950893-.4467783.9950893-.999615v-6.00077002c0-.55709576-.4427143-.99961498-.9950893-.99961498zm-2.0049107-1v-2.00208688c0-.54777062-.4519464-.99791312-1.0085302-.99791312h-7.9829396c-.55661731 0-1.0085302.44910695-1.0085302.99791312v2.00208688zm1 10v2.0018986c0 1.103521-.9019504 1.9981014-2.0085302 1.9981014h-7.9829396c-1.1092806 0-2.0085302-.8867064-2.0085302-1.9981014v-2.0018986h-1.00491071c-1.10185739 0-1.99508929-.8874333-1.99508929-1.999615v-6.00077002c0-1.10435686.8926228-1.99961498 1.99508929-1.99961498h1.00491071v-2.00208688c0-1.10341695.90195036-1.99791312 2.0085302-1.99791312h7.9829396c1.1092806 0 2.0085302.89826062 2.0085302 1.99791312v2.00208688h1.0049107c1.1018574 0 1.9950893.88743329 1.9950893 1.99961498v6.00077002c0 1.1043569-.8926228 1.999615-1.9950893 1.999615zm-1-3h-10v5.0018986c0 .5546075.44702548.9981014 1.0085302.9981014h7.9829396c.5565964 0 1.0085302-.4491701 1.0085302-.9981014zm-9 1h8v1h-8zm0 2h5v1h-5zm9-5c-.5522847 0-1-.44771525-1-1s.4477153-1 1-1 1 .44771525 1 1-.4477153 1-1 1z" fill-rule="evenodd"></path></symbol><symbol id="icon-search" viewBox="0 0 22 22"><path d="M21.697 20.261a1.028 1.028 0 01.01 1.448 1.034 1.034 0 01-1.448-.01l-4.267-4.267A9.812 9.811 0 010 9.812a9.812 9.811 0 1117.43 6.182zM9.812 18.222A8.41 8.41 0 109.81 1.403a8.41 8.41 0 000 16.82z" fill-rule="evenodd"></path></symbol><symbol id="icon-social-facebook" viewBox="0 0 24 24"><path d="m6.00368507 20c-1.10660471 0-2.00368507-.8945138-2.00368507-1.9940603v-12.01187942c0-1.10128908.89451376-1.99406028 1.99406028-1.99406028h12.01187942c1.1012891 0 1.9940603.89451376 1.9940603 1.99406028v12.01187942c0 1.1012891-.88679 1.9940603-2.0032184 1.9940603h-2.9570132v-6.1960818h2.0797387l.3114113-2.414723h-2.39115v-1.54164807c0-.69911803.1941355-1.1755439 1.1966615-1.1755439l1.2786739-.00055875v-2.15974763l-.2339477-.02492088c-.3441234-.03134957-.9500153-.07025255-1.6293054-.07025255-1.8435726 0-3.1057323 1.12531866-3.1057323 3.19187953v1.78079225h-2.0850778v2.414723h2.0850778v6.1960818z" fill-rule="evenodd"></path></symbol><symbol id="icon-social-twitter" viewBox="0 0 24 24"><path d="m18.8767135 6.87445248c.7638174-.46908424 1.351611-1.21167363 1.6250764-2.09636345-.7135248.43394112-1.50406.74870123-2.3464594.91677702-.6695189-.73342162-1.6297913-1.19486605-2.6922204-1.19486605-2.0399895 0-3.6933555 1.69603749-3.6933555 3.78628909 0 .29642457.0314329.58673729.0942985.8617704-3.06469922-.15890802-5.78835241-1.66547825-7.60988389-3.9574208-.3174714.56076194-.49978171 1.21167363-.49978171 1.90536824 0 1.31404706.65223085 2.47224203 1.64236444 3.15218497-.60350999-.0198635-1.17401554-.1925232-1.67222562-.47366811v.04583885c0 1.83355406 1.27302891 3.36609966 2.96411421 3.71294696-.31118484.0886217-.63651445.1329326-.97441718.1329326-.2357461 0-.47149219-.0229194-.69466516-.0672303.47149219 1.5065703 1.83253297 2.6036468 3.44975116 2.632678-1.2651707 1.0160946-2.85724264 1.6196394-4.5891906 1.6196394-.29861172 0-.59093688-.0152796-.88011875-.0504227 1.63450624 1.0726291 3.57548241 1.6990934 5.66104951 1.6990934 6.79263079 0 10.50641749-5.7711113 10.50641749-10.7751859l-.0094298-.48894775c.7229547-.53478659 1.3516109-1.20250585 1.8419628-1.96190282-.6632323.30100846-1.3751855.50422736-2.1217148.59590507z" fill-rule="evenodd"></path></symbol><symbol id="icon-social-youtube" viewBox="0 0 24 24"><path d="m10.1415 14.3973208-.0005625-5.19318431 4.863375 2.60554491zm9.963-7.92753362c-.6845625-.73643756-1.4518125-.73990314-1.803375-.7826454-2.518875-.18714178-6.2971875-.18714178-6.2971875-.18714178-.007875 0-3.7861875 0-6.3050625.18714178-.352125.04274226-1.1188125.04620784-1.8039375.7826454-.5394375.56084773-.7149375 1.8344515-.7149375 1.8344515s-.18 1.49597903-.18 2.99138042v1.4024082c0 1.495979.18 2.9913804.18 2.9913804s.1755 1.2736038.7149375 1.8344515c.685125.7364376 1.5845625.7133337 1.9850625.7901542 1.44.1420891 6.12.1859866 6.12.1859866s3.78225-.005776 6.301125-.1929178c.3515625-.0433198 1.1188125-.0467854 1.803375-.783223.5394375-.5608477.7155-1.8344515.7155-1.8344515s.18-1.4954014.18-2.9913804v-1.4024082c0-1.49540139-.18-2.99138042-.18-2.99138042s-.1760625-1.27360377-.7155-1.8344515z" fill-rule="evenodd"></path></symbol><symbol id="icon-subject-medicine" viewBox="0 0 18 18"><path d="m12.5 8h-6.5c-1.65685425 0-3 1.34314575-3 3v1c0 1.6568542 1.34314575 3 3 3h1v-2h-.5c-.82842712 0-1.5-.6715729-1.5-1.5s.67157288-1.5 1.5-1.5h1.5 2 1 2c1.6568542 0 3-1.34314575 3-3v-1c0-1.65685425-1.3431458-3-3-3h-2v2h1.5c.8284271 0 1.5.67157288 1.5 1.5s-.6715729 1.5-1.5 1.5zm-5.5-1v-1h-3.5c-1.38071187 0-2.5-1.11928813-2.5-2.5s1.11928813-2.5 2.5-2.5h1.02786405c.46573528 0 .92507448.10843528 1.34164078.31671843l1.13382424.56691212c.06026365-1.05041141.93116291-1.88363055 1.99667093-1.88363055 1.1045695 0 2 .8954305 2 2h2c2.209139 0 4 1.790861 4 4v1c0 2.209139-1.790861 4-4 4h-2v1h2c1.1045695 0 2 .8954305 2 2s-.8954305 2-2 2h-2c0 1.1045695-.8954305 2-2 2s-2-.8954305-2-2h-1c-2.209139 0-4-1.790861-4-4v-1c0-2.209139 1.790861-4 4-4zm0-2v-2.05652691c-.14564246-.03538148-.28733393-.08714006-.42229124-.15461871l-1.15541752-.57770876c-.27771087-.13885544-.583937-.21114562-.89442719-.21114562h-1.02786405c-.82842712 0-1.5.67157288-1.5 1.5s.67157288 1.5 1.5 1.5zm4 1v1h1.5c.2761424 0 .5-.22385763.5-.5s-.2238576-.5-.5-.5zm-1 1v-5c0-.55228475-.44771525-1-1-1s-1 .44771525-1 1v5zm-2 4v5c0 .5522847.44771525 1 1 1s1-.4477153 1-1v-5zm3 2v2h2c.5522847 0 1-.4477153 1-1s-.4477153-1-1-1zm-4-1v-1h-.5c-.27614237 0-.5.2238576-.5.5s.22385763.5.5.5zm-3.5-9h1c.27614237 0 .5.22385763.5.5s-.22385763.5-.5.5h-1c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5z" fill-rule="evenodd"></path></symbol><symbol id="icon-success" viewBox="0 0 18 18"><path d="m9 0c4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9zm3.4860198 4.98163161-4.71802968 5.50657859-2.62834168-2.02300024c-.42862421-.36730544-1.06564993-.30775346-1.42283677.13301307-.35718685.44076653-.29927542 1.0958383.12934879 1.46314377l3.40735508 2.7323063c.42215801.3385221 1.03700951.2798252 1.38749189-.1324571l5.38450527-6.33394549c.3613513-.43716226.3096573-1.09278382-.115462-1.46437175-.4251192-.37158792-1.0626796-.31842941-1.4240309.11873285z" fill-rule="evenodd"></path></symbol><symbol id="icon-table" viewBox="0 0 18 18"><path d="m16.0049107 2c1.1018574 0 1.9950893.89706013 1.9950893 2.00585866v9.98828264c0 1.1078052-.8926228 2.0058587-1.9950893 2.0058587l-4.0059107-.001.001.001h-1l-.001-.001h-5l.001.001h-1l-.001-.001-3.00391071.001c-1.10185739 0-1.99508929-.8970601-1.99508929-2.0058587v-9.98828264c0-1.10780515.8926228-2.00585866 1.99508929-2.00585866zm-11.0059107 5h-3.999v6.9941413c0 .5572961.44630695 1.0058587.99508929 1.0058587h3.00391071zm6 0h-5v8h5zm5.0059107-4h-4.0059107v3h5.001v1h-5.001v7.999l4.0059107.001c.5487152 0 .9950893-.4488783.9950893-1.0058587v-9.98828264c0-.55729607-.446307-1.00585866-.9950893-1.00585866zm-12.5049107 9c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-1c-.27614237 0-.5-.2238576-.5-.5s.22385763-.5.5-.5zm12 0c.2761424 0 .5.2238576.5.5s-.2238576.5-.5.5h-2c-.2761424 0-.5-.2238576-.5-.5s.2238576-.5.5-.5zm-6 0c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-2c-.27614237 0-.5-.2238576-.5-.5s.22385763-.5.5-.5zm-6-2c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-1c-.27614237 0-.5-.2238576-.5-.5s.22385763-.5.5-.5zm12 0c.2761424 0 .5.2238576.5.5s-.2238576.5-.5.5h-2c-.2761424 0-.5-.2238576-.5-.5s.2238576-.5.5-.5zm-6 0c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-2c-.27614237 0-.5-.2238576-.5-.5s.22385763-.5.5-.5zm-6-2c.27614237 0 .5.22385763.5.5s-.22385763.5-.5.5h-1c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5zm12 0c.2761424 0 .5.22385763.5.5s-.2238576.5-.5.5h-2c-.2761424 0-.5-.22385763-.5-.5s.2238576-.5.5-.5zm-6 0c.27614237 0 .5.22385763.5.5s-.22385763.5-.5.5h-2c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5zm1.499-5h-5v3h5zm-6 0h-3.00391071c-.54871518 0-.99508929.44887827-.99508929 1.00585866v1.99414134h3.999z" fill-rule="evenodd"></path></symbol><symbol id="icon-tick-circle" viewBox="0 0 24 24"><path d="m12 2c5.5228475 0 10 4.4771525 10 10s-4.4771525 10-10 10-10-4.4771525-10-10 4.4771525-10 10-10zm0 1c-4.97056275 0-9 4.02943725-9 9 0 4.9705627 4.02943725 9 9 9 4.9705627 0 9-4.0294373 9-9 0-4.97056275-4.0294373-9-9-9zm4.2199868 5.36606669c.3613514-.43716226.9989118-.49032077 1.424031-.11873285s.4768133 1.02720949.115462 1.46437175l-6.093335 6.94397871c-.3622945.4128716-.9897871.4562317-1.4054264.0971157l-3.89719065-3.3672071c-.42862421-.3673054-.48653564-1.0223772-.1293488-1.4631437s.99421256-.5003185 1.42283677-.1330131l3.11097438 2.6987741z" fill-rule="evenodd"></path></symbol><symbol id="icon-tick" viewBox="0 0 16 16"><path d="m6.76799012 9.21106946-3.1109744-2.58349728c-.42862421-.35161617-1.06564993-.29460792-1.42283677.12733148s-.29927541 1.04903009.1293488 1.40064626l3.91576307 3.23873978c.41034319.3393961 1.01467563.2976897 1.37450571-.0948578l6.10568327-6.660841c.3613513-.41848908.3096572-1.04610608-.115462-1.4018218-.4251192-.35571573-1.0626796-.30482786-1.424031.11366122z" fill-rule="evenodd"></path></symbol><symbol id="icon-update" viewBox="0 0 18 18"><path d="m1 13v1c0 .5522847.44771525 1 1 1h14c.5522847 0 1-.4477153 1-1v-1h-1v-10h-14v10zm16-1h1v2c0 1.1045695-.8954305 2-2 2h-14c-1.1045695 0-2-.8954305-2-2v-2h1v-9c0-.55228475.44771525-1 1-1h14c.5522847 0 1 .44771525 1 1zm-1 0v1h-4.5857864l-1 1h-2.82842716l-1-1h-4.58578644v-1h5l1 1h2l1-1zm-13-8h12v7h-12zm1 1v5h10v-5zm1 1h4v1h-4zm0 2h4v1h-4z" fill-rule="evenodd"></path></symbol><symbol id="icon-upload" viewBox="0 0 18 18"><path d="m10.0046024 0c.5497429 0 1.3179837.32258606 1.707238.71184039l4.5763192 4.57631922c.3931386.39313859.7118404 1.16760135.7118404 1.71431368v8.98899651c0 1.1092806-.8945138 2.0085302-1.9940603 2.0085302h-12.01187942c-1.10128908 0-1.99406028-.8926228-1.99406028-1.9950893v-14.00982141c0-1.10185739.88743329-1.99508929 1.99961498-1.99508929zm0 1h-7.00498742c-.55709576 0-.99961498.44271433-.99961498.99508929v14.00982141c0 .5500396.44491393.9950893.99406028.9950893h12.01187942c.5463747 0 .9940603-.4506622.9940603-1.0085302v-8.98899651c0-.28393444-.2150684-.80332809-.4189472-1.0072069l-4.5763192-4.57631922c-.2038461-.20384606-.718603-.41894717-1.0001312-.41894717zm-1.85576936 4.14572769c.19483374-.19483375.51177826-.19377714.70556874.00001334l2.59099082 2.59099079c.1948411.19484112.1904373.51514474.0027906.70279143-.1932998.19329987-.5046517.19237083-.7001856-.00692852l-1.74638687-1.7800176v6.14827687c0 .2717771-.23193359.492096-.5.492096-.27614237 0-.5-.216372-.5-.492096v-6.14827641l-1.74627892 1.77990922c-.1933927.1971171-.51252214.19455839-.70016883.0069117-.19329987-.19329988-.19100584-.50899493.00277731-.70277808z" fill-rule="evenodd"></path></symbol><symbol id="icon-video" viewBox="0 0 18 18"><path d="m16.0049107 2c1.1018574 0 1.9950893.89706013 1.9950893 2.00585866v9.98828264c0 1.1078052-.8926228 2.0058587-1.9950893 2.0058587h-14.00982141c-1.10185739 0-1.99508929-.8970601-1.99508929-2.0058587v-9.98828264c0-1.10780515.8926228-2.00585866 1.99508929-2.00585866zm0 1h-14.00982141c-.54871518 0-.99508929.44887827-.99508929 1.00585866v9.98828264c0 .5572961.44630695 1.0058587.99508929 1.0058587h14.00982141c.5487152 0 .9950893-.4488783.9950893-1.0058587v-9.98828264c0-.55729607-.446307-1.00585866-.9950893-1.00585866zm-8.30912922 2.24944486 4.60460462 2.73982242c.9365543.55726659.9290753 1.46522435 0 2.01804082l-4.60460462 2.7398224c-.93655425.5572666-1.69578148.1645632-1.69578148-.8937585v-5.71016863c0-1.05087579.76670616-1.446575 1.69578148-.89375851zm-.67492769.96085624v5.5750128c0 .2995102-.10753745.2442517.16578928.0847713l4.58452283-2.67497259c.3050619-.17799716.3051624-.21655446 0-.39461026l-4.58452283-2.67497264c-.26630747-.15538481-.16578928-.20699944-.16578928.08477139z" fill-rule="evenodd"></path></symbol><symbol id="icon-warning" viewBox="0 0 18 18"><path d="m9 11.75c.69035594 0 1.25.5596441 1.25 1.25s-.55964406 1.25-1.25 1.25-1.25-.5596441-1.25-1.25.55964406-1.25 1.25-1.25zm.41320045-7.75c.55228475 0 1.00000005.44771525 1.00000005 1l-.0034543.08304548-.3333333 4c-.043191.51829212-.47645714.91695452-.99654578.91695452h-.15973424c-.52008864 0-.95335475-.3986624-.99654576-.91695452l-.33333333-4c-.04586475-.55037702.36312325-1.03372649.91350028-1.07959124l.04148683-.00259031zm-.41320045 14c-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9 4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9z" fill-rule="evenodd"></path></symbol><symbol id="icon-checklist-banner" viewBox="0 0 56.69 56.69"><path style="fill:none" d="M0 0h56.69v56.69H0z"></path><clipPath id="b"><use xlink:href="#a" style="overflow:visible"></use></clipPath><path d="M21.14 34.46c0-6.77 5.48-12.26 12.24-12.26s12.24 5.49 12.24 12.26-5.48 12.26-12.24 12.26c-6.76-.01-12.24-5.49-12.24-12.26zm19.33 10.66 10.23 9.22s1.21 1.09 2.3-.12l2.09-2.32s1.09-1.21-.12-2.3l-10.23-9.22m-19.29-5.92c0-4.38 3.55-7.94 7.93-7.94s7.93 3.55 7.93 7.94c0 4.38-3.55 7.94-7.93 7.94-4.38-.01-7.93-3.56-7.93-7.94zm17.58 12.99 4.14-4.81" style="clip-path:url(#b);fill:none;stroke:#01324b;stroke-width:2;stroke-linecap:round"></path><path d="M8.26 9.75H28.6M8.26 15.98H28.6m-20.34 6.2h12.5m14.42-5.2V4.86s0-2.93-2.93-2.93H4.13s-2.93 0-2.93 2.93v37.57s0 2.93 2.93 2.93h15.01M8.26 9.75H28.6M8.26 15.98H28.6m-20.34 6.2h12.5" style="clip-path:url(#b);fill:none;stroke:#01324b;stroke-width:2;stroke-linecap:round;stroke-linejoin:round"></path></symbol><symbol id="icon-chevron-down" viewBox="0 0 16 16"><path d="m5.58578644 3-3.29289322-3.29289322c-.39052429-.39052429-.39052429-1.02368927 0-1.41421356s1.02368927-.39052429 1.41421356 0l4 4c.39052429.39052429.39052429 1.02368927 0 1.41421356l-4 4c-.39052429.39052429-1.02368927.39052429-1.41421356 0s-.39052429-1.02368927 0-1.41421356z" fill-rule="evenodd" transform="matrix(0 1 -1 0 11 1)"></path></symbol><symbol id="icon-eds-i-arrow-right-medium" viewBox="0 0 24 24"><path d="m12.728 3.293 7.98 7.99a.996.996 0 0 1 .281.561l.011.157c0 .32-.15.605-.384.788l-7.908 7.918a1 1 0 0 1-1.416-1.414L17.576 13H4a1 1 0 0 1 0-2h13.598l-6.285-6.293a1 1 0 0 1-.082-1.32l.083-.095a1 1 0 0 1 1.414.001Z"></path></symbol><symbol id="icon-eds-i-check-circle-medium" viewBox="0 0 24 24"><path d="M12 1c6.075 0 11 4.925 11 11s-4.925 11-11 11S1 18.075 1 12 5.925 1 12 1Zm0 2a9 9 0 1 0 0 18 9 9 0 0 0 0-18Zm5.125 4.72a1 1 0 0 1 .156 1.405l-6 7.5a1 1 0 0 1-1.421.143l-3-2.5a1 1 0 0 1 1.28-1.536l2.217 1.846 5.362-6.703a1 1 0 0 1 1.406-.156Z"></path></symbol><symbol id="icon-eds-i-chevron-down-medium" viewBox="0 0 16 16"><path d="m2.00087166 7h4.99912834v-4.99912834c0-.55276616.44386482-1.00087166 1-1.00087166.55228475 0 1 .44463086 1 1.00087166v4.99912834h4.9991283c.5527662 0 1.0008717.44386482 1.0008717 1 0 .55228475-.4446309 1-1.0008717 1h-4.9991283v4.9991283c0 .5527662-.44386482 1.0008717-1 1.0008717-.55228475 0-1-.4446309-1-1.0008717v-4.9991283h-4.99912834c-.55276616 0-1.00087166-.44386482-1.00087166-1 0-.55228475.44463086-1 1.00087166-1z" fill-rule="evenodd"></path></symbol><symbol id="icon-eds-i-chevron-down-small" viewBox="0 0 16 16"><path d="M13.692 5.278a1 1 0 0 1 .03 1.414L9.103 11.51a1.491 1.491 0 0 1-2.188.019L2.278 6.692a1 1 0 0 1 1.444-1.384L8 9.771l4.278-4.463a1 1 0 0 1 1.318-.111l.096.081Z"></path></symbol><symbol id="icon-eds-i-chevron-right-medium" viewBox="0 0 10 10"><path d="m5.96738168 4.70639573 2.39518594-2.41447274c.37913917-.38219212.98637524-.38972225 1.35419292-.01894278.37750606.38054586.37784436.99719163-.00013556 1.37821513l-4.03074001 4.06319683c-.37758093.38062133-.98937525.38100976-1.367372-.00003075l-4.03091981-4.06337806c-.37759778-.38063832-.38381821-.99150444-.01600053-1.3622839.37750607-.38054587.98772445-.38240057 1.37006824.00302197l2.39538588 2.4146743.96295325.98624457z" fill-rule="evenodd" transform="matrix(0 -1 1 0 0 10)"></path></symbol><symbol id="icon-eds-i-chevron-right-small" viewBox="0 0 10 10"><path d="m5.96738168 4.70639573 2.39518594-2.41447274c.37913917-.38219212.98637524-.38972225 1.35419292-.01894278.37750606.38054586.37784436.99719163-.00013556 1.37821513l-4.03074001 4.06319683c-.37758093.38062133-.98937525.38100976-1.367372-.00003075l-4.03091981-4.06337806c-.37759778-.38063832-.38381821-.99150444-.01600053-1.3622839.37750607-.38054587.98772445-.38240057 1.37006824.00302197l2.39538588 2.4146743.96295325.98624457z" fill-rule="evenodd" transform="matrix(0 -1 1 0 0 10)"></path></symbol><symbol id="icon-eds-i-chevron-up-medium" viewBox="0 0 16 16"><path d="m2.00087166 7h11.99825664c.5527662 0 1.0008717.44386482 1.0008717 1 0 .55228475-.4446309 1-1.0008717 1h-11.99825664c-.55276616 0-1.00087166-.44386482-1.00087166-1 0-.55228475.44463086-1 1.00087166-1z" fill-rule="evenodd"></path></symbol><symbol id="icon-eds-i-close-medium" viewBox="0 0 16 16"><path d="m2.29679575 12.2772478c-.39658757.3965876-.39438847 1.0328109-.00062148 1.4265779.39651227.3965123 1.03246768.3934888 1.42657791-.0006214l4.27724782-4.27724787 4.2772478 4.27724787c.3965876.3965875 1.0328109.3943884 1.4265779.0006214.3965123-.3965122.3934888-1.0324677-.0006214-1.4265779l-4.27724787-4.2772478 4.27724787-4.27724782c.3965875-.39658757.3943884-1.03281091.0006214-1.42657791-.3965122-.39651226-1.0324677-.39348875-1.4265779.00062148l-4.2772478 4.27724782-4.27724782-4.27724782c-.39658757-.39658757-1.03281091-.39438847-1.42657791-.00062148-.39651226.39651227-.39348875 1.03246768.00062148 1.42657791l4.27724782 4.27724782z" fill-rule="evenodd"></path></symbol><symbol id="icon-eds-i-copy-link" viewBox="0 0 24 24"><path fill-rule="evenodd" clip-rule="evenodd" d="M19.4594 8.57015C19.0689 8.17963 19.0689 7.54646 19.4594 7.15594L20.2927 6.32261C20.2927 6.32261 20.2927 6.32261 20.2927 6.32261C21.0528 5.56252 21.0528 4.33019 20.2928 3.57014C19.5327 2.81007 18.3004 2.81007 17.5404 3.57014L16.7071 4.40347C16.3165 4.794 15.6834 4.794 15.2928 4.40348C14.9023 4.01296 14.9023 3.3798 15.2928 2.98927L16.1262 2.15594C17.6673 0.614803 20.1659 0.614803 21.707 2.15593C23.2481 3.69705 23.248 6.19569 21.707 7.7368L20.8737 8.57014C20.4831 8.96067 19.85 8.96067 19.4594 8.57015Z"></path><path fill-rule="evenodd" clip-rule="evenodd" d="M18.0944 5.90592C18.4849 6.29643 18.4849 6.9296 18.0944 7.32013L16.4278 8.9868C16.0373 9.37733 15.4041 9.37734 15.0136 8.98682C14.6231 8.59631 14.6231 7.96314 15.0136 7.57261L16.6802 5.90594C17.0707 5.51541 17.7039 5.5154 18.0944 5.90592Z"></path><path fill-rule="evenodd" clip-rule="evenodd" d="M13.5113 6.32243C13.9018 6.71295 13.9018 7.34611 13.5113 7.73664L12.678 8.56997C12.678 8.56997 12.678 8.56997 12.678 8.56997C11.9179 9.33006 11.9179 10.5624 12.6779 11.3224C13.438 12.0825 14.6703 12.0825 15.4303 11.3224L16.2636 10.4891C16.6542 10.0986 17.2873 10.0986 17.6779 10.4891C18.0684 10.8796 18.0684 11.5128 17.6779 11.9033L16.8445 12.7366C15.3034 14.2778 12.8048 14.2778 11.2637 12.7366C9.72262 11.1955 9.72266 8.69689 11.2637 7.15578L12.097 6.32244C12.4876 5.93191 13.1207 5.93191 13.5113 6.32243Z"></path><path d="M8 20V22H19.4619C20.136 22 20.7822 21.7311 21.2582 21.2529C21.7333 20.7757 22 20.1289 22 19.4549V15C22 14.4477 21.5523 14 21 14C20.4477 14 20 14.4477 20 15V19.4549C20 19.6004 19.9426 19.7397 19.8408 19.842C19.7399 19.9433 19.6037 20 19.4619 20H8Z"></path><path d="M4 13H2V19.4619C2 20.136 2.26889 20.7822 2.74705 21.2582C3.22434 21.7333 3.87105 22 4.5451 22H9C9.55228 22 10 21.5523 10 21C10 20.4477 9.55228 20 9 20H4.5451C4.39957 20 4.26028 19.9426 4.15804 19.8408C4.05668 19.7399 4 19.6037 4 19.4619V13Z"></path><path d="M4 13H2V4.53808C2 3.86398 2.26889 3.21777 2.74705 2.74178C3.22434 2.26666 3.87105 2 4.5451 2H9C9.55228 2 10 2.44772 10 3C10 3.55228 9.55228 4 9 4H4.5451C4.39957 4 4.26028 4.05743 4.15804 4.15921C4.05668 4.26011 4 4.39633 4 4.53808V13Z"></path></symbol><symbol id="icon-eds-i-download-medium" viewBox="0 0 16 16"><path d="m12.9975267 12.999368c.5467123 0 1.0024733.4478567 1.0024733 1.000316 0 .5563109-.4488226 1.000316-1.0024733 1.000316h-9.99505341c-.54671233 0-1.00247329-.4478567-1.00247329-1.000316 0-.5563109.44882258-1.000316 1.00247329-1.000316zm-4.9975267-11.999368c.55228475 0 1 .44497754 1 .99589209v6.80214418l2.4816273-2.48241149c.3928222-.39294628 1.0219732-.4006883 1.4030652-.01947579.3911302.39125371.3914806 1.02525073-.0001404 1.41699553l-4.17620792 4.17752758c-.39120769.3913313-1.02508144.3917306-1.41671995-.0000316l-4.17639421-4.17771394c-.39122513-.39134876-.39767006-1.01940351-.01657797-1.40061601.39113012-.39125372 1.02337105-.3931606 1.41951349.00310701l2.48183446 2.48261871v-6.80214418c0-.55001601.44386482-.99589209 1-.99589209z" fill-rule="evenodd"></path></symbol><symbol id="icon-eds-i-info-filled-medium" viewBox="0 0 18 18"><path d="m9 0c4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9zm0 7h-1.5l-.11662113.00672773c-.49733868.05776511-.88337887.48043643-.88337887.99327227 0 .47338693.32893365.86994729.77070917.97358929l.1126697.01968298.11662113.00672773h.5v3h-.5l-.11662113.0067277c-.42082504.0488782-.76196299.3590206-.85696816.7639815l-.01968298.1126697-.00672773.1166211.00672773.1166211c.04887817.4208251.35902055.761963.76398144.8569682l.1126697.019683.11662113.0067277h3l.1166211-.0067277c.4973387-.0577651.8833789-.4804365.8833789-.9932723 0-.4733869-.3289337-.8699473-.7707092-.9735893l-.1126697-.019683-.1166211-.0067277h-.5v-4l-.00672773-.11662113c-.04887817-.42082504-.35902055-.76196299-.76398144-.85696816l-.1126697-.01968298zm0-3.25c-.69035594 0-1.25.55964406-1.25 1.25s.55964406 1.25 1.25 1.25 1.25-.55964406 1.25-1.25-.55964406-1.25-1.25-1.25z" fill-rule="evenodd"></path></symbol><symbol id="icon-eds-i-institution-medium" viewBox="0 0 24 24"><g><path fill-rule="evenodd" clip-rule="evenodd" d="M11.9967 1C11.6364 1 11.279 1.0898 10.961 1.2646C10.9318 1.28061 10.9035 1.29806 10.8761 1.31689L2.79765 6.87C2.46776 7.08001 2.20618 7.38466 2.07836 7.76668C1.94823 8.15561 1.98027 8.55648 2.12665 8.90067C2.42086 9.59246 3.12798 10 3.90107 10H4.99994V16H4.49994C3.11923 16 1.99994 17.1193 1.99994 18.5V19.5C1.99994 20.8807 3.11923 22 4.49994 22H19.4999C20.8807 22 21.9999 20.8807 21.9999 19.5V18.5C21.9999 17.1193 20.8807 16 19.4999 16H18.9999V10H20.0922C20.8653 10 21.5725 9.59252 21.8667 8.90065C22.0131 8.55642 22.0451 8.15553 21.9149 7.7666C21.7871 7.38459 21.5255 7.07997 21.1956 6.86998L13.1172 1.31689C13.0898 1.29806 13.0615 1.28061 13.0324 1.2646C12.7143 1.0898 12.357 1 11.9967 1ZM4.6844 8L11.9472 3.00755C11.9616 3.00295 11.9783 3 11.9967 3C12.015 3 12.0318 3.00295 12.0461 3.00755L19.3089 8H4.6844ZM16.9999 16V10H14.9999V16H16.9999ZM12.9999 16V10H10.9999V16H12.9999ZM8.99994 16V10H6.99994V16H8.99994ZM3.99994 18.5C3.99994 18.2239 4.2238 18 4.49994 18H19.4999C19.7761 18 19.9999 18.2239 19.9999 18.5V19.5C19.9999 19.7761 19.7761 20 19.4999 20H4.49994C4.2238 20 3.99994 19.7761 3.99994 19.5V18.5Z"></path></g></symbol><symbol id="icon-eds-i-mail-medium" viewBox="0 0 24 24"><path d="m19.462 0c1.413 0 2.538 1.184 2.538 2.619v12.762c0 1.435-1.125 2.619-2.538 2.619h-16.924c-1.413 0-2.538-1.184-2.538-2.619v-12.762c0-1.435 1.125-2.619 2.538-2.619zm.538 5.158-7.378 6.258a2.549 2.549 0 0 1 -3.253-.008l-7.369-6.248v10.222c0 .353.253.619.538.619h16.924c.285 0 .538-.266.538-.619zm-.538-3.158h-16.924c-.264 0-.5.228-.534.542l8.65 7.334c.2.165.492.165.684.007l8.656-7.342-.001-.025c-.044-.3-.274-.516-.531-.516z"></path></symbol><symbol id="icon-eds-i-menu-medium" viewBox="0 0 24 24"><path d="M21 4a1 1 0 0 1 0 2H3a1 1 0 1 1 0-2h18Zm-4 7a1 1 0 0 1 0 2H3a1 1 0 0 1 0-2h14Zm4 7a1 1 0 0 1 0 2H3a1 1 0 0 1 0-2h18Z"></path></symbol><symbol id="icon-eds-i-search-medium" viewBox="0 0 24 24"><path d="M11 1c5.523 0 10 4.477 10 10 0 2.4-.846 4.604-2.256 6.328l3.963 3.965a1 1 0 0 1-1.414 1.414l-3.965-3.963A9.959 9.959 0 0 1 11 21C5.477 21 1 16.523 1 11S5.477 1 11 1Zm0 2a8 8 0 1 0 0 16 8 8 0 0 0 0-16Z"></path></symbol><symbol id="icon-eds-i-user-single-medium" viewBox="0 0 24 24"><path d="M12 1a5 5 0 1 1 0 10 5 5 0 0 1 0-10Zm0 2a3 3 0 1 0 0 6 3 3 0 0 0 0-6Zm-.406 9.008a8.965 8.965 0 0 1 6.596 2.494A9.161 9.161 0 0 1 21 21.025V22a1 1 0 0 1-1 1H4a1 1 0 0 1-1-1v-.985c.05-4.825 3.815-8.777 8.594-9.007Zm.39 1.992-.299.006c-3.63.175-6.518 3.127-6.678 6.775L5 21h13.998l-.009-.268a7.157 7.157 0 0 0-1.97-4.573l-.214-.213A6.967 6.967 0 0 0 11.984 14Z"></path></symbol><symbol id="icon-eds-i-warning-filled-medium" viewBox="0 0 18 18"><path d="m9 11.75c.69035594 0 1.25.5596441 1.25 1.25s-.55964406 1.25-1.25 1.25-1.25-.5596441-1.25-1.25.55964406-1.25 1.25-1.25zm.41320045-7.75c.55228475 0 1.00000005.44771525 1.00000005 1l-.0034543.08304548-.3333333 4c-.043191.51829212-.47645714.91695452-.99654578.91695452h-.15973424c-.52008864 0-.95335475-.3986624-.99654576-.91695452l-.33333333-4c-.04586475-.55037702.36312325-1.03372649.91350028-1.07959124l.04148683-.00259031zm-.41320045 14c-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9 4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9z" fill-rule="evenodd"></path></symbol><symbol id="icon-expand-image" viewBox="0 0 18 18"><path d="m7.49754099 11.9178212c.38955542-.3895554.38761957-1.0207846-.00290473-1.4113089-.39324695-.3932469-1.02238878-.3918247-1.41130883-.0029047l-4.10273549 4.1027355.00055454-3.5103985c.00008852-.5603185-.44832171-1.006032-1.00155062-1.0059446-.53903074.0000852-.97857527.4487442-.97866268 1.0021075l-.00093318 5.9072465c-.00008751.553948.44841131 1.001882 1.00174994 1.0017946l5.906983-.0009331c.5539233-.0000875 1.00197907-.4486389 1.00206646-1.0018679.00008515-.5390307-.45026621-.9784332-1.00588841-.9783454l-3.51010549.0005545zm3.00571741-5.83449376c-.3895554.38955541-.3876196 1.02078454.0029047 1.41130883.393247.39324696 1.0223888.39182478 1.4113089.00290473l4.1027355-4.10273549-.0005546 3.5103985c-.0000885.56031852.4483217 1.006032 1.0015506 1.00594461.5390308-.00008516.9785753-.44874418.9786627-1.00210749l.0009332-5.9072465c.0000875-.553948-.4484113-1.00188204-1.0017499-1.00179463l-5.906983.00093313c-.5539233.00008751-1.0019791.44863892-1.0020665 1.00186784-.0000852.53903074.4502662.97843325 1.0058884.97834547l3.5101055-.00055449z" fill-rule="evenodd"></path></symbol><symbol id="icon-github" viewBox="0 0 100 100"><path fill-rule="evenodd" clip-rule="evenodd" d="M48.854 0C21.839 0 0 22 0 49.217c0 21.756 13.993 40.172 33.405 46.69 2.427.49 3.316-1.059 3.316-2.362 0-1.141-.08-5.052-.08-9.127-13.59 2.934-16.42-5.867-16.42-5.867-2.184-5.704-5.42-7.17-5.42-7.17-4.448-3.015.324-3.015.324-3.015 4.934.326 7.523 5.052 7.523 5.052 4.367 7.496 11.404 5.378 14.235 4.074.404-3.178 1.699-5.378 3.074-6.6-10.839-1.141-22.243-5.378-22.243-24.283 0-5.378 1.94-9.778 5.014-13.2-.485-1.222-2.184-6.275.486-13.038 0 0 4.125-1.304 13.426 5.052a46.97 46.97 0 0 1 12.214-1.63c4.125 0 8.33.571 12.213 1.63 9.302-6.356 13.427-5.052 13.427-5.052 2.67 6.763.97 11.816.485 13.038 3.155 3.422 5.015 7.822 5.015 13.2 0 18.905-11.404 23.06-22.324 24.283 1.78 1.548 3.316 4.481 3.316 9.126 0 6.6-.08 11.897-.08 13.526 0 1.304.89 2.853 3.316 2.364 19.412-6.52 33.405-24.935 33.405-46.691C97.707 22 75.788 0 48.854 0z"></path></symbol><symbol id="icon-springer-arrow-left"><path d="M15 7a1 1 0 000-2H3.385l2.482-2.482a.994.994 0 00.02-1.403 1.001 1.001 0 00-1.417 0L.294 5.292a1.001 1.001 0 000 1.416l4.176 4.177a.991.991 0 001.4.016 1 1 0 00-.003-1.42L3.385 7H15z"></path></symbol><symbol id="icon-springer-arrow-right"><path d="M1 7a1 1 0 010-2h11.615l-2.482-2.482a.994.994 0 01-.02-1.403 1.001 1.001 0 011.417 0l4.176 4.177a1.001 1.001 0 010 1.416l-4.176 4.177a.991.991 0 01-1.4.016 1 1 0 01.003-1.42L12.615 7H1z"></path></symbol><symbol id="icon-submit-open" viewBox="0 0 16 17"><path d="M12 0c1.10457 0 2 .895431 2 2v5c0 .276142-.223858.5-.5.5S13 7.276142 13 7V2c0-.512836-.38604-.935507-.883379-.993272L12 1H6v3c0 1.10457-.89543 2-2 2H1v8c0 .512836.38604.935507.883379.993272L2 15h6.5c.276142 0 .5.223858.5.5s-.223858.5-.5.5H2c-1.104569 0-2-.89543-2-2V5.828427c0-.530433.210714-1.039141.585786-1.414213L4.414214.585786C4.789286.210714 5.297994 0 5.828427 0H12Zm3.41 11.14c.250899.250899.250274.659726 0 .91-.242954.242954-.649606.245216-.9-.01l-1.863671-1.900337.001043 5.869492c0 .356992-.289839.637138-.647372.637138-.347077 0-.647371-.285256-.647371-.637138l-.001043-5.869492L9.5 12.04c-.253166.258042-.649726.260274-.9.01-.242954-.242954-.252269-.657731 0-.91l2.942184-2.951303c.250908-.250909.66127-.252277.91353-.000017L15.41 11.14ZM5 1.413 1.413 5H4c.552285 0 1-.447715 1-1V1.413ZM11 3c.276142 0 .5.223858.5.5s-.223858.5-.5.5H7.5c-.276142 0-.5-.223858-.5-.5s.223858-.5.5-.5H11Zm0 2c.276142 0 .5.223858.5.5s-.223858.5-.5.5H7.5c-.276142 0-.5-.223858-.5-.5s.223858-.5.5-.5H11Z" fill-rule="nonzero"></path></symbol></svg>
</div>
</footer>




    

    

<div class="c-site-messages message u-hide u-hide-print c-site-messages--nature-briefing c-site-messages--nature-briefing-email-variant c-site-messages--nature-briefing-redesign-2020 sans-serif c-site-messages--nature-briefing-cancer" data-component-id="nature-briefing-banner" data-component-expirydays="30" data-component-trigger-scroll-percentage="15" data-track="in-view" data-track-action="in-view" data-track-category="nature briefing" data-track-label="Briefing banner visible: Cancer">

    
    <div class="c-site-messages__banner-large">

        
<div class="c-site-messages__close-container">
    <button class="c-site-messages__close" data-track="click" data-track-category="nature briefing" data-track-label="Briefing banner dismiss: Cancer">
        <svg width="25px" height="25px" focusable="false" aria-hidden="true" viewBox="0 0 25 25" version="1.1" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink">
            <title>Close banner</title>
            <defs></defs>
            <g stroke="none" stroke-width="1" fill="none" fill-rule="evenodd">
                <rect opacity="0" x="0" y="0" width="25" height="25"></rect>
                <path d="M6.29679575,16.2772478 C5.90020818,16.6738354 5.90240728,17.3100587 6.29617427,17.7038257 C6.69268654,18.100338 7.32864195,18.0973145 7.72275218,17.7032043 L12,13.4259564 L16.2772478,17.7032043 C16.6738354,18.0997918 17.3100587,18.0975927 17.7038257,17.7038257 C18.100338,17.3073135 18.0973145,16.671358 17.7032043,16.2772478 L13.4259564,12 L17.7032043,7.72275218 C18.0997918,7.32616461 18.0975927,6.68994127 17.7038257,6.29617427 C17.3073135,5.89966201 16.671358,5.90268552 16.2772478,6.29679575 L12,10.5740436 L7.72275218,6.29679575 C7.32616461,5.90020818 6.68994127,5.90240728 6.29617427,6.29617427 C5.89966201,6.69268654 5.90268552,7.32864195 6.29679575,7.72275218 L10.5740436,12 L6.29679575,16.2772478 Z" fill="#ffffff"></path>
            </g>
        </svg>
        <span class="visually-hidden">Close</span>
    </button>
</div>


        <div class="c-site-messages__form-container">

            <div class="grid grid-12 last">
                <div class="grid grid-4">
                    <img alt="Nature Briefing: Cancer" src="/static/images/logos/nature-briefing-logo-cancer-white-bc263e7d57.svg" width="373" height="40">
                    <p class="c-site-messages--nature-briefing__strapline extra-tight-line-height">Sign up for the <em>Nature Briefing: Cancer</em> newsletter — what matters in cancer research, free to your inbox weekly.</p>
                </div>
                <div class="grid grid-8 last">
                    <form action="https://www.nature.com/briefing/cancer" method="post" data-location="banner" data-track="signup_nature_briefing_banner" data-track-action="transmit-form" data-track-category="nature briefing" data-track-label="Briefing banner submit: Cancer">
                        <input id="briefing-banner-signup-form-input-track-originReferralPoint" type="hidden" name="track_originReferralPoint" value="CancerBriefingBanner">
                        <input id="briefing-banner-signup-form-input-track-formType" type="hidden" name="track_formType" value="DirectEmailBanner">

                        <input type="hidden" value="false" name="gdpr_tick" id="gdpr_tick_banner">
                        <input type="hidden" value="false" name="marketing" id="marketing_input_banner">
                        <input type="hidden" value="false" name="marketing_tick" id="marketing_tick_banner">
                        <input type="hidden" value="CancerBriefingBanner" name="brieferEntryPoint" id="brieferEntryPoint_banner">

                        <label class="nature-briefing-banner__email-label" for="emailAddress">Email address</label>

                        <div class="nature-briefing-banner__email-wrapper">
                            <input class="nature-briefing-banner__email-input box-sizing text14" type="email" id="emailAddress" name="emailAddress" value="" placeholder="e.g. jo.smith@university.ac.uk" required="" data-test-element="briefing-emailbanner-email-input">
                            
                            <input type="hidden" value="true" name="N:cancer" id="defaultNewsletter_banner">
                            <button type="submit" class="nature-briefing-banner__submit-button box-sizing text14" data-test-element="briefing-emailbanner-signup-button">Sign up</button>
                        </div>

                        <div class="nature-briefing-banner__checkbox-wrapper grid grid-12 last">
                            <input class="nature-briefing-banner__checkbox-checkbox" id="gdpr-briefing-banner-checkbox" type="checkbox" name="gdpr" value="true" data-test-element="briefing-emailbanner-gdpr-checkbox" required="">
                            <label class="nature-briefing-banner__checkbox-label box-sizing text13 sans-serif block tighten-line-height" for="gdpr-briefing-banner-checkbox">I agree my information will be processed in accordance with the <em>Nature</em> and Springer Nature Limited <a href="https://www.nature.com/info/privacy">Privacy Policy</a>.</label>
                        </div>
                    </form>
                </div>
            </div>

        </div>

    </div>

    
    <div class="c-site-messages__banner-small">

        
<div class="c-site-messages__close-container">
    <button class="c-site-messages__close" data-track="click" data-track-category="nature briefing" data-track-label="Briefing banner dismiss: Cancer">
        <svg width="25px" height="25px" focusable="false" aria-hidden="true" viewBox="0 0 25 25" version="1.1" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink">
            <title>Close banner</title>
            <defs></defs>
            <g stroke="none" stroke-width="1" fill="none" fill-rule="evenodd">
                <rect opacity="0" x="0" y="0" width="25" height="25"></rect>
                <path d="M6.29679575,16.2772478 C5.90020818,16.6738354 5.90240728,17.3100587 6.29617427,17.7038257 C6.69268654,18.100338 7.32864195,18.0973145 7.72275218,17.7032043 L12,13.4259564 L16.2772478,17.7032043 C16.6738354,18.0997918 17.3100587,18.0975927 17.7038257,17.7038257 C18.100338,17.3073135 18.0973145,16.671358 17.7032043,16.2772478 L13.4259564,12 L17.7032043,7.72275218 C18.0997918,7.32616461 18.0975927,6.68994127 17.7038257,6.29617427 C17.3073135,5.89966201 16.671358,5.90268552 16.2772478,6.29679575 L12,10.5740436 L7.72275218,6.29679575 C7.32616461,5.90020818 6.68994127,5.90240728 6.29617427,6.29617427 C5.89966201,6.69268654 5.90268552,7.32864195 6.29679575,7.72275218 L10.5740436,12 L6.29679575,16.2772478 Z" fill="#ffffff"></path>
            </g>
        </svg>
        <span class="visually-hidden">Close</span>
    </button>
</div>


        <div class="c-site-messages__content text14">
            <span class="c-site-messages--nature-briefing__strapline strong">Get what matters in cancer research, free to your inbox weekly.</span>
            <a class="nature-briefing__link text14 sans-serif" data-track="click" data-track-category="nature briefing" data-track-label="Small-screen banner CTA to site" data-test-element="briefing-banner-link" target="_blank" rel="noreferrer noopener" href="/briefing/cancer/?brieferEntryPoint=CancerBriefingBanner">Sign up for Nature Briefing: Cancer
            </a>
        </div>

    </div>

</div>

    




<noscript>
    <img hidden src="https://verify.nature.com/verify/nature.png" width="0" height="0" style="display: none" alt="">
</noscript>




<script src="//content.readcube.com/ping?doi=10.1038/s41591-021-01541-0&amp;format=js&amp;last_modified=2021-11-08" async=""></script>

<eeq-tqhadgqrbedd></eeq-tqhadgqrbedd><div data-cc-ghost="" style="height: 352px;"></div><script type="text/javascript" id="fetch-contextual-ads-campaign-data" charset="">(function(){var g=function(a){a=new CustomEvent("campaignDataLoaded",{detail:a});document.dispatchEvent(a)},b=google_tag_manager["rm"]["50443292"](18);if(b){var k=1500;b=google_tag_manager["rm"]["50443292"](19);b="link"===b?google_tag_manager["rm"]["50443292"](20):google_tag_manager["rm"]["50443292"](21);var m=function(a,c){var h=!1,l=setTimeout(function(){h=!0;c(null)},k),d=new XMLHttpRequest;d.onload=function(){var e=null,f=[];if(200===d.status){try{e=JSON.parse(d.responseText)}catch(p){e={}}f=e.campaigns||[]}h||(clearTimeout(l),c(f.length?f.join(","):null))};d.open("GET",
"/platform/contextual?doi\x3d"+a);d.send()},n=function(a,c){a&&-1===a.indexOf("not set")?m(a,c):setTimeout(c,1)};n(b,function(a){window.campaignsForContextualAds=a;g(a);window.dataLayer.push({content:{article:{campaignID:a}}})})}else window.campaignsForContextualAds="",g(null)})();</script>
<script type="text/javascript" id="gtm-setup-accessdetailsloaded-handler" charset="">document.addEventListener("accessdetailsloaded",function(a){a=a.detail||{};var b={event:"update-access-details"};a.institutional_business_partner_ids&&a.resolved_by||console.log("BPID data could not be retrieved from /exposed-details");a.logged_in_to_sn_profile||console.log("logged_in_to_sn_profile could not be retrieved from /exposed-details");var c=a.institutional_business_partner_ids&&a.institutional_business_partner_ids.join?a.institutional_business_partner_ids.join(";"):"",d=a.resolved_by&&a.resolved_by.join?
a.resolved_by.join(";"):"",e=a.personal_business_partner_id_found,f=a.logged_in_to_sn_profile,g=a.snid;b.user={};b.user.profile={};b.user.profile.profileInfo={resolvedBy:d||null,bpid:c||null,personal:e||null,logged_in_to_sn_profile:f,snid:g||null};b.session={};b.session.authentication={};b.session.authentication.token=a.token||null;b.session.authentication.legacy={};window.dataLayer.push(b);window.idpUserDataLoaded=!0},!1);window.dataLayer.push({event:"accessdetailsloaded-handler-added"});
window.accessDetailsLoadedHandlerAdded=!0;</script><script type="text/javascript" id="gtm-mediatrust" charset="">var s=document.getElementsByTagName("script")[0],p=document.createElement("script");p.async="async";p.src="https://scripts.webcontentassessor.com/scripts/93dabb8d80079a87fec7bb6f67b807fce90e1688f8957ad7ad152bfd58ea01c2";s.parentNode.insertBefore(p,s);</script><script id="crossmark-script" text="" charset="" type="text/javascript" src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script><script type="text/javascript" id="polyfill-matches" charset="">Element.prototype.matches||(Element.prototype.matches=Element.prototype.matchesSelector||Element.prototype.mozMatchesSelector||Element.prototype.msMatchesSelector||Element.prototype.oMatchesSelector||Element.prototype.webkitMatchesSelector||function(a){a=(this.document||this.ownerDocument).querySelectorAll(a);for(var b=a.length;0<=--b&&a.item(b)!==this;);return-1<b});</script><script type="text/javascript" id="fetch-idp-user-data" charset="">(function(a){if("function"===typeof window.CustomEvent)return!1;var c=function(d,b){b=b||{};var e=document.createEvent("CustomEvent");e.initCustomEvent(d,b.bubbles||!1,b.cancelable||!1,b.detail||a);return e};c.prototype=window.Event.prototype;window.CustomEvent=c})();var parse=function(a,c){try{return 200===a?JSON.parse(c):null}catch(d){return null}},dispatch=function(a){a=new CustomEvent("accessdetailsloaded",{detail:a});document.dispatchEvent(a)},site=google_tag_manager["rm"]["50443292"](59),idpUrl;
switch(site){case "nature":idpUrl=-1<window.location.hostname.indexOf("local-www")||-1<window.location.hostname.indexOf("test-www")?"https://staging-idp.nature.com/exposed-details":"https://idp.nature.com/exposed-details";break;case "link":idpUrl=-1<window.location.hostname.indexOf("link-qa")?"https://staging-idp.springer.com/exposed-details":"https://idp.springer.com/exposed-details";break;case "springer":idpUrl=-1<window.location.hostname.indexOf("local-www")||-1<window.location.hostname.indexOf("test-www")?
"https://staging-idp.springer.com/exposed-details":"https://idp.springer.com/exposed-details"}if(void 0!==idpUrl){var transport=new XMLHttpRequest;transport.open("GET",idpUrl,!0);transport.withCredentials=!0;transport.onreadystatechange=function(){4===transport.readyState&&dispatch(parse(transport.status,transport.responseText))};transport.send()}else dispatch(null);</script><script src="https://verify.nature.com/verify/nature.min.js"></script><script type="text/javascript" id="create-ad-slots" charset="">function createAndLoadAds(){function h(b){"nature"===a&&google_tag_manager["rm"]["50443292"](87)(b);"bmc"!==a&&"springeropen"!==a||google_tag_manager["rm"]["50443292"](99)(b);("link"===a&&"oscar"===google_tag_manager["rm"]["50443292"](100)||"springer"===a||"link"===a&&!0===google_tag_manager["rm"]["50443292"](101))&&google_tag_manager["rm"]["50443292"](126)(b);"link"===a&&"bunsen"===google_tag_manager["rm"]["50443292"](127)&&google_tag_manager["rm"]["50443292"](152)(b);"link"===a&&"Core"===google_tag_manager["rm"]["50443292"](153)&&google_tag_manager["rm"]["50443292"](165)(b)}window.googletag=window.googletag||{cmd:[]};var a=google_tag_manager["rm"]["50443292"](166),e=google_tag_manager["rm"]["50443292"](168);
if(-1===window.location.search.indexOf("hide_ads\x3dtrue"))if(window.adSlots&&0!==Object.keys(window.adSlots).length)console.log("Ads previously loaded. Will not update ad slots until next page load.");else{window.adSlots||(window.adSlots={});window.getAd=function(b,f){for(var c in window.adSlots)if(-1<c.indexOf(b)){if("object"===f)return adSlots[c];if("slot"===f)return adSlots[c].slot}};googletag.cmd.push(function(){googletag.pubads().setPrivacySettings({limitedAds:e});console.log("limitedAds is ",
e);googletag.pubads().setRequestNonPersonalizedAds(google_tag_manager["rm"]["50443292"](170));googletag.pubads().enableSingleRequest();googletag.pubads().disableInitialLoad()});for(var g=document.querySelectorAll("[data-gpt]"),d=0;g[d];++d)h(g[d]);googletag.cmd.push(function(){googletag.enableServices()})}}createAndLoadAds();</script>
</body></html>